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Abstract
A systematic review and economic evaluation of 
subcutaneous and sublingual allergen immunotherapy in 
adults and children with seasonal allergic rhinitis
A Meadows,1 B Kaambwa,2 N Novielli,1 A Huissoon,3 
A Fry-Smith,1 C Meads,4 P Barton2 and J Dretzke1*
1Department of Public Health, Epidemiology and Biostatistics, University of Birmingham, 
Birmingham, UK
2Health Economics Unit, University of Birmingham, Birmingham, UK
3Department of Immunology, Birmingham Heartlands Hospital, Birmingham, UK
4Barts and the London School of Medicine and Dentistry, Queen Mary, University of London, 
London, UK
*Corresponding author
Background: Severe allergic rhinitis uncontrolled by conventional medication can substantially affect 
quality of life. Immunotherapy involves administering increasing doses of a specific allergen, with the aim 
of reducing sensitivity and symptomatic reactions. Recent meta-analyses have concluded that both 
subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT) are more effective than placebo 
in reducing symptoms. It is uncertain which route of administration is more effective and whether or not 
treatment is cost-effective.
Objective: To determine the comparative clinical effectiveness and cost-effectiveness of SCIT and SLIT for 
seasonal allergic rhinitis in adults and children.
Data sources: Electronic databases {MEDLINE, EMBASE, The Cochrane Library [Cochrane Central Register 
of Controlled Trials (CENTRAL)], NHS Economic Evaluation Database (NHS EED)} and trial registries (from 
inception up to April 2011).
Review methods: Standard systematic review methods were used for study selection, data extraction and 
quality assessment. Double-blind randomised, placebo-controlled trials of SCIT or SLIT, or of SCIT compared 
with SLIT, and economic evaluations were included. Meta-analysis and indirect comparison meta-analysis 
and meta-regression were carried out. A new economic model was constructed to estimate cost–utility.
Results: Meta-analyses found statistically significant effects for SCIT and SLIT compared with placebo 
across a number of outcome measures and for the vast majority of subgroup analyses (type and amount of 
allergen, duration of treatment). There was less evidence for children, but some results in favour of SLIT 
were statistically significant. Indirect comparisons did not provide conclusive results in favour of either SCIT 
or SLIT. Economic modelling suggested that, when compared with symptomatic treatment (ST), both SCIT 
and SLIT may become cost-effective at a threshold of £20,000–30,000 per quality-adjusted life-year (QALY) 
from around 6 years, or 5 years for SCIT compared with SLIT (NHS and patient perspective).
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Limitations: It is uncertain to what extent changes in the outcome measures used in the trials translate 
into clinically meaningful benefits. Cost-effectiveness estimates are based on a simple model, limited data 
and a number of assumptions, and should be seen as indicative only.
Conclusions: A benefit from both SCIT and SLIT compared with placebo has been consistently 
demonstrated, but the extent of this effectiveness in terms of clinical benefit is unclear. Both SCIT and SLIT 
may be cost-effective compared with ST from around 6 years (threshold of £20,000–30,000 per QALY). 
Further research is needed to establish the comparative effectiveness of SCIT compared with SLIT and to 
provide more robust cost-effectiveness estimates.
Funding: The National Institute for Health Research Health Technology Assessment programme.
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Scientific summary
Background
Allergic rhinitis (AR) is an immunoglobulin E (IgE)-mediated inflammation of the nasal mucosa following 
allergen exposure. The condition is often comorbid with allergic conjunctivitis and is a risk factor for 
asthma. AR is more common in developed countries and the prevalence of allergic sensitisation is > 50% 
in some age groups. The high impact of AR on health-related quality of life (QoL), as well as work or 
educational performance results in a significant individual and economic burden. Conventional treatment 
involves providing symptomatic relief; however, up to two-thirds of patients report only partial or poor 
symptom control.
Allergen immunotherapy involves administering gradually increasing doses of a specific allergen, or part of 
the allergen, to an allergic subject, with the aim of reducing sensitivity and minimising future symptomatic 
reaction on natural exposure to the causative agent. Recent meta-analyses have concluded that both 
subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT) are effective in reducing 
symptoms of AR when compared with placebo. In addition, the clinical benefits of both SCIT and SLIT 
appear to be sustained following cessation of treatment. There is some evidence that immunotherapy can 
prevent disease progression, development of new sensitisations and onset of asthma. However, it is unclear 
whether one route of administration is more effective than the other, and the long-term cost-effectiveness 
of the treatments is uncertain.
Objectives
To determine the comparative clinical effectiveness and cost-effectiveness of SCIT and SLIT for seasonal 
allergic rhinitis (SAR) by (1) undertaking a systematic review of randomised controlled trials (RCTs) in order 
to update existing Cochrane reviews on the topic; (2) undertaking an indirect comparison of SCIT with 
SLIT; (3) undertaking a systematic review of existing economic evaluations (EEs); and (4) conducting an 
independent EE.
Review methods
Major electronic databases {e.g. MEDLINE, EMBASE, The Cochrane Library [Cochrane Central Register of 
Controlled Trials (CENTRAL)] and the NHS Economic Evaluation Database (NHS EED)} and several internet 
sites, including trial registries, were searched from inception up to April 2011. There were no language 
restrictions. For the review of clinical effectiveness, double-blind randomised, placebo-controlled trials 
of SCIT or SLIT were included, as were direct comparisons of SCIT with SLIT. Studies were eligible if they 
included adults and/or children with a clinical diagnosis of moderate to severe SAR with or without 
asthma. For the review of EEs, any suitable evaluations (including analyses of cost-effectiveness, cost–
benefit, cost–utility, cost–consequences and cost minimisation) or reviews of EEs were included, as were 
studies reporting data of potential use for informing an economic model, such as utilities or cost data. 
Standard systematic review methods were used for study selection, data extraction and quality assessment.
For the review of clinical effectiveness, analyses were limited to four patient-centred outcomes – symptom 
scores (SSs), medication scores (MSs), combined symptom and medication scores (SMS), and QoL – as 
well as any reported adverse events (AEs). With the exception of AEs, random-effect meta-analyses were 
conducted for all outcomes. Analyses were also conducted to explore the impact of a range of prespecified 
patient and trial characteristics on outcome measures. Adjusted indirect comparisons of SCIT versus SLIT 
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were conducted across all four patient-centred outcomes, using random-effects meta-regression and 
adjusting for covariates.
The EE was based on a systematic review and critical appraisal of existing EEs and a new cost-effectiveness 
model, based on estimates of QoL, and cost and resource use estimates derived from the literature and 
following consultation with clinical experts.
Results
Clinical effectiveness
Seventeen new RCTs of SCIT compared with placebo and 11 of SLIT compared with placebo were 
identified, which were published subsequent to the corresponding Cochrane reviews of these 
interventions. One small head-to-head trial of SCIT compared with SLIT was found. A further 23 ongoing, 
or not yet reported, RCTs were identified. Risk of bias assessment was hampered by inadequate reporting 
of all quality criteria. The majority of trials appeared to have low risk of bias when sufficient information to 
make a judgement was reported, with only very few instances of high risk of bias identified.
Of the 17 newly identified RCTs of SCIT (vs placebo) and 11 newly identified RCTs of SLIT (vs placebo), only 
five trials of each type of intervention reported data in a form suitable for meta-analysis. However, meta-
analysis also included all previous relevant studies from the Cochrane reviews. Statistically significant results 
were found for both SCIT and SLIT, suggesting a moderate effect size in favour of the active treatment 
for all patient-centred outcomes (SS, MS, SMS, and QoL). This remained the case for the vast majority of 
subgroup analyses performed (e.g. for treatment duration, and type and amount of allergen used). A large 
amount of variability in how outcomes were scored meant that results had to be presented as standardised 
mean differences. Interpretation of these is difficult and the clinical significance of the results is uncertain.
There is less evidence for children, particularly for SCIT. One small SCIT trial found significantly lower SSs 
and MSs, and improved QoL, in the actively treated group (after 3 years of treatment). For SLIT, statistically 
significant results (based on nine studies) were found for SSs but not for MSs. The one study including a 
quality-of-life measure found a statistically significant difference in favour of SLIT.
Indirect comparisons of SCIT with SLIT were suggestive of SCIT being more beneficial for SSs and MSs, 
but this was associated with substantial residual heterogeneity. No statistically significant difference was 
found between the two interventions for combined SMSs or QoL, which could arguably be deemed more 
clinically useful outcomes. These findings were not substantially altered when participant age, treatment 
duration and type or amount of allergen were included as covariates.
Adverse events were common with both SCIT and SLIT, but the majority were local reactions at the point 
of administration and resolved spontaneously without treatment. Systemic reactions were less common, 
occurring in approximately 4.4% of injections for SCIT, and most were graded as mild or moderate in 
severity. However, 19% of systemic reactions following SCIT treatment were considered to be severe, 
compared with only 2% of systemic reactions following SLIT. Discontinuations due to AEs were similar 
between the interventions – 3% and 3.4% for SCIT and SLIT, respectively. No fatalities occurred in any of 
the trials.
Cost-effectiveness
Searches for EEs identified 14 EEs and two reviews of EEs. Overall, the studies found that both SCIT and 
SLIT were more beneficial than symptomatic treatment (ST), and in some cases also become less costly 
than ST over time. Where studies expressed results as incremental cost-effectiveness ratios (ICERs), both 
SCIT and SLIT were found to be cost-effective at thresholds of £20,000 per quality-adjusted life-year 
(QALY). However, there were issues around transparency and/or robustness of parameters for most studies. 
None of the cost–utility analyses were conducted by independent researchers.
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A preferred Markov model was constructed for adults and children but could not be adequately populated 
largely owing to a lack of suitable data on transition probabilities between different health states in SAR. 
An alternative, simpler, model was therefore constructed, which used data on quality-of-life improvement 
based on the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) from the direct and indirect 
comparison meta-analyses. Using a number of assumptions, changes in RQLQ were mapped to changes 
in European Quality of Life-5 Dimensions (EQ-5D), in order to express results as cost per QALY. Based on a 
threshold of £20,000–30,000 per QALY, results showed that immunotherapy compared with ST became 
cost-effective after around 6 years from the start of treatment (NHS and patient perspective; 7 years for 
NHS perspective only).
Subcutaneous immunotherapy was found to be cost-effective compared with SLIT after around 5 years, 
based on the same threshold. This is based on SCIT being both more effective and more costly than SLIT. 
As the difference in RQLQ was not statistically significant (the confidence interval crosses zero), there 
is uncertainty associated with the effectiveness estimate, which, in turn, affects the reliability of the 
cost-effectiveness estimate. Results overall should be seen as indicative because they are based on a very 
simple analysis. Sensitivity analyses were restricted to varying the time horizon and using upper and lower 
confidence limits for RQLQ improvement. Potential cost savings from preventing future cases of asthma 
were not considered in this cost-effectiveness analysis (CEA). It was not possible to undertake a CEA for 
children owing to a paucity of available data.
Conclusions
Based on a substantial number of RCTs, both SCIT and SLIT have been consistently shown to be 
significantly more effective than ST only, and this remains the case for the vast majority of subgroup 
analyses based on differences in population and treatment protocol. It is uncertain to what extent this 
statistical significance translates to clinically significant differences across the different types of outcome 
measures used. An indirect comparison is suggestive of SCIT being more beneficial than SLIT based on 
SSs and MSs, but no such difference could be shown for combined SMSs or QoL, and firm conclusions 
cannot be drawn. CEAs suggest that both SCIT and SLIT may become cost-effective at a threshold of 
£20,000–30,000 per QALY from around 6 years. However, these estimates were based on limited data and 
the use of a number of assumptions. Potential cost savings resulting from future cases of asthma avoided 
were not included in the analysis, but would likely lead to an increase in cost-effectiveness.
Recommendations for future research
Future research should focus on:
 z Head-to-head RCTs comparing SCIT with SLIT, consistent with current guidelines on treatment 
protocols and using standardised outcome and reporting measures to enable between-study 
comparison. Further studies of either intervention compared with placebo are unlikely to add to the 
already extensive literature on this subject.
 z Outcomes that (1) take into consideration that the relative effectiveness of immunotherapy compared 
with symptomatic medication varies depending on prevailing allergen levels and (2) could best 
inform EEs.
 z Evaluation of long-term effectiveness from shorter courses of immunotherapy, as this places less of a 
burden both on the patient in terms of time and inconvenience and in terms of associated costs.
 z The extent to which results of all previous primary research can be made available to independent 
researchers in order to inform model-based value-of-information analysis.
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Chapter 1 Background
Seasonal allergic rhinitis
Allergic rhinitis (AR) is an immunoglobulin E (IgE)-mediated inflammation of the nasal mucosa following 
allergen exposure. Symptoms include rhinorrhoea, nasal obstruction, nasal itching and sneezing. AR is 
often comorbid with allergic conjunctivitis and is a risk factor for asthma.1
Depending on the nature of the triggering allergen, AR has traditionally been categorised as either 
seasonal allergic rhinitis (SAR, e.g. induced by pollen) or perennial allergic rhinitis (PAR, e.g. induced 
by animals, dust mites, etc.). More recently, an alternative classification of either intermittent or 
persistent AR has been proposed [Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update].1 The 
disease can further be categorised as either ‘mild’ or ‘moderate/severe’, depending on the severity of 
symptoms and impact on quality of life (QoL).1 ‘Hay fever’ is the common name classically given to SAR 
or rhinoconjunctivitis.
Diagnosis is based on symptom history and examination, and could include investigations such as peak 
nasal inspiratory flow or nasal endoscopy. Skin prick tests should be carried out routinely in order to 
determine whether rhinitis is allergic or non-allergic.2
Epidemiology and natural history
Allergic rhinitis is a global health problem and affects patients from all ethnic groups, all socioeconomic 
conditions and all ages; in many countries the prevalence of allergic sensitisation is > 50% in some 
age groups.1 It is more common in developed countries. The prevalence of AR based on questionnaire 
studies has been found to range from 1% to 40% worldwide and between 3% and 29% in the UK (18%, 
14.9%, 3%, 11.9%, 29%, 16.5% and 18.9%, based on sample sizes of between 813 and > 12,000, 
including adults and children).1 A clinical definition is difficult to use in surveys of large populations, and 
a questionnaire-only approach may therefore overestimate or underestimate the prevalence of AR. In a 
study using the ARIA definition of AR,3 the prevalence of clinically confirmable AR in the UK was found 
to be 26% in adults [95% confidence interval (CI) 20.3% to 31.7%]. A 2009 report4 estimated that SAR 
affected approximately 16 million people in the UK, with grass pollen allergy the most common form, 
affecting around 95% of sufferers, followed by sensitivity to tree pollen (25%), weed pollen (20%) and 
fungal spores. Many people are sensitised to more than one allergen. A large international survey in 
children5 found a UK prevalence of AR of around 10% in 6- to 7-year-olds and 15–19% in 13- to 14-year-
olds. Although rates of AR are increasing in countries with low prevalence, rates may be plateauing 
or decreasing in countries with high prevalence.1 However, based on climate change predictions, the 
prevalence of SAR is likely to increase, with general practitioner (GP) consultations for SAR forecast to rise 
by 30–40% by 2020.4
There are few data on the prognosis of AR, although symptoms tend to become milder with age, and 
allergic skin reactivity decreases in the elderly.1 Some studies have investigated the incidence and remission 
of AR in the same general population; a Danish study6 found that remission from symptoms was relatively 
infrequent and remission from both symptoms and IgE sensitisation was rare; a Swedish study7 found that 
overall prevalence increased over an 8-year period (from 12.4% to 15.0%), whereas in a proportion of 
cases (23%) symptoms ceased to be reported.
Allergic rhinitis and asthma are frequently comorbid conditions. Both disorders affect the mucosal lining of 
the respiratory tract and are linked by common underlying cellular processes and, thus, may be considered 
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as part of the same allergic disease (‘united airways’ approach).8 There is now widespread evidence to 
suggest that AR in children often predicts development of asthma. A large longitudinal study9 (n = 8275) 
found that childhood AR was associated with a significant two- to sevenfold increased risk of incident 
asthma later in life.
Burden of disease
The burden on primary and secondary care from allergic diseases, particularly asthma, is high, as are the 
associated costs. A 2004 review10 of UK databases found that:
 z Six per cent of all GP consultations were for allergic disease, with allergic rhinoconjunctivitis being the 
third most common reason for consultation after eczema and asthma (1991 data).
 z Eleven per cent of community prescriptions were for asthma and other allergic problems, including 
nasal allergy (4.3 million prescriptions in 2000–1 for nasal allergy).
 z Most hospital admissions for allergic conditions were due to asthma (87% or 92.5/100,000 in 
2000–1); 1.6 per 100,000 admissions were for AR (2000–1).
 z Cost estimates for GP consultations for allergic problems range from £211M to £311M per year.
 z Asthma and other allergic diseases accounted for 11% (£0.7B) of all primary care prescribing costs.
 z Allergic problems are responsible for over 183,000 bed-days each year, with an estimated cost of 
£68M per year (sensitivity analysis limits £56–83M).
Conventional treatment
Conventional treatment of SAR includes oral or topical antihistamines and intranasal corticosteroids as 
required, with the goal of treatment being symptomatic relief. Occasionally, systemic corticosteroids are 
prescribed (see Current guidelines). However, some patients are unable to tolerate pharmacotherapy and 
a substantial number – up to two-thirds in a UK study of patients in 16 general practices11 – report only 
partial or poor symptom control, particularly of systemic symptoms. Pharmacotherapy has no enduring 
effect following discontinuation and is not thought to influence the course of disease.
Allergen immunotherapy
Allergen immunotherapy (IT) involves administering gradually increasing doses of a specific allergen, 
or part of the allergen, to an allergic subject, with the aim of reducing sensitivity and minimising 
future symptomatic reaction on natural exposure to the causative agent.12 Delivery of specific allergen 
immunotherapy (SIT) has traditionally been by subcutaneous injection.13 A number of other routes of 
administration have now been investigated, but only subcutaneous and sublingual administration are 
currently in general use.13
The mechanisms by which allergen-specific IT modulates the immune response have not been fully 
elucidated; however, IT has been shown to increase serum levels of allergen-specific IgG, which 
correlates closely with an IgE-blocking activity and may be partly responsible for the therapeutic 
effect.14 IT also appears to alter the balance of helper T-cells, consequently decreasing production of 
proallergenic cytokines.14
In contrast with the use of conventional symptom relief medication, the clinical benefits of both 
subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT) appear to be sustained 
following cessation of treatment. An uncontrolled cross-sectional study15 of SIT for Japanese cedar 
pollinosis (mean treatment duration 3.6 years; n = 485) reported duration of effect at 10 years post 
completion, with 42% of patients remaining symptom free even in the year with the highest pollen count. 
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A small prospective, open, controlled study16 (treatment duration 3 years; n = 28) recorded ongoing 
clinical benefit 12 years after discontinuation of treatment. However, this study was not randomised, with 
treatment allocation based on patient or parent preference.
Few studies have conducted long-term follow-up while maintaining double-blind conditions. One study17 
of SCIT for grass pollen allergy demonstrated that, following 3–4 years of treatment, clinical benefits were 
maintained over the next three allergy seasons, and did not differ from a continued active treatment arm. 
A 3-year trial of SLIT for grass pollen allergy with 2 years of blinded follow-up has also shown sustained 
effects of IT for all clinical and patient-reported outcomes measured.18
Subcutaneous IT must be delivered in a clinical setting owing the increased risk of severe allergic reactions. 
Full resuscitation facilities must be available and, in the UK, a minimum of 60 minutes post-injection 
supervision is required.19,20 SCIT thus requires a considerable time commitment from patients, as well as 
substantial use of clinical resources. SLIT appears to be safe even at very high doses (up to 500 times the 
usual monthly subcutaneous dose) and is associated with fewer adverse events (AEs).21 Thus, SLIT can 
normally be self-administered outside of a clinical setting, and is therefore more time efficient for the 
patient, as well as reducing resource utilisation. It should be noted, however, that maintenance doses for 
SLIT generally range from 20 to 200 times the dose used in SCIT, with implications for treatment cost.21
Treatment schedule
Owing to the risk of adverse reactions to allergen injection in sensitised patients, conventional SCIT 
treatment schedules involve a gradual increase in the allergen content of injections, usually involving one 
or two injections per week over a 3- to 6-month period.22 Once a prespecified maximum treatment dose 
has been achieved, or the maximum tolerated dose for any given patient attained, treatment continues 
with this maintenance dose at regular intervals, usually monthly, for the duration of therapy.21 Optimal 
maintenance dosing for a given product is often prespecified by the manufacturer, although substantial 
evidence suggests that a maintenance dose in the range of 5–20 µg of major allergen per injection is 
associated with significant clinical improvement.23 However, the maximum tolerated dose varies between 
individual patients and may be lower than the target therapeutic dose.
A number of studies have investigated accelerated updosing schedules for SCIT. For example, rush IT 
involves administering increasing doses of allergen at intervals of between 15 and 60 minutes over a 1- to 
3-day period, until the target therapeutic dose is achieved.22 An alternative form of accelerated schedule is 
cluster IT, whereby two to three incremental doses are administered on non-consecutive days. Maintenance 
dose is usually reached at between 4 and 8 weeks.22
In contrast, treatment schedules for SLIT may or may not include an updosing period, and following initial 
treatment administration under medical supervision, maintenance dosing is undertaken by the patient in a 
non-clinical setting. Typically, dosing continues daily for the period of treatment – up to 3 years. However, 
studies21,24–26 have shown that shorter treatment periods, with SLIT administered for a few months 
before and during the pollen season, or during the pollen season only, may be as effective as year-round 
treatment, in terms of symptom and medication reduction and improved QoL.
Optimal treatment schedules for SLIT have yet to be definitely established, and a wide variety of practices 
are used.19 Updosing may or may not be necessary, and maintenance schedules ranging from once per day 
to once per week have been used,19 although daily dosing is the most common.
More recently, rush or cluster regimens for SLIT have been used. A recent meta-analysis27 of individual 
patient data (IPD) from three open, prospective studies of high-dose SLIT, totalling 1052 adult and 
paediatric pollen-allergic patients, found no significant difference in rhinoconjunctivitis symptom scores 
(SSs) or use of rescue medication between perennial or coseasonal schedules, or standard or ultrarush 
titration. The rate of AEs was also similar between the different treatment schedules. Thus, the major 
benefit of accelerated IT schedules appears to be in terms of patient convenience. As inconvenience is one 
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of the major reasons for treatment discontinuation,28 accelerated schedules may increase both adherence 
and therapy uptake.22
A recent review29 found that accelerated schedules in SCIT may be associated with a higher risk of systemic 
reactions but also suggested that premedication, for example with antihistamines or corticosteroids, may 
result in a risk profile similar to that of conventional treatment schedules.
A number of studies25,30,31 have reported that the clinical effects of SIT are additive over time, with 
increasing benefit following subsequent years of treatment. Based on evidence of sustained clinical 
benefits after treatment cessation following studies with 3 years of active treatment,17,32 current guidelines 
recommend this duration of treatment for both SCIT and SLIT.19 However, there are few double-blind 
discontinuation studies, and none comparing the long-term effects after different lengths of active 
treatment for SAR. One prospective controlled study33 evaluated relapse rates following between 12 and 
96 months of SCIT treatment in 40 adult and paediatric patients with house dust mite allergy. All patients 
were symptom free at completion of treatment, but 55% relapsed over the following 3 years. Relapse 
rate was significantly related to treatment duration, with 62% of those treated for 35 months or less 
experiencing a recurrence of symptoms, compared with 48% of those treated for > 36 months (p < 0.04).
Specific (allergen) immunotherapy formulations
The immunomodulatory effect of SIT is specific to the allergen used. Although single-allergen IT has 
proven effective in reducing symptoms on exposure to the specific allergen in polysensitised patients, no 
additional benefit is obtained in respect of the other allergic triggers. However, there is some indication 
that SIT may prevent the onset of new sensitisations in monosensitised children,16,34,35 possibly due to 
cross-reactivity between related allergen species. For example, there is strong reactivity between members 
of the Festucoideae family of grasses, which includes timothy grass (Phleum pratense L.), rye grass and 
orchard grass, and there is extensive cross-reactivity within and between a number of subfamilies of 
tree pollen.21
In contrast, mixtures of unrelated allergens have failed to show efficacy in double-blind, placebo-controlled 
(DBPC) trials of either SCIT or SLIT in multisensitised populations, possibly due to potential interactions 
between the different enzymatic components and/or dilution of individual allergen dosage.21,36 For 
example, extracts from Alternaria species reduce the immunogenicity of timothy grass extract, and studies 
have shown that extracts of moulds and fungi significantly reduce the potency of grass pollens, some 
weeds, trees, and a number of perennial allergens when mixed together.21 Thus, concurrent treatment of 
multiple sensitivities is not recommended. However, mixtures of related and cross-reacting allergens (e.g. 
antigens from more than one species of grass pollen) are effective, and a number of commercial products 
of this type are currently available.19 It should be noted that multiallergen treatment is commonplace in the 
USA, where vaccines are formulated for individual use by the treating clinician, but separate vaccines may 
need to be given for each allergen.37
A number of modifications in formulation procedures have been made in recent years to improve 
treatment convenience and/or safety, particularly for SCIT products. The development of depot 
formulations by adsorption of allergen extract on to depot materials, for example aluminium hydroxide, 
l-tyrosine or calcium phosphate, is now common practice.23 This results in prolonged, gradual release 
of the allergen at the injection site, allowing for a larger maintenance dose to be given at each injection 
and reducing the number and frequency of maintenance injections required. Another important 
modification involves chemical modification of the allergen extract with adjuvants such as glutaraldehyde 
or formaldehyde.23 The resultant allergoid has reduced specific IgE-binding capacity and therefore 
lower allergenicity, reducing the risk of treatment-emergent AEs. The reduced allergenicity of allergoid 
compounds again allows for larger doses to be used, making treatment schedules more convenient. The 
effect of these modifications on the immunogenicity of the allergoid is unchanged and, hence, clinical 
efficacy is maintained. Again, this situation differs from that in the USA, where the use of unmodified 
aqueous allergen extracts is standard practice.37 More recently, genetically modified allergens or allergen 
derivatives, or use of allergens conjugated with immunostimulatory molecules has been reported.12,38
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Standardisation
The production of allergen extracts derived from natural allergens can result in highly variable potency 
of the end product to be used in SIT. Individual manufacturers have therefore developed in-house 
standardisation procedures for the purpose of quality control and consistency between batches.23 In 
addition, European regulations now specify requirements for starting materials, production processes 
and quality control.39 Nevertheless, in-house reference standards are based on units of biological activity 
obtained from immunological assays and/or skin prick tests in a representative population. Thus, sensitivity 
of the test population, sample size, and the immunological methodologies used may result in differences 
in potency between products with the same nominal activity. Further, manufacturers use a range of specific 
units to measure biological response and these are not readily comparable between different commercial 
products.23 Given these differences, optimal dosages are product specific and cannot be generalised. 
Nevertheless, the degree of clinical improvement appears to be dose dependent in both SLIT and SCIT.40 
In injection IT, increased efficacy with higher doses must be balanced with increased risk of systemic 
reactions.41 In contrast, a meta-analysis of 25 studies42 in SLIT found that this route of administration did 
not result in a dose-dependent increase in AEs. These findings were confirmed by a 2011 report from the 
European Academy of Allergy and Clinical Immunology (EAACI) task force on dose–response relationships 
in SIT.40
It has been recommended that manufacturers state the major allergen content (MAC) of their products 
in mass units (g/ml),43,44 although differences in assay methods may still limit comparability, and the 
variable contribution of minor allergen content to total biological potency is not accounted for. The use 
of recombinant allergen products may improve standardisation in the future but these are not yet widely 
available and few have been tested in large-scale randomised controlled trials (RCTs).23
Commercial products in the UK
The only aeroallergen SLIT product licensed in the UK for adults and children (5 years) is Grazax® (75,000 
SQ-T oral lyophilisate; ALK-Abelló Ltd, Hørsholm, Denmark), a standardised allergen extract of grass pollen 
from timothy grass. Tablets (one per day) are placed under the tongue and allowed to disperse. Treatment 
is ideally initiated 4 months before the grass pollen season and continued for a period of 3 years. 
Where no improvement in symptoms is observed during the first pollen season, there is no indication 
for continuing the treatment.45 Grazax costs £66.77 for 30 tablets [source: British National Formulary 
(BNF) (2012)].46
The only SCIT product licensed in the UK is Pollinex® (Allergy Therapeutics, Worthing, UK), a standardised 
l-tyrosine-adsorbed allergoid of grass or tree pollens. Pollinex for grass allergy contains allergen extracts 
of 12 grass species plus rye, and the tree pollen vaccine contains birch, alder and hazel. Both vaccines 
may be prescribed to adults and children (≥ 6 years) and are given in six preseasonal injections.19 An 
initial treatment set (three vials) and extension course treatment (one vial) of Pollinex costs £450 [source: 
BNF (2012)46].
A variety of unlicensed products may be prescribed by specialists on an individual ‘named-patient’ 
basis [see the 2011 British Society for Allergy and Clinical Immunology (BSACI) guidelines for AR19 for 
an overview].
Non-standard therapies
A number of researchers have investigated highly truncated SIT schedules, including single-injection 
treatment47,48 and the Rinkel method.49,50 These are not considered to be standard IT, have proven 
ineffective in double-blind placebo-controlled studies49,50 and, therefore, have not been included in this 
review. More recent developments in IT formulations have included the use of peptides fragments of 
relevant T-cell epitopes of an allergen, as opposed to whole allergens; vaccination with immunostimulatory 
compounds without a specific allergen attached; and the use of recombinant wild allergens or allergen 
fragments.51 Genetically engineered allergens have the potential to reduce allergenicity while maintaining 
immunogenicity52,53 and are thus a promising avenue for future research. However, these products are 
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generally in the early stages of development and are therefore not currently used in standard practice. 
These therapies have also not been included in this review.
The role of specific (allergen) immunotherapy in asthma 
prevention
As well as treating symptoms of AR (and allergic asthma), there is evidence that SIT can prevent disease 
progression, development of new sensitisations, and onset of asthma.8,19 The review by Fiocchi and Fox8 
identifies a number of studies54–56 demonstrating the preventative effect of SIT, including the Preventative 
Allergy Treatment (PAT) study. The PAT study54–56 was an open-label RCT (n = 205) of SCIT compared 
with control, which followed children aged 6–14 years for up to 7 years after a 3-year treatment period. 
Symptomatic rescue medication was allowed in both treatment arms. At 10 years, the number of patients 
who had developed asthma was 16 out of 64 (25%) in the SCIT group and 24 out of 53 (45%, control 
OR = 2.5, 95% CI 1.1 to 5.9; p-value not reported) in the control group.54 Loss to follow-up at this point 
was 23% in the SCIT and 33% in the control group. When adjusted for bronchial hyper-responsiveness 
and asthma status at baseline, the treatment effect was found to be statistically significant (OR for no 
asthma = 4.6, 95% CI 1.5 to 13.7; p = 0.0075).
Fiocchi and Fox8 identify a number of additional studies that support these findings. Overall, they showed 
that SCIT or SLIT is beneficial compared with medication only in the prevention of new asthma cases and/
or new sensitisations, or for reducing asthma severity or the number of asthma cases. The studies included 
in the review are mainly open-label RCTs or use non-randomised designs, so are likely to be subject to 
greater bias than blinded RCTs, which, in turn, may influence the effect size. Loss to follow-up may also be 
an issue in those studies with long follow-up periods and fairly small numbers of patients.
Three studies54–58 report on the preventative effect of SIT in the development of new asthma cases; these 
are summarised in Table 1.
An ongoing RCT, which may be able to further substantiate these findings, is the Grazax Asthma 
Prevention (GAP) RCT,59 which commenced in 2010 and is due to finish in 2015. It randomised children 
aged 6–12 years with grass pollen-induced AR and no asthma to receive SLIT with Grazax or a placebo 
tablet. The primary outcome measure is the evaluation of allergy and asthma symptoms.
TABLE 1 Preventative effect of SIT in asthma development
Study Participants Study design Outcome
Novembre 
200457
Children (n = 113, aged 
5–14 years) with AR (grass) 
and fewer than three 
episodes of asthma per 
season
Open-label RCT, 3 years of 
SLIT or medication only
At 3 years, asthma development less 
frequent in active group (OR = 3.8, 95% CI 
1.5 to 10)
Polosa 
200458
Adults (n = 30, aged 
20–54 years) with AR 
(grass) and no asthma
Double-blind RCT, 3 years of 
SCIT or placebo
At 3 years, 7/15 (47%) in the placebo group 
developed asthma symptoms compared with 
2/14 (14%) in the SCIT group (p = 0.0056)
PAT 
study54–56 
(2002, 2006, 
2007)
Children (n = 205, aged 
6–14 years) with AR (grass/
birch) and no asthma 
needing daily treatment
Open-label RCT, 3 years of 
SCIT or medication only, 
follow-up up to 10 years
For those with no asthma at baseline, lower 
incidence of new asthma in SCIT group at 3, 
5 and 10 years:
 z 3 years: OR = 2.5 (95% CI 1.3 to 5.1)
 z 5 years: OR = 2.7 (95% CI 1.3 to 5.7)
 z 10 years: OR = 2.5 (95% CI 1.1 to 5.9)
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Current guidelines
Guidance for the management of patients with AR and non-allergic rhinitis prepared by the Standards 
of Care Committee (SOCC) of BSACI in 20082 can be summarised as follows. Following diagnosis, first-
line treatment of AR is allergen avoidance (where possible and practicable). The nature and severity of 
symptoms determines the type of medication offered; if symptoms are mild, a non-sedating oral or topical 
H1-antihistamine is given. Where symptoms are moderate to severe, first-line therapy is with a topical 
intranasal steroid. If these treatments fail, further agents may be added according to the troublesome 
symptom: ipratropium for watery rhinorrhoea, a non-sedating H1-antihistamine for itch or sneeze, or a 
leukotriene-receptor antagonist for catarrh if asthmatic. Blockage of the nose may require a decongestant, 
oral corticosteroids or a long-acting non-sedating H1-antihistamine.
If there is further treatment failure, and if the symptoms are predominantly due to one allergen, then IT 
may be considered. Specific guidelines from BSACI on the use of allergen IT for AR,19 published in 2011, 
conclude that both injection and SLIT are effective in patients with IgE-mediated seasonal pollen-induced 
rhinitis and/or conjunctivitis whose symptoms respond inadequately to usual therapy, although the relative 
efficacy of SCIT and SLIT has still to be determined. The BSACI highlights the need for both head-to-head 
trials of SCIT compared with SLIT, and for long-term studies that include pharmacoeconomic evaluation 
comparing SIT with antiallergic drugs.19 The 2011 BSACI guidelines also update the position on the use 
of SIT in asthmatic patients. SIT has been shown to improve symptoms in atopic, asthmatic adults and 
children clinically sensitised to seasonal and perennial allergens, and treatment is generally considered safe 
in patients with pollen-induced seasonal allergic asthma (SAA), provided any updosing is conducted out 
of season.19 However, owing to the slightly elevated risk of severe systemic reactions in asthmatic patients, 
perennial, unstable or uncontrolled asthma is still considered a relative contraindication for SIT.
The ARIA guidelines (2010 revision)60 on the role of SIT in the treatment of AR make the following 
recommendations (a summary is shown in Table 2). The guidelines suggest that both SLIT and SCIT can 
TABLE 2 Summary of ARIA recommendations (2010 revision)60 for the treatment of AR with SIT
Treatment Recommendation Underlying values/preferences
SCIT for adults 
with AR and 
without asthma
Suggest use in adults with seasonal AR 
(moderate-quality evidence) and persistent 
AR caused by house dust mites (low-quality 
evidence)
Relatively high value placed on symptom relief; 
relatively low value placed on avoidance of AEs 
and resource expenditure
SCIT for children 
with AR and 
without asthma
Suggest use in children (low-quality evidence) Relatively high value placed on probable 
reduction in symptoms and potential prevention 
of development of asthma; relatively low value 
placed on avoidance of AEs and resource 
expenditure
SLIT for adults 
with AR and 
without asthma
Suggest use in adults with rhinitis caused by 
pollen (moderate-quality evidence) or house 
dust mites (low-quality evidence)
Relatively high value placed on symptom relief; 
relatively low value placed on avoidance of AEs 
and resource expenditure
Local AEs are relatively frequent (around 35%)
SLIT for children 
with AR and 
without asthma
Suggest use in children with rhinitis caused by 
pollen (moderate-quality evidence), but not in 
children with AR caused by house dust mites 
outside clinical trials (very low-quality evidence)
Relatively high value placed on symptom relief; 
relatively low value placed on avoidance of AEs 
and resource expenditure
Local AEs are relatively frequent (around 35%)
SCIT or SLIT in 
patients with AR 
and asthma
Suggest use of SCIT or SLIT to treat asthma and/
or rhinitis (moderate-quality evidence)
Relatively high value placed on symptom relief; 
relatively low value placed on avoidance of AEs 
and resource expenditure 
Source: 2010 revision60 of the ARIA guidelines.
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be used in both adults and children for treating AR, but note that a higher value is placed on relieving 
symptoms, and a lower value on avoiding AEs and resource expenditure.
No guidelines from the National Institute for Health and Care Excellence (NICE) regarding IT for AR were 
identified. The British Guidelines on the Management of Asthma,61 produced by the British Thoracic Society 
and the Scottish Intercollegiate Guidelines Network (SIGN), mention IT in the context of primary prevention 
of asthma, but find that more studies are required to establish this role and no recommendations 
are made.
UK clinical practice
A 2010 report61 from the Royal College of Physicians reported an increasing trend in the use of SLIT 
compared with figures from 2007. Sales figures for SCIT products have remained relatively unchanged over 
this time. The authors estimate that approximately 2000 patients per year are receiving each treatment.
One possible explanation for the relatively low uptake of SIT is the perception of risk associated with the 
practice following reports of serious AEs in early studies of SCIT.62,63 Consequently, outside of specialist 
centres, there remains an unwillingness to utilise SIT in clinical practice. Knowledge of safety improvements 
in SCIT preparations and the relatively favourable safety profile of SLIT remains lacking.62 In addition, 
primary care trust funding for SIT is still uncommon, leading to wide geographic variations in treatment 
access. The shortage of trained specialists and the absence of clinical guidelines from NICE may be 
compounding factors in this matter.62
With increasing evidence that SIT may result in the prevention of new sensitisations and incidence of 
asthma, the uptake of SIT in paediatric allergy sufferers is likely to have long-term clinical and economic 
impacts. However, although children attending specialist centres are more likely to be treated with SIT than 
those in non-specialist practices,62,64 a recent audit of NHS paediatricians offering pollen IT in England and 
Wales65 identified only 20 centres, all of which were in England, with three located in London. Further, 
absolute numbers of children treated with SIT were still low, although the trend was for increasing 
numbers over time. Approximately twice as many children had been treated with SLIT (n = 363 courses) 
than with SCIT (n = 165 cycles) over the 10-year audit period. The most commonly used SCIT products 
were Pollinex Quattro (Allergy Therapeutics, 53%), Pollinex (Allergy Therapeutics, 32%), Allergovit® 
(Allergopharma, Reinbek, Germany, 8%) and Alutard SQ® P. pratense (ALK-Abelló, 8%). Only two SLIT 
products were used in these centres: Staloral® (Stallergènes, Antony Cedex, France) made up the majority 
of treatment courses (70%), with the remainder accounted for by Grazax®.65 Despite earlier guidelines 
that asthma was a contraindication for SIT in children,2 49% of children receiving SCIT and 58% of those 
receiving SLIT had a diagnosis of asthma. Of these, nearly three-quarters had perennial asthma (126/174, 
72%),65 which remains a contraindication to SIT in the updated BSACI guidelines.19
Patient perspective
A survey was conducted in 2005 by Allergy UK, in conjunction with the General Practice Airways Group;66 
1000 individuals with AR were asked about their symptoms and the impact of SAR on their lives. It should 
be noted that there were no details on how patients were sampled and it is unclear whether or not 
patients across the whole of the severity spectrum are represented. The results are shown in Table 3.
The same survey66 found that over half of those patients taking medication felt that their symptoms were 
not fully controlled, and that one in four patients had tried more than five different oral antihistamines.
Another UK report67 found that students who have AR symptoms are 40% more likely to drop a grade in 
their General Certificate of Secondary Education (GCSE) examinations, with the figure rising to 70% if they 
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were taking antihistamines. Onset of hay fever peaks in adolescence and GCSE examinations run from 
mid-May to the end of June, coinciding with the height of the grass pollen season.
For this report, a patient representative, Lynne Deason (LD), shared her experiences of living with hay fever 
and other allergies, and receiving treatment with SCIT at Birmingham Heartlands Hospital, Birmingham, 
UK. These are summarised below.
Patient experience
Lynne Deason developed allergies to different moulds and dog dander in her mid-teens. In her mid-20s 
she also suffered increasingly with SAR (mainly birch) and allergic reactions to fruit (oral allergy syndrome). 
In addition, she regularly experienced episodes of anaphylaxis, for which she sought help on several 
occasions from the accident and emergency (A&E) department; the allergen responsible for these episodes 
has to date not been identified. No treatment was initiated as a result of visits to the A&E department. 
As a teenager, LD’s parents had paid for her to have private allergy testing and standard medication 
was recommended (antihistamines and nasal sprays). LD ‘managed’ her anaphylaxis by quickly taking 
antihistamines whenever signs appeared that an episode was imminent, such as an itching sensation in 
her ears. More recently, conventional medication provided reasonable relief for SAR, although this still 
impacted negatively on daily activities, particularly work. Symptoms from both SAR and the oral allergies 
included puffy eyes, not being able to see very clearly, changes in voice quality, looking like ‘someone had 
punched me in the face’, feeling ‘groggy’ and an itchy throat; these symptoms made giving presentations 
at work difficult.
After seeing a nurse at her local GP practice and describing her history of oral allergies, SAR and 
regular anaphylaxis, LD was referred to hospital and was eventually placed under consultant care for 
treatment. The nurse expressed disbelief that there had been no earlier referral. Treatment with SCIT 
was time intensive as it initially involved weekly 2-hour appointments, which then decreased to monthly 
appointments for approximately 3 years. It also involved a travelling distance of around 25 miles to the 
hospital. Undergoing treatment was facilitated by having an employer willing to allow time off work. LD 
did not experience the treatment itself as being particularly unpleasant and felt that professional members 
of staff who provided good explanations of the procedure were a positive aspect of treatment. LD stated 
that treatment would be more difficult to incorporate into daily life for parents, as it would involve 
additional childcare. Additional positive aspects of undergoing SCIT included meeting people with similar 
experiences at hospital, sharing tips on managing symptoms, feeling less isolated and feeling that people 
were being empathic. LD also started carrying an EpiPen® (Mylan Speciality L.P., Basking Ridge, NJ, USA) for 
the first time.
Subcutaneous IT significantly improved LD’s SAR symptoms, which became both milder and less frequent. 
Four years after completing the treatment, significant improvement is still noticeable, with only mild 
irritation experienced in response to particularly high pollen counts. Medication use also decreased and 
TABLE 3 Impact of AR symptoms (Allergy UK survey66)
Impact Percentage
AR symptoms for > 2 months/year 92
AR symptoms for > 10 years 73
AR symptoms affect school/work moderately to severely 49
AR symptoms affect how social/leisure time is spent 80
AR symptoms disrupt sleep 85
Disrupted sleep affects school/work 56
Disrupted sleep affects planned social activities 33
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LD now rarely takes antihistamines. No occurrences of anaphylaxis have arisen since treatment and LD no 
longer carries an EpiPen. The lessening of symptoms also had a positive knock-on effect on general QoL.
Side effects of the treatment included tiredness (particularly after updosing) and some fairly mild swelling 
and redness of the arm immediately afterwards. LD noted that other patients had more severe swellings. 
The treatment has had no effect on the oral allergies. A single allergen was used in the treatment 
(birch), and LD now knows she is also allergic to almond and hazel. LD felt that there was generally little 
awareness of severe allergy and treatments with SCIT or SLIT and little empathy for affected individuals. 
Although, in her own estimation, LD was not among the worst affected, she felt that other people might 
benefit even more from SCIT or SLIT, for example individuals who are confined indoors during peak 
allergen times.
Existing evidence for allergen immunotherapy
Subcutaneous immunotherapy
To date, the most comprehensive systematic review of SCIT for SAR is a Cochrane review,68 with searches 
up to February 2006. The review identified 51 RCTs including a total of 2871 participants (1645 active, 
1226 placebo), with only one study69 including children of < 12 years. There was significant heterogeneity 
in treatment durations (3 days to 3 years) but, on average, participants received 18 injections each. Pooled 
standardised mean differences (SMDs) from meta-analyses found statistically significant results in favour 
of active treatment across all outcomes [symptoms scores, rescue medication use, combined symptom and 
medication scores (SMS) and QoL]. AE reporting was highly variable, making comparisons difficult. Local 
reactions at site of injection were the most commonly reported event, with the majority resolving without 
treatment. Systemic reactions occurred in over half of studies, with more severe reactions occurring less 
frequently than milder reactions. No deaths were reported.
However, evidence from surveillance studies in the USA suggests that fatal reactions still occur following 
SCIT in clinical practice.70 Between 1973 and 2007, 82 direct or indirect reports of fatal reactions were 
identified, although the frequency appears to be decreasing – only six of these deaths occurred between 
2001 and 2007, presumably due to improved vaccines, protocols and safety measures. No fatalities were 
identified between 2008 and 2010.
A 2008 systematic review71 of the paediatric literature included only four randomised, placebo-controlled 
studies72–75 of SCIT for seasonal allergens, all of which were conducted between 1966 and 1986. Adequacy 
of blinding could be ascertained in only one study,72 although this may be due to less transparent reporting 
practices in earlier studies. Overall, only one study72 reported positive effects of SCIT on symptoms, but 
medication use was not monitored in this study. None of the other studies73–75 reported benefits of SCIT on 
either SSs, or, when reported, medication scores (MSs). The authors concluded that there was insufficient 
good-quality evidence to draw conclusions regarding the effectiveness of SCIT in this patient group.
Sublingual immunotherapy
A number of systematic reviews evaluating the effectiveness of SLIT for SAR have been published,71,76–82 
the largest and most recent of which was the Cochrane review of SLIT for AR.83 Although this review 
included studies in both SAR and PAR, subgroup analysis was performed for both types of allergen. 
The review identified 39 studies24,26,35,84–119 conducted in patients with SAR, comprising a total of 4084 
participants (2081 active, 2003 placebo). Meta-analysis of both symptom and MS data suggested a 
moderate effect size in favour of SLIT, with similar results reported for MS outcomes. Subgroup analyses 
were conducted in adults or children; short-, medium- and long-term duration; low, medium and high 
levels of MAC; and type of allergen. All of the subgroup analyses included studies of both SAR and PAR, 
but all reported pooled effect sizes favouring the active treatment. The majority of these findings were 
statistically significant, although a few were not: MSs in children, SSs in studies using IT with < 5 µg MAC, 
MSs in studies with > 20 µg MAC and MSs in ragweed pollen. QoL was reported in only two studies,102,112 
both involving seasonal allergens, and combined SMD was in favour of SLIT. As for SCIT, AEs for SLIT are 
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reported quite variably between studies. The majority of systemic reactions were of mild to moderate 
severity; none required administration of adrenaline and no fatalities were reported. Discontinuations due 
to AE were rare and more often associated with unpleasant local side effects than with systemic reactions.
One recent meta-analysis77 has been conducted for studies of SLIT for SAR only, specifically grass pollen AR. 
This meta-analysis included 19 RCTs (compared with 23 studies in grass allergen in the Cochrane review) 
and produced almost identical results. Subgroup analysis by age showed that effect sizes were greater in 
adult populations than in children, with neither symptom nor MSs reaching statistical significance in the 
five included paediatric studies.
Several reviews of the paediatric literature have been published.71,78–80,82 Although all included both SAR 
and PAR, results are often separable for the two types of allergen. The most recent, and inclusive, of these 
(Larenas-Linneman 2009)78 included 1084–89,120–122 double-blind studies of SLIT in children with SAR (as 
well as three with SAA), which reported clinical outcomes. All of these studies were identified in the 2010 
Cochrane review.83 Interestingly, earlier studies deemed to be of high quality84,89 (total n = 192) failed to 
report statistically significant effects of SLIT on rhinitis outcomes, whereas studies deemed to be of lower 
quality86,88,121,122 (total n = 158) favoured SLIT. In contrast, three26,85,90 of the four studies conducted since 
2006 (total n = 560)26,84,85,90 reported significant improvements in both SSs and MSs with active treatment. 
It is not clear whether this change was due to improvement in SLIT treatments over time or to the larger 
study sizes. One recent study87 (n = 168) did not find an advantage for SLIT treatment in grass allergy. 
However, this study87 was conducted in a primary care setting, inclusion criteria did not specify objective 
diagnosis of AR, and dropout rates were high (44%).
Sublingual immunotherapy has a good safety profile. One report, based on 41 studies, identified 1047 
AEs in an estimated 386,149 doses, equivalent to 2.7 AEs per 1000 doses.123 Based on 49 studies, 
approximately 12% (529/4378) patients experienced at least one AE, although most of these were local 
reactions in the oral cavity or gastrointestinal symptoms, also considered a local reaction in SLIT.124 Systemic 
reactions occurred in 169 of 314,959 doses, or 0.54 per 1000 doses. Only 14 treatment-related serious 
adverse events (SAEs) were recorded in 5377 treatment-years, mostly involving asthma or gastrointestinal 
symptoms, equivalent to one SAE per 384 treatment-years. A 2010 Cochrane review83 reported no 
occurrences of anaphylaxis in six trials reporting this outcome (n = 579) and no reports of adrenaline use 
for systemic reactions following active treatment. Again, the vast majority of AEs were of mild to moderate 
severity, and gastrointestinal symptoms were the only systemic reactions reported more frequently in 
patients receiving active treatment than in placebo (88 events in 630 patients vs 10 events in 561 patients, 
respectively). Discontinuations due to AEs were more often associated with unpleasant local side effects 
than with systemic reactions, and were reported in 5% of active patients (41/824) in 15 studies.
Outcome measures in randomised controlled trials of specific 
(allergen) immunotherapy
Outcome measures used in trials of SIT are highly variable. SSs are the most widely used, and often the 
only outcome measure used in older trials. Although no individual scoring system has been thoroughly 
validated for clinical trials,64 the vast majority of RCTs conducted in the last 20 years utilise a four-point 
scoring scale for describing symptom severity, ranging from a score of ‘0’ to indicate absence of symptoms 
to a score of ‘3’ representing severe symptoms that interfere with activities of daily living. Despite this 
common system of measuring symptom severity, there is significant heterogeneity in the actual number of 
symptoms that are scored in any given trial, meaning that maximum possible scores vary between studies. 
Indeed, the six major European manufacturers (ALK-Abelló, Allergopharma, Allergy Therapeutics, HAL 
Allergy, Leiden, the Netherlands, Laboratorios LETI/Novartis, Barcelona, Spain, and Stallergènes) all use 
different systems.125 There are also differences in the way that SS data are reported, for example as mean 
daily score, cumulative score over 1 week or an entire season, differences from baseline, or area under 
the curve (AUC). In addition, some studies record outcomes over an entire pollen season (EPS), whereas 
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others use values for a 1- or 2-week period around the peak recorded pollen value. These differences make 
comparisons between studies very difficult.
One limitation of the use of SSs as the sole outcome measure is that most trials allow the use of 
rescue medication on an as-needed basis, under varying conditions of stringency. As placebo patients 
might be expected to use more rescue medication, the use of SSs alone may underestimate the effects 
of treatment.125 Reporting of MSs, a measure of rescue medication use, is intended to address this 
problem. However, although a 2008 report126 from the World Allergy Organization (WAO) taskforce 
on standardisation of clinical trials suggested a three-point scoring system for anti-allergy medications, 
scoring of this outcome remains somewhat arbitrary and highly variable between trials. As with SSs, 
methods for reporting MSs also vary. In addition, the use of separate SSs and MSs does not account for 
the interdependence of these two measures.125
Thus, the WAO taskforce also recommended that weighted SSs and MSs be combined into a SMS, and 
that this combined score should be used as the primary outcome in clinical trials.126 Indeed, an increasing 
number of recent trials have reported SMSs (15 out of 28 trials in this report). Further, the ‘Allergy-Control-
SCORE©’, a combined symptom and MS, has recently been formally evaluated, and was found to be 
a valid and reliable tool for assessing and monitoring allergy severity.127 However, there is currently no 
standardised method for calculating SMSs, and the methods used are frequently not reported. As with SSs 
and MSs, the units of statistical analysis of SMS differ between studies, and are often not stated explicitly. 
Again, the six major European manufacturers of IT products use different protocols and scoring systems 
for usage of rescue medication, and different methods of weight symptom and MSs into a combined 
measure.125 Thus, despite the increasing convergence in outcome measurements used in clinical trials, 
between-trial comparison is still problematic.
Other outcomes that have been recommended by the WAO126 and European Medicines Agency (EMA)64 
include responder analysis – the percentage of patients with a combined SMS below a prespecified level, 
visual analogue scales (VASs) for long-term treatment outcomes, number of ‘well-days’ – i.e. SSs below 
a predefined threshold and no requirement for rescue medication, and patient-reported outcomes, such 
as overall impact on health-related QoL, which may provide more useful information on the impact of 
treatment than measuring organ-specific SSs. However, data on these outcomes are available in only a 
small proportion of the SIT literature.
It has been argued in an ARIA-GA(2)LEN statement128 that RCTs in IT cannot be interpreted in the same 
way as RCTs in drug treatment. One of the factors that has been criticised in SIT RCTs is the relatively low 
level of efficacy compared with medications, which may prevent regulatory bodies from recommending 
SIT. One of the reasons for this apparently lower efficacy may be that exposure to allergens varies over 
the pollen season, yet the averaged score is presented for the whole season. It is for this reason that the 
concept of ‘worst-days’,129 i.e. days with severe symptoms as an outcome measure, has been introduced, 
as it may better reflect the impact of IT compared with placebo on days when pollen counts are high and 
symptoms are severe.
The majority of studies reporting on QoL have used the validated disease-specific Rhinoconjunctivitis 
Quality of Life Questionnaire (RQLQ),130–132 although there are a number of different versions of this 
instrument. A few studies have used more global measures, such as the Short Form questionnaire-36 
items (SF-36). Generic tools are broad and are likely to be less sensitive to measuring changes in AR, where 
disease-specific instruments may be more appropriate.125 QoL is a difficult parameter to be measured in 
trials of IT: patients do not have impaired QoL at inclusion, but this will deteriorate during the course of 
the trial. The difference in QoL between IT and placebo groups will depend on the pollen exposure on the 
day(s) that QoL is measured. If pollen exposure is low then QoL in the placebo group may appear relatively 
high compared with that of the IT group.128
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Even within a single trial, results may be difficult to interpret clinically. So, for example, a difference in 
reduction in symptoms scores may be statistically significant but not necessarily clinically significant. 
Malling has proposed ranges of improvement in SSs or MSs to discriminate between effective and non-
effective therapy (no effect, improvement of < 30%; little effect, improvement of 30–44%; moderate effect, 
improvement of 45–59%; strong effect, improvement of ≥ 60%).133 This outcome is not at present reported 
consistently. In contrast, an expert group134 has estimated that an improvement of 20% is clinically relevant 
given that SIT trials may show relatively lower effectiveness (than drug trials) given the reasons outlined 
above. There is no consensus on a minimum meaningful difference.
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Chapter 2 Aim of the review
T he aim of this systematic review and cost-effectiveness analysis (CEA) was to:
 z update the Cochrane review68 on the clinical effectiveness of SCIT based on double-blind RCTs of SCIT 
compared with placebo
 z update the Cochrane review83 on the clinical effectiveness of SLIT based on double-blind RCTs of SLIT 
compared with placebo
 z more specifically, to update the meta-analyses (including those for prespecified subgroups 
including adults and children) undertaken in the Cochrane reviews in order to provide up-to-date 
summary estimates
 z evaluate the clinical effectiveness of SCIT compared with SLIT using both direct and 
indirect comparisons
 z undertake a systematic review and critical appraisal of existing economic evaluations (EEs) of SCIT or 
SLIT compared with placebo or SCIT compared with SLIT
 z develop a de novo cost-effectiveness model, based where possible on clinical data from this report
 z estimate cost-effectiveness separately for SCIT compared with placebo, SLIT compared with placebo, 
SCIT compared with SLIT, and for adults and children.
This report did not aim to address questions relating to the optimum dosing schedules (e.g. rush or cluster 
compared with conventional dosing) or optimum length of treatment of SCIT or SLIT. It also did not 
address other methods of administration, such as epicutaneous or intralymphatic IT.
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Chapter 3 Clinical effectiveness
Methods
The original protocol can be found in Appendix 1.
Searches
Randomised controlled trials of SCIT compared with placebo and SLIT compared with placebo were 
sought, as were any existing RCTs of head-to-head comparisons (SCIT vs SLIT). A sensitive search strategy, 
based broadly on those employed in the Cochrane reviews, but with no restriction on routes of IT 
administration or dates, was used in order to cover both the update and the search for head-to-head 
trials. There were no language restrictions. Appropriate filters for study design were used where possible. 
Searches were carried out during April 2011. See Appendix 2 for full details of the search strategies.
The following resources were searched:
 z bibliographic databases: MEDLINE (Ovid) 1948–April week 2 2011; EMBASE (Ovid) 1980–April 
week 15 2011; The Cochrane Library [Cochrane Central Register of Controlled Trials (CENTRAL)] 2011 
Issue 1; Cumulative Index to Nursing and Allied Health Literature (CINAHL) (EBSCOhost) 1982–2011; 
Science Citation Index (Web of Knowledge) 1900–2011. Searches were based on index and text words 
that encompassed the population and intervention (e.g. ‘seasonal allergic rhinitis’, ‘immunotherapy’)
 z ClinicalTrials.gov, UK Clinical Research Network Portfolio Database and metaRegister of Current 
Controlled Trials (mRCT) (http://controlled-trials.com) were searched for ongoing studies, as well as the 
lists of ongoing trials identified in the Cochrane reviews
 z references lists of relevant reviews and included studies
 z consultation with clinical advisors
 z selected websites.
Study selection
The following inclusion and exclusion criteria were used (Table 4). These are broadly consistent with those 
listed in the Cochrane reviews.
The brief specified adults and children (examined separately) with severe hay fever, which does not 
respond to conventional treatment. We anticipated that not all trials would provide this information, or 
that they would use different classifications for ‘severe’ or ‘not responding to conventional treatment’. We 
therefore did not restrict inclusion by severity. We did restrict inclusion to treatment-naive patients; where 
this was not explicitly stated we noted this but included the study.
Titles and abstracts of retrieved studies underwent an initial screen by one reviewer, and studies that were 
clearly not relevant were excluded. The remaining studies were independently screened for inclusion by 
two reviewers. Where it was unclear whether or not studies met the inclusion criteria on the basis of title 
and abstract, full copies were obtained for assessment. Any discrepancy between reviewers was resolved 
through discussion or referral to a third reviewer. Reference Manager software, version 11 (Thompson 
ResearchSoft, San Francisco, CA, USA) was used to track and record study selection decisions and reasons 
for exclusion. Foreign-language papers were translated, where necessary, by the authors or colleagues.
Assessment of trial validity
Cochrane collaboration guidelines were followed for risk of bias assessment.135 The following criteria 
were considered: adequate sequence generation, concealment of allocation, blinding of patients and 
personnel, completeness of outcome data, selective reporting of outcomes and IT treatment history. This 
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last point is relevant as it is known that SIT can have long-lasting effects. Blinding of outcome assessors 
was not assessed, as outcomes were largely patient reported. Each item was classified as having a low risk 
of bias, high risk of bias or unclear risk of bias. Assessment of trial validity was at study level rather than 
outcome level.
Data extraction
Data extraction, including quality assessment, was conducted by one reviewer and checked by another 
using a standard, piloted, extraction form. There were no discrepancies that could not be resolved through 
discussion. Data were extracted on main study characteristics, main patient characteristics, study quality 
and all included outcomes. Data previously reported in the Cochrane reviews and included in this report 
were not checked.
Analysis
Where possible, we updated the meta-analyses, including subgroup analyses, from the existing Cochrane 
reviews. Meta-analysis assumes similarity between trials, and this was explored for both population and 
study characteristics in the newer studies identified. Studies included in meta-analyses in the Cochrane 
reviews were assumed to satisfy the similarity criteria.
Meta-analysis was limited to the following outcomes that were consistently reported across a high 
proportion of trials, and where data suitable for use in meta-analysis were provided or calculable: SSs, 
MSs, combined SMS and QoL scores. Where not reported, standard deviations (SDs) were calculated from 
other appropriate measures of variance (e.g. standard error, 95% CIs) according to Cochrane guidelines.136 
Results not suitable for meta-analyses were tabulated and described.
TABLE 4 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
Study design
Double-blind RCTs of SCIT compared with placebo, or SLIT 
compared with placebo or SCIT compared with SLIT
Single-blind or open-label RCTs. Any other study design
Population
Treatment-naive adults or children with a confirmed diagnosis 
and symptoms of SAR (hay fever). Patients with comorbidities 
such as (seasonal allergic) asthma will be included. All or 
majority (≥ 90%) of included patients (adults or children) with 
SAR
Adults or children with a different allergic disease (e.g. 
food allergy, perennial rhinitis). Population (or > 10%) 
with SAA only
Intervention
Allergen-specific subcutaneous (injection) or SLIT in any setting. 
Any allergen responsible for inducing SAR (e.g. grass, tree). No 
restrictions regarding a particular dose or dosing regimen
Any other route of administration [e.g. oral (swallowed 
rather than sublingual), nasal, epicutaneous, 
intralymphatic]; specific allergen IT with other allergens 
(e.g. house dust mite, cat dander). Non-standard 
therapy protocols or products, e.g. Rinkel method, 
peptide IT
Comparator
Placebo [with or without conventional (rescue) medication], SCIT 
or SLIT
Any other route of administration (e.g. oral, nasal). 
Studies comparing different doses or schedules of IT 
that did not include a placebo arm
Outcomes
At least one of the following: symptom severity, medication 
use, combined SMSs, frequency of exacerbations, QoL, AEs, the 
prevention of new asthma cases
RCTs not reporting any of the listed outcomes (e.g. 
laboratory parameters, such as IgE levels only). Studies 
evaluating clinical effectiveness without natural 
exposure (e.g. allergen chamber)
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All meta-analyses were undertaken in RevMan software version 5.1 (The Cochrane Collaboration, The 
Nordic Cochrane Centre, Copenhagen, Denmark) using a random-effects model. SMDs were presented, as 
there was little overlap between outcome measures across trials. So, for example, although AR symptoms 
were frequently measured, the number of symptoms measured was different across trials, as was the 
maximum score that could be achieved. As a rule of thumb, SMDs (effect sizes) can be described as small 
(< 0.4), moderate (0.4–0.7) or large (> 0.7).137
In studies with more than one active intervention arm receiving different dosage IT, data for the group 
receiving the highest dose were used in meta-analysis, consistent with the Cochrane reviews. Where data 
were reported at different time points, data for the longest treatment duration were used. Outcome values 
were sometimes reported both for peak pollen season (PPS) and averaged over an EPS. Consistent with the 
Cochrane review, the mean values for the EPS were used when available.
Indirect comparison meta-analysis (ICMA) and indirect comparison meta-regression (ICMR) were used 
to compare the efficacy of SCIT and SLIT for each of the four outcomes (SSs, MSs, combined SMSs 
and QoL). Similarity of trial and population characteristics within (1) SCIT compared with placebo and 
(2) SLIT compared with placebo trials was assessed qualitatively and statistically (to test the assumption 
of homogeneity138); similarity between population and trial characteristics between SCIT compared with 
placebo and SLIT compared with placebo trials was also assessed (to test the assumption of similarity138). 
Possible sources of heterogeneity were explored and adjusted for using meta-regression, with a number 
of trial, population and reporting characteristics being used as covariates; specifically, these comprised 
participant age (adult/child), treatment duration, MAC of IT product and type of allergen (covariates as 
prespecified in subgroup analyses in the Cochrane review). We also conducted a post hoc exploration 
using year of publication and number of separate symptoms for which outcome data had been obtained 
as covariates. Improvement in model fit was expressed using the deviance information criterion (DIC), a 
compound measure of model fit and complexity, and extent of residual variation was monitored. As scores 
were measured on different scales, standardised score differences were calculated, except for RQLQ scores. 
Analyses were conducted in WinBUGS 1.4 (MRC Biostatistics Unit, Cambridge, UK).139 Full methodological 
details for the indirect comparison can be found in Appendix 3.
Results
Quantity of evidence (subcutaneous immunotherapy versus placebo studies)
Searches identified 84 publications of DBPC RCTs of SCIT (see PRISMA flow diagram in Appendix 4). Of 
these, 48 were included in the relevant Cochrane review.68 Of the remaining 36 publications, 10 pre-dated 
the Cochrane searches but were not included in that review, and a further four had been excluded by the 
Cochrane review, despite appearing to meet the inclusion criteria. Details of excluded studies are presented 
in Appendix 5. The remaining 22 publications,30,140–160 reporting on 18 distinct RCTs, post-dated the 
final search date listed in the Cochrane review (February 2006). Two151,156 of these publications provided 
additional data relating to the trial reported in Frew et al. in 2006,161 which was included in the Cochrane 
review. Thus, 20 publications30,140–150,152–155,157–160 relating to 17 new RCTs were identified. As the purpose 
of this report was to update, rather than repeat, the Cochrane review, results are presented only for those 
17 trials initially published from 2006 onwards. However, all relevant studies have been included in the 
meta-analyses.
Main study characteristics and risk of bias (subcutaneous immunotherapy 
versus placebo studies)
The main study and population characteristics, and assessment of risk of bias are detailed for each of the 
17 newly identified RCTs30,142–146,148–150,152–155,157–160 in Appendix 5. All studies were DBPC RCTs. Approximately 
half of the studies (nine trials30,142–144,146,148,152,158,160) involved fewer than 65 participants, but the remaining 
trials included at least 100 patients, and the largest145 represented over 1000 participants. Skin prick 
tests were performed in all patients to demonstrate specific sensitivity. Allergy symptoms were described 
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as moderate to severe in 2 out of 17 trials,145,146 whereas level of severity was not stated in 15 out of 
17.30,142–144,148–150,152–155,157–160 Ten studies30,142,143,148–150,152,154,155,160 stated that some patients also had asthma 
symptoms. Patients with previous IT were excluded in five studies,30,142,152,154,160 four trials143,145,157,159 
allowed patients who had not received SIT in the last 3–5 years or ‘recently’, and previous treatment 
status was unclear in eight trials.144,146,148–150,153,155,157 Outcomes included SSs, MSs, combined symptom and 
medication scores, QoL and AEs (note: only outcomes consistent with the inclusion criteria for this report 
have been listed). Approximately half of the studies (930,145,148,149,152,153,155,157,160 out of 1713,30,142–146,148–150,152–
155,157,159,160) reported a combined score, either alone or in addition to individual SSs and MSs. Although 
SSs were consistently reported across trials, the number and types of symptom assessed varied widely (see 
Appendix 7 – SSs across studies). Similarly, there were differences in how SMSs were calculated.
Tree and mixed-grass allergens were the most commonly investigated (eight30,142,148,149,154,155,158,160 and 
three trials,145,150,157 respectively), followed by two trials each of timothy grass (P. pratense)146,153 and 
ragweed,144,159 one trial in Alternaria142 and one in Russian thistle143 (Salsola kali L.). The main study 
characteristics are summarised in Table 5.
Similarity between trials was explored for a range of study and population characteristics. Trial duration 
and type and amount of allergen used varied between trials; however, this was explored as a source of 
heterogeneity in subgroup analyses. Where reported, inclusion criteria were very similar across trials, with 
the majority stipulating a minimum of 2 years’ clinical history of moderate to severe SAR, incompletely 
controlled by standard medication, and no prior experience of SIT. Rates of asthma across trials were 
largely consistent, comprising between one-quarter and one-third of participants. Prevalence of asthma 
was higher in one paediatric trial122 (38 out of 50 patients). All studies excluded patients with severe or 
perennial asthma.
Results of the risk of bias assessment are summarised in Table 6. Full details are given in Appendix 5.
The risk of bias was low in three or more areas of potential bias for 1230,142–146,148,152,154,158,160 out of 17 
studies. A lack of detail in the published reports, most notably for those reported in abstract form only, 
meant that the risk of bias was unclear in many cases. Lack of detail related most often to allocation 
concealment, sequence generation and whether or not patients were treatment naive. In all studies, apart 
from those reported as abstracts, there were details on blinding. Study authors were not contacted and 
an ‘unclear’ rating may be due to a lack of reporting rather than a reflection of poor trial quality. There 
were only two instances for which a high risk of bias was identified, in the area of data completeness. 
Only one114 of these studies contributed to any meta-analyses (QoL data); owing to its small sample size 
(n = 25) it is unlikely to have a large influence on overall results. It should be noted that a certain degree of 
subjectivity remains in assigning a rating of low/high/unclear risk of bias.
Effectiveness of subcutaneous immunotherapy compared with placebo
Of the 17 newly identified RCTs, only five142–144,152,154 reported data in a form suitable for meta-analyses. Of 
these, three studies provided new SS and MS data,142,152,154 and two provided QoL data143,144 (Table 7).
Symptom scores
Of the 15 studies91,162–174 included in the Cochrane review meta-analysis, one162 was excluded 
from this study as patients were not treatment naive. Searches for this report identified 10 new 
studies142–144,148,152,154,155,157,158,160 reporting this outcome, of which only three142,152,154 provided data suitable 
for inclusion in meta-analysis. Thus, a total of 17 studies, comprising 659 active and 525 placebo patients, 
were included (Figure 1).
The combined SMD was –0.65 (95% CI –0.85 to –0.45; p < 0.00001) favouring SCIT, with evidence of 
moderate heterogeneity, similar to the findings of the Cochrane review68 (SMD –0.73, 95% CI –0.97 to 
–0.50; p < 0.00001, based on 15 trials).
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TABLE 6 Risk of bias assessment: newly identified SCIT studies
Study
Sequence 
generation
Allocation 
concealment Blinding
Data 
completeness
Selective 
reporting
Patients 
treatment 
naive
Casale 2006159 ? ? + + + ?
Ceuppens 2009160 ? ? + + + +
Chakraborty 200630 ? ? + + + +
Charpin 2007142 + ? + ? + +
Colas 2006143 ? ? + + + ?
Creticos 2006144 + + + – ? ?
DuBuske 2011145 + + + + + +
Francis 2008146 ? ? + + + ?
Hoiby 2010148 + ? + ? + ?
Kettner 2007149 (A) ? ? ? ? ? ?
Klimek 2010150 (A) ? ? ? ? + ?
Kuna 2011152 + + + ? + +
Ljorring 2009153 (A) ? ? ? ? + ?
Pauli 2008154 ? ? + + + +
Pfaar 2010155 ? ? + – + ?
Sahin 2011157 (A) ? ? ? ? + ?
Ventura 2009158 + ? + + + ?
+, low risk; –, high risk; ?, unclear; (A), abstract.
Subgroup analyses were conducted by age, study duration, MAC and type of allergen. All favoured the 
active treatment and were statistically significant. Results of subgroup analyses are shown in Table 8. 
Forest plots of all subgroup analyses are shown in Appendix 7. Note that the Cochrane review of SCIT 
did not include subgroup analyses, but that studies identified in that review are included in subgroup 
analyses here.
Sixteen142,154,161,163–174 of the 17 studies were conducted in an adult population and the results did not 
differ from those of the entire sample. Only one study152 involved a paediatric population. In this study,152 
rhinitis, conjunctivitis and asthma SSs were all significantly lower following 3 years of active treatment than 
with placebo.
Analysis by treatment duration found that studies of ≥ 6 months in duration resulted in similar effect sizes 
to the sample as a whole. All three142,152,154 of the more recent trials lasted for > 12 months. Shorter studies 
gave a larger effect size; this was associated with a high degree of between-study heterogeneity.
In line with current guidelines, all three of the newer studies142,152,154 used vaccines with between 
5 and 20 µg MAC. Subgroup analyses (see Appendix 7, Figures 31–95) suggest that effectiveness 
increases with increasing MAC; this finding should be interpreted cautiously, as it is not based on a 
randomised comparison.
Immunotherapy with grass allergens made up the largest subgroup (47% total sample). Combined effect 
size was similar to that of the entire sample, with a moderate degree of heterogeneity. Similar effect sizes 
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TABLE 7 Outcome measures in recent SCIT RCTs
Study ID Not in meta-analyses In meta-analyses
Casale 2006159 AEs None
Ceuppens 2009160 SSs, MSs, SMSs, AEs None
Chakraborty 200630 SMSs, global measure, spirometry, AEs None
Charpin 2007142 Days with asthma, AEs, QoL SSs, MSs
Colas 2006143 SSs, MSs, global assessment, AEs QoL
Creticos 2006144 SSs, AEs QoL
DuBuske 2011145 SMSs, well-days, bad-days, well patients, AEs None
Francis 2008146 Overall clinical assessment, AEs None
Hoiby 2010148 SMSs, SSs, MSs, AEs, QoL None
Kettner 2007149 (A) SMSs, AEs None
Klimek 2010150 (A) AEs None
Kuna 2011152 SMSs, AEs, QoL SSs, MSs
Ljorring 2009153 (A) SMSs None
Pauli 2008154 AEs SSs, MSs
Pfaar 2010155 SSs, MSs, SMSs, responder analysis, AEs None
Sahin 2011157 (A) SMSs, symptom-free days, global evaluation, AEs None
Ventura 2009158 SSs None
(A), abstract.
Study or subgroup
Balda 1998163
Bodtger 2002169
Bousquet 1990170
Brewczynski 1999171
Charpin 2007142
Corrigan 2005164
Drachenberg 200191
Ferrer 2005165
Frew 2006161
Jutel 2005166 
Kuna 2011152
Ortolani 1984174
Ortolani 1994167
Pauli 2008154
Varney 1991172
Walker 2001173
Zenner 1997168
Total (95% CI)
Heterogeneity: τ2 = 0.09; χ2 = 36.98, df = 16 (p = 0.002); I2 = 57%
Test for overall effect: z = 6.36 (p < 0.00001)
Mean
6.56
2.2
63.6
59.5
3.3
166.5
0.75
0.44
3.31
3.93
85
2.01
0.61
0
1531
-1212
82.24
SD
10.43
1
32.5
32.6
2.42
114.93
0.44
0.32
2.42
3.28
140
0.57
0.12
6.8
1875
2632
64.38
Total
49
16
20
10
14
77
74
22
187
29
25
8
18
33
19
17
41
659
Mean
9.07
3.3
108.6
122.4
5.06
218
0.95
0.8
4.59
5.82
140
5.86
2.3
3.41
2230
-115
115.98
SD
8.19
1.4
33.2
85.13
2.66
135.39
0.41
0.54
2.93
3.44
240
1.63
0.98
7.1
856
1159
83.67
Total
56
17
18
8
14
77
50
20
89
28
19
7
17
36
16
13
40
525
Weight
8.3%
4.7%
4.8%
3.0%
4.4%
9.2%
8.6%
5.5%
10.0%
6.5%
5.8%
1.3%
3.6%
7.1%
5.1%
4.6%
7.6%
100.0%
IV, random, 95% CI
-0.27 (-0.65 to 0.12)
-0.88 (-1.60 to -0.16)
-1.34 (-2.05 to -0.63)
-0.98 (-1.97 to 0.02)
-0.67 (-1.44 to 0.09)
-0.41 (-0.73 to -0.09)
-0.46 (-0.83 to -0.10)
-0.81 (-1.44 to -0.17)
-0.49 (-0.75 to -0.24)
-0.55 (-1.08 to -0.02)
-0.29 (-0.88 to 0.31)
-3.06 (-4.69 to -1.43)
-2.40 (-3.29 to -1.51)
-0.48 (-0.96 to -0.00)
-0.46 (-1.13 to 0.22)
-0.50 (-1.24 to 0.23)
-0.45 (-0.89 to -0.01)
-0.65 (-0.85 to -0.45)
SCIT Placebo Standard mean difference Standard mean difference
IV, random, 95% CI
-4 -2 0 2 4
Favours SCIT Favours placebo
FIGURE 1 Subcutaneous immunotherapy vs placebo: SSs.
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were found for tree pollen allergy. Only three studies involved Parietaria pollen.161,165,167 Combined effect 
size was quite large, but was associated with wide CIs and a high degree of heterogeneity. None of the 
studies conducted in ragweed that were identified in the Cochrane review were suitable for meta-analysis, 
and no new studies were found. Only one study152 was conducted in Alternaria.
Details of SS data from the seven studies not included in the meta-analysis143,144,148,155,157,158,160 are presented 
in Table 9. All favoured the active treatment over placebo.
Medication scores
Medication scores suitable for meta-analysis were available in 16 studies (13 from the Cochrane 
review,91,161,163–166,169–173,175,176 three142,152,154 more recent), which together included 621 active and 483 
placebo patients. The combined SMD was –0.55 (95% CI –0.75 to –0.34; p < 0.00001); this was very 
similar to that reported in the Cochrane review (SMD –0.57, 95% CI –0.82 to –0.33; p < 0.00001). 
Heterogeneity was reduced slightly, but remained statistically significant (Figure 2).
Subgroup analyses were conducted by age, study duration, MAC and type of allergen. All favoured the 
active treatment and, with the exception of studies using a < 5 µg MAC, were statistically significant. 
However, this non-significant result was based on only two trials163,165 totalling 147 patients. Results of the 
subgroup analyses are shown in Table 10.
Fifteen91,126,142,154,161,163–166,169–173,176 of the 16 trials91,126,142,152,154,161,163–166,169–173,176 reporting MSs were 
conducted in adults, and the results did not differ greatly from the sample as a whole. Only one study152 
was conducted in children, and also reported that active treatment resulted in statistically improved MSs 
compared with placebo.
Nine126,142,152,154,164–166,171,173 of the 14 studies126,142,152,154,161,163–166,169–171,173,176 in the meta-analysis for which 
treatment duration could be determined lasted for > 12 months. All subgroups favoured active treatment 
and were statistically significant, although effect size appeared to increase with treatment duration.
TABLE 8 Subcutaneous immunotherapy vs placebo, subgroup analyses: SSs
Subgroup No. of studies Total n SMD (IV, random 95% CI)
Age
Adults 16 1140 –0.68 (–0.89 to –0.47)
Duration (months)
< 6 5 274 –1.29 (–2.10 to –0.49)
6–12 2 309 –0.54 (–0.78 to –0.29)
> 12 8 442 –0.51 (–0.70 to –0.32)
MAC
< 5 µg 3 228 –0.43 (–0.69 to –0.16)
5–20 µg 5 231 –0.54 (–0.80 to –0.27)
> 20 µg 3 341 –1.06 (–2.08 to –0.05)
Allergen
Grass 9 552 –0.64 (–0.91 to –0.37)
Parietaria 3 353 –1.15 (–2.09 to –0.21)
Tree 4 235 –0.46 (–0.72 to –0.20)
IV, inverse variance.
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TABLE 9 Subcutaneous immunotherapy SSs: studies not in meta-analysis
Study ID Results
Ceuppens 2009160 Median nasal SSs (IQR) 0.3 (0.1–0.6) vs 0.7 (0.5–1.1) in the active and placebo groups, respectively 
(p = 0.041)
Colas 2006143 Over the EPS, median (IQR) TSSs were 4.3 (3.4–4.6) and 6.4 (4.0–8.4) in the IT and placebo 
groups, respectively (p < 0.001)
Creticos 2006144 During the first ragweed season post treatment, mean rhinitis visual analogue score was 13.8 in 
the AIC-treated group, vs 35.1 in the placebo group (p = 0.01). Daily nasal SSs were also lower in 
the active group (p = 0.03)
Hoiby 2010148 Median SS was not significantly different between treatment groups (p = 0.375), despite a 
reduction of 25% in the SCIT group compared with placebo
Pfaar 2010155 Median SSs were 0.54 (IQR 0.27–0.77) for Depigoid-treated patients completing the study and 
0.61 (IQR 0.48–0.75) for placebo [median difference –0.1 (95% CI –0.20 to –0.02); p < 0.01]
Sahin 2011157 (A) Compared with placebo, the overall SS in the active group was significantly reduced by 36% 
(p = 0.006)
Ventura 2009158 Not possible to extract data from graphs. Clinical improvements were noted with active treatment 
compared with placebo
(A), abstract; AIC, Amb a 1-immunostimulatory oligodeoxyribonucleotide conjugate; IQR, interquartile range; TSS, total 
symptom score.
Study or subgroup
Balda 1998163
Bodtger 2002169
Bousquet 1990170
Brewczynski 1999171
Charpin 2007142
Corrigan 2005164
Dolz 1996175
Drachenberg 200191
Ferrer 2005165
Frew 2006161
Jutel 2005166
Kuna 2011152
Mirone 2004176
Pauli 2008154
Varney 1991172
Walker 2001173
Total (95% CI)
Heterogeneity: τ2 = 0.09; χ2 = 34.87, df = 15 (p = 0.003); I2 = 57%
Test for overall effect: z = 5.15 (p<0.00001)
Mean
9.03
9.9
38.6
17.2
3.98
68.58
6
0.54
0.35
2.93
2.73
2.3
0.7
0
2146
-1308
SD
16.03
7
37.6
10.4
4.15
96.15
6.07
0.71
0.47
2.95
4.48
5
1.4
4.6
2513
983
Total
49
17
20
10
14
77
18
74
22
187
29
25
11
33
19
16
621
Mean
13.63
14.5
66.4
36.8
5.23
101.21
48.66
0.71
0.92
4.29
3.78
21.4
2.2
1.9
14,491
101
SD
19.67
8.5
51.7
35.46
4.41
126.01
17.95
0.77
1.73
3.53
4.92
35
3.1
4.8
15,066
1899
Total
56
17
18
8
14
77
10
50
20
89
28
19
12
36
16
13
483
Weight
8.8%
5.3%
5.6%
3.4%
4.8%
9.8%
2.2%
9.2%
6.0%
10.6%
7.1%
5.9%
4.1%
7.6%
5.0%
4.6%
100.0%
IV, random, 95% CI IV, random, 95% CI
-0.25 (-0.64 to 0.13)
-0.58 (-1.26 to 0.11)
-0.61 (-1.26 to 0.05)
-0.76 (-1.73 to 0.22)
-0.28 (-1.03 to 0.46)
-0.29 (-0.61 to 0.03)
-3.56 (-4.82 to -2.29)
-0.23 (-0.59 to 0.13)
-0.45 (-1.06 to 0.16)
-0.43 (-0.69 to -0.18)
-0.22 (-0.74 to 0.30)
-0.81 (-1.43 to -0.19)
-0.59 (-1.43 to 0.25)
-0.40 (-0.88 to 0.08)
-1.17 (-1.89 to -0.44)
-0.94 (-1.71 to -0.16)
-0.55 (-0.75 to -0.34)
SCIT Placebo Standard mean difference Standard mean difference
Favours SCIT Favours placebo
-4 -2 0 2 4
FIGURE 2 Subcutaneous immunotherapy vs placebo: MSs.
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Six142,152,154,166,169,176 of the 10 included studies,142,152,154,161,163,165,166,169,173,176 including all three of the recent 
trials, utilised vaccines with between 5 and 20 µg MAC. Again, combined SMD increased with increasing 
dosage. Improvements in MS in the lowest dosage group were not significantly better than placebo, but 
this finding was based on only two studies163,165 (total n = 147).
The most commonly investigated allergen was grass pollen, representing 483 subjects across eight 
trials,91,126,164,166,170–173 and this was associated with the largest effect size, but also with a high degree of 
between-study heterogeneity. Tree pollen allergy was studied in four trials,142,154,163,169 and Parietaria (a plant 
of the nettle family) in two trials.161,165 Combined SMD favoured active treatment and were statistically 
significant in all allergen subgroups. Only one study152 was performed in Alternaria (a fungus) and thus 
meta-analysis was not possible. No studies in ragweed reported MSs suitable for meta-analysis.
Medication score results from five recent studies143,148,155,157,160 were not suitable for inclusion in meta-
analysis, and details are shown in Table 11. Two studies reported quite large reductions in MSs in actively 
treated patients (43%157 and 52%148); however, three studies143,155,160 reported no significant difference 
between the groups. These contrasting results cannot be explained by differences in sample size, treatment 
duration, MAC or type of allergen.
Symptom and medication scores
Only the eight studies91,163–168 (total n = 617) previously reported in the Cochrane review reported this 
outcome in a manner suitable for meta-analysis. Thus, the combined effect size calculated in that review 
remains valid (SMD –0.48; 95% CI –0.67 to –0.29; p < 0.00001) (Figure 3).68 However, it was possible to 
conduct a number of subgroup analyses on this sample.
TABLE 10 Subcutaneous immunotherapy vs placebo, subgroup analyses: MSs
Subgroup No. of studies Total n SMD (IV, random 95% CI)
Age
Adults 15 1059 –0.53 (–0.75 to –0.32)
Duration (months)
< 6 2 143 –0.34 (–0.68 to –0.01)
6–12 3 332 –0.46 (–0.69 to –0.23)
> 12 9 469 –0.67 (–1.06 to –0.29)
MAC
< 5 µg 2 147 –0.31 (–0.63 to 0.02)
5–20 µg 6 254 –0.45 (–0.70 to –0.20)
> 20 µg 2 305 –0.55 (–0.96 to –0.13)
Allergen
Grass 8 483 –0.77 (–1.22 to –0.33)
Parietaria 2 318 –0.43 (–0.67 to –0.20)
Tree 4 235 –0.34 (–0.60 to –0.09)
IV, inverse variance.
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TABLE 11 Subcutaneous immunotherapy MSs: studies not in meta-analysis
Study ID Results
Ceuppens 2009160 No significant differences between groups (p = 0.155)
Colas 2006143 Over the EPS, median (IQR) MSs were 0.8 (0.7–0.8) and 0.9 (0.5–1.1) in the IT and placebo groups, 
respectively (p = 0.115)
Hoiby 2010148 Median MS were significantly different between treatment groups after 18 months: median (IQR) 
2.1 (0.6–3.7) in the SCIT group and 4.4 (1.9–14.0) in the placebo group (p = 0.016), a reduction of 
51.9% in the SCIT group compared with placebo
Pfaar 2010155 Median MSs were 1.36 (IQR 0.4–2.9) for Depigoid-treated patients completing the study and 2.95 
(IQR 1.7–3.9) for placebo [median difference –1.3 (95% CI –1.87 to –0.34); p = 0.09]
Sahin 2011157 (A) Compared with placebo, the overall MS in the verum group was significantly reduced by 43% 
(p = 0.002)
(A), abstract; IQR, interquartile range.
Balda 1998163
Corrigan 2005164
Drachenberg 200191
Ferrer 2005165
Jutel 2005166
Ortolani 1994167
Pastorello 1992177
Zenner 1997168
Total (95% CI)
Heterogeneity: τ2 = 0.02; χ2 = 8.98, df = 7 (p = 0.25); I2 = 22%
201.42
235.08
0.65
0.62
6.66
12.88
1.7
153.8
97.41
172.02
0.48
0.37
6.02
3.61
0.57
63.47
49
77
74
22
29
18
10
41
320
221.26
319.21
0.83
1.27
9.59
17.81
3.15
174.45
87.54
201.67
0.47
1.03
7.23
4.91
1.54
58.95
56
77
50
20
28
17
9
40
297
17.2%
21.9%
18.7%
7.8%
10.7%
6.2%
3.4%
14.2%
100.0%
-0.21 (-0.60 to 0.17)
-0.45 (-0.77 to -0.13)
-0.38 (-0.74 to -0.01)
-0.84 (-1.47 to -0.21)
-0.44 (-0.96 to 0.09)
-1.12 (-1.84 to -0.40)
-1.22 (-2.22 to -0.22)
-0.33 (-0.77 to 0.10)
-0.48 (-0.67 to -0.29)
-4 -2 0 2 4
Study or subgroup
Test for overall effect: z = 4.90 (p < 0.00001)
Mean SD Total Mean SD Total Weight IV, random, 95% CI IV, random, 95% CI
SCIT Placebo Standard mean difference Standard mean difference
Favours SCIT Favours placebo
FIGURE 3 Subcutaneous immunotherapy vs placebo: SMSs.
All of the eight included studies91,163–169 were conducted in adults. Thus, subgroup analyses were 
conducted for study duration, MAC and type of allergen. All favoured the active treatment and were 
statistically significant. Results of subgroup analyses are shown in Table 12.
Treatment duration could not be determined for two studies.91,177 Three of the included studies164–166 
were of < 6 months’ duration. Combined effect size was similar to that in the overall sample, although 
significantly more heterogeneity was indicated in this subgroup (I2 = 59% vs 22%). A further three 
studies163,167,168 lasted over 12 months, and effect sizes were again similar. However, these studies163,167,168 
were more homogeneous (I2 = 0%). None of the studies reporting this outcome lasted between 6 and 
12 months in length.
Major allergen content could not be determined for three studies.91,164,177 Three studies163,165,168 utilised a 
dose of < 5 µg major allergen. Effect size was a little smaller than for the sample as a whole but remained 
significant. Only one study each used a vaccine with 5–20 µg166 and > 20 µg167 major allergen, and thus 
meta-analysis was not possible in these subgroups.
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Again, the largest subgroup of studies was for grass pollen: five studies,91,164,166,168,177 (total n = 435) 
resulted in a moderate effect size in favour of active treatment. Two studies165,167 were conducted with 
Parietaria allergen, with the combined effect size strongly favouring the active treatment. Only one study164 
was conducted with tree allergen and meta-analysis was therefore not possible.
None of the nine newer studies30,145,148,149,152,153,155,157,160 reporting combined SMSs was suitable for meta-
analysis. Results from all nine studies30,145,148,149,152,153,155,157,160 favoured active SCIT; details of the data from 
these studies are shown in Table 13. Studies that involved > 1 year of treatment reported that the effect 
size increased with each year of active treatment.
Quality of life
Quality-of-life data suitable for meta-analysis were available for eight RCTs (five from the Cochrane 
review,161,164–166,173 three more recent;143,144,146 Figure 4). The addition of the three newer studies resulted in 
a nearly 70% increase in sample size for this outcome (total n = 955). Nevertheless, the results (SMD –0.53, 
95% CI –0.66 to –0.39; p < 0.00001) were almost identical to those reported in the Cochrane review (SMD 
–0.52, 95% CI –0.69 to –0.34; p < 0.00001). No heterogeneity between studies was found.
Where subgroup analyses were possible, treatment duration, MAC and type of allergen did not appear to 
affect the outcome (Table 14). All of the studies included in the meta-analysis were conducted in adults 
and thus analysis by participant age was not possible. However, based on results from one paediatric 
study,152 SCIT appears to be effective for the improvement of QoL in children and adolescents when used 
long term.
As all eight of the included studies143,144,156,161,164–166,173 assessed QoL using the Juniper RQLQ, an additional 
meta-analysis was conducted to calculate weighted mean difference (MD) (Figure 5). Active treatment 
had a significant positive effect on QoL, equivalent to a 0.74 unit reduction in RQLQ score compared 
with placebo.
Three new studies142,148,152 reported QoL data in a manner not suitable for inclusion in meta-analysis. 
Details of data from these studies142,148,152 are shown in Table 15. The smallest142 of the three studies 
(total n = 28) found no difference in overall QoL between treatment groups using SF–36. The other two 
studies148,152 used disease-specific instruments (age-appropriate versions of the RQLQ) and both reported 
clinically significant improvements in QoL in active- but not placebo-treated subjects. However, in the 
3-year paediatric study,152 improvements became statistically significant only in later years of treatment.
TABLE 12 Subcutaneous immunotherapy vs placebo, subgroup analyses: SMSs
Subgroup No. of studies Total n SMD (IV, random, 95% CI)
Duration (months) 
< 6 3 221 –0.47 (–0.91 to –0.02)
> 12 3 253 –0.51 (–0.76 to –0.25)
MAC
< 5 µg 3 228 –0.39 (–0.70 to –0.07)
Allergen
Grass 5 435 –0.43 (–0.62 to –0.24)
Parietaria 2 77 –0.96 (–1.44 to –0.49)
IV, inverse variance.
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TABLE 13 Subcutaneous immunotherapy SMSs: studies not in meta-analysis
Study ID Results
Chakraborty 200630 The SIT group had a 33.5% (p < 0.01) and 57% (p < 0.001) decrease in the SMS during the 
first and second treatment seasons of 2000 and 2001 when compared with the baseline peak 
month. There were no significant changes in the control group
Ceuppens 2009160 Clinical index score (a combined score of symptoms and medication use) was reduced in the 
verum group by 24% compared with placebo [median (IQR) 0.5721 (0.2759–1.2830) vs 1.0322 
(0.5882–1.6080), respectively; p = 0.055]
DuBuske 2011145 Median (SD) combined SMS during the four peak weeks of the grass pollen season was 6.00 
(5.57) in the Grass MATA MPL-treated subjects and 7.06 (5.57) in the placebo-treated subjects. 
In the ITT analysis (n = 1028), the least squares mean combined SMS was reduced by 13.4% 
with Grass MATA MPL compared with placebo (p = 0.0038). Similar differences were seen 
during the EPS
Hoiby 2010148 After 18 months, the median (IQR) combined SMS of the SCIT and placebo groups were 8.0 
(5.8–10.3) and 12.6 (8.6–16.2), respectively (p = 0.004) – a 36.5% reduction in the SCIT group 
compared with the placebo
Kettner 2007149 (A) After 1.5 years of therapy, a highly significant and clinically relevant reduction in the median 
AUC of the SMS from 389.6 to 207.8 in the active group compared with the placebo group 
(from 382.5 to 306.5; p = 0.0137) was observed in the full analysis set
Kuna 2011152 Reductions in combined SMS after therapy, compared with placebo, were 10.8%, 38.7%, 
and 63.5% after the first, second, and third years of SIT, respectively (p = 0.73, 0.102, < 0.001 
and < 0.001 for baseline, 1, 2 and 3 years of SIT, respectively, active therapy vs placebo, one-way 
ANOVA test)
Ljorring 2009153 (A) The estimated treatment effect on combined SMS over peak season was –4.45 (95% CI –6.84 to 
–2.06) in favour of active treatment. (Abstract; patient numbers in each group not reported)
Pfaar 2010155 At 18 months, the median AUC for the combined SMS was 2.3 (IQR 0.9–3.2) for the actively 
treated patients and 2.6 (IQR 2.2–4.4) for placebo-treated patients [median difference –0.4 
(95% CI –1.22 to –0.03); p < 0.04] for the ITT population
Sahin 2011157 (A) There was a significant reduction in total combined scores in the active group compared with 
the placebo group (p = 0.005)
(A), abstract; ANOVA, analysis of variance; IQR, interquartile range; ITT, intention to treat; MATA MPL, modified allergen 
tyrosine adsorbate monophosphoryl lipid A.
Colas 2006143
Corrigan 2005164
Creticos 2006144
Ferrer 2005165
Frew 2006161
Jutel 2005166
Powell 2007156
Walker  2001173
Total (95% CI)
Heterogeneity: τ2 = 0.00; χ2 = 5.46, df = 7 (p = 0.60); I2 = 0%
1.9
1.63
0.5
1.39
1.4
1.43
1.4
1.6
1
1.09
0.6
1.03
1.42
1.31
2
1.2
41
77
9
21
183
29
203
22
585
2.7
1.95
1.6
2.06
2.29
2.27
2.3
2.4
1.1
1.27
1.2
1.18
1.34
1.51
1.6
1.5
19
77
9
20
92
28
103
22
370
5.7%
17.9%
1.8%
4.6%
27.5%
6.4%
31.3%
4.9%
100.0%
-0.77 (-1.33 to -0.20)
-0.27 (-0.59 to 0.05)
-1.10 (-2.11 to -0.09)
-0.59 (-1.22 to 0.03)
-0.64 (-0.89 to -0.38)
-0.59 (-1.12 to -0.06)
-0.48 (-0.72 to -0.24)
-0.58 (-1.18 to 0.03)
-0.53 (-0.66 to -0.39)
Study or subgroup
Test for overall effect: z = 7.72 (p < 0.00001)
Mean SD Total Mean SD Total Weight IV, random, 95% CI
SCIT Placebo Standard mean difference Standard mean difference
IV, random, 95% CI
-4 -2 0 2 4
Favours SCIT Favours placebo
FIGURE 4 Subcutaneous immunotherapy vs placebo: QoL.
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TABLE 14 Subcutaneous immunotherapy vs placebo, subgroup analyses: QoL
Subgroup No. of studies Total n SMD (IV, random, 95% CI)
Duration (months)
> 12 6 662 –0.47 (–0.63 to –0.31)
MAC (µg)
5–20 3 381 –0.52 (–0.74 to –0.31)
> 20 3 379 –0.65 (–0.87 to –0.43)
Allergen
Grass 4 561 –0.44 (–0.61 to –0.26)
Parietaria 2 316 –0.63 (–0.87 to –0.39)
IV, inverse variance.
Study or subgroup
C olas  2006143
C orrigan 2005164
C reticos  2006144
F errer 2005165
F rew 2006161
J utel 2001166
P owell 2007156
Walker 2001173
Total (95% C I)
Heterogeneity: τ2 = 0.00; χ2 = 6.98, df = 7 (p = 0.43); I2 = 0%
Test for overall effect: z = 8.11 (p < 0.00001)
Mean
1.9
1.63
0.5
1.39
1.4
1.43
1.4
1.6
SD
1
1.09
0.6
1.03
1.42
1.31
2
1.2
Total
41
77
9
21
183
29
203
22
585
Mean
2.7
1.95
1.6
2.06
2.29
2.27
2.3
2.4
SD
1.1
1.27
1.2
1.18
1.34
1.51
1.6
1.5
Total
19
77
9
20
92
28
103
22
370
Weight
9.4%
22.8%
4.2%
6.9%
27.2%
5.9%
18.6%
5.0%
100.0%
IV, random, 95% CI
-0.80 (-1.38 to -0.22)
-0.32 (-0.69 to 0.05)
-1.10 (-1.98 to -0.22)
-0.67 (-1.35 to 0.01)
-0.89 (-1.23 to -0.55)
-0.84 (-1.57 to -0.11)
-0.90 (-1.31 to -0.49)
-0.80 (-1.60 to 0.00)
-0.74 (-0.92 -0.56)
SCIT Placebo Mean difference
IV, random, 95% CI
Mean difference
-4 -2 0 2 4
Favours SCIT Favours placebo
FIGURE 5 Subcutaneous immunotherapy vs placebo: QoL (RQLQ scores).
TABLE 15 Subcutaneous immunotherapy QoL scores: studies not in meta-analysis
Study ID Results
Charpin 
2007142
Assessment measure was SF–36. There was no significant difference between the two treatment groups 
except for variations in social function after the first season
Hoiby 
2010148
At baseline, there was a statistically significant difference between the two treatment groups in the mean 
RQLQ (SCIT: 2.58; placebo: 2.7; p < 0.0001). During the study, RQLQ improved in both groups. The change 
in mean RQLQ between baseline and assessment during pollen season 2005 after 6 months of treatment 
was significantly different between the two groups (SCIT –3.8; placebo –0.1; p < 0.0001)
Kuna 
2011152
Active treatment was associated with an improvement in QoL for children (up to 12 years of age) with 
rhinoconjunctivitis. The mean baseline RQLQ score was 1.7 and decreased significantly in consecutive years 
of therapy to 1.4, 1.0, and 0.7 (p = 0.009, 0.008 and 0.003 after the first, second and third years of SIT, 
respectively). In the comparable group of children receiving placebo, the baseline QoL score was 2.0 and 
increased in consecutive years of therapy to 2.3, 2.3 and 2.7 (p = 0.08, 0.09 and 0.019, respectively). 
The group of adolescents who received active treatment also showed significant improvements in QoL: 
a baseline QoL score of 2.7 decreased significantly in consecutive years of therapy to 2.0, 1.4 and 0.9 
(p = 0.0018, 0.0006 and 0.0006, respectively). The comparable placebo group showed no change during 
the entire study, with a baseline mean QoL score of 2.0, and scores of 1.9, 1.9 and 2.2 after the first, 
second, and third years, respectively (p = 0.034, 0.5 and 0.68, respectively). Comparisons of the actively 
treated and placebo groups showed statistically significant differences for children after the second 
and third years of SIT (p = 0.015 and 0.001, respectively) and for adolescents after the third year of SIT 
(p = 0.03)
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TABLE 16 Subcutaneous immunotherapy: other clinical outcomes
Study ID Results
Chakraborty 
200630
Pulmonary function tests: After 2 years of treatment, % predicted FEV1 during pollen season in patients 
with both AR and asthma (n = 8 active, n = 6 placebo) was better in patients receiving active treatment, 
and was also significantly better than baseline values in patients receiving SCIT (p < 0.001) but not the 
control group (p > 0.05)
New sensitivities: During the 2-year treatment period, two patients in the placebo group and none in the 
active group developed new allergic sensitivities
Charpin 
2007142
Days with asthma: Six active and four placebo patients suffered with comorbid asthma. During the first 
pollen season after commencement of treatment, patients receiving active SCIT experienced 0.4 days 
with asthma symptoms vs 2 days for placebo patients. During the second pollen season, the figures were 
0.8 days vs 4 days, respectively. These differences were not statistically significant
Colas 
2006143
SMFDs: During the EPS, 368/1230 (29.9%) patient-days were symptom and medication free in patients 
receiving active treatment, compared with 50/570 (8.7%) patient-days in patients receiving placebo 
(p < 0.01). Similar results were reported for the active group during the PPS but fewer SMFD were reported 
in the placebo group (29.1% vs 1.4%; p < 0.01)
Visual scale of health situation related to symptomatology (100 mm VAS, from ‘very poor’ to ‘very good’): 
No differences in scores between active and placebo groups were apparent before or after the pollen 
season – median (cm) (IQR) 9.00 (8.20–9.30) vs 8.75 (6.80–9.58) and 9.35 (8.50–10.00) vs 8.20 (7.10–
9.25), respectively; both p > 0.05. During the pollen season, scores decreased in both groups, but were 
significantly better in the active group compared with placebo – 7.00 (6.50–7.70) vs 4.30 (3.43–4.90), 
respectively; p < 0.001
DuBuske 
2011145
No. of well-days (days without rescue medication and low TSS):
Maximum TSS = 24. Total n = 491 active, 499 placebo
TSS ≤ 2: 78% more well-days in active group – median 16 days vs 9 days n active and placebo, respectively; 
p = 0.007
TSS ≤ 3: 28% more well-days in active group – median 32 days vs 25 days; p = 0.008
TSS ≤ 4: 22% more well-days in active group – median 39 days vs 32 days; p = 0.004
No. of bad-days (combined SMS ≥ 8 or 10):
SMS ≥ 8: 35% fewer bad-days in active group – median 20 days vs 27 days in active and placebo, 
respectively; p = 0.008
SMS ≥ 10: 86% fewer bad-days in active group – median 7 days vs 13 days; p = 0.0046
No. of well subjects (overall median combined SMS ≤ 2 during the 4-week PPS). Total n = 485 active, 488 
placebo
85% more well subjects in active group compared with placebo – median 78 vs 42 active and placebo 
subjects, respectively; p = 0.0005
Francis 
2008146
Overall assessment: On completion of 1-year treatment, subjects answered question ‘How has your hay 
fever been this year compared with previous years?’ on a numerical scale of –3, a lot worse, to +3, a lot 
better; mean (standard error) 2.42 (0.22) in active group vs 1.50 (0.34) in placebo group; p < 0.05
Pfaar 
2010155
Responder analysis: Based on receiver operating curves, responders were defined as those subjects with 
AUC of at least 30% less than median AUC for placebo group during the pollen season; 64% (87/137) of 
the active group were defined as treatment responders compared with 32% (15/47) of the placebo group; 
p < 0.01
Sahin 
2011157 (A)
Well-days (symptom-free days): Significantly more well-days in active group than placebo group
Global evaluation: 85% active SCIT group improved (p = 0.002), and 91% were satisfied with the treatment 
(p < 0.001)
(A), abstract; FEV1, forced expiratory volume in one second; IQR, interquartile range; SMFD, symptom- and medication-
free day; TSS, total symptom score.
Other clinical outcomes
Recent guidelines64,134 have recommended the use of a number of secondary efficacy outcomes, including 
patient-reported assessments of improvement, symptom control (well-/bad-days) and responder analysis. 
Seven of the recent SCIT studies30,142,143,145,146,155,157 reported additional clinical outcomes, all of which 
favoured the active treatment (Table 16). No studies reported on the development of new asthma cases.
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Adverse events
Adverse event data were available from 15 of the newly identified trials.30,142–146,148–150,152,154,155,157,159,160 
Comparison of AE data between trials was not straightforward as methods of reporting varied 
considerably. Most studies reported only the number of patients experiencing events rather than the 
number of events; some only counted patients once, by their worst-case event, whereas others counted 
all events; and some studies only reported events considered to be treatment related. In addition, the 
amount of information regarding AEs varied greatly between trials, from brief narrative reports to detailed 
analyses of events. The following results are based on both newly identified trials and those in the 
Cochrane review.68
At least one AE was experienced by 79% (667 out of 849) of patients receiving active injections, 
compared with 57% (418 out of 729) of patients receiving placebo in the nine trials that reported this 
outcome.30,142–145,148,154,155,159
Incidence of local reactions was reported in eight trials,30,142,143,148,152,154,155,160 comprising 352 SCIT and 222 
placebo patients in total. The active and control groups experienced a total of 138 and 39 localised AEs, 
respectively. Where actual number of injections delivered was reported, the rates of injection site reactions 
were 2.8% (67 events in 2428 injections),155 1.1% (11 events in 987 active injections),152 0.5% (29 events 
in 1672 injections)160 and 0.02% (five events in 2095 injections).30 In the four trials143,144,148,152 (total n = 116 
active, 80 placebo) that reported on treatment of local reactions, 103 local reactions occurred after active 
treatment, compared with 84 after placebo, none of which required treatment.
Systemic AEs were relatively uncommon, with 129 events occurring after 2909 injections (4.4%) in six trials 
that reported this statistic.155,166,178–181 Six trials30,143,144,148,155,157 gave some indication of the event severity 
(Table 17). The majority (81%) were of mild or moderate intensity. However, severe AEs constituted 19% of 
the total. Three per cent of patients receiving active treatment withdrew owing to AEs.
In addition, eight trials142,146,148,152,154,155,159,160 reported systemic reactions by type of event. Table 18 shows 
systemic events reported in more than one trial. Thirteen studies (n = 557)23,161,164–167,175,176,178,182–185 reported 
using adrenalin after 19 of 14,085 injections (0.13%).
Post-injection anaphylaxis was reported in one trial,159 and was experienced in 10 patients receiving 
active SCIT (n = 39), with eight requiring administration of adrenaline, and in one patient receiving 
placebo (n = 37).
TABLE 17 Systemic AEs in SCIT: severity and withdrawals
Severity of reaction
No. studies 
reporting
SCIT Placebo
n No. of events n No. of events
Mild 4 227 38 113 8
Moderate 4 227 25 113 25
Severe 6a 302 12 183 11
AE leading to study withdrawal 2 536 15 532 4
a One trial (Sahin et al.157) reported only severe AEs that were considered to be treatment related, with no instances 
occurring.
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TABLE 18 Systemic AEs in SCIT: type of event
Type of reaction
No. studies 
reporting
SCIT Placebo
n No. of events n No. of events
Wheezing/asthma 6 271 9 169 7
Urticaria/oedema 5 241 19 138 2
Rhinitis 4 223 44 131 22
Conjunctivitis 4 223 25 131 17
Headache 3 91 18 81 8
Flushing 3 91 16 73 51
Light-headedness 2 69 8 68 2
BOX 1 Summary of findings: SCIT 
 z Treatment with SCIT resulted in a statistically significant reduction in SSs, MSs and combined SMSs compared 
with placebo. Moderate effect sizes were observed in most cases, and these were largely unrelated to treatment 
duration and type of allergen. All but one152 trials were conducted in adults; the one small (n = 50) trial122 in 
children found a statistically significant reduction in SSs and MSs with SCIT after 3 years of treatment. Larger 
effect sizes observed in some analyses were always associated with wide CIs and a very high degree of between-
study heterogeneity. Subgroup analyses suggested an increased benefit with greater allergen content
 z Subcutaneous immunotherapy treatment had a moderate effect on QoL scores, independent of treatment 
duration, MAC or type of allergen. Results from the one trial in children152 are suggestive of a benefit from SCIT 
in the long term
 z A range of other clinical outcomes were reported in a number of trials, and all favoured the active treatment
 z The majority of AEs were local injection site reactions and were more prevalent in participants receiving active 
treatment. Local reactions occurred in between 0.02% and 2.8% of injections (based on four studies30,152,155,160)
 z Most (81%) of systemic reactions were graded as mild or moderate; however, one-fifth were classified as severe
 z Discontinuation rates due to AEs were around 3% (reported in two trials, total n = 1068)
 z Post-injection anaphylaxis was reported in only one small trial159 (total n = 76) but was considerably more 
frequent following active treatment, occurring in approximately 10 of 39 patients (compared with 1 of 37 
receiving placebo); 8 of the 10 patients were treated with adrenaline
Occurrence of SAEs was reported by seven studies.142,144,148–150,155,159 Sixteen SAEs occurred in 770 
patients, none of which was considered treatment related. Treatment of AEs was not widely reported. 
Eleven trials126,143,144,148,152,163,168,169,186–188 (total active n = 324) reported 21 local reactions that required 
treatment. In contrast, 28 trials (total active n = 1023) reported 936 local reactions that did not require 
any treatment. Approximately one-third of systemic reactions (69 out of 206 events, based on 20 studies, 
n = 558) required treatment, with antihistamines, bronchodilators and glucocorticoids being the most 
commonly used. Administration of adrenaline is reported above.
Summary of findings: subcutaneous immunotherapy
A summary is shown below in Box 1.
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Quantity of evidence (sublingual immunotherapy vs placebo studies)
Searches identified 85 publications of DBPC RCTs of SLIT (see PRISMA flow diagram in Appendix 4). Of 
these, 52 publications relating to 44 RCTs were already included in the relevant Cochrane review83 (note: 
the other RCTs in the Cochrane review related to dust mites or animal dander). Of the remaining 33 
publications, 15 were within the Cochrane search period but appear not to have been identified and 
two had been excluded from the Cochrane review despite apparently meeting the inclusion criteria. 
Details of the excluded studies are presented in Appendix 5. Sixteen publications25,32,158,188–199 post-dated 
the Cochrane searches; thirteen25,158,188–199 of these related to 11 new RCTs, three were updates of trials 
previously included in the Cochrane review: two32,200 related to the Dahl et al. (GT–08) trial201 and one202 
provided additional data from the trial described in Didier et al.24 As the purpose of this report was to 
update, rather than repeat, the Cochrane review, results are presented for only the 11 studies25,158,189–199 
published from 2009 onwards, although all relevant studies were included in the meta-analyses.
Main study characteristics and risk of bias (sublingual immunotherapy 
compared with placebo studies)
The main study and population characteristics, and assessment of risk of bias, are detailed for each of the 
11 new studies25,158,189–199 in Appendix 6. All studies were double-blind placebo-controlled RCTs. The largest 
four trials25,189,192,195 had between 276 and 633 participants, with the number of participants in the smaller 
trials ranging from 20 to 115. Skin prick tests were performed in all patients to demonstrate specific 
sensitivity. Allergy symptoms were described as moderate to severe in 6 out of 11 trials,189–191,195–197 with 
no indication of severity given in 5 out of 11 trials.25,158,192–194 Seven studies25,189,190,192,193,195,197 stated that 
some patients also had asthma symptoms. Two trials specified that patients were treatment naive,190,191 
four reported no details,25,158,189,197 and in five trials192–196 it was stated that patients had not received SIT 
within the last 3–5 years, although it was unclear if any patients had ever been treated with SIT. This may 
be important, as it is known that SIT can have long-term effects. Outcomes included SSs, MSs, combined 
SMSs, QoL and AEs (note: only outcomes consistent with the inclusion criteria of this report have been 
listed). Six25,189–192,196 of the eleven studies reported SMSs compared with none of the studies in the 
Cochrane review. As for SCIT compared with placebo trials, the number and types of symptom assessed 
varied widely (see Appendix 7 – SSs across studies).
The most commonly tested allergen was timothy grass (P. pratense), investigated in four trials,174,177–179 
followed by tree pollen (three trials),158,191,197 a mix of several grasses (two trials),25,194 one trial196 with 
ragweed and one190 with Alternaria. Length of treatment varied between 8 and 10 weeks and over three 
pollen seasons, and there was also variation in treatment schedules (e.g. daily or weekly dosing). One 
study189 was in children and adolescents, one190 in both children and adults, with the remaining studies all 
conducted in adults. The main study characteristics are summarised in Table 19.
Similarity between trials was explored for a range of study and population characteristics. Trial duration 
and type and amount of allergen used varied between trials; however, this was explored as a source of 
heterogeneity in subgroup analyses. Where reported, inclusion criteria were very similar across trials, with 
the majority stipulating a minimum of 2 years’ clinical history of moderate to severe SAR, incompletely 
controlled by standard medication; actual SAR history of included patients ranged from approximately 5 to 
18 years. Four studies158,191,194,196 did not report whether or not patients with previous SIT were included. 
Rates of asthma across trials were largely consistent, with none greater than one-quarter (range 7–26%). 
All studies excluded patients with severe or perennial asthma.
Results of the risk of bias assessment are summarised in Table 20 (full details are given in Appendix 5).
Overall, the risk of bias was low for three or more areas of potential bias in most of the studies, although 
a lack of detail in the published reports meant that risk of bias was unclear in many cases. Study authors 
were not contacted, and an ‘unclear’ rating may be due to lack of reporting rather than a reflection 
of poor trial quality. All but one study191 indicated that endeavours were made to maintain blinding. 
There were only two instances191,197 in which a high risk of bias was identified; neither of these studies 
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TABLE 20 Risk of bias assessment: newly identified SLIT studies
Study
Sequence 
generation
Allocation 
concealment Blinding
Data 
completeness
Selective 
reporting
Patients 
treatment 
naive
Blaiss 2011189 + + + ? + ?
Cortellini 2010190 + ? + + + +
Didier 201125 ? ? + ? + ?
Fujimura 2011191 + + ? +a + +
–b
Nelson 2011192 + + + + + ?
Panizo 2010193 ? ? + + + ?
Pfaar 2011194 ? ? + + + ?
Reich 2011195 + + + + + ?
Skoner 2010196 + + + ? + ?
Ventura 2009158 + ? + + + ?
Voltolini 2010197 + ? + + – ?
+, low risk; –, high risk; ?, unclear.
a For SMS data.
b For QoL data.
contributed to any meta-analyses. It should be noted that a certain degree of subjectivity remains in 
assigning a rating of low/unclear/high.
Effectiveness of sublingual immunotherapy compared with placebo
Of the 11 newly identified RCTs,25,158,189–197 only five reported data in a form suitable for meta-
analysis.25,189,190,192,196 All five studies provided SS, MS and combined SMS data,25,189,190,192,196 and three 
additionally provided QoL data25,189,192 (Table 21).
TABLE 21 Outcome measures in recent SLIT RCTs
Study ID Not in meta-analyses In meta-analyses
Blaiss 2011189 AEs, effects on asthma SSs, MSs, SMSs, QoL
Cortellini 2010190 AEs SSs, MSs, SMSs
Didier 201125 SMFDs, AEs SSs, MSs, SMSs, QoL
Fujimura 2011191 SMSs, AEs, QoL None
Nelson 2011192 AEs, effects on asthma SSs, MSs, SMSs, QoL
Panizo 2010193 AEs None
Pfaar 2011194 AEs None
Reich 2011195 Days with medication, AEs, global evaluation, spirometry None
Skoner 2010196 AEs SSs, MSs, SMSs
Ventura 2009158 SSs None
Voltolini 2010197 SSs, AEs, asthma days/severity None
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Symptom scores
A total of 39 SAR studies24,26,38,84–91,94–118,197,200 were included in the meta-analysis in the Cochrane review. 
Of these, two were excluded by this review,35,92 one92 reported combined results for patients with SAR 
and SAA, and one35 was restricted to patients with SAA. Further, 3-year results of the GT–08 trial200 
superseded the 1-year results reported by Dahl,93 which was consequently removed from the meta-
analysis. Searches for this review identified eight25,158,189–191,196,197,200 new studies reporting this outcome, of 
which six25,189,190,192,196,200 were included in the meta-analysis. In total, 2440 active (SLIT) and 2379 patients 
receiving placebo were included in 42 studies.
The combined SMD following SLIT was –0.33 (95% CI –0.42 to –0.25; p < 0.00001) favouring active 
treatment (Figure 6). This result is very similar to that found in the Cochrane review (SMD –0.34, 95% CI 
–0.44 to –0.25; p < 0.00001). Heterogeneity was also similar to the earlier review.
Subgroup analyses in this report were limited to studies in SAR, whereas data from the earlier Cochrane 
review included studies of SLIT for the treatment of PAR. Small to moderate effect sizes favouring active 
SLIT were found in all subgroup analyses, and these did not differ significantly with age, study duration, 
MAC or type of allergen. All were statistically significant, with the exception of the four studies in Parietaria 
allergy;99,110,115,125 however, this was based on a total of only 124 participants. Results of subgroup analyses 
are shown below in Table 22. Forest plots of all subgroup analyses are shown in Appendix 6.
Compared with the Cochrane review, subgroup analysis by age resulted in very similar effect sizes in adult 
participants but a much smaller effect in children (SMD –0.24 compared with –0.52 in the Cochrane 
review), although this remained statistically significant. Although only nine paediatric studies have been 
included here,26,84–90,189 compared with 15 in the Cochrane review,26,35,84–90,92,203–207 total participant numbers 
were very similar (1343 vs 1392 children, respectively) and heterogeneity was significantly reduced 
(I2 = 0%, compared with 92% in the Cochrane review).
Analysis by treatment duration found reduced effect sizes in trials lasting < 6 months and over 12 months 
(the latter associated with a 69% increase in sample size) compared with the Cochrane review, but all 
remained statistically significant.
Few differences were found compared with the earlier review in subgroup analysis by allergen content, 
with the exception of studies using < 5 µg of major allergen.88,99,111,116,190 Despite a small reduction in both 
study number and total sample size, effect size was larger in the present review (SMD –0.53, compared 
with SMD –0.32 in the Cochrane review), and became statistically significant. There was no apparent 
dose–response relationship for SLIT.
Subgroup analysis by allergen type gave effect sizes very similar to those in the earlier review, despite 
a 34% rise in sample size in the grass allergen subgroup. This latter was associated with a reduction in 
heterogeneity, which became non-significant. Effect size decreased slightly in Parietaria allergen, becoming 
non-significant, but total participant numbers were small (total n = 124 in present review).
Two studies158,197 reported results in a manner not suitable for meta-analysis and details are shown in 
Table 23. Data could be extracted from only one study,197 which showed a significant improvement in SSs 
compared with placebo.
Medication scores
A total of 32 SAR studies26,35,84–86,88–109, 111,114,116,117,197 were included in the meta-analysis in the Cochrane 
review. Of these, two35,92 were excluded by this review, as described above. Further 3-year results of the 
GT–08 trial200 superseded the 1-year results reported by Dahl et al.,93 which was consequently removed 
from the meta-analysis. Six new studies25,189,190,192,196,200 reported this outcome and were included in the 
meta-analysis.
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FIGURE 6 Sublingual immunotherapy vs placebo: SSs.
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In total, 1934 active and 1845 placebo patients were included in 35 
studies.25,26,84–86,88–91,94–109,111,114,116,117,189,190,192,196,197,200 The combined SMD was –0.27 (95% CI –0.37 to –0.17; 
p < 0.00001) favouring active treatment (Figure 7). This result is very similar to that found in the Cochrane 
review (–0.30, 95% CI –0.41 to –0.19; p < 0.00001). Heterogeneity was also similar to the earlier review.
Small to moderate effect sizes favouring active SLIT were found in all subgroup analyses. MSs in children 
were not significantly better than with placebo treatment. This finding was consistent with that of the 
earlier Cochrane review, and effect size was decreased further with the addition of the more recent studies. 
Of the eight included studies,26,84–86,88–90,93 only one favouring placebo treatment was statistically significant. 
All others favoured active SLIT, but did not reach significance either alone or when combined. All other 
subgroup analyses were statistically significant, and most did not differ greatly from effect sizes reported 
in the earlier review, despite sometimes large increases in participant numbers (e.g. 31% increase in grass 
allergen; 69% increase in studies with duration of > 12 months). Analyses in two subgroups – > 20 µg 
TABLE 22 Sublingual immunotherapy vs placebo, subgroup analyses: SSs
Subgroup 
No. of 
studies Total n
SMD  
(IV, random, 95% CI) Comparison with CR
Age group
Adults 33 3476 –0.38 (–0.49 to –0.27) Similar
Children 9 1343 –0.24 (–0.35 to –0.13) ES smaller, but remained statistically significant
Duration (months)
< 6 15 1882 –0.34 (–0.47 to –0.20) ES smaller, but remained statistically significant
6–12 15 1539 –0.31 (–0.47 to –0.16) Similar
> 12 12 1398 –0.35 (–0.52 to –0.18) ES smaller, but remained statistically significant
MAC
< 5 µg 6 229 –0.53 (–1.03 to –0.03) ES larger; becomes statistically significant
5–20 µg 13 2287 –0.29 (–0.37 to –0.20) Similar
> 20 µg 12 1088 –0.33 (–0.48 to –0.18) Similar
Allergen
Grass 25 4042 –0.31 (–0.39 to –0.24) 34% increase n; ES similar
Ragweed 3 244 –0.44 (–0.69 to –0.18) Similar
Parietaria 4 124 –0.27 (–0.62 to 0.09) ES smaller and became non-significant
Tree 9 380 –0.42 (–0.77 to 0.06) Data as per Cochrane review
CR, Cochrane review; ES, effect size; IV, inverse variance.
TABLE 23 Symptom score results: studies not in meta-analysis
Study ID Results
Ventura 2009158 Not possible to extract data from graphs. Clinical improvements were noted with active treatment 
compared with placebo
Voltolini 2010197 Median baseline rhinorrhoea score in both groups was 2 (5–95 percentiles: 1–3); after 1 year IT 
median scores were 1 (5–95 percentiles: 0–2) with active SLIT and 1.5 (5–95 percentiles: 0–2) with 
placebo (p < 0.05)
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FIGURE 7 Sublingual immunotherapy vs placebo: MSs.
major allergen and ragweed pollen SLIT – became statistically significant in the present review. Results of 
subgroup analyses are shown in Table 24.
Symptom and medication scores
The Cochrane review did not report on this outcome. We identified seven new studies25,189–192,196,200 that 
reported combined SMS, of which six25,189,190,192,196,200 were suitable for meta-analysis. Details of the 
remaining study191 are shown in Table 25. Although inadequate reporting means the results are difficult to 
interpret, active treatment appeared to result in improved outcomes in the second year of treatment.
The six studies25,189,190,192,196,200 included in the meta-analysis represented a total of 690 patients who 
received active treatment and 704 receiving placebo (Figure 8). Combined SMD was –0.40 (95% CI –0.55 
to –0.25; p < 0.00001) in favour of SLIT. Some heterogeneity between studies was indicated, but this was 
not statistically significant.
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Moderate effect sizes favouring active SLIT were found in all subgroup analyses conducted (Table 26), 
and these were similar between studies. Combined SMD in the two studies190,191 lasting between 6 and 
12 months was larger but a high degree of heterogeneity was indicated and this result was not statistically 
significant. Only one study189 conducted in children (n = 307) reported SMS and, therefore, meta-analysis 
was not possible. However, SMD for this study favoured active treatment and was statistically significant. 
Only one study190 was conducted using < 5 µg of major allergen and in Alternaria allergy, and only one 
study196 used > 20 µg of major allergen and was conducted in ragweed. Meta-analyses were, therefore, not 
possible in these subgroups. However, both of these studies190,196 favoured active treatment. No studies of 
SLIT for tree allergy reported usable data and no new studies were conducted in Parietaria allergy.
Quality of life
Eight studies25,102,112,189,191,192,200,202 reported QoL data (three from Cochrane review,102,112,200 five 
new25,189,191,192,202). All assessed QoL using versions of the disease-specific RQLQ.
TABLE 24  Sublingual immunotherapy vs placebo, subgroup analyses: MSs
Subgroup No. of Total n
SMD  
(IV, random, 95% CI) Comparison with CR
Age group
Adults 27 2604 –0.35 (–0.47 to –0.23) Similar
Children 8 1175 –0.08 (–0.25 to 0.08) ES smaller; remained non-significant
Duration (months)
< 6 14 1517 –0.33 (–0.47 to –0.19) Similar
6–12 13 1223 –0.31 (–0.53 to –0.08) Similar
> 12 8 1039 –0.16 (–0.31 to –0.01) 69% increase n; ES smaller, but remained 
significant
MAC
< 5 µg 5 194 –0.63 (–1.08 to –0.18) Similar
5–20 µg 12 2285 –0.18 (–0.30 to –0.05) Similar
> 20 µg 10 708 –0.26 (–0.47 to –0.06) ES similar; however, became statistically 
significant
Allergen
Grass 19 3028 –0.20 (–0.32 to –0.08) 31% increase in n; ES similar
Ragweed 3 244 –0.34 (–0.60 to –0.09) ES similar; however, became statistically 
significant
Parietaria 4 124 –0.49 (–0.85 to –0.13) No new studies; one study from CR excluded;34 
ES smaller, but remained statistically significant
Tree 9 380 –0.38 (–0.62 to –0.13) Data as per CR
CR, Cochrane review; ES, effect size; IV, inverse variance.
TABLE 25 Symptom and medication score results: studies not in meta-analysis
Study ID Results
Fujimura 
2011191
Data presented in graphical form only; summary statistic used unclear. No apparent difference in scores 
between treatment groups during first pollen season, but in second season better scores were reported in 
the active group
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FIGURE 8 Sublingual immunotherapy vs placebo: SMSs.
TABLE 26 Sublingual immunotherapy vs placebo, subgroup analyses: SMSs
Subgroup No. of studies Total n SMD (IV, random, 95% CI)
Age group
Adults 5 1087 –0.44 (–0.62 to –0.27)
Duration (months)
< 6 2 376 –0.31 (–0.51 to –0.11)
6–12 2 417 –0.66 (–1.63 to 0.30)
> 12 2 601 –0.48 (–0.64 to –0.31)
MAC
5–20 µg 3 985 –0.32 (–0.45 to –0.19)
Allergen
Grass 4 1299 –0.36 (–0.48 to –0.24)
IV, inverse variance.
Seven studies25,102,189,192,200,202 suitable for meta-analysis included 927 active and 951 placebo patients in 
total, a 473% increase from the Cochrane review (Figure 9). Nevertheless, the effect size (SMD –0.37; 95% 
CI –0.52 to –0.22; p < 0.00001) was very similar to that in the earlier review (SMD –0.42; 95% CI –0.73 
to –0.12; p = 0.0063). Heterogeneity between studies was reduced, but remained significant (c2 = 14.62; 
p = 0.02; I2 = 59%).
Summary of subgroup analyses are shown in Table 27.
One189 of the new studies reported the first QoL results for children and adolescents, and these were 
statistically significant in favour of SLIT. Subgroup analysis of the remaining six studies25,102,112,192,200,202 did 
not lead to significantly different results from those reported above.
Four102,112,189,202 of the seven studies25,102,112,189,192,200,202 reporting QoL data lasted for < 6 months. Subgroup 
analysis found a moderate effect size in favour of SLIT, although heterogeneity between these studies 
was high (c2 = 11.54, p = 0.009, I2 = 74%). One study192 was of between 6 and 12 months duration and, 
therefore, meta-analysis of this subgroup was not performed; however, the SMD was small and failed to 
reach statistical significance. In contrast, two studies25,200 presented data from trials lasting > 12 months, 
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comprising a total of 601 participants. These longer studies25,200 reported a moderate effect size for QoL, 
which was statistically significant and no between-study heterogeneity was detected (I2 = 0%).
None of the studies included in the meta-analysis used vaccines with < 5 µg MAC. Two studies each used 
medium and high doses, and results are suggestive of a positive correlation between dose and effect size, 
although, given the small number of studies involved, particularly at the higher dose, these results should 
be interpreted with caution.
Four of the included studies25,102,200,202 used the full version of the disease-specific RQLQ to measure QoL, 
and random-effect meta-analysis was conducted for these studies (Figure 10). Two studies182,192 used 
alternate versions of the RQLQ (age-specific or standardised activities), which do not use the same scale 
or domains as the original, and these could therefore not be included in the meta-analysis. It was not 
possible to identify the instrument used in one study.112
Weighted MD indicated an overall reduction in RQLQ scores of 0.34 units in the active SLIT group, 
indicating a positive effect of treatment.
One study191 did not present data in a manner suitable for meta-analysis (Table 28), but active treatment 
resulted in significantly improved QoL scores compared with placebo during the second year of treatment.
TABLE 27 Sublingual immunotherapy vs placebo, subgroup analyses: QoL
Subgroup No. of studies Total n SMD (IV, random, 95% CI)
Age group
Adults 6 1658 –0.37 (–0.52 to –0.22)
Duration (months)
< 6 4 908 –0.45 (–0.74 to –0.17)
> 12 2 601 –0.37 (–0.54 to –0.21)
MAC
5–20 µg 2 507 –0.32 (–0.49 to –0.14)
> 20 µg 2 323 –0.70 (–0.93 to 0.48)
IV, inverse variance.
Blaiss 2011189
Di Rienzo 2006102
Didier 201125
Durham 2010200
Horak 2009202
Nelson 2011192
Peter 2009112
Total (95% CI)
Heterogeneity: τ2 = 0.02; χ2 = 14.62, df = 6 (p = 0.02); I2 = 59%
 
Test for overall effect: z = 4.88 (p < 0.00001)
1.45
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0
1.01
0
1.57
– 0.81
1.05
1.14
1.02
0.71
0.44
1.4
1.601
111
14
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197
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14.2%
3.5%
16.3%
15.7%
15.6%
17.3%
17.3%
100.0%
Study or subgroup Mean SD Total Mean SD Total Weight IV, random, 95% CI
SLIT Placebo Standard mean difference Standard mean difference
IV, random, 95% CI
-4 -2 0 2 4
Favours SLIT Favours placebo
-0.31 (-0.57 to -0.04)
-0.95 (-1.69 to -0.21)
-0.42 (-0.64 to -0.20)
-0.32 (-0.56 to -0.09)
-0.68 (-0.92 to -0.44)
-0.20 (-0.40 to 0.01)
-0.20 (-0.41 to 0.00)
-0.37 (-0.52 to -0.22)
FIGURE 9 Sublingual immunotherapy vs placebo: QoL.
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Other clinical outcomes
Five of the recent SLIT studies189,192,195,197,202 reported additional clinical outcomes, as did the updates 
from the GT–08200 and Didier 200724 trials (Table 29). All trials reported that active treatment resulted 
in significantly better AR symptom control. Asthma SSs tended to be lower in actively treated patients, 
but the use of asthma medication appeared to be significantly lower in active groups. In addition, active 
SLIT may reduce the severity of asthma during the pollen season. One study195 reported no significant 
differences between active treatment in terms of medication use, spirometry or global assessment. This 
trial195 was of quite short duration, lasting only for 8–10 weeks, with treatment initiated during the pollen 
season. No studies reported development of new cases of asthma.
Adverse events
Again, reporting of AEs was highly variable between studies, making comparisons difficult. It should be 
noted that SLIT is usually self-administered outside the clinic, and thus AE reporting will depend on non-
clinical judgement and patient recall.134 Only one158 of the 11 new RCTs did not report AE data.
Overall, the incidence of AE was quite high, with 65% (420 out of 646) of patients receiving active 
treatment experiencing at least one AE, compared with 42% (194/467) of patients receiving placebo in 
the six trials25,189,193,195–197 that reported on AEs. The most commonly reported local reactions were itching, 
swelling and burning in the oral cavity. Four trials189,190,192,194 (total n = 890) reported oral pruritus in 39% of 
active and 5% of placebo patients; two trials189,192 (total n = 782) reported throat irritation in 33% of active 
patients compared with 4% of control patients, and mild erythema in 11% of active patients compared 
with 1% of control patients; and three trials189,192,194 (total n = 863) reported oral paraesthesia in 10% of 
SLIT patients compared with 2% of placebo patients, and mouth oedema in 9% of SLIT patients compared 
with 1% of placebo patients. The numbers of events were generally not reported.
Six trials88,189,192,194,195,208 reported systemic events by severity (Table 30). The vast majority (73%) of systemic 
AEs in these trials were of mild intensity, 24% were of moderate intensity and 3% were graded as severe. 
Anaphylaxis was reported in two trials192,195 and occurred in 4 of 427 patients receiving active treatment 
and in none of 282 patients receiving placebo. Only two trials189,192 (total n = 782) reported on adrenaline 
use. In each study, one instance of an AE in response to SLIT administration was treated with adrenaline. 
In both cases, the patients were receiving active treatment. Two instances of hospitalisation were 
reported,88,208 both for asthma attacks.
Di Rienzo 2006102
Didier 201125
Durham 2010200
Horak 2009202
Total (95% CI)
Heterogeneity: τ2 = 0.01; χ2 = 6.72, df = 3 (p = 0.08); I2 = 55%
Test for overall effect: z = 4.33 (p < 0.0001)
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Mean difference
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-0.43 (-0.66 to -0.20)
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-0.30 (-0.40 to -0.20)
-0.34 (-0.49 to -0.18)
FIGURE 10 Sublingual immunotherapy vs placebo: QoL (RQLQ scores).
TABLE 28 Quality-of-life results: studies not in meta-analysis
Study ID Results
Fujimura 
2011191
Data presented in graphical form only; summary statistic used unclear. Total scores on the Japanese Allergic 
Rhinitis QoL Standard Questionnaire No. 1 were significantly better in the active group (p < 0.01) during the 
second pollen season. Data are not presented for the first pollen season
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TABLE 29 Sublingual immunotherapy: other clinical outcomes
Study ID Results
Blaiss 2011189 Effects on asthma: Both treatment groups (asthmatic subjects: n = 46 active, n = 44 placebo) reported 
low mean daily asthma SSs during the pollen season – 0.86 vs 1.08, respectively, out of a maximum of 
12 (21% lower in the active group). The difference was not statistically significant
Didier 201125 Proportion SMFD: Active group (n = 188) experienced mean 37.9% SMFD vs 26.4% in placebo group 
(n = 205)
Durham 
2010200/2011129
Proportion SMFD: After third treatment-year, subjects in active group experienced a mean 34.1% SMFD, 
compared with 24.1% in placebo group (p = 0.0035). This difference remained at the 1-year follow-up, 
with 35.2% vs 27.6% SMFD in the two groups, respectively (p = 0.0384)
No. of severe days: Severe days defined as having a maximum score on at least two of four nasal SSs 
measured; maximum score on at least one of two ocular SSs; or an overall SS > 9 out of a maximum 18. 
Mean number of severe days was 55.3% lower in Grazax-treated patients than in placebo; it is unclear 
to which time point or period this figure refers
Horak 2009202 Global assessment: Patient global assessment after first pollen season, compared with pre-treatment 
season, was significantly better than placebo (p < 0.0001). Details of assessment and absolute values not 
reported
Nelson 2011192 Effects on asthma: Both treatment groups (asthmatic subjects: n = 44 active, n = 59 placebo) reported 
low mean daily asthma SSs over the EPS – 0.84 vs 1.10, respectively, out of a maximum of 12 
(24% lower in the active group, p = 0.04). During the PPS, the difference between the groups was not 
statistically significant. However, the mean daily asthma MSs were 46% lower in the active than the 
placebo group (p = 0.01). In addition, only two patients in the actively treated group required treatment 
for worsening asthma (defined as four or more inhalations of short-acting b2-agonist per day, at any 
time) compared with 13 patients in the placebo group. The number of patients requiring initiation of 
treatment with inhaled corticosteroids during the pollen season was similar between the groups – six 
patients in the active group and five patients in the placebo group
Reich 2011195 Use of rhinitis/asthma rescue medication: Use of rescue medication was similar between treatment 
groups – 176 out of 219 (81%) active and 51 out of 57 (89%) placebo subjects used allergy or asthma 
medication. Number of days with medication during the 10-week trial were 34.9 and 37.5 days, 
respectively
Spirometry: No pronounced changes in FEV1 occurred during the trial in either group
Global evaluation: ‘Compared to your rhinoconjunctivitis symptoms in the previous grass pollen season, 
how have you felt overall in this grass pollen season: much worse, worse, the same, better, much 
better?’ Results were similar between the treatment groups: 68% active and 72% placebo patients 
reported improvements (better/much better); no change was reported in 28% and 26% of patients, 
respectively; only 4% (9/219) active and 2% (1/57) placebo patients felt worse or much worse
Voltolini 
2010197
Days with asthma: During the second pollen season, reduction in the median number of days with 
asthma from visit three to visit six was much greater in the active than placebo group – from 10 (range 
0–27) to 2 (0–6) days in the active group compared with 13 (0–29) to 7 (0–15) days in the placebo 
group (difference between groups, p < 0.05)
Asthma severity: Ten of the thirteen active patients stepped down an asthma severity grading level 
(GINA criteria) following treatment, compared with none of the nine placebo patients
FEV1, forced expiratory volume in 1 second; GINA, Global Initiative for Asthma; SMFD, symptom- and medication-free 
day.
TABLE 30 Adverse systemic events in SLIT: severity and withdrawals
Severity of reaction
No. of studies 
reporting
SLIT Placebo
n No. of events n No. of events
Mild 5 669 830 458 314
Moderate 5 669 253 458 129
Severe 6 744 30 498 12
AEs leading to study withdrawal 5 879 30 686 14
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Five trials25,189,192,194,195 reported a total of 20 SAEs in a total of 1565 study participants, of which only one, 
abdominal pain in a placebo-treated patient, was considered likely to be treatment related.
Only four small trials107,118,175,209 (total active n = 107) reported on treatment of AEs. Based on this small 
data set, 109 out of 1000 (11%) AEs required treatment, whereas 891 out of 1000 (89%) resolved 
spontaneously without treatment. This includes both local and systemic reactions, which were usually 
not reported separately. Most reports did not specify the nature of treatment required but based on one 
study209 (n = 43) the most commonly used treatments were salbutamol [used in 49% of cases (73 out of 
149 treated AEs)] and analgesics (used in 40% of treated cases). Antiseptics, cold sore medication cold 
medication and glucocorticoids made up only 9% of all treatments between them. Details of adrenaline 
administration and hospitalisations are noted above.
Five studies189,190,192,194,195 reported discontinuations due to AEs. Thirty patients (3.4%) out of a total of 879 
receiving active treatment were withdrawn for this reason. This number is similar to the 5% withdrawal 
rate reported in the Cochrane review.
Summary of findings: sublingual immunotherapy
A summary is shown below in Box 2.
Quantity of evidence sublingual immunotherapy compared with 
subcutaneous immunotherapy
Searches identified only one randomised, double-blind, double-dummy comparison study210 of SLIT 
with SCIT (n = 71). Three further studies158,211,212 were initially identified as potentially relevant, but were 
subsequently excluded. One study158 (n = 40) was not a double-blind, double-dummy comparison; it 
included a comparison of SCIT with placebo and SLIT with placebo but no adequately blinded direct 
comparison of SCIT with SLIT, and results for SLIT compared with SCIT were not reported (this study is 
included in the relevant sections on placebo-controlled studies in this report). A second study211 (n = 47) 
compared a SLIT with a SCIT treatment arm, but there was no blinding (no treatment with placebo). 
Finally, a small, double-blind, double-dummy study (n = 20) by Quirino et al.212 used 10 ‘matched pairs’ 
and does not appear to have used random allocation. The three studies that reported results for SCIT 
 z Treatment with SLIT resulted in statistically significant reductions in symptom, medication and SMSs 
compared with placebo, and these effects were largely unrelated to participant age, treatment duration 
or type of allergen. SMD for SS improvement was not statistically significant in SLIT with Parietaria 
allergen, but this was based on only four studies86,99,111,116 (total n = 124). MSs were not significantly 
improved in paediatric patients compared with placebo (eight studies,26,84–86,88–90,174 total n = 1175)
 z Seven trials (total n = 1878) reported on QoL. Overall, SLIT had a statistically significant effect on QoL. Six 
of these trials25,112,190,192,200,202 were conducted in adults and there remains a shortage of paediatric QoL 
data; the one study189 in children reported a statistically significant difference in favour of SLIT
 z SLIT also appeared to result in better overall symptom control compared with placebo, and may reduce 
asthma severity and medication requirements
 z AEs were relatively common and more frequent in patients receiving active treatment. Local reactions 
in the oral cavity were the most frequently reported event and the majority of systemic reactions were 
of mild or moderate severity. Only one serious AE deemed to be treatment related occurred in five 
trials25,189,192,194,195 reporting this outcome (total n = 1565). Two trials192,195 (total n = 709) reported on 
anaphylaxis, which occurred in 0.9% patients receiving active treatment, compared with none receiving 
placebo. Two trials189,192 (total n = 782) reported on adrenaline use, which was required for only one 
treatment-related event; this event occurred in a patient receiving active SLIT. Discontinuations due to 
AEs occurred in 3.4% of participants receiving active treatment in five trials189,190,192,194,195 reporting this 
outcome (SLIT n = 879)
BOX 2 Summary of findings: SLIT 
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compared with SLIT found no significant differences between the two. Results for the one study210 meeting 
inclusion criteria are reported in more detail below.
Main study characteristics sublingual immunotherapy compared with 
subcutaneous immunotherapy
The main study and population characteristics of the included study, and the assessment of risk of bias are 
detailed in Appendix 5.
The main characteristics are summarised in Table 31.
Results of the risk of bias assessment are summarised in Table 32 (full details are given in Appendix 5).
As in many of the placebo-controlled studies, details of randomisation and blinding are reported but a lack 
of detail on other aspects of quality make it difficult to judge the overall quality.
Effectiveness of subcutaneous immunotherapy compared with sublingual 
immunotherapy
Results were reported for SSs, MSs, QoL and AEs and are summarised below (Box 3). Results were not 
presented in a way that is consistent with most other RCTs in this area, in that absolute mean SSs or 
MSs post treatment are not presented; instead median changes relative to the preceding pollen season 
are given. Nevertheless, the findings are consistent with other studies showing a benefit in terms of 
symptoms and MSs with both SCIT and SLIT compared with placebo. No significant differences between 
SLIT and SCIT groups were identified in this small study.210 This does not mean that such differences do not 
potentially exist.
Indirect comparison of subcutaneous immunotherapy with sublingual 
immunotherapy
Given the paucity of direct comparisons (head-to-head trials) between SCIT and SLIT, it was decided 
to undertake an indirect comparison of SCIT with SLIT using data from the separate meta-analyses of 
SCIT compared with placebo and SLIT compared with placebo. Indirect comparison analyses rely on the 
assumptions (explored below) that there is sufficient similarity both within the SCIT compared with placebo 
and the SLIT compared with placebo trials (homogeneity assumption138), and that the true treatment effect 
comparing any two interventions would be similar across all trials, irrespective of whether they included 
one or both of those interventions (similarity assumption138).
The direct (head-to-head) evidence from the one small SCIT compared with SLIT trial210 included in this 
report could not be incorporated into this analysis, as the outcomes were not reported in a way that 
would allow this.
This section presents the most relevant results of the statistical analysis. The full list of parameter estimates 
and modelling approach is reported in Appendix 3.
Homogeneity assumption
For both SCIT compared with placebo and SLIT compared with placebo trials, heterogeneity was explored 
qualitatively by looking at patient and study characteristics, and statistically through meta-analysis (with 
I2 giving an indication of the extent of heterogeneity). Where reported, inclusion criteria were very similar 
across trials and it is likely that included populations had similar severity of AR. There was also not much 
variation in asthma rates where these were reported. All studies excluded patients with severe or perennial 
asthma. There was variation between trials in trial duration and type and amount of allergen. There was 
statistical evidence of moderate heterogeneity in the meta-analyses for some outcome measures (I2 of 
57% for SS and MS for SCIT compared with placebo; I2 of 59% for QoL for SLIT compared with placebo). 
Statistical heterogeneity was less than moderate for the other outcome measures.
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Similarity assumption
This was explored qualitatively. Overall, patient characteristics appeared to be similar between SCIT and 
SLIT populations (in terms of SAR history, severity, prior experience of SIT and prevalence of asthma). 
There was variation between trials in trial duration and type and amount of allergen. An attempt was 
made to assess whether placebo rates between SCIT and SLIT populations were similar. If populations are 
comparable, then placebo rates could also be expected to be similar. In this particular set of trials, placebo 
is administered in different ways (sublingual or subcutaneous) and given at different frequencies (daily for 
TABLE 32 Risk of bias assessment: SCIT vs SLIT studies
Study
Sequence 
generation
Allocation 
concealment Blinding
Data 
completeness
Selective 
reporting
Patients 
treatment 
naive
Khinchi 
2004210
+ ? + ? ? ?
+, low risk; –, high risk; ?, unclear.
Results
Rhinoconjunctivitis SSs
Method 1: subtraction of pre-treatment values from treatment season values
Median rhinoconjunctivitis SS (0–3 scale) improved by 0.36 score points (95% CI 0.18 to 0.86) in the SLIT arm, by 
0.75 score points (95% CI 0.02 to 1.31) in the SCIT arm and decreased by 0.2 score points (95% CI –1.05 to 0.22) 
in the placebo arm. Significant difference in change between SLIT/SCIT and placebo (both p < 0.002). No significant 
difference in change between SLIT and SCIT
MSs
Method 1: subtraction of pre-treatment values from treatment season values
Median MS increased by 0.29 score points (95% CI –2.57 to 0.82) in the SLIT arm, were unchanged in the SCIT 
arm (95% CI –1.52 to 2.65) and increased by 1.35 score points (95% CI –4.04 to 0.12) in the placebo arm. 
Significant difference in change between SLIT/SCIT and placebo (p < 0.02 and p < 0.002, respectively). No significant 
difference in change between SLIT and SCIT
Rhinoconjunctivitis SSs
Method 2: values of first treatment season relative to pre-treatment season
Deterioration in SS by a factor of 1.45 (95% CI 0.87 to 2.09) in placebo group compared with an improvement in 
the SLIT group (by a factor of 0.78; 95% CI 0.6 to 1.06, p < 0.01) and the SCIT group (by a factor of 0.48; 95% CI 
0.28 to 1.02, p < 0.001). No significant difference between SLIT and SCIT groups
MSs
Method 2: values of first treatment season relative to pre-treatment season
Increase in MS by a factor of 2.01 (95% CI 1.02 to 3.56) in placebo group compared with a change by a factor 
of 1.03 (95% CI 0.77 to 1.75; p < 0.05) in the SLIT group and a decrease by a factor of 0.78 (95% CI 0.3 to 2.0, 
p < 0.02) in the SCIT group. No significant difference between SLIT and SCIT groups
BOX 3 Subcutaneous immunotherapy vs SLIT: SSs and MSs
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sublingual and weekly, then monthly for subcutaneous). There is evidence from different clinical areas that 
placebo rates may differ according to how the placebo is administered.213
Although clinical opinion suggests that placebo rates between SCIT and SLIT are likely to be comparable 
(Stephen Durham, Imperial College London, 2 March 2012, personal communication), placebo rates could 
not be compared directly between SLIT and SCIT trials owing to (1) the use of different outcome measures 
and (2) the fact that any differences between baseline and follow-up measures are likely to differ between 
studies conducted at different times and in different geographical areas owing to variations in pollen 
count. However, failing to make this assumption would have precluded any indirect comparison analysis.
Given that there was some evidence of heterogeneity, a number of variables (treatment duration and type 
and amount of allergen, as well as age of participants – adults or children) were explored and adjusted for 
using ICMR.
A random-effects model was a better fit for the data and was therefore used in all further modelling 
(see Appendix 3 for methodology and full results). Standardised score differences were calculated and 
indicate the difference in effect size between SCIT and SLIT; positive values favour SCIT and negative 
values favour SLIT. When interpreting results, the 95% credible intervals (CrIs) need to be considered,214 
with wider intervals indicating greater uncertainty. Best estimate probabilities were also presented. These 
show the probability of either SLIT or SCIT being the best treatment; however, the probability does not 
give any information on how much better one treatment is likely to be (i.e. they are not a measure of 
effectiveness). Note that even where there is a very high probability of one treatment being best, the 95% 
CrIs around the pooled standardised score differences may include zero and the results will therefore not 
be statistically significant.
According to the DIC measure, random-effects modelling fitted the data better than fixed-effects 
modelling (see Appendix 3), indicating a degree of unexplained heterogeneity in the data. Therefore, only 
results from random-effects modelling are presented in the following sections.
Symptom scores
When covariates were not included in the model (unadjusted model), the standardised score difference 
was 0.351 (95% CrI 0.127 to 0.586), a statistically significant result in favour of SCIT. Probabilistic 
analysis suggests that SCIT has a greater probability of being the best treatment compared with SLIT 
overall (unadjusted model) and also when participant age, study duration, MAC and type of allergen are 
accounted for (Table 33). However, not all the standardised score differences were statistically significant. 
For Alternaria allergy, the best estimate probability suggests that SLIT is the preferred treatment; however, 
this is based on only a single study for each intervention and a non-significant standardised score 
difference. Residual heterogeneity in the model could not be accounted for by participant age or type of 
allergen, while including MAC as a covariate reduced heterogeneity slightly (as shown by a decrease in s2).
The ICMR model included comparisons where there were no studies (no data) in either the SCIT or the SLIT 
arm (e.g. no SCIT trials for ragweed compared with three SLIT trials95,97,196 for ragweed); here the extremely 
large CrIs around the standardised score difference reflect the uncertainty resulting from this absence 
of data.
In order to explore unexplained residual heterogeneity further, two post hoc meta-regressions were 
conducted. In the first analysis, year of publication was used as a covariate in the model, and a strong 
effect for year was identified. An improvement in the fit of the model to the data was also observed (DIC 
502, compared with 508 for the null model) and the heterogeneity parameter estimate was also lower 
[s2 0.067 (95% CrI 0.017 to 0.147) compared with 0.089 (95% CrI 0.027 to 0.187), respectively].
Figure 11a shows pooled SMD point estimates for placebo-controlled trials and suggests that results from 
older studies show a greater benefit for SCIT, with more recent studies finding a decreasing benefit (more 
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negative SMD values indicate a greater improvement in SSs compared with placebo). In contrast, SMD 
estimates for SLIT compared with placebo appear to remain more stable over time. The ICMR with year 
as a covariate (Figure 11b) finds that from approximately 2007 there is an increased probability that SLIT 
is more beneficial than SCIT. Note that standardised score differences at different time points are not all 
statistically significant (see Appendix 3).
Given the huge variability in symptoms recorded between trials (see Appendix 7 for types and numbers of 
symptoms scored in different trials), a second post hoc analysis was conducted to explore any effect of this 
variable on trial outcome. It was found that increasing numbers of symptoms being measured in a trial 
appeared to favour SCIT over SLIT (Figure 12). Again, standardised score differences are not all statistically 
significant (see Appendix 3) and residual heterogeneity increases in this analysis.
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FIGURE 11 Symptoms scores: year of publication as covariate in the model. (a) theoretical and observed SMD and 
credible boundaries by year of publication for SCIT vs placebo and SLIT vs placebo; (b) probability of intervention being 
superior.
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Medication scores
The unadjusted model (no covariates included), found a standardised score difference of 0.273 (95% 
CrI 0.027 to 0.529) in favour of SCIT (Table 34). This was associated with a > 99% chance of SCIT being 
the best treatment. Where meta-regressions resulted in standardised score differences in favour of SLIT, 
these were not statistically significant. It appears that some of the heterogeneity could be reduced by 
introducing MAC and particularly age (adult/child) as a covariate.
As for SSs above, adjusting for year of publication found changes in benefit from SCIT and SLIT over time, 
although the effect was not as pronounced and more difficult to interpret (Figure 13).
Symptom and medication scores
No significant difference between SCIT or SLIT could be shown in this analysis (Table 35), and this is 
associated with a large degree of uncertainty, as reflected in the wide CrIs. The combined SMS may be 
seen as a more robust outcome measure compared with the SS or MS alone, and this analysis could 
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FIGURE 12 Number of symptoms measured as covariate in the model. (a) theoretical and observed SMD and credible 
boundaries by year of publication for SCIT vs placebo and SLIT vs placebo; (b) probability of intervention being 
superior.
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arguably be given more weight. Heterogeneity is lower for this analysis (compared with SSs and MSs 
separately) and is further reduced when type of allergen is used as a covariate.
Quality of life
Results of adjusted indirect comparison of QoL scores find that, although there is a high probability of SCIT 
being the best treatment, the standardised score difference is not statistically significant and is associated 
with a high degree of heterogeneity (Table 36). None of the adjusted standardised score differences are 
statistically significant. The analysis was repeated with trials using only the RQLQ for measuring QoL, and 
the result is therefore expressed as a difference in RQLQ units (Table 37). The results are very similar.
Discussion of the indirect comparisons
There was some evidence of heterogeneity within trials of SCIT or SLIT compared with placebo and 
between placebo-controlled trials. Therefore, possible sources of heterogeneity were explored through 
ICMR. No substantial reduction in heterogeneity when adjusting for type of allergen, allergen content 
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FIGURE 13 Medication scores: year of publication as covariate in the model. (a) theoretical and observed SMD and 
credible boundaries by year of publication for SCIT vs placebo and SLIT vs placebo; (b) probability of intervention being 
superior.
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or duration of treatment in the analyses for SSs, MSs or QoL scores was found. A smaller amount of 
heterogeneity was evident in the analysis for combined SMSs [s2 of 0.017 (95% CrI 0.0 to 0.086), no 
covariates included], and this was further reduced when type of allergen was introduced as a covariate 
[s2 of 0.011 (95% CrI 0.000 to 0.059)]. It should be noted that this is based on a smaller number of 
studies compared with the SS and MS analyses, which may also have an effect on heterogeneity. In the 
indirect comparison based on combined SMSs, the standardised score difference was not statistically 
significant and was associated with very wide credibility intervals. This is reflected in the best estimate 
probability, which found that SCIT and SLIT had roughly equal probability of being the best treatment. 
The analysis using combined SMS is based on fewer studies compared with the SS and MS analyses, but 
it has been argued that it is a more appropriate outcome measure as it takes into account the relationship 
between symptoms and medication use. The overall results are consistent with the results from small and 
mainly poor-quality studies directly comparing SCIT to SLIT (see Chapter 3, Effectiveness of subcutaneous 
immunotherapy versus sublingual immunotherapy), which found no significant difference between the 
two treatments.
Unadjusted analyses (no covariates) using SSs and MSs found significant differences in standardised scores 
favouring SCIT but, given the high residual heterogeneity, these results need to be interpreted cautiously. 
Using RQLQ, the standardised score difference was non-significant and the result was associated with 
substantial heterogeneity.
Using ‘year of publication’ and ‘number of symptoms recorded in a trial’ as covariates in the ICMR 
suggested a decreasing benefit from SCIT over time (with SLIT appearing relatively more effective) and an 
increasing benefit from SCIT the more symptoms were measured. These covariates were not prespecified 
and findings should be seen as suggestive only, and interpreted very cautiously. Possible explanations for 
changes over time include changes in treatment protocols (e.g. use of standardised products) or reporting/
publication bias. With regard to an increasing benefit for SCIT the more symptoms are measured, it could 
be speculated that SCIT is better at alleviating a broader range of symptoms. It is also possible that these 
findings are due to chance.
Owing to the differences in outcome measures used, results were expressed as standardised score 
differences (except for the RQLQ). As with the meta-analyses of placebo-controlled studies, these 
results are difficult to interpret clinically, and statistical differences may not be consistent with clinically 
important differences.
There are several relevant trials that have not been included in the meta-analyses or indirect comparison 
meta-analyses, as data were not reported in a suitable manner (see Tables 7 and 21). The results are 
therefore not based on all of the available data; the effect of this is uncertain.
It is difficult to draw firm conclusions from these results as (1) they vary depending on which outcome 
measure is used and (2) they are associated in some instances with substantial residual heterogeneity. 
A more useful data set would include studies using validated standardised outcome measures and 
treatment regimens.
Ongoing trials
Searches identified 22 (12 SLIT, 10 SCIT) Phase III double-blind, randomised placebo-controlled trials 
that are still ongoing or had recently finished but for which no published results were yet available 
(see Appendix 9). The majority of trials are being conducted in adults (some including adolescents), 
comprising over 4500 adult subjects in total, with only two SLIT trials (n = 1450) and one SCIT trial 
(number of participants not stated) recruiting children and adolescents specifically. We identified only 
one Phase II/III double-blind, double-dummy study of SLIT compared with SCIT, initiated in March 2011 
and due for completion September 2014.215 Four studies216–219 are investigating the efficacy and safety of 
SCIT with recombinant allergens, of which one includes off-treatment follow-up:216 a SCIT trial will collect 
data for one season after 2 years of treatment; a further trial will look at long-term allergy and asthma 
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outcomes over a 5-year period in 1000 children aged 5–12 years (the Grazax Asthma Prevention study59). 
However, in general, the majority of trials do not appear to differ extensively from previously published 
studies in terms of patients and treatment regimens. Although beyond the scope of this report, it would 
be of interest to investigate the type of outcome measures being used given recent recommendations in 
this area.
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Chapter 4 Cost-effectiveness
This chapter is divided into the following sections: (1) a systematic review of published EEs on SCIT and SLIT for the treatment of SAR; (2) a description of our preferred Markov models (for adults and children 
separately) that were constructed to assess the cost-effectiveness of SCIT and SLIT for the treatment of 
SAR; (3) challenges met when trying to identify data to populate the preferred Markov models; and (4) 
results of an EE of SCIT and SLIT for treating SAR based on a simpler decision model.
Systematic review of existing evidence
This section reports the results of a systematic review of published EEs evaluating the costs and benefits 
of SCIT and/or SLIT compared with standard care [symptomatic treatment (ST)], or of SCIT compared with 
SLIT. The purpose of the systematic review was to (1) gain an overview of existing evidence in this area and 
(2) identify any suitable data (e.g. costs, utilities, transition probabilities) with which to populate a new 
Markov model.
Methods
Searches
Studies on costs, cost-effectiveness, modelling and QoL were sought in The Cochrane Library [NHS 
Economic Evaluation Database (NHS EED)] 2011 Issue 1, MEDLINE (Ovid) 1948–April week 2 2011 and 
EMBASE (Ovid) 1980–week 15 2011. Quality-of-life studies were sought in MEDLINE (Ovid) 1948–June 
week 5 2011. Reference lists of included studies were also checked. There were no language restrictions. 
See Appendix 2 for full details of the search strategies.
Study selection
Inclusion and exclusion criteria were used as outlined in Table 38. These were slightly broader than 
those for clinical effectiveness in order to cover the breadth of available evidence. Titles and abstracts of 
retrieved studies were screened for inclusion and exclusion by one reviewer. Full texts were obtained for 
any potentially relevant studies. All uncertainties around study selection were resolved through discussion 
with two other reviewers. Reference Manager was used to track and record study selection decisions and 
reasons for exclusion.
Data extraction
Data extraction was performed by one reviewer using a standard extraction form and checked by a 
second reviewer. Data were extracted on type of EE, study population, intervention and comparator, 
perspective, time horizon, model structure and model assumptions if applicable, resource and cost data 
and main findings.
Assessment of quality of included studies
The methodology of all included EEs was critically appraised using checklists recommended by the 
Cochrane Collaboration, i.e. the Philips checklist220 for model-based EEs and the Evers checklist221 for 
non-model-based EEs. For the Philips checklist,220 this involved assessment of a range of factors relating 
to objectives and structure of the model, the theory underpinning the model, assumptions and treatment 
of uncertainty as well as the appropriateness and evaluation of the data used to populate the model. 
The Evers checklist221 assesses details around the interventions being compared, assumptions made when 
valuing costs and benefits as well as the generalisability of the results obtained. Reviews of EEs were used 
as a source for identifying primary studies and were not formally quality assessed.
NIHR Journals Library www.journalslibrary.nihr.ac.uk
COST-EffECTIVENESS
64
Quantity of evidence
Searches identified 406 potentially relevant publications, of which 330 were excluded at the title/abstract 
stage. Of the 76 publications that were potentially relevant, full texts could not be obtained for eight. 
Full-text copies of 68 papers were examined, of which 52 were excluded (reasons for exclusion are detailed 
in Appendix 5). Sixteen publications were included. Of these, 14 were primary EEs and two were reviews 
of EE studies. In addition, three studies were identified that reported utility-based outcomes for SAR.
Main characteristics of economic evaluations
The main study characteristics and findings are shown below. Further details can be found below 
(see Table 40) and Appendix 9.
Type of economic studies
Different types of EEs were identified:
 z four cost–consequences analyses (CCAs)222–225
 z two CEAs226,227
 z five cost–utility analyses (CUAs)228–232
 z one study reported both a CEA and CUA analysis233
 z one study reported both a CEA and cost–benefit analysis (CBA)234
 z one study reported both a CEA and CCA analysis.235
The different forms of EEs differ in the way outcomes are measured and/or expressed. Results from CEAs, 
CBAs and CUAs are typically reported in terms of a single measure of economic benefit, the incremental 
TABLE 38 Inclusion and exclusion criteria for EEs
Inclusion criteria Exclusion criteria
Study design
1. Any EE (including CEAs, CBAs, CUAs, CCAs and CMAs)
2. Any study not in (1) reporting data that could 
potentially be used in an model-based EEs (e.g. studies 
reporting transition probabilities, utilities or cost data)
3. Review of EEs
Any study not including or reporting on an EE or reporting 
data that could potentially be used in a model-based EE
Population
Adults or children with SAR, with or without asthma. 
Where populations have included some patients with PAR, 
the study has been included
Adults or children with a different allergic disease, such as 
food allergy, or with PAR or asthma only
Intervention 
Allergen-specific subcutaneous (injection) or sublingual 
immunotherapy in any setting. Where SIT covered both 
seasonal and perennial AR (e.g. dust mite allergy), the 
study was included
Any other route of administration [e.g. oral (swallowed 
rather than sublingual), nasal, epicutaneous, intralymphatic]
Comparator
Placebo [with or without conventional (rescue) 
medication], SCIT or SLIT
Any other route of administration (e.g. oral, nasal)
Outcomes
Any measure of cost, cost-effectiveness, resource use, QoL 
or utility associated with SCIT or SLIT
Outcomes relating to clinical effectiveness only with no cost 
or quality-of-life/utility data suitable for use in a model
CBA, cost–benefit analysis; CCA, cost–consequences analysis; CMA, cost minimisation analysis; CUA, cost–utility analysis.
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cost-effectiveness ratio (ICER), whereas results (costs and outcomes) from CCA are expressed in a 
disaggregated way.
Population
All of the primary studies were based on European populations, whereas the two reviews236,237 additionally 
considered US populations. Sample sizes ranged from 30 to 2230 (for cohorts used in model-based 
analyses). Populations considered were those with SAR only (nine studies222,224–226,228,230–233) or SAR/PAR (five 
studies223,227,229,234,235 and the two reviews238,239), either with or without asthma. Where patients had PAR, 
this related to dust mite allergy.
Routes of immunotherapy and comparators
Five studies222,229,233–235 compared SCIT with standard care, six studies223,226,228,230–232 compared SLIT with 
standard care and two studies225,227 compared both SCIT and SLIT with standard care. One study224 
compared different forms of SCIT (short and long term and with an adjuvant) to SLIT and standard care.
Cost perspectives and costs included
Six studies223,228,230–232,234 were undertaken from a purely societal perspective, and two224,227 were from a 
health insurer perspective. Five studies considered a combination of cost perspectives: two222,225 considered 
societal, health service and patient perspectives, one226 used societal and NHS (Italy) perspectives, one used 
societal and third-party payer points of view,229 and one235 used societal, NHS (Germany) and health insurer 
perspectives. The perspective used was not stated in one study.233
Costs associated with IT were divided into direct medical costs [e.g. costs related to GP visits, hospital visits 
(inpatient and outpatient), drugs and specialist examinations/tests] and indirect costs (e.g. cost related to 
productivity losses owing to time missed from work as a result of AR, or costs associated with productivity 
gains through reduced number of working days lost). Most EEs included both direct and indirect costs.
Outcomes within economic evaluations
A number of effectiveness or cost-effectiveness outcomes were reported in the EEs. These are listed by type 
of EE below.
For studies with a CCA, outcomes included SSs,222 number of asthma and rhinitis exacerbations and 
number of nursery/school days lost223 and VAS for allergic symptoms.233 Other outcomes were number 
of medical visits and health-care use,223,225 RQLQ and symptomatic medication reduction225 and 
break-even points of costs/expenses per patient.101 One study201 included development of asthma and 
new sensitisation.
The following outcomes were reported in the CEA studies: cost per number of patients improved and 
number of asthma cases avoided,226 cost per well-day and symptom-free day,233 number of additional 
patients free from asthma symptoms,235 and cost per asthma case avoided.227
Only six studies228–233 conducted CUAs, and therefore reported outcomes based on utility-based measures. 
For the four studies228,230–232 based on the GT–08 GRAZAX trial,93 the chosen measure of utility was the 
European Quality of Life-5 Dimensions (EQ-5D), which was then converted into quality-adjusted life-years 
(QALYs). The instrument or outcome measure on which the utilities, subsequently converted into QALYs, 
were based was not specified in Brüggenjürgen et al.229 In the fifth CUA study,233 QALY estimates were 
based on EQ-5D values mapped from RQLQ scores.
Model-based economic evaluations
Five studies224,226,227,229,234 reported analyses based on decision-analytic models. Of these, two224,229 used 
Markov models, whereas three226,227,235 were based on decision tree models. Six main health states were 
considered in Brüggenjürgen et al.,229 including mild AR, moderate to severe AR, severe AR and mild 
allergic asthma, severe AR and moderate to severe allergic asthma, no symptoms, and dead. Transition 
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probabilities depicting movement between these health states and annual costs were obtained from 
published sources. In Claes et al.,224 three main health states were modelled: SAR, non-SAR and asthma. 
Model inputs were not clearly described, but included data based on the PAT study.54–56 Assumptions were 
made for effectiveness, adherence and discontinuation rates.
Berto et al.226 considered five main health states in their decision tree: improvement, stabilisation, 
aggravation, inadequate response and asymptomatic. Data for the model came from the Retrospective 
Observation Physician Panel (ROPP). The same health states were considered in Omnes et al.,227 with most 
of the model inputs coming from a Delphi panel of 10 allergologists and one epidemiologist. In Schädlich 
and Brecht,235 two main health states were considered and divided by type of intervention (ST compared 
with specific IT): patients without asthma symptoms and patients with asthma symptoms. Data to 
populate this model came from a number of sources including observational studies and epidemiological 
information, statutory health insurance data, Uniform Assessment Standard information and cost-of-illness 
studies in Germany.238–240
Funding sources
Ten of the 14 EEs, and all of the CUAs, were funded by a manufacturer of SIT products or had an author 
who was affiliated to a manufacturer. Exceptions were the studies by Ariano et al.,222 Petersen et al.234 and 
Pokladnikova et al.225
Quality of economic evaluations
Quality assessment of the EEs identified a number of methodological issues, which are outlined below 
(see Appendix 10 for completed checklists and see Table 39 for key issues for each study).
Sources of clinical effectiveness data
Some studies222,225,228,230–232 were based on randomised trials and therefore were able to use robust 
resource use and outcome data. Four of the CUAs228,230–232 were based on findings from the GT–08 trial.93 
In other studies, however, there were limitations associated with the data sources. The use of self-reported 
data relying on patient recall over very long periods of time introduced imprecision in the calculating of 
parameters; for example, the recall period was 6 years in Petersen et al.234 Other studies, such as that by 
Omnes et al.,227 did not use patient-level data but instead used expert panels to estimate efficacy and 
health resource use data, which could lead to biases. In the Claes et al. study,224 assumptions were made 
regarding clinical effectiveness parameters.
Assumptions made
Some of the assumptions made in the studies did not appear realistic. In Schädlich and Brecht,235 for 
instance, non-adherence to IT was not accounted for as the model assumed 100% compliance. A number 
of studies made the assumption that resource use would be sustained over a period of extrapolation; 
Bachert et al.,228 for example, extrapolated 3-year outcome and resource use estimates to a 9-year period, 
whereas Keiding and Jørgensen 2007233 extrapolated 1-year data to a 9-year period.
Cost data
Overall, many studies provided sufficient detail in terms of resource use and unit cost data to allow for 
the potential use of these data in other studies. Some costs may have been underestimated owing to the 
non-inclusion of certain resource use data in the estimation of both direct and indirect costs, for example 
costs of hospitalisations222,223 or costs for non-allergy-related resource use.233
Discounting
The majority of studies discounted their costs by between 3% and 6%.
Generalisability of studies
It is unclear to what extent results (assuming that they are otherwise robust) can be generalised to 
wider populations. Some evaluations were based on small sample sizes222 or restricted to a single 
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allergy centre.223 Selection bias may be an issue, as in one evaluation226 clinicians from different centres 
retrospectively reported data for 100 patients each. Where assumptions have been made regarding base-
line and post-treatment effectiveness,223,227 results are unlikely to be representative of real-life populations.
Reporting
Inadequate or incomplete reporting hampered analysis of the studies included in this review. For instance, 
parameter estimates used to populate decision tree or Markov models were either partly reported222 or not 
reported at all.229 In particular, actual EQ-5D and QALY estimates, although used in the analyses, were not 
reported.228,230–232 One study233 did not report the size of the sample analysed, making it difficult to assess 
the validity of the analysis. Some studies did not clearly describe the sources of the data used (e.g. sources 
of health-care resource data for Berto et al.223), making it difficult to comment on the appropriateness of 
the costs estimates. Furthermore, some studies222,223 did not provide information on whether or not they 
had discounted their costs, making it difficult to ascertain the accuracy of these costs.
Sensitivity analyses
No sensitivity analyses were conducted in three studies,222,223,233 although this would have been 
appropriate. Sensitivity analyses in the other 11 studies took the form of univariate deterministic sensitivity 
analyses, varying a number of parameters, such as costs,224–231 disease and severity levels,226,239 thresholds 
for cost-effectiveness,228,230 cost perspectives,226,229 IT treatment time,229,232 excluding certain patient 
groups,230 time horizon of model224,225,231 and discount rates.224,229 These analyses enabled the robustness of 
the study results to be tested. However, no probabilistic sensitivity analyses were undertaken for the model-
based studies as is usual practice.241 This, therefore, meant that uncertainty around model inputs was not 
accounted for in the model results.
Results of economic evaluations
Seven studies134,223,226–228,231,232 compared SLIT with standard care, and all found that SLIT was more cost-
effective. Studies reporting results of EEs based on data from randomised studies134,222,225,228,231,232 seemed 
to have been the most robust. The quality of reporting for resource use and unit cost data in these trial-
based studies also appeared to be adequate. Four studies228,230–232 reported cost per QALY (Table 39); all 
were based on the same multinational trial (GT–0893) and included populations from different European 
countries in the respective analyses. All found that Grazax was cost-effective (below a threshold of 
£20,000), providing that annual costs of Grazax remain below £2200. The current annual cost in the UK 
is £814 (at £2.23 per tablet).46 The evaluations appear to be well conducted; however, there was a general 
lack of detailed reporting on the outcome side, for example lack of disaggregated baseline and follow-up 
EQ-5D values and QALY gains. All four studies were funded by the manufacturer of Grazax.
Six studies222,227,229,233–235 compared SCIT with standard treatment. All found that SCIT was associated 
with better outcomes and/or lower long-term costs. Two studies229,233 calculated a cost per QALY for SCIT 
(see Table 39). Brüggenjürgen et al.229 found a low ICER, but the robustness of this result is uncertain, as 
there was insufficient detail on the instrument used to derive utilities, and on cost and resource use data. 
The evaluation by Keiding and Jørgensen233 found that SCIT either dominated ST or was associated with 
very low ICERs, although robust sensitivity analyses were not conducted.
Where SCIT and SLIT were directly compared against each other, SCIT was found to be both more effective 
and more cost-effective over the long term. The sample size of the only trial225 that has directly compared 
the cost-effectiveness of SCIT and SLIT was, however, small (n = 64), and therefore more studies based 
on larger samples are needed. As this was a CCA, there is no combined cost-effectiveness measure. 
Assumptions made in the other study224 that directly compared the two interventions were not robust 
enough and variations of such assumptions should ideally be tested within a sensitivity analysis.
Other useful studies
Three studies242–244 were identified that reported utility-based outcomes for AR. Tamayama et al.242 used 
the rating scale and time trade-off methods to estimate utility weights for four AR severity levels (mild, 
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moderate, severe and severest) based on a Japanese sample. From mild to severest, time-trade-off 
estimates were 0.96, 0.94, 0.89 and 0.83, respectively. The rating scale counterpart weights were 0.82, 
0.71, 0.56 and 0.43. Chen et al.243 collected EQ-5D data for three groups in the USA and reported the 
following values: 0.76 (for individuals with asthma and rhinitis), 0.76 (for those with asthma only) and 
0.92 (for individuals with rhinitis only). In Wasserfallen et al.,244 the responsiveness of the EQ-5D when 
used on asthma patients with AR was compared with that of the McMaster Asthma Quality of Life 
Questionnaire (MAQOL). The EQ-5D was found to be less responsive than the MAQOL.
Two abstracts245,246 reporting EEs of Grazax based on populations of children with AR were identified at a 
late stage of writing this report and have thus not been formally included. A detailed appraisal was not 
possible, as the information was in abstract form only, but the results of these studies were consistent 
with those found for adults in that Grazax was found to be cost-effective compared with ST below a 
£20,000 threshold.
Reviews of economic evaluations
Both reviews of EEs237,247 considered studies that applied simple cost analyses as well as full EEs from 
societal, health service and patient perspectives (Table 40).
Nine EEs222,223,225–228,230,233,235 included in Berto et al.247 were also identified in the present review. All of the 
EEs reported in Hankin et al.237 were included in our review with the exception of Buchner and Siepe,248 
which seems to be a cost analysis rather than a CBA. Neither review presents a detailed search strategy. An 
additional seven EEs224,225,229–232,234 were identified for this report.
TABLE 39 Incremental cost-effectiveness ratios reported in the literature for SIT vs standard care
Study Intervention Cost per QALY Comments
Bachert 2007228 SLIT (Grazax) Cost per QALY gained between 
€12,930 and €18,263 for 
different northern European 
countries, including the UK
SLIT was cost-effective at an annual cost 
of €2200 [tablet < €6 (£4) and based on a 
threshold of €29,000 (£20,000) per QALY]
Beriot-Mathiot 
2007232
SLIT (Grazax) Cost per QALY gained between 
€7894 and €47,844 for different 
northern European countries, 
including UK
WHO-recommended SLIT pattern was cost-
effective if sustained effect after treatment 
is ≥ 2 years based on a threshold of €29,000 
(£20,000) per QALY, whereas seasonal SLIT 
pattern was cost-effective regardless of time 
horizon with ICER of €21,829
Brüggenjürgen 
2008229
SCIT (product 
not stated)
From a third-party payer’s 
perspective, SCIT + ST is 
associated with a cost per QALY 
of €8308
From a societal point of view break-even 
point is reached after 10 years, after 15 years 
SCIT dominates ST (i.e. is cheaper and more 
effective)
Canonica 2007230 SLIT (Grazax) Cost per QALY gained between 
€13,870 and €21,695 for 
different European countries 
(Spain, France, Italy and Austria)
Cost-effective at annual cost of Grazax of 
between €1500 and €1900
Keiding and 
Jørgensen 2007233
SCIT (Alutard 
SQ)
Cost per QALY gained between 
€9716 and €25,863 per QALY 
(without indirect costs)
With indirect costs included, SCIT dominates 
ST or has low ICERs
Nasser 2008231 SLIT (Grazax) Cost per QALY gained between 
£4319 and £11,769 (UK only)
Cost-effective up to an annual cost of Grazax 
of £1850. The highest cost per QALY in 
sensitivity analyses was £11,769
WHO, World Health Organization.
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Consistent with our findings, both reviews found that IT (SCIT or SLIT) was (just) more effective or, in 
some cases, both more effective and cost-effective when compared with standard care. Hankin et al.237 
also highlighted limitations associated with the data sources used in the EEs, a finding similar to ours. In 
particular, there were issues around generalisability and short time horizons associated with trial-based 
studies, and concerns about the quality of data obtained from observational studies were also raised.
Conclusions
Economic evaluations varied widely in the type of analysis used, outcome measures, sources for cost 
and effectiveness data, and adequacy of reporting for different parameters (Table 41). They did find 
consistently that where either SCIT or SLIT was compared with standard therapy, IT was (just) more 
effective or, in some cases, both more effective and cost-effective. The most robust studies228,230–232 found 
that SLIT is likely to be cost-effective at thresholds of £20,000; these studies did not, however, report all 
of the utility data in a disaggregated form and all were funded by a manufacturer of SIT products. SCIT 
was also found to be cost-effective at a threshold of £20,000 (based on two studies229,233); however, these 
results were associated with slightly greater uncertainty.
Only two studies224,225 looked at the cost-effectiveness of SCIT compared with SLIT. Although suggestive of 
greater cost-effectiveness for SCIT, both studies had some methodological concerns associated with them 
and neither presented combined cost-effectiveness measures.
Preferred adult and child Markov models
To estimate the comparative long-term cost-effectiveness of SCIT and SLIT when used to treat SAR, two 
Markov models were constructed (adults and children) in TreeAge Pro 2009 (TreeAge Software, Inc., 
Williamstown, MA, USA). Both models were built to combine costs and outcomes associated with three 
different treatment pathways, SCIT, SLIT or standard (symptomatic) treatment.
Briefly, this entailed dividing a patient’s possible course of disease progression into a number of health 
states with transition probabilities assigned for the movement between these states over a discrete time 
period (Markov cycle). Long-term costs and health outcomes are assessed by attaching estimates of 
resource use and health outcomes to the states in the model and then running the model over a large 
number of cycles to evaluate patient movement between states. Clinical advice was taken into account for 
the model structure (e.g. types of health states).
Adult Markov model
The long-term progress of a hypothetical cohort of AR patients moving along the three alternative 
pathways of care (SCIT, SLIT and ST) was to be compared. The treatment schedules for SCIT, SLIT and ST 
are presented in more detail in Chapter 1 (see Allergen immunotherapy). Briefly, patients would receive 
weekly subcutaneous injections (SCIT) for 16 weeks in a clinical setting, followed by monthly injections 
for up to 3 years. Patients receiving SLIT would take daily tablets or drops at home, also for up to 3 years. 
Symptomatic treatments may be oral, topical or intranasal. Occasionally, systemic corticosteroids may 
be prescribed.
Patients would then follow clinical pathways designed to mirror the natural progression of the condition 
in the population, with health resources use for all three groups also modelled. The aim was to enable 
model-based predictions of costs and outcomes to be compared for the SCIT, SLIT and ST groups in a CUA 
from the UK NHS and patient perspectives.
Adult Markov model structure and model inputs
The structure of the adult Markov model is shown in Figures 14–16. Only health states for the SCIT and ST 
arms are presented. The health states for the SLIT arm are identical to those in the SCIT arm.
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FIGURE 14 Adult Markov model structure: SLIT arm. Note that the health states for the SLIT arm are identical to those 
in the SCIT arm.
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FIGURE 15 Adult Markov model structure: SCIT arm. [+], same structure as the first expanded structure directly above 
but with appropriate changes in probabilities.
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Subcutaneous immunotherapy arm
The Markov process for the SCIT arm begins with the initial health state called ‘Start IT’ representing 
individuals with SAR eligible for treatment with SCIT. Following the ‘Start IT’ health state, the model then 
distinguishes between patients who, in addition to SCIT, would receive treatment to control all, or some, of 
their symptoms (symptoms controlled and symptoms part controlled), as well as patients who would not 
receive any ST at all as they are assumed to be symptom free (no ST).
In the second or third year, patients who complete the previous year of SCIT (with or without ST) may then 
continue with, or quit, SCIT. In total, patients can move to one of 10 possible health states. The first three 
represent variations of patients continuing with SCIT with or without ST (‘on IT no ST’, ‘on IT symptoms 
controlled’ or ‘on IT symptoms partly controlled’). The next three health states are for patients who have 
completed SCIT and then continue with or without ST (i.e. ‘complete IT no ST’, ‘complete IT symptoms 
controlled’ or ‘complete IT symptoms partly controlled’). Patients who remained on SCIT for 3 years move 
to one of these states at the end of the third year. Another three health states depict options for patients 
who continue with or without ST having quit SCIT in the first or second year (i.e. ‘Early quit IT no ST’, ‘Early 
quit IT symptoms controlled’ or ‘Early quit IT symptoms partly controlled’). The last health state is ‘Dead’. 
Moving on from nine of these 10 health states (excluding ‘Dead’), the model also allowed for a change in 
ST. For instance, given that an adult with AR completed treatment with SCIT in the first or second year and 
was not on any other treatment, what was the probability that they would add treatments to control all, 
or some, of their symptoms at some point within the following year?
The symptomatic treatment-only arm
The starting point for the Markov process in the ST-only arm is the health state called ‘Start Symptomatic 
Rx only’ representing individuals with SAR eligible for treatment with SCIT or SLIT, but only receiving 
treatment to relieve their AR symptoms. Following the ‘Start Symptomatic Rx only’ health state, the 
model then distinguishes between patients who continue with treatment to control all or some of their 
symptoms (symptoms controlled and symptoms part controlled) as well as patients who stop receiving any 
ST completely (no ST). In the second or third year, patients who survive the previous year with or without 
ST can then move to one of four possible health states: have no ST (No ST), have treatment to control all 
Survive
No symptomatic treatment (SUBTREE 10)
Die
Survive
Die
Survive
Die
Dead
Dead
Dead
No symptomatic treatment
Symptoms controlled (SUBTREE 11)
Symptoms controlled
Symptoms part controlled (SUBTREE 12)
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1
No symptomatic treatment (SUBTREE 10)
0
[+] 
[+] 
[+] 
Symptoms controlled (SUBTREE 11)
0
Symptoms part controlled (SUBTREE 12)
0
Dead
0
Symptomatic Rx only
FIGURE 16 Adult Markov model structure: ST arm. [+], same structure as the first expanded structure directly above 
but with appropriate changes in probabilities.
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of their symptoms (Symptoms controlled), have treatment to control some of their symptoms (Symptoms 
partly controlled) or die (Dead).
Child Markov model
Methods of delivering SIT were similar to those in the adult model, but with appropriate adjustments in 
dosages. The resultant clinical pathways were also designed to mirror the natural progression of AR in the 
children with health resources use for all three groups also modelled. The goal for this model was also to 
enable model-based predictions of costs and outcomes to be compared for the SCIT, SLIT and ST groups in 
a CUA from the UK NHS and patient perspectives.
Child model structure and model inputs
The structure of the child Markov model is similar to that for adults except it incorporates asthma in all 
outcomes in order to account for the probability of developing the condition among children with AR 
(Figures 17–20). Only health states for the SCIT and ‘Symptomatic treatment’ arms are presented. The 
health states for the ‘SLIT’ arm are identical to those in the ‘SCIT’ arm.
Subcutaneous immunotherapy arm
The Markov process for the SCIT arm begins with the initial health state called ‘Start IT’, representing 
children with SAR who are eligible for treatment with SCIT. Following the ‘Start IT’ health state, the model 
then distinguishes between children who, in addition to SCIT, would receive treatment to control all, or 
some of their symptoms (symptoms controlled and symptoms part controlled), as well as children who 
would not receive any ST at all (no ST). In the second or third year, asthmatic and non-asthmatic children 
who complete the previous year following SCIT (with or without ST) may then continue with, or quit, 
SCIT. Therefore, patients can move to 1 of 19 possible health states. The first six represent variations of 
asthmatic and non-asthmatic children continuing with SCIT with or without ST (‘on IT no ST with asthma’, 
‘on IT no ST without asthma’, ‘on IT symptoms controlled with asthma’, ‘on IT symptoms controlled 
without asthma’, ‘on IT symptoms partly controlled with asthma’ or ‘on IT symptoms partly controlled 
without asthma’). The next six present states for asthmatic and non-asthmatic children who complete 
SCIT and then continue with or without ST (i.e. ‘complete IT no ST with asthma’, ‘complete IT no ST 
without asthma’, ‘complete IT symptoms controlled with asthma’, ‘complete IT symptoms controlled 
without asthma’, ‘complete IT symptoms partly controlled with asthma’ or ‘complete IT symptoms partly 
controlled without asthma’). Patients who remained on SCIT for 3 years move to one of these states at the 
end of the third year. Another six health states depict options for asthmatic and non-asthmatic children 
who continue with or without ST having quit SCIT in the first or second year (i.e. ‘Early quit IT no ST with 
asthma’, ‘Early quit IT no ST without asthma’, ‘Early quit IT symptoms controlled with asthma’, ‘Early quit 
IT symptoms controlled without asthma’, ‘Early quit IT symptoms partly controlled with asthma’ or ‘Early 
quit IT symptoms partly controlled without asthma’). The last health state is ‘Dead’. Moving from 18 of 
these 19 health states (excluding ‘Dead’), the model also allowed for a change in ST. For instance, given 
that an asthmatic child with AR completed treatment with SCIT in the first or second year and was not on 
any other treatment, what was the probability that they would add treatments to control all or some of 
their symptoms at some point within the following year?
The symptomatic treatment-only arm
The starting point for the Markov process in the ST-only arm is the health state called ‘Start Symptomatic 
Rx only’, representing children with SAR who are eligible for treatment with SIT but who are receiving 
treatment to relieve only their AR symptoms. Following the ‘Start Symptomatic Rx only’ health state, the 
model then distinguishes between children who continue with treatment to control all or some of their 
symptoms (symptoms controlled and symptoms part controlled), as well as children who would not 
receive any ST at all (no ST). In the second or third year, both asthmatic and non-asthmatic patients who 
complete the previous year with or without ST can then move to one of seven possible health states. 
These include states for asthmatic children who have no ST (‘No ST with asthma’), non-asthmatic children 
who have no ST (‘No ST without asthma’), asthmatic children who have treatment to control all of their 
symptoms (‘Symptoms controlled with asthma’) and non-asthmatic children who have treatment to 
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Symptoms part controlled with asthma (SUBTREE 24)
FIGURE 17 Child Markov model structure. Note that the health states for the SLIT arm are identical to those in the 
SCIT arm.
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On IT no symptomatic treatment without asthma (SUBTREE 1)
Early quit IT no symptomatic treatment without asthma (SUBTREE 13)
On IT no symptomatic treatment with asthma (SUBTREE 2)
Early quit IT no symptomatic treatment with asthma (SUBTREE 14)
No symptomatic treatment
On IT symptoms controlled without asthma (SUBTREE 3)
Early quit IT symptoms controlled without asthma (SUBTREE 15)
On IT symptoms controlled with asthma (SUBTREE 4)
Early quit IT symptoms controlled with asthma (SUBTREE 16)
On IT symptoms part controlled without asthma (SUBTREE 5)
Early quit IT symptoms part controlled without asthma (SUBTREE 17)
Continue IT
On IT symptoms part controlled with asthma (SUBTREE 6)
Quit IT
Continue IT
Quit IT
Continue IT
Quit IT
Continue IT
Quit IT
Continue IT
Quit IT
Continue IT
Quit IT
Early quit IT symptoms part controlled with asthma (SUBTREE 18)
Symptoms part controlled
Start IT
1
Completed IT no symptomatic treatment without asthma (SUBTREE 7)
On IT no symptomatic treatment without asthma (SUBTREE 1)
Early quit IT no symptomatic treatment without asthma (SUBTREE 13)
Completed IT no symptomatic treatment with asthma (SUBTREE 8)
On IT no symptomatic treatment with asthma (SUBTREE 2)
Early quit IT no symptomatic treatment with asthma (SUBTREE 14)
No symptomatic treatment
Completed IT symptoms controlled without asthma (SUBTREE 9)
On IT symptoms controlled without asthma (SUBTREE 3)
Early quit IT symptoms controlled without asthma (SUBTREE 15)
Completed IT symptoms controlled with asthma (SUBTREE 10)
On IT symptoms controlled with asthma (SUBTREE 4)
Early quit IT no symptomatic treatment with asthma (SUBTREE 14)
Symptoms controlled
Completed
Completed IT symptoms part controlled without asthma (SUBTREE 11)
On IT symptoms part controlled without asthma (SUBTREE 5)
Early quit IT symptoms part controlled without asthma (SUBTREE 17)
Not completed
Completed
Not completed
Completed
Not completed
Completed
Not completed
Completed
Not completed
Completed
Not completed
No asthma
Completed IT symptoms part controlled with asthma (SUBTREE 12)
Continue IT On IT symptoms part controlled with asthma (SUBTREE 6)
Quit IT
Continue IT
Quit IT
Continue IT
Quit IT
Continue IT
Quit IT
Continue IT
Quit IT
Continue IT
Quit IT
Early quit IT symptoms part controlled with asthma (SUBTREE 18)
Asthma
No asthma
Asthma
On IT no symptomatic treatment without asthma (SUBTREE 1)
0
Completed IT no symptomatic treatment with asthma (SUBTREE 8)
On IT no symptomatic treatment with asthma (SUBTREE 2)
Early quit IT no symptomatic treatment with asthma (SUBTREE 14)
Completed IT symptoms controlled with asthma (SUBTREE 10)
On IT symptoms controlled with asthma (SUBTREE 4)
Early quit IT symptoms controlled with asthma (SUBTREE 16)
Dead
Dead
Completed Completed IT symptoms part controlled with asthma (SUBTREE 12)
On IT symptoms part controlled with asthma (SUBTREE 6)
Early quit IT symptoms part controlled with asthma (SUBTREE 18)
On IT symptoms controlled without asthma (SUBTREE 3)
On IT symptoms controlled with asthma (SUBTREE 4)  
On IT symptoms part controlled without asthma (SUBTREE 5)  
On IT symptoms part controlled with asthma (SUBTREE 6)
0  
Dead
0
SCIT
 [+] 
 [+] 
 [+] 
 [+] 
Dead
Die
Die
Die
Die
Survive
Survive
Survive
Survive
Symptoms part controlled Not completed
Completed
Not completed
Symptoms controlled
No symptomatic treatment
On IT no symptomatic treatment with asthma (SUBTREE 2)
Quit IT
Continue IT
Quit IT
Continue IT
Dead
Survive
Die
Survive
Dead
No asthma
Asthma
Dead
Die
Survive
No asthma
Asthma
Dead
Die
Survive
Die
Survive
No asthma
Asthma
No asthma
Asthma
Dead
Completed
Not completed
Quit IT
Continue IT
Symptoms part controlled
Symptoms controlled
FIGURE 18 Child Markov model structure: SCIT arm (subtrees 1–6). [+], same structure as the first expanded structure 
directly above but with appropriate changes in probabilities.
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On IT no symptomatic treatment without asthma (SUBTREE 1)
Early quit IT no symptomatic treatment without asthma (SUBTREE 13)
On IT no symptomatic treatment with asthma (SUBTREE 2)
Early quit IT no symptomatic treatment with asthma (SUBTREE 14)
No symptomatic treatment
On IT symptoms controlled without asthma (SUBTREE 3)
Early quit IT symptoms controlled without asthma (SUBTREE 15)
On IT symptoms controlled with asthma (SUBTREE 4)
Early quit IT symptoms controlled with asthma (SUBTREE 16)
Symptoms controlled
On IT symptoms part controlled without asthma (SUBTREE 5)
Early quit IT symptoms part controlled without asthma (SUBTREE 17)
No asthma
Continue IT
On IT symptoms part controlled with asthma (SUBTREE 6)
Quit IT
Continue IT
Quit IT
Continue IT
Quit IT
Continue IT
Quit IT
Continue IT
Quit IT
Continue IT
Quit IT
Early quit IT symptoms part controlled with asthma (SUBTREE 18)
Asthma
No asthma
Asthma
No asthma
Asthma
Symptoms part controlled
Start IT
1
Completed IT no symptomatic treatment without asthma (SUBTREE 7)
Completed IT no symptomatic treatment with asthma (SUBTREE 8)No symptomatic treatment
Completed IT symptoms controlled without asthma (SUBTREE 9)
Completed IT symptoms controlled with asthma (SUBTREE 10)Symptoms controlled
No asthma Completed IT symptoms part controlled without asthma (SUBTREE 11)
Asthma
No asthma
Asthma
No asthma
Asthma
Completed IT symptoms part controlled with asthma (SUBTREE 12)Symptoms part controlled
Completed IT no symptomatic treatment without asthma (SUBTREE 7)
Completed IT no symptomatic treatment with asthma (SUBTREE 8)No symptomatic treatment
Completed IT symptoms controlled with asthma (SUBTREE 10)Symptoms controlled
Survive
Survive
Survive
Survive
Survive
Survive
Survive
Survive
Completed IT symptoms part controlled with asthma (SUBTREE 12)
Die
Die
Die
Die
Die
Die
Die
Die
Dead
Dead
Dead
Dead
Dead
Dead
Dead
Dead
Survive
Die Dead
Symptoms part controlled
Completed IT no symptomatic treatment with asthma (SUBTREE 8)
0
Completed IT symptoms controlled without asthma (SUBTREE 9)  
Completed IT symptoms controlled with asthma (SUBTREE 10)
0
Completed IT symptoms part controlled without asthma (SUBTREE 11)
Completed IT symptoms part controlled with asthma (SUBTREE 12)
0
Early quit IT no symptomatic treatment without asthma (SUBTREE 13)
Early quit IT no symptomatic treatment with asthma (SUBTREE 14)
Early quit IT symptoms controlled without asthma (SUBTREE 15)
Early quit IT symptoms controlled with asthma (SUBTREE 16)Symptoms controlled
No asthma
Early quit IT symptoms part controlled without asthma (SUBTREE 17)
Asthma
No asthma
Asthma
No asthma
Asthma
Early quit IT symptoms part controlled with asthma (SUBTREE 18)
Survive
Survive
Survive
Survive
Survive
Survive
Symptoms part controlled
Early quit IT no symptomatic treatment without asthma (SUBTREE 13)
Early quit IT no symptomatic treatment with asthma (SUBTREE 14)No symptomatic treatment
No symptomatic treatment
Early quit IT symptoms controlled with asthma (SUBTREE 16)Symptoms controlled
Early quit IT symptoms controlled with asthma (SUBTREE 16)
Die
Die
Die
Die
Die
Die
Dead
Dead
Dead
Dead
Dead
Dead
Symptoms part controlled
Early quit IT no symptomatic treatment with asthma (SUBTREE 14)
0
Early quit IT symptoms controlled without asthma (SUBTREE 15)
Early quit IT symptoms controlled with asthma (SUBTREE 16)
0
Early quit IT symptoms part controlled without asthma (SUBTREE 17)
Early quit IT symptoms part controlled with asthma (SUBTREE 18)
0
Dead
0
SCIT
[+] 
[+] 
[+] 
[+] 
[+] 
[+] 
[+] 
[+] 
FIGURE 19 Child Markov model structure: SCIT arm (subtrees 7–18). [+], same structure as the first expanded 
structure directly above but with appropriate changes in probabilities.
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No asthma No symptomatic treatment without asthma (SUBTREE 19)
Asthma No symptomatic treatment with asthma (SUBTREE 20)
Survive
Die
Survive
Die
Survive
Die
Survive
Die
Survive
Die
Survive
Die
Survive
Die
Survive
Die
Survive
Die
Dead
No asthma
Asthma
Dead
No asthma
Asthma
Dead
No asthma
Asthma
No asthma
Asthma
No asthma
Asthma
Dead
Dead
Dead
Dead
Dead
Dead
No symptomatic treatment
Symptoms controlled without asthma (SUBTREE 21)
Symptoms controlled with asthma (SUBTREE 22)Symptoms controlled
Symptoms part controlled without asthma (SUBTREE 23)
Symptoms part controlled with asthma (SUBTREE 24)Symptoms part controlled
Start Symptomatic RX only
1
No symptomatic treatment without asthma (SUBTREE 19)
No symptomatic treatment with asthma (SUBTREE 20)No symptomatic treatment
Symptoms controlled without asthma (SUBTREE 21)
Symptoms controlled with asthma (SUBTREE 22)Symptoms controlled
Symptoms part controlled without asthma (SUBTREE 23)
Symptoms part controlled with asthma (SUBTREE 24)Symptoms part controlled
No symptomatic treatment without asthma (SUBTREE 19)
No symptomatic treatment with asthma (SUBTREE 20)
No symptomatic treatment
Symptoms controlled with asthma (SUBTREE 22)
Symptoms controlled
Symptoms part controlled with asthma (SUBTREE 24)
Symptoms part controlled
No symptomatic treatment with asthma (SUBTREE 20)
0
Symptoms controlled without asthma (SUBTREE 21)
Symptoms controlled with asthma (SUBTREE 22)
0
Symptoms part controlled without asthma (SUBTREE 23)
Symptoms part controlled with asthma (SUBTREE 24)
0
Dead
0
Symptomatic Rx only
[+] 
[+] 
[+] 
[+] 
FIGURE 20 Child Markov model structure: ST arm. [+], same structure as the first expanded structure directly above 
but with appropriate changes in probabilities.
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control all of their symptoms (‘Symptoms controlled without asthma’). The rest of health states are for 
asthmatic children who have treatment to control some of their symptoms (‘Symptoms partly controlled 
with asthma’), non-asthmatic children who have treatment to control some of their symptoms (‘Symptoms 
partly controlled without asthma’) and ‘Dead’.
Inputs for both the adult and child Markov models
To conduct long-term comparative cost-effectiveness analyses of SCIT and SLIT when used to treat AR, a 
number of parameters (costs, outcomes and probabilities) were to be identified from the systematic review 
of EEs, systematic review of clinical effectiveness and other relevant studies.
Resource use and costs
All costs were to be reported in UK pounds at 2011–12 unit prices and, where appropriate, discounted at 
3.5% as recommended by the UK NICE.249 Resource use data were to be obtained from studies reviewed, 
as well as from expert opinion. Unit cost data were to be derived from nationally representative sources, 
such as the BNF (2012),250 the National Schedule for Reference Costs and the Unit Costs of Health and 
Social Care (PSSRU).251
Utility values
As the primary outcome was to be expressed in terms of costs per QALYs gained, studies were of interest if 
they reported utility scores to reflect the health-related QoL associated with each health state in the model.
Transition probabilities
To complete the process of populating the model, it is necessary to obtain transition probabilities 
governing movement between the different health states in both adult and child models from studies in 
this review. A full list of transition probabilities required for the two models is provided in Appendix 11.
Challenges met when identifying model inputs for the 
preferred Markov models
One purpose of conducting the systematic review was to identify data associated with IT interventions or 
that on health states within AR pathways that could be used to populate the preferred Markov models 
described above. Both model- and non-model-based studies were considered in this respect. In particular, 
four types of model inputs and information were sought:
1. UK costs associated with IT strategies. Where UK cost data were not available, other data from 
countries with similar or transferable characteristics were sought.
2. Utility-based outcome data associated with health states within AR pathways.
3. Markov model structures that could be populated with UK specific data to enable the modelling 
of long-term cost-effectiveness of different types of IT treatments. Where possible, data on health 
states (from both Markov and decision tree models) that could be adapted and used in the preferred 
Markov models.
4. Information on transition probabilities governing movements between health states in Markov and 
decision tree models.
It was not possible to identify much suitable data from the 16 included EEs and reviews. The reasons are 
discussed below by type of model input/information.
Cost data
Two studies228,231 were conducted using samples that included subjects from the UK, both of which 
compared SLIT with standard care. They presented detailed UK costs associated with AR, based on 
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resource use data such as visits to the GP, allergy specialist, and A&E department. In addition, costs of 
symptomatic and asthma medication, as well as indirect costs associated with production loss, were also 
presented. The cost estimates reported in these studies lend themselves to replication in our model and we 
would therefore consider these estimates to be credible inputs to our model. Despite these cost estimates 
all being based on the GT–08 GRAZAX trial,93 it is likely that these results would be transferable to the UK 
generally. Other potentially useful cost estimates were identified in four other European studies.225,226,230,234
Outcome measures
Over 15 different types of outcome measures have been reported in the studies evaluated.
As described above (see Quality of economic evaluations), the vast number of these outcomes were not 
expressed as utilities but rather as ‘natural’ outcomes, and, as such, cannot be used in the Markov model. 
These include the number of asthma and rhinitis exacerbations, number of hospital visits and absence 
from nursery or school, SSs and MSs or the RQLQ.
Some studies did report utility-based outcome measures that could be converted into QALYs. As outlined 
above (see Main characteristics of economic evaluations), these utility-based outcomes were based on 
EQ-5D for four of the studies228,230–232 and on an unspecified instrument for one study.229 Studies whose 
QALYs were based on EQ-5D did not present EQ-5D data in sufficient detail to allow for their replication 
in our model. In particular, no baseline or follow-up values were reported in three of these studies,228,230,231 
with only the final results being reported in terms of cost per QALY gained. In the Beriot-Mathiot et al. 
study,232 EQ-5D could be read off a diagram, but these were not disaggregated according to SLIT or ST. 
Brüggenjürgen et al.229 reported utility scores for the following health states: mild AR (0.7579); moderate 
to severe AR (0.7378); severe AR and mild allergic asthma (0.7317); severe AR and moderate to severe 
allergic asthma (0.6985); no symptoms (0.7841); and death (0.0). Much higher utility scores were reported 
by Tamayama et al.242 for similar AR health states: 0.96 (mild), 0.94 (moderate), 0.89 (severe) and 0.83 
(severest). Provided that information on transition probabilities could have been obtained, these values 
could potentially have been used. In order to explore the possibility of using utility data based on a UK 
population, study authors from the GT–08 trial93 were contacted, but it was not possible to obtain the 
necessary data.
Model structure and transition probabilities
Only five studies224,226,227,229,235 were model-based studies (EEs or effectiveness studies): three226,227,235 were 
based on decision tree models, whereas the other two224,229 used Markov models.
Berto et al.226 compared SLIT (with standard care) to standard care only, in a decision tree framework 
based on a sample of 2230 patients. A model structure was presented but the health states analysed are 
not the same or adaptable to those in our model. More importantly, information of transition probabilities 
depicting movements between health states is not presented in the study,226 making it impossible for the 
model to be replicated using UK cost data.
The second decision tree model-based evaluation235 was based on a cohort of 2000 patients and 
compared SCIT with ST. This study235 presented some potentially useful data on probabilities in terms 
of asthma symptoms: the proportion of patients with AR and asthma compared with those with AR 
only; patients with asthma symptoms compared with those without asthma symptoms following either 
symptomatic or specific IT treatment; proportion of patients who develop asthma compared with 
proportion who do not among patients previously without asthma; and the proportion of patients who 
stop having asthma symptoms compared with proportion who continue with the symptoms among 
patients previously with asthma. The target outcome was the number of additional patients free from 
asthma symptoms after 10 years. However, it was difficult to ascertain how robust these probabilities were 
as the sources were not described in detail. Changes in symptoms or severity of AR were not incorporated 
into this analysis.
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The third evaluation based on a decision tree model226 compared SCIT, SLIT and ST for adults and 
children with AR and asthma. Some potentially important transition probabilities were also presented 
in this study.226 However, most of these were based on expert opinion from a Delphi panel, whereas 
some information was obtained from an unpublished report. All epidemiological data (‘hypotheses’) for 
children were determined by the Delphi panel. For both children and adults, for example, the study227 gives 
proportions that help determine the following probabilities: having rhinitis only as opposed to having 
rhinitis and asthma; having moderate compared with having severe rhinitis; and having mild compared 
with moderate asthma, as well as the percentage decrease in ST associated with IT by type of allergy and 
by SCIT or SLIT. However, attempts to replicate the model using UK cost data are not possible, as not all 
of the probabilities required to populate the model are presented, for example the proportion of patients 
who were either asymptomatic, who had an improvement in symptoms or those for whom the response 
to IT was inadequate.
Brüggenjürgen et al.229 presented an analysis based on a Markov model. This study229 was based on a 
hypothetical cohort of 2000 patients and compared SCIT in addition to ST to ST alone. An overview of 
the Markov model was given in the paper but the actual structure or the parameter estimates are not 
presented. This makes it difficult to assess the suitability of the model inputs for use in our model or for 
replicating the model using UK cost data.
The second Markov model-based study224 was a cost analysis comparing SCIT, SLIT and variations of SCIT 
with standard care. The structure of the model was presented in the paper showing various pathways 
taken by patients following different treatment options. The health states presented in this model are 
not the same as those in our preferred model, and, more importantly, there was a lack of detail on the 
transition probabilities governing movement between health states, which precluded attempts to replicate 
the model using UK cost data.
Suitable data on transition probabilities, i.e. proportion of patients moving between different health 
states or levels of disease severity depending on treatment, were also not identified in any of the clinical 
effectiveness studies reviewed for this report.
Summary
Detailed information was available on cost data. A number of studies (both UK and non-UK) reported 
direct and indirect costs in sufficient detail to allow for their replication in our model. In particular, data 
from Bachert et al.228 and Nasser et al.231 were useful, supplemented with those obtained from expert 
opinion. Furthermore, data on utility scores associated with some severity levels of AR were also available 
based on German229 and Japanese230 populations. It may therefore have been possible to adapt these data 
for use in our models.
The biggest challenge faced, however, was the lack of information on transition probabilities. Although 
some model structures were presented in sufficient detail in some studies,224,227 and utility data were 
provided in others,229 not enough information on transition probabilities was given in all of the studies to 
allow for model replication using UK cost data.
Economic evaluation of immunotherapy
Because of the challenges faced with obtaining model inputs for the preferred Markov models, it was 
decided that an alternative approach to estimating the cost-effectiveness of SCIT, SLIT and ST would be 
taken. A novel EE was conducted, with results expressed in terms of ICERs calculated as costs per unit 
improvement in RQLQ and costs per QALY gain.
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Methods
Costs estimation
Total costs were estimated by combining resource use data on staff, medication, supplies and productivity 
loss with unit costs. Resource use data are reported in Table 42, and unit costs are shown in Table 43.
Resource use for the sublingual immunotherapy group
The number of clinic visits for patients receiving SLIT was assumed to be 13 over a 3-year period, with an 
initial visit before commencing SLIT, followed by four outpatient visits per year (A Huissoon, Birmingham 
Heartlands Hospital, 9 March 2012, personal communication). Each visit for SLIT was assumed to last 
20 minutes (0.33 hours) and patients would be seen by a consultant and a grade 8 nurse. Estimates of 
SLIT medication were based on Grazax, with one tablet taken daily throughout the year.46 Over a 3-year 
period, the total number of tablets taken was 1095. Information on doses for two STs [desloratadine 
(Neoclarityn®, Schering-Plough) and budesonide (Budelin Novolizer®, Meda)] was obtained from the BNF 
(2012);46 the dose of desloratadine was 5 mg daily, whereas 0.1–0.8 mg of budesonide was given twice 
daily. In line with the BSACI guidelines2 (2008), ST was assumed to be administered for 3.5 months per 
year (2 weeks before, and then during the EPS). Estimates of productivity loss due to hours missed from 
work and hours at work with reduced productivity were obtained from a trial231 that assessed the cost-
effectiveness of Grazax in the UK.
Resource use for the subcutaneous immunotherapy group
Subcutaneous immunotherapy medication costs were based on Alutard. Although Pollinex is the only 
licensed product in the UK, treatment using Alutard is more representative of clinical practice in the UK 
(A Huissoon, personal communication). Pollinex is a preseasonal treatment consisting of six injections each 
year for 3 years, whereas Alutard is given throughout the year. After an updosing period (weekly injection 
for 12 weeks, followed by one injection after 2 weeks), maintenance injections are given once every 
4 weeks. Thus, the total number of injections with Alutard over a 3-year period was assumed to be 46, i.e. 
20 in year 1, and 13 in both years 2 and 3. Treatment with Alutard using 6-weekly, rather than 4-weekly, 
maintenance injections was also explored in an additional analysis. A clinic visit to receive an injection 
was assumed to last 0.27 hours, on the basis that a typical clinic, staffed by a consultant and a grade 8 
nurse, would last about 4 hours, during which time 15 patients would be seen (A Huissoon, personal 
communication). Supplies used during each clinic visit were assumed to be one swab, one syringe, two 
hypodermic needles and a pair of gloves for each patient. Proportional differences in doses of symptomatic 
medication between SCIT and SLIT were taken from the study by Pokladnikova et al.,225 which assessed the 
comparative cost-effectiveness of SCIT and SLIT; these proportions were 204/241 (SCIT/SLIT). Estimates of 
productivity loss for SCIT and SLIT were calculated based on data in the Pokladnikova et al. study225 and the 
Nasser et al. study231 Hours missed from work and hours at work with reduced productivity for the SCIT 
group were 14.03/5.75 and 16.25/7.77 those for SLIT, respectively.
Resource use for the symptomatic treatment group
The only resources considered in this group were symptomatic medication and estimates of productivity 
loss. Proportional differences in symptomatic medication doses between SLIT and ST observed in Nasser et 
al.231 were used in estimating incremental doses for SLIT and ST. Desloratadine and budesonide doses for 
ST were therefore assumed to be 15.88/13.22 and 22.43/15.68 those of SLIT, respectively. The estimates 
of productivity loss due to hours missed from work and hours at work with reduced productivity were 
obtained from Nasser et al.231
Unit costs for the sublingual immunotherapy, subcutaneous immunotherapy 
and symptomatic treatment groups
These are shown in Table 43. Hourly wages for consultants (£137) and averaged hourly wages for band 8 
nurses (£40.69) were obtained from Curtis.251 The costs of supplies (swabs, syringes, needles and gloves) 
were estimated from a commercial website.252 Drug costs for SLIT and symptomatic medications were 
based on the BNF (2012)46 or were obtained from the manufacturer of Alutard (A Young, ALK-Abelló, 
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TABLE 42 Resource use (SLIT, SCIT and ST)
Staff costs, consumables and productivity loss Units Source
Staff (hours per visit)
SLIT clinic visits
Consultant 0.33a Expert opinion
Band 8 nurse 0.33a Expert opinion
SCIT clinic visits
Consultant 0.27b Expert opinion
Band 8 nurse 0.27b Expert opinion
Supplies (no. of items per SCIT injection/visit)
Swabs 1 Expert opinion
Syringes 1 Expert opinion
Needles 2 Expert opinion
Gloves 1 Expert opinion
Medication
SLIT medication
Grazaxc One tablet daily BNF (2012)46
SCIT medication
Alutardd 10–100,000 units/ml Personal communication
Symptomatic medicinee
Desloratadine 5 mg/daily BNF (2012)46
Budesonide 0.1–0.8 mg twice dailyf BNF (2012)46
Productivity loss (SLIT)
Hours missed from work 2.12 Nasser et al. (2007)231
Hours at work with reduced productivity 4.73 Nasser et al. (2007)231
Productivity loss (SCIT)g
Hours missed from work 5.17 Pokladnikova et al. (2008),225 Nasser et 
al. (2007)231
Hours at work with reduced productivity 9.89
continued
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Staff costs, consumables and productivity loss Units Source
Productivity loss (ST)
Hours missed from work 6.27 Nasser et al. (2007)231
Hours at work with reduced productivity 14.04 Nasser et al. (2007)231
a It was assumed that patients would make five visits in year 1 and four visits in each of years 2 and 3, with every visit 
taking 20 minutes (0.33 hours).
b This was estimated as 4 hours in a typical SCIT clinic for 15 patients.
c Grazax tablets were assumed to be taken daily over the course of 3 years, i.e. 365 tablets per year.
d It was assumed that patients undergoing SCIT would have 46 injections over 3 years: 20 in year 1 and 13 in each of 
years 2 and 3.
e Proportional differences in symptomatic medication dosages between SCIT and SLIT observed in Pokladnikova et al.225 
were applied. As a result, total symptomatic treatment dosage for SCIT was assumed to be 204/241 that of SLIT. 
Similarly, proportional differences in symptomatic medication dosages between SLIT and ST observed in Nasser et 
al.231 were used in estimating incremental dosages for SLIT and ST. Desloratadine and budesonide dosages for ST were 
assumed to be 15.88/13.22 and 22.43/15.68 those of SLIT, respectively.
f The average of this dosage range was used in the base-case analysis, i.e. 0.45 mg twice daily.
g Based on the proportional differences in estimates of productivity loss between SCIT and SLIT observed in 
Pokladnikova et al.,225 estimates used for SCIT were inflated from those applied to the SLIT group, i.e. hours missed 
from work and hours at work with reduced productivity were 14.03/5.75 and 16.25/7.77 those of SLIT, respectively.
TABLE 43 Unit costs (SLIT, SCIT and ST)
Staff costs, consumables and productivity loss Units Source
Staff (wage per hour)
Consultant £137.00 Curtis (2011)251
Band 8 nurse £40.69a Curtis (2011)251
Supplies (cost per item)
Swabs £0.01 Medisave (2011)252
Syringes £0.10 Medisave (2011)252
Needles £0.03 Medisave (2011)252
Gloves £0.03 Medisave (2011)252
Medication
SLIT medication
Grazax £2.23 per tablet BNF (2012)46
SCIT medication
Alutard £61.97–93.82/mlb Manufacturer communication
Symptomatic medicine
Desloratadine £0.02/mg BNF (2012)46
Budesonide £0.44/mg BNF (2012)46
Productivity loss
Average wage/hour £9.62c Office for National Statistics (2011)253
a An average wage for the four grades within band 8 was used.
b This unit cost varies according to the amount of Alutard vaccine units in each 1-ml injection, i.e. from 10 to 100,000 
units per millilitre.
c This was estimated as the gross hourly rate for the UK in 2011 (£14.82) minus tax, pension and national insurance 
contributions, valued at 35% of the average gross rate.
TABLE 42 Resource use (SLIT, SCIT and ST) (continued)
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29 March 2012, personal communication). The opportunity costs associated with productivity loss 
were estimated as the gross hourly rate for the UK in 2011 minus tax, pension and national insurance 
contributions valued at 35% of the average gross rate.254 As this hourly rate was £14.82 (Office for 
National Statistics253), the opportunity cost associated with productivity loss was assumed to be £9.62.
Outcome estimation
Two outcomes were assessed in this EE: the RQLQ and QALYs.
Rhinoconjunctivitis Quality of Life Questionnaire
Two sets of mean RQLQ changes (and associated CIs) were used in this model. The first set was based on 
meta-analyses of SLIT compared with ST, and SCIT compared with ST (direct comparisons; see Chapter 3, 
Results). The second set was based on results from the ICMR (SLIT compared with ST, SCIT compared with 
ST and SCIT compared with SLIT (see Chapter 3, Indirect comparison subcutaneous immunotherapy versus 
sublingual immunotherapy).
Quality-adjusted life-years
These were based on changes in the EQ-5D, with an assumption that the EQ-5D changes applied to a 
3-month period during the pollen season. To calculate EQ-5D, a mapping algorithm was used to convert 
mean RQLQ changes associated with either SCIT or SLIT to mean EQ-5D changes. The most appropriate 
method of developing a mapping equation between two measures is to apply both measures to a 
common group of patients. As no data set based on such a comparison was available, nor the result of 
any mapping exercise based on such a comparison, it was necessary to make a number of assumptions 
in calculating the EQ-5D values. The RQLQ scale is from 0 (best) to 6 (worst). It is assumed that the top 
end of the scale maps to the EQ-5D state representing no problems in any of the five dimensions. By 
definition, this state has a QoL score of ‘1’. The bottom end of the RQLQ scale was mapped to the EQ-5D 
state representing maximum problems with usual activities, pain/discomfort and anxiety/depression, but 
no problems with mobility or self-care, which are assumed to be unaffected by SAR. This state has a QoL 
score of –0.07 on the standard UK tariff. Therefore, it was assumed that going from worst to best was a 
six-point reduction in RQLQ and a 1.07-point increase in the EQ-5D score. As a result, each unit decrease 
(improvement) in RQLQ was assumed to map to a 0.178-point increase in QoL score (assuming that a unit 
decrease has the same value at all points on the scale).
Incremental cost-effectiveness ratio calculation
The generic formula for an ICER255 was used to calculate cost-effectiveness estimates. For an outcome 
based on costs per QALY in a comparison between SCIT and ST, for example, the formula would be 
given by:
ICER =
Cost of SCIT – Cost of ST
QALYs for SCIT – QALYs for ST
  (1)
Discounting
All costs are reported in UK pounds at 2010–11 unit prices. All future costs and outcomes, where 
appropriate, were discounted at 3.5% as recommended by NICE.249
Duration of analysis
Based on expert clinical opinion and observations from clinical trials (the GT–08 trial93), it was assumed 
that 3 years of IT would result in a sustained effect of a further 3 years. Therefore, a 6-year time horizon 
was used in the base-case analysis of this study.93 For illustration purposes, however, a time horizon of 
up to 10 years (7 years post IT) was also considered. Costs included from years 4 to 10 were only those 
associated with ST and productivity loss. As SLIT and SCIT medication was assumed to be given for only 
3 years, only 3-year cumulative costs were incorporated in the analysis of costs beyond 3 years.
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Results
Costs
The annual and cumulative costs associated with SLIT, SCIT and ST are shown in Tables 44–46. The annual 
costs of SCIT were higher than those for either SLIT or ST. Over a 3-year period, the cumulative costs for 
SCIT were £2869 and £5537 higher than those for SLIT and ST, respectively. The major cost drivers for the 
SCIT group were staff and SCIT medication costs; this was the same in the SLIT group, although not to the 
same extent as for SCIT. Costs associated with productivity loss were highest in the ST group (about 35% 
and 30% higher than for the SCIT and SLIT groups, respectively).
A similar hierarchy of costs could be observed when costs were extrapolated from 3 years to a time 
horizon of between 4 and 10 years (Tables 47–49). However, the differences between SCIT and ST and 
between SLIT and ST reduced gradually with time, whereas those between SCIT and SLIT increased.
Cost-effectiveness results
Results based on both direct comparisons and indirect comparisons of the difference in RQLQ between the 
three groups are presented below.
Direct comparisons
As shown in Table 50, the mean change in RQLQ for the comparison between SLIT and ST was 0.340 
(95% CI 0.18 to 0.49) in favour of SLIT. Based on a cost difference between the two groups of £2668, 
an ICER of £7848 per unit improvement in RQLQ was obtained. Table 50 also shows that between 3 and 
10 years after the start of IT, the cost difference between SLIT and ST reduces from £2668 to £1820. Over 
the same period, QALY gains favouring SLIT increase from 0.0440 to 0.1305. The ICERs based on QALYs 
gained over this period therefore reduce from £60,704 to £13,951. An ICER of £27,269 was obtained 
6 years after the start of IT. This reduction in costs per QALY gained is shown graphically in Figure 21.
TABLE 44 Costs: SLIT
Staff costs, consumables and 
productivity loss
Costs
Year 1 Year 2a Year 3a
Staff during clinic visits
Consultant £226.05 £174.72 £168.82
Band 8 nurse £67.14 £51.89 £50.14
SLIT medication
Grazax £813.95 £786.42 £759.83
Symptomatic medicine
Desloratadine £20.44 £19.75 £19.08
Budesonide £35.43 £34.24 £33.08
Productivity loss
Hours missed from work £20.39 £19.70 £19.04
Hours at work with reduced productivity £45.50 £43.96 £42.48
Total annual costs £1228.91 £1130.70 £1092.46
Total cumulative costs £1228.91 £2359.61 £3452.07
a Costs discounted at 3.5%.
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TABLE 45 Costs: SCIT
Staff costs, consumables and 
productivity loss
Costs
Year 1 Year 2a Year 3a
Staff during clinic visits
Consultant £739.80 £464.61 £448.90
Band 8 nurse £219.73 £137.99 £133.33
Supplies/consumablesb £4.00 £2.51 £2.43
SCIT medication
Allergy medicine
Alutard £1239.46 £1178.42 £1138.57
Symptomatic medicine
Desloratadine £24.15 £23.33 £22.54
Budesonide £41.86 £40.45 £39.08
Productivity loss
Hours missed from work £49.74 £48.05 £46.43
Hours at work with reduced productivity £95.14 £91.92 £88.82
Total annual costs £2413.88 £1987.29 £1920.08
Total cumulative costs £2413.88 £4401.16 £6321.25
a Costs discounted at 3.5%.
b Supplies are made up of swabs, syringes, hypodermic needles and gloves.
TABLE 46 Costs: ST
Consumables and productivity loss
Costs
Year 1 Year 2a Year 3a
Medication
Symptomatic medicine
Desloratadine £24.55 £23.72 £22.92
Budesonide £50.68 £48.97 £47.31
Productivity loss
Hours missed from work £60.32 £58.28 £56.31
Hours at work with reduced productivity £134.78 £130.22 £125.82
Total annual costs £270.33 £261.19 £252.35
Total cumulative costs £270.33 £531.52 £783.87
a Costs discounted at 3.5%.
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TABLE 47 Sublingual immunotherapy costs from years 4 to 10
Staff costs, 
consumables 
and 
productivity 
lossa,b
Costs
Year 4 Year 5 Year 6 Year 7 Year 8 Year 9 Year 10
Staff during clinic visits
Consultant – – – – – – –
Band 8 nurse – – – – – – –
SLIT medication
Grazax – – – – – – –
Symptomatic medicine
Desloratadine £18.44 £17.81 £17.21 £16.63 £16.07 £15.52 £15.00
Budesonide £31.96 £30.88 £29.83 £28.83 £27.85 £26.91 £26.00
Productivity loss
Hours missed 
from work
£18.39 £17.77 £17.17 £16.59 £16.03 £15.49 £14.96
Hours at work 
with reduced 
productivity
£41.04 £39.65 £38.31 £37.02 £35.76 £34.56 £33.39
Total annual 
costs 
£109.83 £106.12 £102.53 £99.06 £95.71 £92.48 £89.35
Total 
cumulative 
costsb
£3561.91 £3668.02 £3770.55 £3869.61 £3965.33 £4057.80 £4147.15
a Costs discounted at 3.5%.
b Includes cumulative cost of SLIT incurred in years 1–3.
TABLE 48 Subcutaneous immunotherapy costs for years 4–10
Staff costs, 
consumables 
and 
productivity 
loss
Costs
Year 4 Year 5 Year 6 Year 7 Year 8 Year 9 Year 10
Staff during clinic visits
Consultant – – – – – – –
Band 8 nurse – – – – – – –
SCIT medication
Alutard – – – – – – –
Symptomatic medicine
Desloratadine £21.78 £21.05 £20.33 £19.65 £18.98 £18.34 £17.72
Budesonide £37.76 £36.48 £35.25 £34.06 £32.90 £31.79 £30.72
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Staff costs, 
consumables 
and 
productivity 
loss
Costs
Year 4 Year 5 Year 6 Year 7 Year 8 Year 9 Year 10
Productivity loss
Hours missed 
from work
£44.86 £43.34 £41.88 £40.46 £39.09 £37.77 £36.49
Hours at work 
with reduced 
productivity
£85.81 £82.91 £80.11 £77.40 £74.78 £72.25 £69.81
Total annual 
costs 
£190.21 £183.78 £177.56 £171.56 £165.76 £160.15 £154.74
Total 
cumulative 
costsa,b
£6511.46 £6695.24 £6872.80 £7044.36 £7210.12 £7370.27 £7525.01
a Costs discounted at 3.5%.
b. Includes cumulative cost of SCIT incurred in years 1–3.
TABLE 49 Symptomatic treatment costs for years 4–10
Consumables 
and 
productivity 
loss
Costs
Year 4 Year 5 Year 6 Year 7 Year 8 Year 9 Year 10
Medication
Symptomatic medicine
Desloratadine £22.15 £21.40 £20.67 £19.97 £19.30 £18.65 £18.02
Budesonide £45.71 £44.17 £42.67 £41.23 £39.84 £38.49 £37.19
Productivity loss
Hours missed 
from work
£54.40 £52.56 £50.79 £49.07 £47.41 £45.81 £44.26
Hours at work 
with reduced 
productivity
£121.56 £117.45 £113.48 £109.64 £105.93 £102.35 £98.89
Total annual 
costs
£243.82 £235.58 £227.61 £219.91 £212.48 £205.29 £198.35
Total 
cumulative 
costsa,b
£1027.69 £1263.27 £1490.88 £1710.79 £1923.26 £2128.55 £2326.90
a Costs discounted at 3.5%.
b Includes cumulative cost of SCIT incurred in years 1–3.
TABLE 48 Subcutaneous immunotherapy costs for years 4–10 (continued)
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Table 51 shows the results comparing SCIT with ST. The mean change in RQLQ in favour of SCIT was 0.740 
(95% CI 0.56 to 0.92) and this resulted in an ICER of £7483 per unit improvement in RQLQ (based on a 
cost difference of £5537). Between 3 and 10 years after starting IT, the cost difference between SCIT and 
ST reduced from £5537 to £5198, whereas the QALY gains in favour of SCIT increased from 0.0957 to 
0.2840. Consequently, the cost per QALY gained between the same time period reduced from £57,883 to 
£18,304 as shown in Figure 22. The value of this ICER was £29,579 6 years after the start of IT.
Indirect comparisons
Table 52 presents the results of the comparison between SLIT and ST. The mean change in RQLQ favouring 
SLIT was 0.247 (95% CrI –0.156 to 0.729) and this resulted in an ICER of £10,802 per unit improvement 
in RQLQ (based on a cost difference of £2668). The cost differences between the two groups reduced 
from £2668 to £1820 over a period of 3–10 years post commencement of IT. As in the direct comparison, 
the QALY gains favouring SLIT increased from 0.0319 to 0.0948 over the same period. This resulted in a 
TABLE 50 Economic evaluation results: SLIT vs ST (based on direct comparisons)
Cost difference (£) at
3 years 2668
4 years 2534
5 years 2405
6 years 2280
7 years 2159
8 years 2042
9 years 1929
10 years 1820
RQLQ difference 0.340 (95% CI 0.180 to 0.490)
ICER (£): costs/unit improvement in RQLQ 7848 (95% CI 5445 to 14,823)
Total QALY gain in 3 years 0.0440 (95% CI 0.0233 to 0.0633)
ICER (£): costs per QALY 60,704 (95% CI 42,121 to 114,663)
Total QALY gain in 4 years 0.0576 (95% CI 0.0305 to 0.0830)
ICER (£): costs per QALY 43,977 (95% CI 30,514 to 83,067)
Total QALY gain in 5 years 0.0708 (95% CI 0.0305 to 0.0830)
ICER (£): costs per QALY 33,948 (95% CI 23,556 to 64,124)
Total QALY gain in 6 years 0.0836 (95% CI 0.0443 to 0.1205)
ICER (£): costs per QALY 27,269 (95% CI 18,921 to 51,508)
Total QALY gain in 7 years 0.0959 (95% CI 0.0508 to 0.1383)
ICER (£): costs per QALY 22,504 (95% CI 15,615 to 42,508)
Total QALY gain in 8 years 0.1078 (95% CI 0.0571 to 0.1554)
ICER (£): costs per QALY 18,935 (95% CI 13,139 to 35,767)
Total QALY gain in 9 years 0.1194 (95% CI 0.0632 to 0.1720)
ICER (£): costs per QALY 16,164 (95% CI 11,216 to 30,532)
Total QALY gain in 10 years 0.1305 (95% CI 0.0691 to 0.1880)
ICER (£): costs per QALY 13,951 (95% CI 9680 to 26,351)
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FIGURE 21 Cost-effectiveness of SLIT vs ST (direct comparisons).
TABLE 51 Economic evaluation results: SCIT vs ST (based on direct comparisons)
Cost difference (£) at
3 years 5537
4 years 5484
5 years 5432
6 years 5382
7 years 5334
8 years 5287
9 years 5242
10 years 5198
RQLQ difference 0.740 (95% CI 0.560 to 0.920)
ICER (£): costs/unit improvement in RQLQ 7483 (95% CI 6019 to 9889)
Total QALY gain in 3 years 0.0957 (95% CI 0.0724 to 0.1189)
ICER (£): costs per QALY 57,883 (95% CI 46,558 to 76,488)
Total QALY gain in 4 years 0.1254 (95% CI 0.0949 to 0.1559)
ICER (£): costs per QALY 43,722 (95% CI 35,168 to 57,776)
Total QALY gain in 5 years 0.1542 (95% CI 0.1167 to 0.1917)
ICER (£): costs per QALY 35,233 (95% CI 28,340 to 46,558)
Total QALY gain in 6 years 0.1820 (95% CI 0.1377 to 0.2262)
ICER (£): costs per QALY 29,579 (95% CI 23,792 to 39,087)
Total QALY gain in 7 years 0.2088 (95% CI 0.1580 to 0.2596)
ICER (£): costs per QALY 25,545 (95% CI 20,547 to 33,756)
Total QALY gain in 8 years 0.2347 (95% CI 0.1776 to 0.2918)
ICER (£): costs per QALY 22,524 (95% CI 18,117 to 29,764)
Total QALY gain in 9 years 0.2598 (95% CI 0.1966 to 0.3230)
ICER (£): costs per QALY 20,178 (95% CI 16,230 to 26,664)
Total QALY gain in 10 years 0.2840 (95% CI 0.2149 to 0.3531)
ICER (£): costs per QALY 18,304 (95% CI 14,723 to 24,188)
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reduction in the costs per QALY gained from £83,560 to £19,203 over the same period of time as depicted 
in Figure 23. The value of the ICER 6 years after the start of IT was £37,537.
In the comparison between SCIT and ST (Table 53), the mean change in RQLQ favouring SCIT was 0.764 
(95% CrI 0.425 to 1.116). Based on a cost difference of £5537, an ICER of £7248 per unit improvement in 
RQLQ was found. As in the direct comparisons, the cost difference between the two groups reduced over 
a period of 8 years (3–10 years after the start of IT) from £5537 to £5198. The QALY gains in favour of 
SCIT increased from 0.0988 to 0.2932 over the same period. As depicted in Figure 24, the resultant ICERs 
therefore decreased from £56,064 to £17,729 over this period. The ICER, 6 years after the start of IT, was 
£28,650 per QALY gained.
The last comparison was between SCIT and SLIT (Table 54). The mean change in RQLQ (favouring SCIT) 
was 0.517 (95% CrI –0.0710 to 1.045) resulting in an ICER of £5550 per unit improvement in RQLQ, 
based on a cost difference of £2869. The cost differences between the two groups reduced from £2869 
to £3378 over a period of 3–10 years following commencement of IT. QALY gains favouring SCIT increased 
from 0.0668 to 0.1984 over the same period. This resulted in a reduction in the costs per QALY gained 
from £42,928 to £17,025 over the same period of time as depicted in Figure 25. The value of the ICER, 
6 years after the start of IT, was £24,404.
Six-weekly treatment schedule
Using a 6-weekly maintenance schedule instead of a 4-weekly one resulted in lower costs (fewer clinic 
visits and fewer injections) (Table 55). The effectiveness was assumed to be the same, therefore the cost-
effectiveness was increased. The differences in ICERs (at 6 years) between the two maintenance schedules 
are shown below (full details are shown in Appendix 12).
NHS perspective only
Costs were considered from the NHS and patient perspectives because of the burden that AR places on 
both the NHS and patients. For purposes of reimbursement, however, only NHS costs are important. We 
therefore also conducted a CEA (results not shown) based on NHS costs only, and the results were not 
altered significantly. IT (when compared with ST) was found to be cost-effective around 7 years after the 
start of treatment (1 year later than when productivity costs are included). The only exception was the 
comparison between SLIT and ST based on indirect comparison results where this threshold increased to 
more than 10 years after the start of IT. In the comparison between SCIT and SLIT, SCIT was shown to be 
more cost-effective as early as 4 years after the start of treatment (1 year earlier than when productivity 
costs are included).
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FIGURE 22 Cost-effectiveness of SCIT vs ST (direct comparisons).
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TABLE 52 Economic evaluation results: SLIT vs ST (based on indirect comparisons)
Cost difference (£) at
3 years 2668
4 years 2534
5 years 2405
6 years 2280
7 years 2159
8 years 2042
9 years 1929
10 years 1820
RQLQ difference 0.247 (95% CI –0.1560 to 0.729)
ICER (£): costs/unit improvement in RQLQ 10,802 (3660 to ST dominates)
Total QALY gain in 3 years 0.0319 (95% CI –0.0202 to 0.0942)
ICER (£): costs per QALY 83,560 (28,312 to ST dominates)
Total QALY gain in 4 years 0.0419 (95% CI –0.0264 to 0.1236)
ICER (£): costs per QALY 60,535 (20,510 to ST dominates)
Total QALY gain in 5 years 0.0515 (95% CI –0.0325 to 0.1519)
ICER (£): costs per QALY 46,730 (15,833 to ST dominates)
Total QALY gain in 6 years 0.0607 (95% CI –0.0384 to 0.1792)
ICER (£): costs per QALY 37,537 (12,718 to ST dominates)
Total QALY gain in 7 years 0.0697 (95% CI –0.0440 to 0.2057)
ICER (£): costs per QALY 30,977 (10,496 to ST dominates)
Total QALY gain in 8 years 0.0783 (95% CI –0.0495 to 0.2312)
ICER (£): costs per QALY 26,065 (8831 to ST dominates)
Total QALY gain in 9 years 0.0867 (95% CI –0.0548 to 0.2559)
ICER (£): costs per QALY 22,250 (7539 to ST dominates)
Total QALY gain in 10 years 0.0948 (95% CI –0.0599 to 0.2798)
ICER (£): costs per QALY 19,203 (6506 to ST dominates)
‘ST dominates’ means that ST is more effective and also cheaper.
Interpretation of the cost-effectiveness results
Staff costs for SCIT were higher compared with those for SLIT owing to the greater number of clinic 
visits made by patients in this group over a 3-year period, i.e. 46 compared with 13. The costs of SCIT 
medication per unit were also higher than those for SLIT thereby driving the costs for SCIT further up. As 
would be expected, SCIT was associated with higher productivity losses owing to the nature of treatment 
that warranted absence from work. Individuals in the ST group had highest overall productivity losses. 
This finding is consistent with those found in other studies.228,230,231 Costs associated with asthma and AE 
medication were not included in the analysis because the cost differences in medications between SCIT, 
SLIT and ST were assumed to be negligible. This was based on expert clinical opinion and a review of 
the literature.
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FIGURE 23 Cost-effectiveness of SLIT vs ST (indirect comparisons).
TABLE 53 Economic evaluation results: SCIT vs ST (based on indirect comparisons)
Cost difference (£) at
3 years 5537
4 years 5484
5 years 5432
6 years 5382
7 years 5334
8 years 5287
9 years 5242
10 years 5198
RQLQ difference 0.764 (95% CI 0.425 to 1.116)
ICER (£): costs/unit improvement in RQLQ 7248 (95% CI 4962 to 13,029)
Total QALY gain in 3 years 0.0988 (95% CI 0.0549 to 0.1443)
ICER (£): costs per QALY 56,064 (95% CI 38,381 to 100,784)
Total QALY gain in 4 years 0.1295 (95% CI 0.0720 to 0.1892)
ICER (£): costs per QALY 42,349 (95% CI 28,992 to 76,128)
Total QALY gain in 5 years 0.1592 (95% CI 0.0885 to 0.2325)
ICER (£): costs per QALY 34,126 (95% CI 23,362 to 61,347)
Total QALY gain in 6 years 0.1879 (95% CI 0.1045 to 0.2744)
ICER (£): costs per QALY 28,650 (95% CI 19,613 to 51,502)
Total QALY gain in 7 years 0.2156 (95% CI 0.1199 to 0.3149)
ICER (£): costs per QALY 24,743 (95% CI 16,939 to 44,479)
Total QALY gain in 8 years 0.2423 (95% CI 0.1348 to 0.3540)
ICER (£): costs per QALY 21,816 (95% CI 14,935 to 39,218)
Total QALY gain in 9 years 0.2682 (95% CI 0.1492 to 0.3918)
ICER (£): costs per QALY 19,544 (95% CI 13,380 to 35,133)
Total QALY gain in 10 years 0.2932 (95% CI 0.1631 to 0.4283)
ICER (£): costs per QALY 17,729 (95% CI 12,137 to 31,871)
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FIGURE 24 Cost-effectiveness of SCIT vs ST (indirect comparisons).
In the results based on direct and indirect comparisons, SCIT and SLIT were both found to be more 
effective than ST as shown by the difference in RQLQ. The results from the indirect comparison also 
suggest that SCIT may be more effective than SLIT; however, this is associated with uncertainty (a non-
significant result) and must be interpreted cautiously (see Chapter 3, Indirect comparison of subcutaneous 
immunotherapy versus sublingual immunotherapy). As the QALYs used in this analysis were based on an 
algorithm that mapped the RQLQ to EQ-5D, the same direction of effect observed in the RQLQ was also 
seen in the QALY gains.
In terms of cost per unit improvement in RQLQ, ICERs of £7848 and £10,802 were obtained in the 
comparison between SLIT and ST, whereas ICERS of £7483 and £7248 were estimated for the comparison 
between SCIT and ST. As IT in the two sets of comparisons was both more costly and effective, it would 
be considered to be cost-effective only if decision-makers were willing to pay at least £11,000 for each 
unit improvement in RQLQ. For the comparison between SCIT and SLIT, SCIT would be considered a more 
cost-effective alternative if decision-makers were willing to pay at least £5600 for a similar improvement in 
RQLQ. A unit change of 0.5 may be considered clinically significant.
Cost-effectiveness results based on costs per QALY gained can be assessed against a threshold of £20,000–
30,000, the conventional threshold adopted by decision-makers in the UK NHS, such as NICE.249 The 
results of the analysis show that IT, when compared with ST, becomes cost-effective around 6 years after 
the start of treatment (7 years for NHS perspective only). The only exception is the comparison between 
SLIT and ST based on indirect comparisons, where this threshold increased to 7 years (10 years for NHS 
perspective only). In the comparison between SCIT and SLIT, SCIT was shown to be more cost-effective as 
early as 5 years after the start of treatment (4 years for NHS perspective only). These results are consistent 
with those for studies that reported outcomes in terms of ICERs (shown in Table 39), although the ICERs in 
our study were much higher.
In view of the many simplifications required in performing the CEA, these results must be regarded as 
indicative. The results using direct comparisons suggest that either SLIT or SCIT may be cost-effective 
compared with symptomatic treatment (ST), applying usual UK standards of cost-effectiveness. However, 
this tentative conclusion depends on there being a good reason to believe that clinical effectiveness will be 
sustained for somewhat longer than the 3 years’ period following cessation of treatment.
When the results from the indirect comparisons were used, the cost-effectiveness results for SCIT 
compared with ST were largely unchanged. For SLIT compared with ST, however, the results for a 
difference in RQLQ were no longer statistically significant at the 95% confidence level. It is clear that SLIT is 
more costly than ST. Accordingly, there is no finite upper confidence limit for the ICER: the CI stretches into 
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TABLE 54 Economic evaluation results: SCIT vs SLIT (based on indirect comparisons)
Cost difference (£) at
3 years 2869
4 years 2950
5 years 3027
6 years 3102
7 years 3175
8 years 3245
9 years 3312
10 years 3378
RQLQ difference 0.517 (95% CI –0.0710 to 1.045)
ICER (£): costs/unit improvement in RQLQ 5550 (2746 to SLIT dominates)
Total QALY gain in 3 years 0.0668 (95% CI –0.0092 to 0.1351)
ICER (£): costs per QALY 42,928 (21,238 to SLIT dominates)
Total QALY gain in 4 years 0.0876 (95% CI –0.0120 to 0.1771)
ICER (£): costs per QALY 33,661 (16,653 to SLIT dominates)
Total QALY gain in 5 years 0.1077 (95% CI –0.0148 to 0.2177)
ICER (£): costs per QALY 28,105 (13,904 to SLIT dominates)
Total QALY gain in 6 years 0.1271 (95% CI –0.0175 to 0.2569)
ICER (£): costs per QALY 24,404 (12,074 to SLIT dominates)
Total QALY gain in 7 years 0.1459 (95% CI –0.0200 to 0.2948)
ICER (£): costs per QALY 21,764 (10,768 to SLIT dominates)
Total QALY gain in 8 years 0.1640 (95% CI –0.0225 to 0.3315)
ICER (£): costs per QALY 19,787 (9789 to SLIT dominates)
Total QALY gain in 9 years 0.1815 (95% CI –0.0249 to 0.3668)
ICER (£): costs per QALY 18,251 (9030 to SLIT dominates)
Total QALY gain in 10 years 0.1984 (95% CI –0.0272 to 0.4010)
ICER (£): costs per QALY 17,025 (8423 to SLIT dominates)
‘ST dominates’ means that ST is more effective and also cheaper.
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the region where ST dominates (is less costly and more effective than) SLIT. Figure 26 illustrates this point. 
It is shown in terms of mean improvement in RQLQ, but exactly the same principles apply to the results 
when effectiveness is estimated in QALYs.
Using the point estimate of difference in effectiveness based on RQLQ, SCIT appears to be cost-effective 
compared with SLIT. However, as for SLIT compared with ST, the CI for difference in effectiveness crosses 
zero, so again there is no finite upper limit for the CI in the ICER.
It is acknowledged that there is considerable relative uncertainty in the inputs concerning costs relating 
to symptomatic medication and productivity loss. However, these form a sufficiently small part of the 
overall cost difference between treatments that making plausible changes to those values would not 
make any appreciable difference to the results quoted. Formal sensitivity analysis on these inputs has not 
been carried out, as such analysis would add nothing of value to the illustrative results already quoted, 
and risks being quoted out of context as giving some spurious indication of the robustness of the results. 
In particular, it is not possible, on the evidence available to the research team, to produce a meaningful 
estimate of the probability that each treatment is cost-effective at any given threshold ICER, or the value of 
perfect information at any such threshold.
Repeating the CEA using a 6-weekly (rather than 4-weekly) maintenance schedule for Alutard resulted in 
slightly lower ICERs. This was based on an assumption that clinical effectiveness remained the same and 
was undertaken only to illustrate the potential impact of a reduction in costs. The use of shorter treatment 
courses, such as preseasonal treatment using Pollinex, is likely to reduce costs even further, but there is 
uncertainty around the long-term effectiveness.
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FIGURE 25 Cost-effectiveness of SCIT vs SLIT.
TABLE 55 Incremental cost-effectiveness ratios for 4- and 6-week maintenance schedules (at 6 years)
Comparison
Alutard maintenance
4-weekly 6-weekly
SCIT vs ST (direct comparisons) £29,579 £21,599
SCIT vs ST (indirect comparisons) £28,650 £20,920
SCIT vs SLIT £24,404 £12,982
NIHR Journals Library www.journalslibrary.nihr.ac.uk
COST-EffECTIVENESS
106
No analysis based on RQLQ was possible for children. One study that reported a paediatric version of 
the RQLQ was identified;152 however, differences compared with the adult RQLQ meant that equivalent 
mapping to the EQ-5D could not be undertaken.
One of the limitations of the CEA is that it does not take into account any health benefits or potential 
cost savings from future cases of asthma prevented. This would be particularly relevant when considering 
the treatment of children with SAR, as they are more likely to develop asthma than children without SAR. 
A simple calculation based on costs for SCIT and SLIT as outlined above, and number of asthma cases 
avoided based on the PAT study54–56 (for SCIT) and Novembre et al.57 (for SLIT) is presented below [see 
also Chapter 1, The role of specific (allergen) immunotherapy in asthma prevention]. Both studies are 
in children with SAR, with no asthma at the start of treatment. The numbers needed to treat (NNT) to 
prevent one case of asthma were derived from the number of patients with and without asthma in the 
respective treatment arms, and CIs were calculated around these (method given in Armitage et al.256). The 
NNT was multiplied by the cost difference (at 3 years) between SCIT (or SLIT) and symptomatic treatment 
only (Table 56).
The results suggests that if each case of asthma costs over £10,627 (SLIT) or over £22,000–27,500 (SCIT) 
in treatment costs over a lifetime (appropriately discounted) then SLIT or SCIT could be potentially cost 
saving compared with symptomatic treatment. These results should be seen as indicative only, as they are 
based on effectiveness data from relatively small open-label studies. Health benefits and costs associated 
with a reduction in SAR symptoms are not considered in these calculations.
What is required as a top priority is to establish the extent to which the data already collected in past 
primary research can be used to populate a useful cost-effectiveness model, which captures all relevant 
benefits and costs. This means making the data available to independent researchers who will be able to 
analyse it using a common, and economically useful, framework. Only when this has been done will it 
be possible to carry out a more meaningful analysis, possibly using a value of information framework, to 
determine whether or not further primary research is worthwhile and to set the priorities for such research.
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FIGURE 26 Incremental cost-effectiveness plane for SLIT vs ST using the results of the indirect comparison. The 
incremental cost is fixed at approximately £2700 per patient. The points L, M and U show this incremental cost 
combined with the lower, mean and upper limits of the CI for improvement in RQLQ, respectively. The gradient of the 
line from the origin to M is the point estimate of the ICER. The gradient of the line from the origin to U is the lower 
confidence limit of the ICER. The dashed line from the origin to L has a negative gradient indicating that, if L were the 
true representation of the cost and effect difference, ST would dominate (be less costly and more effective than) SLIT. 
In such a case, the magnitude of the slope of the dashed line is of no importance: ST would be preferred in any case. 
It should also be noted that the negative ICER represented by point L should be considered as higher than all positive 
ICERs, not lower. For the reasons given in the preceding sentences, it is not appropriate to quote a numerical upper 
confidence limit for the ICER, and the statement ‘ST dominates’ has been placed instead of such a limit in the results 
tables.
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TABLE 56 Cost per asthma case avoided
Study NNT
Cost difference IT 
and ST (£)
Cost (£) per asthma case 
avoided (95% CI)
SCIT: PAT study,55 3-year data (n = 205) 5 5537 27,500 (15,598 to 104,660)
SCIT: PAT study,56 5-year data (n = 183) 4 5537 22,000 (14,374 to 68,807)
SCIT: PAT study,54 10-year data (n = 147) 5 5537 27,500 (14,745 to 183,571)
SLIT: Novembre et al. 2004,57 3-year data (n = 113) 4 2668 10,627 (6348 to 63,004)
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Chapter 5 Discussion
Clinical effectiveness
Main findings
A total of 28 new DBPC RCTs of SCIT (n = 17) or SLIT (n = 11) compared with placebo for SAR were 
identified, bringing the total number of relevant RCTs in this area to around 128. Assessment of the risk of 
bias was hampered by a lack of reporting of all relevant criteria, but, while risk of bias was often unclear, 
there were very few instances of high risk of bias. Overall, results were unlikely to be affected by the 
studies reporting instances of high risk of bias.
The updated findings are consistent with the Cochrane reviews and find statistically significant benefits for 
both SCIT compared with placebo and SLIT compared with placebo across all outcome measures and for 
the majority of subgroup analyses.
In trials of SCIT for SAR, the total number of studies and participants included in the present review was 
only slightly higher than those for the earlier Cochrane review, and results of meta-analyses remained very 
similar, with moderate effect sizes in favour of SCIT for all outcomes. Greater improvements in both SSs 
and MSs, compared with placebo,were found with increasing vaccine allergen content, consistent with the 
recognised dose–response relationship in SCIT. Note that this was based on non-randomised comparisons 
from subgroup analyses and should therefore be interpreted cautiously. It was beyond the scope of this 
report to look at randomised comparisons of allergen content, although such comparisons exist. There 
was only one small trial152 of SCIT in children and this found significantly lower SSs and MSs, and improved 
QoL, in the actively treated group (after 3 years of treatment).
Consistent with previous literature, randomised, double-blind trials of SLIT show efficacy in all major 
outcomes compared with placebo. Few differences were found compared with the earlier Cochrane review, 
despite restriction to SAR and increased sample sizes in many cases. However, a number of previously 
non-significant results reached statistical significance in the present review – namely, SSs in studies with 
< 5 µg of MAC, MSs in studies with > 20 µg of MAC, and MSs in ragweed allergy. Only one previously 
significant result became non-significant: of the five studies in Parietaria allergy included in the Cochrane 
review, removal of the study by Pajno et al.35 (which was restricted to SAA) resulted in loss of significance; 
however, all of these studies had very small sample sizes (total number in remaining studies was 124).
Perhaps more importantly, despite a small increase in total sample size, and limitation to SAR, MSs in 
children still failed to show a significant improvement with active treatment compared with placebo. 
The clinical significance of this finding is unclear. The MS in isolation may not be able to reflect the 
effectiveness of SLIT, which is why the combined SMS is a preferred measure. It is also possible that 
medication use differs in children compared with adults, as it may be influenced by parental preferences. 
Another possibility is that SLIT is less effective in children than in adults.
Consistent with this hypothesis, the pooled SMD in SSs in children decreased by over 50% compared with 
the Cochrane review of SLIT. However, the result did remain statistically significant in favour of SLIT. The 
Cochrane review included studies of both SAR and PAR, and subgroup analysis of SAR studies only (while 
maintaining very similar participant numbers of > 1300 children) appears to have been associated with 
a reduction in treatment effect. It may be possible that SLIT treatment is more appropriate for perennial 
allergens in paediatric populations than for seasonal allergens. Consistent with this, exploratory subgroup 
analysis of SSs from paediatric studies in PAR only indicates a much larger effect size than for SAR 
(combined SMD –0.89 vs –0.24, respectively). Although the findings in the PAR studies were more variable 
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than those in SAR, and the pooled result failed to reach statistical significance, this was based on a much 
smaller sample size overall (total n = 328, compared with n = 1343 for SAR).
None of the trials in children included in this review take into consideration future benefits from SLIT, such 
as avoidance of asthma or new sensitisations, although there are trials currently under way to evaluate 
this (see Chapter 3, Ongoing trials). Ten-year data from the PAT study54 (open-label RCT) suggests that the 
incidence of asthma in the treatment arm was lower than that of the control arm. Further follow-up of this 
study is ongoing.
In contrast with SCIT, no relationship between increased MAC and effect size was apparent from subgroup 
analyses, but this finding may be related to different sample sizes or due to other sources of heterogeneity 
in the allergen content subgroups. The estimate for the low-allergen group had wider CIs and is associated 
with more uncertainty. Again, these findings are not based on randomised groups and should thus be 
interpreted cautiously.
Overall, both SLIT and SCIT resulted in statistically significant improvements in QoL scores. Although 
SCIT improved RQLQ scores by 0.74 points compared with placebo, SLIT resulted in only a 0.31-point 
improvement compared with placebo, despite both of these meta-analyses including a similar number of 
participants (955 compared with 924, respectively).
All of these studies were conducted in adults (alternative versions of the RQLQ have been validated for 
use in paediatric and adolescent populations) and the findings are consistent with those for SSs and MSs, 
suggesting a greater clinical benefit from SCIT, at least in adults.
Quality-of-life data in children are scarce; eight studies of SCIT25,102,112,189,191,192,200,202 and 11 of 
SLIT142–144,148,152,156,161,164–166,173 reported QoL outcomes (not all included in the meta-analyses), but only 
one study in each intervention was restricted to paediatric or adolescent152,189 participants. SLIT is more 
commonly prescribed than SCIT in this population, largely due to a perceived reduced risk of potentially 
severe AEs. Given the possibility that efficacy of SLIT in children is poorer in terms of SSs and MSs than 
in adults, the presence or absence of benefit in terms of QoL in children should be further explored. In 
addition, more studies using the paediatric or adolescent version of the RQLQ are needed in order that 
clinical as well as statistical significance may be assessed. Nevertheless, both studies (one for SCIT and SLIT, 
respectively) found statistically significant benefits in terms of QoL in children with active treatment.
The overall incidence of AEs following treatment with SCIT was slightly higher than for SLIT (79% vs 65%, 
respectively, experienced at least one AE); however, as SCIT is administered under clinical supervision, 
reporting of AEs could be expected to be more stringent. With both routes of administration, the majority 
of AEs were local reactions at the site of injection (SCIT) or in the oral cavity or gastrointestinal system 
(SLIT), and resolved spontaneously without treatment. Where severity of systemic AEs was reported, most 
were graded as mild or moderate, and, again, many did not require special treatment; however, 19% of 
systemic AEs occurring following SCIT treatment were graded as severe, compared with only 2% following 
SLIT treatment.
Based on six trials155,166,179,181,185,257 that reported rates of events per injection, 129 systemic reactions 
occurred following 2909 administrations of active SCIT (4.4%). This number is much higher than the 0.2% 
suggested by a recent review of the literature.258 However, that review included studies of both seasonal, 
perennial and venom IT, IT for other atopic conditions besides AR, and reports from trials, retrospective 
studies, surveys, and clinical observations. It seems likely that the strict reporting requirements of RCTs may 
provide a more realistic representation of the true rate of systemic reactions. Similar incidence-per-dose 
data were not available from the studies of SLIT included in the present review. No fatalities as a result of 
treatment were reported for either SCIT or SLIT.
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Funnel plot evaluations of SSs for both SCIT and SLIT trials showed slight evidence of plot asymmetry (see 
Appendix 13), with larger effect sizes tending to be associated with smaller trial size. Possible sources of 
asymmetry include publication bias or poorer methodological quality in smaller studies, sampling variation 
or chance,259 and these findings should be interpreted with caution. Further, not all studies reported 
large effect size estimates in favour of the active treatment, and comparison of combined SMD using 
both fixed-effect and random-effect meta-analyses identified little difference between the two methods. 
Thus, any small-study effects are unlikely to impact significantly on the overall effect estimates for 
the interventions.259
In contrast to the large number of placebo-controlled trials, only one small double-blinded head-to-head 
RCT of SCIT compared with SLIT was identified; this study did not find a significant difference between the 
two types of treatment, although both were better than placebo. Given the paucity of this type of data, an 
indirect comparison was conducted.
As there was some evidence of heterogeneity both within and between sets of placebo-controlled trials, 
ICMR with various covariates was performed in order to explore and potentially reduce heterogeneity. 
However, adjusting for type of allergen, allergen content and duration of treatment did not substantially 
reduce heterogeneity. Statistically significant findings favouring SCIT over SLIT (for SSs and MSs, not 
adjusted for covariates) were associated with substantial heterogeneity. In the analysis using combined 
SMS, arguably a preferred outcome measure, none of the differences in adjusted and non-adjusted 
analyses were statistically significant, but were associated with reduced heterogeneity. The difference in 
RQLQ score (0.517; 95% CrI –0.071 to 1.045) was also found to be not statistically significant. Many of 
the best estimate probabilities found that SCIT was most likely to be the best treatment, but this needs to 
be interpreted in the context of the standardised score difference results.
Year of publication appeared to account for a degree of heterogeneity (for SSs). Analyses were suggestive 
of earlier studies showing greater benefit for SCIT compared with studies published at a later date finding 
less benefit. It seems unlikely that SCIT has become less effective over time, and alternative explanations 
for the apparent reduction in effectiveness of SCIT include improved trial protocols and reduced dosages 
of SCIT being administered for safety reasons. Another possibility is that with increasingly stringent 
requirements for registration of clinical trials, the potential for publication bias may have reduced over 
time. However, these results are based on use of a post hoc defined variable and must be considered 
exploratory in nature.
The use of standardised units makes interpretation difficult, and where significant differences were found 
favouring SCIT, it is difficult to gauge how much of a clinical difference this would make.
A strength of this review is that a robust review methodology was used, including a comprehensive search 
strategy. It is unlikely that many relevant studies were missed in this update.
One limitation of both the Cochrane reviews and this review is that many studies do not contribute to 
the direct and indirect comparison meta-analyses. In this review only 5 out of 17 SCIT and 5 out of 11 
SLIT RCTs contributed to at least one meta-analysis. This was partly because different outcome measures 
were used or that data were not presented in a way that was suitable for meta-analysis. Findings from 
any studies not represented in a meta-analysis were presented and were found to be consistent with the 
meta-analyses in their findings (benefit from IT over placebo). By far the largest of the new trials identified 
for SCIT compared with placebo (DuBuske et al.,145 n = 1028) did not contribute to meta-analyses, as 
outcomes were expressed as number of ‘well-days’ and ‘bad-days’. This study145 evaluated the effect of 
an ultrashort course of SCIT and found significant benefits for SCIT over a 4-week period; longer-term 
outcomes were not reported.
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A major limitation is the inconsistent use of outcome measures across studies [see Chapter 1, Outcome 
measures in randomised controlled trials of specific (allergen) immunotherapy, for further details]. 
Although almost all studies use the same four-point scale to assess symptom severity, the number and type 
of symptoms measured in different studies is so diverse as to preclude any useful comparison of results 
(see Appendix 7). The inconsistency in choice of outcome measure is also reflected in MSs and combined 
SMSs. A consequence of the highly variable outcome reporting across studies is that the pooled summary 
measures from meta-analyses can only be reported as SMDs, which are difficult to interpret clinically. 
Although effect sizes can be classified as small, moderate or large, these do not necessarily correspond 
to clinically meaningful changes. So, although it can be stated with some certainty that allergen IT shows 
consistent benefit, and that pooled results are statistically significant, there is no good estimate of the 
proportion of patients who, for example, have more ‘well-days’ or fewer ‘worst-days’.
The COMET (Core Outcome Measures in Effectiveness Trials) Initiative260 is attempting to develop 
standardised sets of outcomes (‘core outcomes’) that represent the minimum that should be measured 
and reported in all clinical trials of a specific condition, although this does not mean that outcomes 
have to be restricted to only core ones. Ultimately, this would make it easier for the results of trials 
to be compared and combined. Similarly, guidelines on AE reporting23,134,261 should be followed 
more consistently.
A further limitation was the inclusion of studies of variable methodological study design or risk of bias. 
This is in addition to the clinical heterogeneity observed. We did not use a quality threshold for including 
studies, as quality criteria were often poorly reported and inclusion would therefore have been on the basis 
of reporting rather than actual quality. Contacting all study authors would have been beyond the scope of 
this report.
The impact of IT in patients with severe, uncontrolled SAR was of particular interest when conducting 
this review; however, this information was not always included in the published reports of trials, and it is 
conceivable that there was a degree of variation in severity across trials. The concept of ‘severe chronic 
upper airway disease’ has recently been proposed;262 this defines patients with uncontrolled AR despite 
adequate pharmacological treatment based on guidelines, and could potentially be used as an inclusion 
criterion for future trials.
It was beyond the scope of this review to address the issue of optimum dosing and treatment regimen 
(see Chapter 1, Treatment schedule, for further details). Similarly, the review did not address issues around 
the efficacy of different SIT products [e.g. differences in depot formulations, modification of the allergen 
extract with adjuvants, use of allergen fragments; see Chapter 1, Specific (allergen) immunotherapy 
formulations and Non-standard therapies]. Routes of administration other than sublingual or subcutaneous 
were also not explored (e.g. epicutaneous, intralymphatic).
Cost-effectiveness
A systematic review of EEs identified 13 relevant studies of varying quality, most funded by a manufacturer 
of SIT products. All studies had some limitations regarding the reporting and/or robustness of data feeding 
into their analyses or models.
Overall, results from some of the better-quality studies suggested that SLIT was likely to be cost-effective in 
terms of cost per QALY compared with symptomatic treatment at thresholds of £20,000. Two studies229,233 
of SCIT compared with symptomatic treatment reporting cost per QALY also found that SCIT was likely 
to be cost-effective at this threshold, but these studies were less transparent in their reporting. Limited 
evidence of SCIT compared with SLIT was suggestive of SCIT being more beneficial and less costly. None 
of the models included in the evaluations were described with sufficient information to be suitable for 
adaptation to a UK setting.
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A preferred model was therefore constructed, which included health states describing patients with and 
without symptoms, or with partly controlled symptoms for the different treatment arms (SCIT, SLIT or 
symptomatic treatment). Although cost data were readily available from the literature and standard UK 
sources, and it may have been possible to make plausible utility estimates, it was not possible to identify 
suitable data on transition probabilities with which to populate the model.
Obtaining data on transition probabilities was problematic as effectiveness outcomes are almost exclusively 
reported as changes in a mean score (e.g. symptom and/or medication), and it is not possible to translate 
this into proportions (probabilities) of patients moving from one health state to another. Where this sort 
of data has been used in previous EEs, it has either not been adequately reported, or has been based on 
assumptions or expert opinion. It was also not possible to obtain EQ-5D data for different health states 
directly from the study authors.
An alternative cost-effectiveness model was therefore constructed based on pooled MDs in RQLQ from 
meta-analyses, and indirect comparison meta-analyses.
Incremental cost-effectiveness ratios (cost per QALY) varied depending on the effectiveness data used (from 
direct or indirect comparisons) and consistently decreased with increasing years of treatment. Up to year 6, 
they ranged from £28,650 (year 6) to £57,883 (year 3) for SCIT compared with symptomatic treatment, 
and from £27,269 to £83,560 for SLIT compared with symptomatic treatment. Thus, with increasing 
time, both SCIT and SLIT were found to be approaching cost-effectiveness thresholds of £20,000–30,000. 
Estimates of effectiveness post year 6 are associated with uncertainty as good-quality data supporting 
sustained effectiveness after this time are not (yet) available. These ICERs are higher than those reported in 
the literature.
The indirect comparison found an ICER of between £24,404 (year 6) and £42,928 (year 3) for SCIT 
compared with SLIT, with SCIT being both more costly and more effective. It should be noted that 
this is based on a difference in effectiveness obtained from an indirect comparison analysis that was 
non-significant, and associated with a substantial degree of heterogeneity. This finding of SCIT being 
more costly is in contrast with the two EEs identified, which found SCIT to be both better and less costly; 
however, one of these was associated with substantial uncertainty around model inputs and neither 
reported a combined cost-effectiveness measure.
The ICERs should be seen as indicative mainly because they are based on a very simple analysis. There are 
a number of other factors that limit their robustness. They are based on results from a relatively small 
pool of studies (eight143,144,156,161,164–166,173 for SCIT and four25,102,200,202 for SLIT vs symptomatic treatment). A 
large proportion of available effectiveness evidence is thus not contributing to this analysis. Furthermore, 
sustained effectiveness (up to 6–10 years) has been assumed and, although this has been shown in 
randomised trials and/or cohort studies for other effectiveness measures, the RQLQ data used here are 
based on more variable treatment and follow-up periods. Furthermore, the RQLQ used in isolation may not 
be the most appropriate outcome measure to demonstrate effectiveness of SIT; increasingly, the combined 
SMS or improvement during ‘worst-days’ are being recommended as outcome measures.
A number of assumptions were made when using RQLQ data in the absence of a validated mapping from 
RQLQ to EQ-5D based on the same patients answering both questionnaires. One was that the 0–6 point 
scale of the RQLQ scale could be mapped to the whole range of three of the five dimensions of the EQ-5D 
scale (usual activities, pain/discomfort and anxiety/depression). The effect of this was that a score of 6 
(representing severe impairment in the domains of activity limitation, sleep problems, nose symptoms, eye 
symptoms, non-nose/eye symptoms, practical problems and emotional function) would be equivalent to a 
score of –0.07 on the EQ-5D (representing a state worse than death). It could be argued that these are not 
comparable states, and that even the most severe impairment of QoL due to AR would not be equivalent 
to the lowest possible EQ-5D score. If this were the case, then QALY gains would be lower than those 
reported, and ICERs correspondingly higher. An alternative would be to use only a proportion of the EQ-5D 
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scale; however, no source could be found for any validated cut-off points and any point chosen would 
have been completely arbitrary.
Sensitivity analyses were restricted to varying the time horizon of the analysis and using the upper and 
lower confidence limits of the RQLQ improvement. More detailed sensitivity analysis was not performed, as 
the effect of plausible changes to cost inputs would have been much smaller than the effect of uncertainty 
in the clinical outcome and therefore would be unlikely to substantially affect the overall results. The 
estimates have been based on costs for a 3-year treatment schedule, which has been found to be 
associated with sustained benefits. Increasingly, shorter, more intensive courses of SCIT are being evaluated 
(rush or cluster IT), which are associated with less clinic time and are therefore less costly. However, there 
is as yet no evidence of long-term effectiveness and, therefore, such an analysis was not included. Should 
long-term effectiveness be demonstrated, this would likely result in greater cost-effectiveness.
It was not possible to model cost-effectiveness in children owing to limitations in the available data. Given 
the resource use associated with treating asthma, and the potential of SIT to prevent the development of 
asthma in this population, there is a potential for substantial cost savings. Including this in a model would 
likely decrease the ICER further over time. Although associated with some uncertainty, our calculations 
suggest that if each case of asthma costs > £10,627 (SLIT) or > £22,000–27,500 (SCIT) in treatment costs 
over a lifetime (appropriately discounted), then SLIT or SCIT could be potentially cost saving compared with 
symptomatic treatment.
Overall, the disparate nature of the existing research and the lack of reporting of key parameters have 
made it difficult to generate robust findings that are of use to inform reimbursement decisions. However, 
the results are indicative of IT being cost-effective in the longer term (6–7 years) at conventional thresholds 
used by decision-makers in the UK NHS.
Current guidelines suggest severity criteria for selecting patients, i.e. those uncontrolled on conventional 
treatment, but if the aim of treatment is asthma prevention then the initial severity is less of an issue. The 
presence of AR identifies a population at risk of asthma, with no evidence to suggest that the level of risk 
is affected by the level of severity.
Future research recommendations
Given the difficulties in comparing and combining results across studies using different outcome measures, 
there is a clear need for greater consistency in the use of validated outcome measures. Further research is 
also needed into outcomes that (1) take into consideration that the relative effectiveness of IT compared 
with symptomatic medication varies depending on prevailing allergen levels and (2) could best inform 
more meaningful EEs.
In view of the limitations of the indirect comparison analysis in this report, consideration should be given 
to a head-to-head trial of SCIT compared with SLIT. For both SCIT and SLIT, at present the most appropriate 
treatment regimens to be compared would be those with 3-year protocols, as this is where the best 
evidence exists in terms of long-lasting efficacy.
Ultra-short IT treatment schedules have shown promise in terms of clinical efficacy, and these protocols 
place considerably less burden on patients in terms of time and inconvenience. Ultra-short IT is also likely 
to have major cost benefits compared with conventional schedules. However, little evidence exists as to 
the duration of clinical benefits beyond treatment cessation and this is likely to be an important area of 
future research.
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In terms of EEs, the main priority for future research will be to assess the extent to which results of 
all previous primary research can be made available to independent researchers. Only when this has 
been done can meaningful model-based value of information analysis be carried out to direct future 
primary research.

© Queen’s Printer and Controller of HMSO 2013. This work was produced by Meadows et al. under the terms of a commissioning contract issued by the Secretary of State 
for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals 
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be 
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science 
Park, Southampton SO16 7NS, UK.
DOI: 10.3310/hta17270 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 27
117
Chapter 6 Conclusions
Based on a large number of RCTs, both SCIT and SLIT have been consistently shown to be significantly more effective than symptomatic treatment only and this remains the case for the vast majority of 
subgroups analyses based on differences in population and treatment protocols. It is uncertain to what 
extent this statistical significance translates to clinically significant differences across the different types 
of outcome measures used. An indirect comparison is suggestive of SCIT being more beneficial than 
SLIT based on SSs and MSs, but no such difference could be shown for combined SMSs or QoL and firm 
conclusions cannot be drawn. Cost-effectiveness analyses suggest that both SCIT and SLIT may become 
cost-effective at a threshold of £20,000–30,000 per QALY at around 6 years (NHS and patient perspective). 
This is based on limited data and the use of a number of assumptions. Potential future cost savings 
resulting from cases of asthma avoided were not included in this analysis. There is a need for consistent 
reporting of validated outcome measures, ideally in head-to-head trials, which would allow for a more 
meaningful data synthesis and use of results to inform model-based economic analyses.
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Appendix 1 Original protocol
Project title
Allergen immunotherapy in adults and children with severe hay fever: systematic review of effectiveness 
and economic modelling
Planned investigation
Background
‘Hay fever’ is the common name classically given to seasonal allergic rhinitis or rhinoconjunctivitis. This is 
a disorder of the nose and eyes characterised by nasal obstruction, rhinorrhoea, itching of the nose and 
sneezing, with itching, redness, soreness and watering of the eyes. The relative severity of these symptoms 
varies between patients. Symptoms are caused by an IgE-mediated inflammation of the membranes lining 
the nasal cavity and conjunctiva occurring in response to an allergen. Common allergens include tree or 
grass pollen, moulds, animal dander and house dust mite. In Britain, the main cause of allergic rhinitis 
is grass pollen, particularly perennial rye (Lolium perenne) and timothy grass (Phleum pratense), with 
symptoms peaking in June and July.1
The term ‘hay fever’ emerges from the traditional classification of allergic rhinitis into ‘seasonal’, ‘perennial’ 
and ‘occupational’ according to the time of exposure to the underlying allergen. Seasonal allergic rhinitis, 
or hay fever, is typically caused by a response to pollens and outdoor moulds while perennial allergic 
rhinitis is caused by house dust mites, animal dander and indoor moulds. In 2001 a new classification was 
suggested by the World Health Organisation ARIA (Allergic Rhinitis and its Impact on Asthma) Workshop.2 
This new classification relies on the measurement of the frequency and duration of symptoms (see table 1) 
rather than upon the timing of the presence of the allergen.
Allergic rhinitis is an extremely common disease, with estimates of worldwide prevalence being in the 
region of 25% of the population. Estimates of the prevalence of allergic rhinitis in the UK vary from 
15–30%3,4 although the true prevalence is difficult to ascertain because many people with symptoms 
self-diagnose and use over-the-counter remedies. It is believed the prevalence of seasonal allergic rhinitis is 
higher in children and adolescents than it is in adults, with perennial allergic rhinitis being more common 
in adults.2 Allergic rhinitis tends to be more common in ‘Western’ developed countries.
General practice consultation rates for allergic rhinitis in England show an increase in new patients with 
this diagnosis year on year between 2001 and 2005. A rate of 5.57 per 1000 person years in 2001 rose 
TABLE 1 ARIA classification of allergic rhinitis, 20012
Intermittent Symptoms
< 4 days / week
 or
< 4 weeks
Persistent Symptoms
 ≥ 4 days / week
 and
 ≥ 4 weeks
Severity: Mild
Normal sleep
Normal daily activities, sport, leisure
Normal work and school
No troublesome symptom
Severity: Moderate – Severe
Abnormal sleep
Impairment of daily activities, sport, leisure
Problems caused at work or school
Troublesome symptoms (one or more items)
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to 7.41 by 2005, an increase of 33%. At the same time there was a 41% increase in the number of 
prescriptions issued (antihistamines 45.5%, ‘drugs used in nasal allergies’ 35.5%).5
Allergic rhinitis is not usually a severe or life threatening disease but it can detrimentally affect school6 and 
work performance7, as well as causing social disruption to individuals who suffer from it. The economic 
burden of allergic rhinitis is high, both in terms of costs to the NHS and due to work days lost.3,8
Allergic rhinitis is an independent risk factor for asthma. Around 80% of people with asthma also have 
symptoms of allergic rhinitis. Studies have shown a temporal relationship – with rhinitis frequently 
preceding asthma.2 Those who have allergic rhinitis are around three times more likely to get asthma than 
those who do not.9
Inflammation of the nasal membranes in allergic rhinitis can cause a worsening of asthma through 
various different mechanisms and so optimal treatment of rhinitis may, to some extent, improve 
coexisting asthma.2
Diagnosis of allergic rhinitis is usually clinical with a typical history being given, in the case of hay fever, of 
seasonal symptoms over several years. The more common symptoms of sneezing, rhinorrhoea, stuffy nose 
and conjunctivitis may be accompanied by others such as anosmia (loss of smell), snoring or other sleep 
problems, facial pain, wheezing and tightness of the chest. Diagnosis is confirmed by a skin prick test, 
which demonstrates an IgE mediated allergic reaction of the skin to a specific allergen. There is no widely 
accepted measure of the severity of nasal obstruction. In the new ARIA classification severity of allergic 
rhinitis is assessed through the effect the condition has on everyday functioning of the individual.
In clinical trials, the primary outcome measures generally used are symptom score and use of (rescue) 
medication. Symptom scoring systems vary widely across trials, and can include physician or patient 
self-rated questionnaires. One more common scoring system is a score from 0–3 (0 = absent, 1 = mild, 
2 = moderate, 3 = severe symptoms) for symptoms such as runny nose, blocked nose, sneezing, itchy nose, 
gritty feeling/red/itchy eyes and watery eyes.10 QoL is more likely to be a secondary outcome measure. 
A well validated scale is the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ)11, a disease specific 
quality of life measure. Generic QoL measures have also been used in some trials, such as the EQ–5D or 
SF–36. Objective outcome measures include blood IgE levels.
Treatment
The British Society for Allergy and Clinical Immunology (BSACI) have produced guidelines4 for 
the management of allergic rhinitis. Management may include allergen avoidance, medication 
(pharmacological treatment), education and immunotherapy.
BSACI guidelines can be summarised as follows. Following diagnosis, first-line treatment of allergic rhinitis 
is allergen avoidance (where possible and practicable). The nature and severity of symptoms determines 
the type of medication offered. If symptoms are mild a non-sedating oral or topical H1-antihistamine is 
given. Where symptoms are moderate to severe, first-line therapy is with a topical intranasal steroid. If 
these treatments fail further agents may be added according to the troublesome symptom – ipratropium 
for watery rhinorrhoea, a non-sedating H1-antihistamine for itch or sneeze, a leukotriene-receptor 
antagonist for catarrh if asthmatic. Blockage of the nose may require a decongestant, oral corticosteroids 
or a long-acting non-sedating H1 antihistamine. If there is further treatment failure, and if the symptoms 
are predominantly due to one allergen, then immunotherapy may be considered. The guidelines lack 
specific or broadly authorised recommendations for immunotherapy, which may be a reflection of the lack 
of an international consensus to date on the role of this therapy.12 There are currently no NICE guidelines 
on treatment of allergic rhinitis.
A survey13 of UK general practices found that 54% of patients with seasonal allergic rhinitis reported 
partial or poor control of their symptoms. Of these, 69.4% were not taking their medication as per current 
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guidelines, the remaining 30.6% were already using their drugs as per guidelines and were still sub-
optimally controlled. For these patients immunotherapy may be beneficial.
Immunotherapy
Allergen immunotherapy is a method of reducing sensitivity to a specific allergen by repeated 
administration of a dose of that allergen. The benefit is dependent on the dose and the route of 
administration. Various mechanisms have been proposed to explain the efficacy of immunotherapy, 
including the induction of allergen-specific IgG4, deviation of allergen-induced cytokine production, 
and allergen-specific T regulatory cells that reduce the late-phase response to the allergen. For 
any form of specific immunotherapy, the patient’s symptoms must be attributable to one or a few 
dominant allergens.12
There are different routes of administration for specific allergen immunotherapy: subcutaneous (injection), 
sublingual, nasal and oral. For subcutaneous (injection) immunotherapy, weekly injections of incremental 
doses of allergen are given until a maintenance dose is reached. This maintenance dose is given monthly 
for 2–3 years. Injections can cause minor adverse events and, whilst systemic reactions are rare, occasional 
fatalities due to anaphylaxis have been reported.14 Nasal administration is thought to be effective, but may 
be limited by local side effects, whilst studies assessing the oral route have indicated a lack of efficacy. 
Trials comparing sublingual immunotherapy to placebo have found significant reductions in symptoms and 
medication requirements.14
Immunotherapy can be effective in the treatment of symptoms of allergic rhinitis and is the only treatment 
that can have an effect upon the natural history of the condition i.e. offer long term remission.4 In one 
randomised controlled trial a three- year course of immunotherapy to grass pollen remained effective three 
years after treatment ceased.15 Where patients have allergic rhinitis only, immunotherapy may prevent the 
onset of asthma, as shown by the results of a10-year multicentre prospective study of immunotherapy in 
children with seasonal allergic rhinitis.16
There are two licensed products available in the UK for the treatment of seasonal allergic hay fever due 
to grass or tree pollen in patients who have failed to respond to anti-allergy drugs. Pollinex® (grasses 
and rye or tree pollen extract) is given by subcutaneous injection, but this was licensed in the 1970s and 
uses a shortened dosing regime. Grazax® (grass pollen Phleum pratense extract) was recently licensed 
and is given sublingually.17 Furthermore, there is considerable specialist use of unlicensed subcutaneous 
immunotherapy products (mainly Alutard® and Allergopharma®), under CTA (clinical trial authorisation). 
These include various allergens such as grass and tree pollens, house dust mite, cat and dog danders 
(personal communication AH). Most recent data regarding the efficacy of subcutaneous immunotherapy is 
derived from dosage regimes using such products.
Existing research
Clinical effectiveness reviews
The Cochrane review by Calderon et al. (2007)18 identified 51 RCTs comparing subcutaneous (injection) 
allergen-specific immunotherapy to placebo in patients with seasonal allergic rhinitis. Eight RCTs included 
participants younger than 18 years and one had an age range of 6–56 years. There were no studies 
exclusively in children. It is unclear to what extent conventional treatment was inadequate in the included 
populations. The review found significant reductions in symptom scores and medication use and a 
relatively low risk of severe adverse events. Searches for this review were completed in February 2006.
The Cochrane review by Wilson et al. (2003)19 included 22 RCTs comparing sublingual immunotherapy 
(SLIT) to placebo in patients with seasonal allergic rhinitis. The authors found that SLIT significantly 
reduces symptoms and medication requirements in adults. The treatment effect in children, based on 
five studies (n = 218), was not significant. The treatment appeared to be very safe with no systemic side 
effects identified in any of the studies. Searches for this review were completed in February 2003. The 
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review was updated in 2006 and results presented in 2007 at EAACI (European Academy of Allergy & 
Clinical Immunology) and in 2008 at AAAAI20 (American Academy of Allergy, Asthma & Immunology) and 
a further update is due shortly with searches up to September 2009 (personal communication DW). The 
results of the updated review were broadly consistent with the previous review and showed that sublingual 
immunotherapy was effective in reducing symptoms and use of medication, with mostly mild side effects.
There is a Cochrane protocol only (McDonald et al., 2009)21 for local nasal immunotherapy for 
allergic rhinitis.
The systematic review by Penagos (2006)22 included ten studies of sublingual immunotherapy for allergic 
rhinitis in children and found evidence of effectiveness of immunotherapy compared to placebo. This was 
confirmed by the review by Larenas-Linnemann (2009), which included later studies. The review by Röder 
(2008)23 included 28 studies on the effectiveness of immunotherapy compared to placebo or another 
route of administration. In contrast to the reviews by Penagos (2006) and Larenas-Linnemann (2009), the 
authors found no evidence of benefit for sublingual immunotherapy. Moderate evidence of effect was 
found for nasal immunotherapy. (It should be noted that these reviews included some trials where the 
children had house mite allergies).
Head-to-head comparisons of different routes of administration 
of immunotherapy
Compared to the evidence base of immunotherapy compared to placebo, there appear to be few 
studies directly comparing different routes of administration. Two RCTs24,25 were identified comparing 
subcutaneous with sublingual immunotherapy. No significant differences were found between the 
treatments in these two small studies.
Cost-effectiveness reviews
There are several studies, which have conducted cost comparisons only. Ariano (2006)26 found overall 
lower costs for subcutaneous immunotherapy compared to symptomatic drug treatment (based on a study 
with 30 patients with pollen-induced rhinitis and asthma). Pokladnikova (2008)27 compared the mean 
costs of subcutaneous with sublingual grass pollen immunotherapy and found that sublingual therapy was 
cheaper overall. Berto (2005)28 found that in a study of children with pollen and dust mite induced asthma 
and rhinitis, sublingual immunotherapy was comparable in cost to conventional treatment. None of these 
studies incorporate quality of life measurements.
Our scoping search identified four studies that conducted cost-effectiveness analyses and calculated 
cost per QALY gained. Two of these were based on a large multi-centre RCT10,11 comparing Grazax® with 
standard care. Quality of life was measured by the EQ–5D. Canonica (2007) looked at a group of southern 
European countries (France, Italy, Austria and Spain) and found a cost per QALY of between 13,870 and 
21,659 Euros for Grazax® compared to standard care. Bachert (2007)29 conducted the analysis for a 
group of northern European countries including the UK and calculated a cost per QALY of Grazax® versus 
standard care of between 12,930 and 18,263 Euros. These values are all below a threshold of £20,000. 
Both these studies assumed that, after three years of treatment, tolerance to grass pollen would continue 
for another six years. A further study (Nasser 2008)8, also based on the same trial, found a cost per QALY 
of between £4319 and £11,769 in UK patients with allergic rhinitis co-existing with asthma. The cost was 
found to be sensitive to duration of effect and productivity at work.
One German study was identified (Brüggenjürgen 2008),30 which found a cost per QALY of 8308 Euros for 
subcutaneous immunotherapy compared to symptomatic treatment in patients with allergic rhinitis and 
allergic asthma. This study was not conducted as part of an effectiveness study, but comprised a model 
with inputs estimated from various literature sources or informed by an expert panel. The cost per QALY 
was found to be sensitive to costs of subcutaneous therapy and the target population (e.g. age).
We did not identify any cost-effectiveness studies solely in children.
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Rationale for project
Allergic rhinitis is an increasing problem with high associated costs, both monetary and social. 
Conventional therapies cannot control symptoms well for all patients and do not represent a cure. There 
is a wealth of evidence in the form of randomised controlled trials, particularly for adults, which overall 
shows benefit of immunotherapy over placebo. Despite this, there is a lack of clear guidelines in the UK 
on whether immunotherapy should be recommended as standard where conventional treatments have 
failed. There are two well conducted Cochrane reviews, with the one on sublingual immunotherapy due 
to be updated shortly (searches up to September 2009, personal communication DW). The searches for 
the one on subcutaneous immunotherapy were completed in 2006, and we would expect to identify 
additional data for the time period 2006–2010 as this is a topic of ongoing interest. Further data from the 
final years of the GT08 Grazax® trial are also expected by the time this project would commence (personal 
communication AH).
For children there is a smaller evidence base, with some reports finding conflicting evidence of 
effectiveness for immunotherapy. A definitive and up-to-date conclusion on the evidence of effectiveness 
for children for both sublingual and subcutaneous immunotherapy is clearly needed.
None of the above reviews include an economic evaluation. A scoping search identified four studies that 
generated cost-effectiveness estimates in terms of cost per QALY gained, for sublingual (three studies) and 
subcutaneous immunotherapy (one study). However, none of the cost-effectiveness analyses were based 
on a systematic review of clinical effectiveness. The two main cost-effectiveness analyses (Canonica 2007 
and Bachert 2007) made an assumption of ongoing tolerance to grass pollen for six years after treatment. 
The availability of further data from the GT08 Grazax® trial would provide further evidence on long-term 
effectiveness and make an economic model less reliant on assumptions. We did not identify a cost-
effectiveness analysis/model solely for children, or for a comparison of different routes of administration 
of immunotherapy.
For these reasons we believe that a cost-effectiveness analysis/economic model for both adults and children 
based on an up-to date systematic review of clinical effectiveness is necessary and could contribute to 
establishing more specific UK guidelines on whether immunotherapy should be recommended, and 
for whom.
Research methods
Key research questions
Based on the scoping search and clinical advice, we have found little evidence that oral or nasal 
immunotherapy is of benefit or likely to be used in practice, and we will therefore not include these types 
of immunotherapy. The key questions are thus as follows:
Clinical effectiveness
1. To identify the evidence for the clinical effectiveness of sublingual specific allergen immunotherapy 
compared to standard care in adults and children.
2. To identify the evidence for the clinical effectiveness of subcutaneous specific allergen immunotherapy 
compared to standard care in adults and children.
3. To identify the evidence for the relative clinical effectiveness of sublingual versus subcutaneous allergen 
immunotherapy in adults and children.
Further questions of interest are:
 z duration of effect/recurrence of symptoms
 z adverse events
 z evidence for the prevention of asthma or other allergies
 z most effective dose and dosing regimen
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 z impact of findings on policy.
Cost-effectiveness
Cost-effectiveness modelling will be performed based on the systematic review evidence of clinical 
effectiveness. Preliminary research questions are:
1. To determine the cost-effectiveness of sublingual immunotherapy compared to standard care in adults 
and children.
2. To determine the cost-effectiveness of subcutaneous immunotherapy compared to standard care in 
adults and children.
3. To compare the cost-effectiveness of subcutaneous versus sublingual immunotherapy compared to 
standard care in adults and children.
Future research
Any gaps in the current evidence base will be highlighted and will inform recommendations for future 
primary research. This will include recommendations on study design, populations, intervention, 
comparators and relevant outcomes based on the EPICOT guidelines.31
Search strategy
A scoping search has already been undertaken, which involved interrogation of bibliographic databases 
such as MEDLINE and EMBASE, health economic databases, the Cochrane Library and HTA websites. 
The purpose of this was to identify existing reviews and cost-effectiveness studies, to inform this project 
description, and to gauge the number of relevant studies likely to be included.
Given that there are two relevant well-conducted Cochrane reviews on sublingual and subcutaneous 
immunotherapy (reviewing 73 RCTs), we plan to build on these and update the searches rather than repeat 
them. New searches will thus run from 2006 to 2010. Separate searches will be performed to identify 
relevant studies on cost-effectiveness and for relevant economic model parameters. Search strategies will 
be developed by an experienced information specialist. Search filters for study design will be included 
where possible. A combination of text words and index terms relating to the condition and the treatment 
will be used. There will be no language restrictions.
The following sources will be searched:
 z bibliographic databases (MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials (CENTRAL), 
Science Citation Index)
 z MEDLINE, EMBASE, NHS EED for studies relating to cost and cost-effectiveness
 z Current Controlled Trials metaRegister, ISRCTN database and ClinicalTrials.gov for ongoing studies
 z consultation with experts in the field
 z checking of reference lists of relevant reviews
 z selected websites
 z hand-searching of a selection of relevant journals guided by clinical expertise in the project team.
Study selection strategy
Titles and abstracts of retrieved studies will be screened independently for inclusion by two reviewers. 
Where it is unclear whether studies meet the inclusion criteria on the basis of title and abstract, full 
copies will be obtained for assessment. Any discrepancy between reviewers will be resolved through 
discussion or referral to a third reviewer. The following inclusion and exclusion criteria will apply to clinical 
effectiveness studies:
Study design
Randomised controlled trials (RCTs). RCTs constitute the most robust form of evidence and given the 
availability of in excess of 73 RCTs, we are unlikely to extend the inclusion criteria to other study designs. 
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However, if we find that there is insufficient long-term follow-up data for use in the economic model, we 
may look at large well-designed cohort studies. Scoping searches indicate that follow-up times of RCTs vary 
between less than six months to more than a year.
Population
Adults or children with a confirmed diagnosis of seasonal allergic rhinitis (hay fever). Confirmation is 
likely to be through a skin prick test and/or blood test. If we identify any trials where patients have been 
included on the basis of symptoms only, we will include these and consider them separately. Patients with 
co-morbidities such as asthma will be included.
The brief specifies adults and children (examined separately) with severe hay fever, which does not respond 
to conventional treatment. We anticipate that not all trials will provide this information, or use different 
classifications for ‘severe’ or ‘not responding to conventional treatment’. Where the information is 
provided, populations may still be heterogeneous. Where possible we will consider trials (or subgroups of 
trials) separately where patients meet specified severity criteria.
Where we are using existing Cochrane reviews, we will check whether the included trials meet our 
inclusion criteria.
Intervention
Allergen-specific subcutaneous (injection) or sublingual immunotherapy in any setting. There will be no 
restrictions regarding a particular dose or dosing regimen.
Comparator
This is likely to be placebo in most cases, with conventional (rescue) medication given alongside 
in both treatment arms. We will also include as a comparator a different route of administration 
of immunotherapy.
Outcomes
As specified in the brief, at least one of the following will need to be reported for the trial to be included: 
symptom severity, reduction in medication, cost-effectiveness, frequency of exacerbations, quality of life, 
adverse events, dose-effect relationships. We are also interested in any studies reporting the prevention of 
new asthma cases.
Data extraction
Data extraction will be performed by one reviewer and independently checked by a second reviewer. A 
piloted data-extraction form will be used. Data will be extracted on trial design, patient characteristics, 
intervention (route of administration, dose, frequency), comparator and outcomes.
Quality assessment
Quality assessment of all included studies will be performed using the Cochrane guidelines32 on assessment 
of risk of bias (selection bias, performance bias, attrition bias, detection bias, reporting bias). Of particular 
importance to these trials is blinding of patients, investigators and outcome assessors, due to the 
subjective nature of some of the outcomes (e.g. reduction in symptom severity).
Data synthesis
As there is a large number of trials, meta-analysis has been undertaken in the two relevant Cochrane 
reviews. We would expect to update these analyses using Stata 10 where new data is available. If data is 
available, we will also consider conducting meta-analysis for immunotherapy in children.
There is likely to be a large amount of heterogeneity between trials, for example in terms of how patients 
were recruited, severity of hay fever, type of allergen, dosage as well as route of administration. We will 
examine clinical and statistical heterogeneity before attempting to pool data. There are also likely to be a 
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variety of outcome measures used to measure reduction in symptom severity, therefore the standardised 
mean difference will be used when pooling data. Studies on sublingual and subcutaneous immunotherapy 
will be pooled separately. Where we are unable to incorporate study results into meta-analyses, 
these will be tabulated and described separately, and the consistency of the results with those of the 
meta-analyses discussed.
The likelihood of publication bias will be investigated through the construction and evaluation of 
Funnel plots.
We are likely to identify only few head-to-head trials of different routes of administration. We will 
investigate the possibility of conducting an indirect comparison, however this is likely to be hampered by 
heterogeneity between the studies.
Economic evaluation
Literature review
A formal search will be undertaken as outlined in section 3.2 in order to identify additional studies 
reporting cost or resource use, quality of life and cost-effectiveness. Relevant cost-effectiveness studies 
will be summarised formally appraised using the Drummond checklist33 and may be used to inform the 
model. Information on the following key items will be extracted: type of economic analysis, population, 
intervention, comparator, perspective, time horizon, structure and assumptions of model, effectiveness 
data, resource and cost data, discounting and results of base case and sensitivity analyses.
We will conduct a systematic search of the QoL literature in order to identify studies that directly measure 
utility values for example through the use of the EQ–5D.
Economic model
Depending on the suitability of existing models we may adapt these, or develop our own model. The 
model structure will be informed by the patient pathway and will be developed with the help of our 
clinical experts. As this is a long-term disease we are likely to use a state transition model such as a 
Markov model.
The systematic review of effectiveness will generate the most evidence based parameters to be used in the 
economic model. Depending on the extent of the evidence base, these may not be summary estimates 
but represent qualified, best estimates representing current practice. Trials that have measured QoL using 
the EQ–5D such as the large multi-centre trial10,11 of Grazax® will be particularly useful. We will approach 
the trial investigators in order to obtain, if available, effectiveness and QoL data beyond three years (on 
which the previous economic evaluations were based). Where studies have measured QoL using outcome 
measures other than the EQ–5D, we will investigate whether QoL results can be converted into a form that 
will allow them to be combined with the EQ–5D values. Drug and resource costs will be obtained from 
the literature review, standard sources, and consultation with clinical experts. These will include costs of 
medication, GP visits, hospitalisation and hours lost from work. We will also include the costs resulting 
from adverse events wherever possible.
The results of the economic modelling will be expressed as incremental cost per QALY gained. We will 
run the model using a ‘base case’ scenario, which will be varied for a number of sensitivity analyses. 
Parameters which are expected to influence the cost per QALY are drug costs, duration of benefit and 
population characteristics. If the available data allows, we will conduct separate analyses for adults and 
children and for subcutaneous and sublingual immunotherapy. Deterministic and probabilistic sensitivity 
analyses will be undertaken. Decision uncertainty will be displayed through the use of cost-effectiveness 
acceptability curves and value of information analysis as appropriate. If the evidence is available we will 
also look at different types of allergen (e.g. grass, tree). We will attempt to incorporate costs savings of 
prevented cases of asthma.
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Our scoping searches indicate that the most evidence is likely to exist for sublingual immunotherapy with 
grass pollen versus conventional treatment and this is likely to be the primary focus of the economic 
model. We will however endeavour to also model subcutaneous immunotherapy versus conventional 
treatment, as well as a comparison between sublingual and subcutaneous administration.
Project timetable
The project is expected to run over a 12-month period. Key stages are outlined below:
A M J J A S O N D J F M
Clinical effectiveness and cost-effectiveness review
Literature searches
Study selection
Synthesis of cost-effectiveness data
Data extraction / quality assessment of 
clinical effectiveness data
Data synthesis and analysis
Write up of systematic review
Economic model
Preliminary model structure
Identify additional model parameters 
from literature
Final model structure
Run model and sensitivity analyses
Write up of economic analysis
Milestones
At 3 months: all relevant studies for inclusion into systematic review identified; preliminary 
model structure.
At 6 months: submission of HTA progress report; final model structure.
At 7 months: all data extracted and quality appraised.
At 10 months: all data synthesis/analysis completed, all model sensitivity analyses completed.
Expertise
The applicants have extensive experience of conducting systematic reviews and health technology 
assessments, meta-analysis, economic modelling, information science and clinical immunology. The 
West Midlands Health Technology Assessment Collaboration (WMHTAC) members have worked together 
successfully on numerous previous projects and have no commercial interests in their projects.
Janine Dretzke (JD) has been a systematic reviewer with WMHTAC since 2001 and was the main reviewer 
on four large HTA reports (for NICE/NETSCC HTA), working closely with health economists, clinical experts 
and information specialists. JD has considerable experience in the subject of this proposal as she has 
recently completed a systematic review of clinical and cost-effectiveness on provocation/neutralisation 
testing in food allergy and also contributed to a review on acupuncture for allergic rhinitis. JD will 
contribute mainly to the systematic review of effectiveness, data analysis and report writing.
NIHR Journals Library www.journalslibrary.nihr.ac.uk
AppENDIx 1
148
Dr Catherine Meads (CM) is a senior systematic reviewer and the Director of WMHTAC. This collaboration 
has conducted numerous HTAs, systematic reviews and other evidence synthesis reports for a variety of 
customers including the NIHR HTA programme over the last ten years. She has experience of managing 
large research grants, particularly for National Institute for Health and Care Excellence (NICE) Technology 
Appraisals and for the Centre for Public Health Excellence. CM has worked in the Unit of Public Health, 
Epidemiology and Biostatistics for over 12 years and has extensive systematic review experience, having 
worked on numerous systematic reviews for NICE, NIHR and other customers. CM will contribute to the 
systematic review of effectiveness, management of the project and report writing.
Professor Jayne Parry (JP) is the Head of the Unit of Public Health in the University of Birmingham and has 
an active research programme focusing on the evaluation of health impacts of public policy. She is a senior 
researcher with excellent project management skills and substantial experience of leading multi-disciplinary 
research teams. JP will provide input into project management and any other duties as required.
Dr Pelham Barton (PB) is a highly experienced mathematical modeller whose main research area is the 
application of appropriate simulation modelling techniques to choose between a range of possible 
strategies for treating a given patient group. He has many published models, dealing with both hospital-
based health care interventions, where the focus is on individual patient pathways, and health care 
interventions where it is essential to consider the effects on the whole population. PB joined the Health 
Economics Unit in the School of Health and Population Sciences in 1998 and has been closely involved 
in the WMHTAC technology appraisals for NICE. PB will supervise a health economist, who will carry 
out most of the work on the economic component, and will contribute to the economic modelling and 
report writing.
Dr Kristina Routh (KR) is a medical doctor in her final year of Higher Specialist Training in Public Health. 
Previously trained in Pathology, she has over five years experience of working within a variety of health 
organisations at both local and regional level. Her public health training will allow her to bring a 
population-based perspective to this review and, having worked both within the Regional Specialised 
Commissioning Team and with commissioners in two Primary Care Trusts, she will contribute valuable 
insights into the requirements of commissioners. KR will contribute to data analysis and report writing, 
particularly with regard to policy impact.
Anne Fry-Smith (AFS) is a senior information specialist, who leads the information team supporting 
WMHTAC and ARIF. She has extensive knowledge of research information searching and retrieval 
strategies. She is the co-author on several NICE reports. AFS will develop and run the search strategies.
The following clinical experts (AH, TK, DW) will support the team with clinical input and access to contacts. 
Further, we anticipate forming a steering committee consisting of the clinical experts as well as PB, CM and 
JD in order to ensure that the economic component of the review links up with the clinical effectiveness 
component, and to enable clinical input to inform the structure of the model from the outset.
Dr Aarn Huissoon (AH) is a consultant immunologist at Birmingham Heartlands Hospital (Heart of 
England NHS Foundation Trust) and honorary senior lecturer at the Department of Immunity and 
Infection, University of Birmingham. He has been providing an allergy service including desensitisation 
immunotherapy for allergic rhinitis for the last 8 years. AH is the local investigator for a number of 
multicentre placebo-controlled trials of both subcutaneous and sublingual immunotherapy for allergic 
rhinitis and can therefore bring first-hand in-depth experience of both clinical use and investigation of 
immunotherapy to the team. In addition he has undertaken a course in systematic reviews, and has 
published a review of acupuncture in allergic rhinitis.
Dr M Thirumala Krishna (TK) is a consultant immunologist and allergist and honorary senior lecturer at 
Birmingham Heartlands Hospital. His main interests include allergen immunotherapy and novel treatments 
in allergic disease, and air pollution and health.
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Dr Duncan Wilson (DW) is a consultant respiratory physician at Selly Oak Hospital (University Hospitals 
Birmingham). His main clinical interest is in airway allergy: allergic rhinitis, asthma and the link between 
those two conditions. His MD thesis covered clinical and immunological aspects of specific allergen 
immunotherapy. As well as his clinical duties, he is an honorary senior lecturer at the University of 
Birmingham and is Clinical Service Lead for Respiratory Medicine. He is the main author of one of the 
relevant Cochrane reviews on sublingual immunotherapy for allergic rhinitis, and is also involved in the 
upcoming update of this review. DW can thus act both as a clinical advisor and give advice on systematic 
review methodological issues.
Service users
Patients who suffer from severe hay fever will have views on the usefulness and appropriateness of 
immunotherapy treatment. AH has extensive patient contact and is well placed to approach a patient 
or patients who would act as a patient representative(s) on the project. A patient perspective will help 
us to put the findings of our review into a patient-relevant context. We also propose to disseminate our 
findings to service users through leading charities such as Allergy UK (www.allergyuk.org), for example by 
contributing to one of their Allergy Fact Sheets.
Justification for the support requested
We have, as a group of applicants, very carefully analysed the degree and complexity of the work required 
to produce high quality clinical effectiveness reviews and economic model. We are in an excellent position 
to gauge the level of resources required to deliver this type of project as we have several years experience 
in the delivery of such projects in a variety of topic areas.
We think that one year will be a sufficient time scale for all the work proposed in this application. We 
have recently conducted similar projects involving systematic reviews and economic modelling for a several 
customers and the nature of this project is similar in complexity and workload to previous projects. We 
have found that a senior reviewer with a medical background is invaluable because of the complex nature 
of the clinical terminology and lack of reporting standards in clinical and methodological terms. The 
burden of work related to effectiveness review will require two reviewers to enable double study selection, 
data extraction etc. but neither need to be full-time. For the modelling work, one modeller will need to 
focus on this work full time for six months, with supervision from the experienced senior modeller. Funding 
is therefore requested for:
 z One systematic reviewer 0.2 WTE and one systematic reviewer 0.5 WTE for 1 year who will carry out 
mainly the effectiveness review.
 z One WTE health economist for 6 months for the economic evaluation.
 z Suitable supervision for the clinical effectiveness, economic modelling and the project as a whole.
 z A small amount of time from an information specialist, appropriate for one project.
As this work will be performed by staff embedded within a larger HTA organisation, we are able to draw 
on additional in-house expertise as necessary. In addition, some WMHTAC team members are core-funded 
so not being paid to work on this project.
The non-staff costs comprise the following:
 z Travel and subsistence for one conference to disseminate findings of the research.
 z The consumables budget of £1,000 is based on our experience of the number of inter-library loans 
required for a systematic review, and sundry other administration costs. The small amount for 
consultancy will be used to nominally reimburse our clinical experts for their time, particularly Dr Aarn 
Huissoon who will be closely involved with the project
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Appendix 2 Search strategies
Clinical effectiveness
Source: The Cochrane Library (Cochrane Central Register of Controlled 
Trials) 2011 Issue 1
#1 MeSH descriptor Rhinitis, Allergic, Seasonal, this term only
#2 (rhinoconjunctivitis or rhino next conjunctivitis)
#3 hay next fever
#4 pollen next allergen*
#5 season* next allergic
#6 hayfever or pollinosis or pollenosis or sar
#7 (#1 OR #2 OR #3 OR #4 OR #5 OR #6)
#8 MeSH descriptor Rhinitis, this term only
#9 rhinitis
#10 (#8 OR #9)
#11 intermittent* or season* or spring or summer
#12 pollen* or grass* or birch or ragweed or tree*
#13 weed* or mugwort or willow or alder
#14 MeSH descriptor Trees, this term only
#15 (#11 OR #12 OR #13 OR #14)
#16 (#10 AND #15)
#17 MeSH descriptor Desensitization, Immunologic, this term only
#18 MeSH descriptor Allergens, this term only
#19 desensiti* or hyposensiti*
#20 MeSH descriptor Immunotherapy, this term only
#21 immunotherap* or immunomodulatory or allergen* or antigen*
#22 immune next therapy
#23 immunologic next response*
#24 grazax or pollinex or alutard
#25 (#17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24)
#26 (#7 OR #16)
#27 (#25 AND #26)
Source: Ovid MEDLINE(R) 1948 to week 2 April 2011
1. Rhinitis, Allergic, Seasonal/ (11,107)
2. (rhinoconjunctivitis or rhino conjunctivitis).ti,ab. (1334)
3. (hay fever or hayfever or pollinosis or pollenosis or SAR or pollen allergen* or season* allergic).ti,ab. 
(13,935)
4. or/1–3 (22,044)
5. Rhinitis/ (7156)
6. rhinitis.ti,ab. (15,813)
7. or/5–6 (19,981)
8. (intermittent* or season* or spring or summer or pollen* or grass* or birch or ragweed or tree* or 
weed* or mugwort or willow or alder).ti,ab. (223,342)
9. Trees/ or Poaceae/ (23,581)
10. 8 or 9 (234,891)
11. 7 and 10 (3812)
12. Desensitization, Immunologic/ (7170)
13. allergens/ (28,104)
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14. (desensiti* or hyposensiti*).ti,ab. (22,895)
15. immunotherapy/ (25,148)
16. (immunotherap* or immunomodulatory or immune therapy or immunologic response* or allergen* or 
antigen*).ti,ab. (509,932)
17. (grazax or pollinex or alutard).ti,ab. (101)
18. or/12–17 (552,055)
19. 4 or 11 (23,106)
20. 18 and 19 (7716)
21. exp animals/ not humans/ (3,565,261)
22. 20 not 21 (7358)
23. limit 22 to “therapy (optimized)” (1051)
Source: EMBASE (Ovid) 1980 to 2011 week 15
1. exp allergic rhinitis/ (22,724)
2. (rhinoconjunctivitis or rhino conjunctivitis).ti,ab. (2038)
3. (hay fever or hayfever or pollinosis or pollenosis or SAR or pollen allergen* or season* allergic).ti,ab. 
(16,538)
4. or/1–3 (35,766)
5. rhinitis/ (11,928)
6. rhinitis.ti,ab. (20,790)
7. or/5–6 (27,861)
8. (intermittent* or season* or spring or summer or pollen* or grass* or birch or ragweed or tree* or 
weed* or mugwort or willow or alder).ti,ab. (278,114)
9. tree/ or grass pollen/ (16,418)
10. or/8–9 (284,179)
11. 7 and 10 (5386)
12. desensitization immunologic/ (13,113)
13. allergen/ (31,586)
14. (desensiti* or hyposensiti*).ti,ab. (25,828)
15. immunotherapy/ (38,113)
16. (immunotherap* or immunomodulatory or immune therapy or immunologic response* or allergen* or 
antigen*).ti,ab. (552,975)
17. (grazax or pollinex or alutard).ti,ab. (191)
18. or/12–17 (604,305)
19. 4 or 11 (36,735)
20. 18 and 19 (12,139)
21. exp animal/ not human/ (1,254,356)
22. 20 not 21 (12,046)
23. limit 22 to “treatment (2 or more terms min difference)” (1982)
Source: Cumulative Index to Nursing and Allied Health Literature 
(EBSCOhost) 1982–2011
S1 
(MH “Rhinitis, Allergic, Seasonal”)
S2 
TX rhinoconjunctivitis or TX “rhino conjunctivitis”
S3 
TX “hay fever” or TX hayfever or TX pollinosis or TX pollenosis or TX sar or TX par or TX “pollen allergen*” 
or TX “season*allergic”
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S4 
S1 or S2 or S3
S5
(MH “Rhinitis”)
S6 
TX Rhinitis
S7 
S5 or S6
S8 
TX intermittent* or TX season* or TX spring or TX summer or TX pollen* or TX grass* or TX birch or TX 
ragweed or TX tree* or TX weed* or TX mugwort or TX willow
S9 
TX alder or TX poaceae
S10 
S8 or S9
S11 
S7 and S10
S12 
(MH “Desensitization, Immunologic”)
S13 
(MH “Allergens”)
S14 
TX desensiti* or hyposensiti*
S15 
(MH “Immunotherapy”)
S16 
TX immunotherap* or TX immunomodulatory or TX “immune therapy” or TX “immunologic response*” or 
TX allergen* or TX antigen*
S17 
TX grazax or TX pollinex or TX alutard
S18 
s12 or s13 or s14 or s15 or s16 or s17
S19 
s4 or s11
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S20 
s18 and s19View Results (455)
S21 
s18 and s19
Limiters - Clinical Queries: Therapy - Best Balance; Human
View Results (93)
Source: Science Citation Index (Web of Knowledge) 1900–2011
#1 
12,037 
TS=”seasonal allergic rhinitis
#2 
1757 
TS=rhinoconjunctivitis
#3 
95 
TS=”rhino conjunctivitis”
#4 
21,338 
TS=(hayfever or pollinosis or pollenosis or sar)
#5 
7479 
TS=(“hay fever” or “pollen allergen*” or “season* allergic”)
#6 
29,405  
#5 OR #4 OR #3 OR #2 OR #1
#7 
17,492  
TS=rhinitis
#8 
>100,000  
TS=(intermittent* or season* or spring or summer or pollen* or grass* or birch or ragweed or tree* or 
weed* or mugwort or willow or alder or poaceae)
#9 
4902 
#8 AND #7
#10 
>100,000  
TS=(allergen* or desensiti* or hyposensiti* or immunotherap* or immunomodulatory or antigen* or 
grazax or pollinex or alutard)
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#11 
774 
TS=”immune therapy”
#12 
1640  
TS=”immunologic response*”
#13 
>100,000  
#12 OR #11 OR #10
#14 
31,306  
#9 OR #6
#15 
6212  
#14 AND #13
#16 
>100,000  
TS=(trial OR random* OR control* OR placebo)
#17 
2068  
#15 AND #16
Economic evaluations
Source: The Cochrane Library (NHS Economic Evaluation Database)
Refer to The Cochrane Library effectiveness search strategy above.
Source: Ovid MEDLINE(R) 1948 to week 2 April 2011
1. Rhinitis, Allergic, Seasonal/ (11,107)
2. (rhinoconjunctivitis or rhino conjunctivitis).ti,ab. (1334)
3. (hay fever or hayfever or pollinosis or pollenosis or SAR or pollen allergen* or season* allergic).ti,ab. 
(13,935)
4. or/1–3 (22,044)
5. Rhinitis/ (7156)
6. rhinitis.ti,ab. (15,813)
7. or/5–6 (19,981)
8. (intermittent* or season* or spring or summer or pollen* or grass* or birch or ragweed or tree* or 
weed* or mugwort or willow or alder).ti,ab. (223,342)
9. Trees/ or Poaceae/ (23,581)
10. 8 or 9 (234,891)
11. 7 and 10 (3812)
12. Desensitization, Immunologic/ (7170)
13. allergens/ (28,104)
14. (desensiti* or hyposensiti*).ti,ab. (22,895)
15. immunotherapy/ (25,148)
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16. (immunotherap* or immunomodulatory or immune therapy or immunologic response* or allergen* or 
antigen*).ti,ab. (509,932)
17. (grazax or pollinex or alutard).ti,ab. (101)
18. or/12–17 (552,055)
19. 4 or 11 (23,106)
20. 18 and 19 (7716)
21. exp animals/ not humans/ (3,565,261)
22. 20 not 21 (7358)
23. economics/ (25,995)
24. exp “costs and cost analysis”/ (155,450)
25. cost of illness/ (13,777)
26. exp health care costs/ (37,323)
27. economic value of life/ (5134)
28. exp economics medical/ (13,145)
29. exp economics hospital/ (17,088)
30. economics pharmaceutical/ (2221)
31. exp “fees and charges”/ (25,111)
32. (econom$ or cost or costs or costly or costing or price or pricing or pharmacoeconomic$).tw. 
(338,786)
33. (expenditure$ not energy).tw. (14,033)
34. (value adj1 money).tw. (18)
35. budget$.tw. (14,277)
36. or/23–35 (462,608)
37. 22 and 36 (164)
Source: EMBASE (Ovid) 1980–2011 week 15
1. exp allergic rhinitis/ (22,724)
2. (rhinoconjunctivitis or rhino conjunctivitis).ti,ab. (2038)
3. (hay fever or hayfever or pollinosis or pollenosis or SAR or pollen allergen* or season* allergic).ti,ab. 
(16,538)
4. or/1–3 (35,766)
5. rhinitis/ (11,928)
6. rhinitis.ti,ab. (20,790)
7. or/5–6 (27,861)
8. (intermittent* or season* or spring or summer or pollen* or grass* or birch or ragweed or tree* or 
weed* or mugwort or willow or alder).ti,ab. (278,114)
9. tree/ or grass pollen/ (16,418)
10. or/8–9 (284,179)
11. 7 and 10 (5386)
12. desensitization immunologic/ (13,113)
13. allergen/ (31,586)
14. (desensiti* or hyposensiti*).ti,ab. (25,828)
15. immunotherapy/ (38,113)
16. (immunotherap* or immunomodulatory or immune therapy or immunologic response* or allergen* or 
antigen*).ti,ab. (552,975)
17. (grazax or pollinex or alutard).ti,ab. (191)
18. or/12–17 (604,305)
19. 4 or 11 (36,735)
20. 18 and 19 (12,139)
21. exp animal/ not human/ (1,254,356)
22. 20 not 21 (12,046)
23. cost benefit analysis/ (55,170)
24. cost effectiveness analysis/ (71,637)
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25. cost minimization analysis/ (1826)
26. cost utility analysis/ (3413)
27. economic evaluation/ (6090)
28. (cost or costs or costed or costly or costing).tw. (300,972)
29. (economic$ or pharmacoeconomic$ or price$ or pricing).tw. (157,655)
30. (technology adj assessment$).tw. (3043)
31. or/23–30 (466,067)
32. 22 and 31 (375)
Quality of life
Source: Ovid MEDLINE(R) 1948 to week 5 June 2011
1. Rhinitis, Allergic, Seasonal/ (11,285)
2. (rhinoconjunctivitis or rhino conjunctivitis).ti,ab. (1375)
3. (hay fever or hayfever or pollinosis or pollenosis or SAR or pollen allergen* or season* allergic).ti,ab. 
(14,414)
4. or/1–3 (22,665)
5. Rhinitis/ (7326)
6. rhinitis.ti,ab. (16,122)
7. or/5–6 (20,398)
8. (intermittent* or season* or spring or summer or pollen* or grass* or birch or ragweed or tree* or 
weed* or mugwort or willow or alder).ti,ab. (228,206)
9. Trees/ or Poaceae/ (24,071)
10. 8 or 9 (239,962)
11. 7 and 10 (3885)
12. 4 or 11 (23,747)
13. quality of life/ (92,016)
14. life style/ (35,811)
15. health status/ (48,471)
16. health status indicators/ (16,723)
17. value of life/ (5167)
18. quality adjusted life.mp. (6813)
19. or/13–18 (183,446)
20. 12 and 19 (472)
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Appendix 3 Indirect comparison methodology 
and results
Methods
Indirect comparison meta-analysis
Four continuous outcomes were included in the review (SSs, MSs, SMSs and QoL scores). Each score yjk can 
be assumed to have a normal likelihood with standard deviation sdjk, sample size Njk and, therefore, 
standard error sejk =
sdjk
Njk
 for study j and arm k (Equation 2). Scores have been measured on different 
scales across studies. Therefore, these needed to be standardised before the inclusion in the meta-analysis 
by means of the pooled SD (SDj)
263,264 (Equation 3). Standardised mean scores are represented by mjk in 
Equation 3, whereas SMDs djks are estimated via a linear regression model (Equations 4a and 4b), where 
a random-effects parameter s2 can be estimated as an alternative to the fixed-effects model, where 
djk = dk  – dbj would replace Equation 4b, where dk is the pooled SMD score between treatment k (2 = SCIT; 
3 = SLIT) and placebo (i.e. bj = 1 for every study j, the reference baseline intervention arm for every study 
included in the ICMA). Finally, the indirect comparison of SLIT vs SCIT can be estimated by subtracting the 
pooled SMD slope between SLIT and placebo and the pooled SMD slope between SCIT and placebo as 
in Equation 5. A positive value for d32 would indicate that the SLIT pooled score is higher than the SCIT 
pooled score (i.e. SCIT is a better treatment); similarly, a negative value for d32 would indicate that SLIT is a 
better treatment.
y jk  dnorm mean_ scorejk , sejk =
sdjk
Njk
⎛
⎝⎜
⎞
⎠⎟
 (2)
mean_ scorejk = µ jk ∗ SDj  (3)
µ jk =
basej       Interventionbj
basej +δ jk Interventionk
⎧
⎨⎪
⎩⎪
⎫
⎬⎪
⎭⎪
 (4a)
δ jk  Normal dk – dbj( ),σ 2( )  (4b)
d32 = d3 – d2  (5)
Indirect comparison meta-regression
Random-effects modelling is a first step to account for unexplained between-study variability or 
heterogeneity.265 Heterogeneity can be further explored by means of meta-regression when covariates are 
available from the review. In this review a number of covariates were available. The linear regression model 
described in Equations 4a and 4b would instead become as in Equation 6a, where each comparison dk is 
substituted by a regression equation where ak is the intercept, bk is the slope and Xj is the covariate for 
study j (i.e. dk = ak + bk ∗ Xj). The indirect comparison of SCIT compared with SLIT for a given level of the 
covariate Xj = x is then described in Equation 6b.
δ jk  Normal ak – bbj( )+ βk – βbj( )Χ j ,σ 2( )  (6a)
d32,x = a3 – a2( )+ β3 – β2( )χ  (6b)
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In meta-regressions, ak corresponds to dk,x = 0 (i.e. when the covariate value is zero). For example, the 
dichotomous covariate Age has been coded as 1 = Adult and 0 = Child; therefore, a2 represents the 
SMD between treatment 2 and placebo for those studies that only recruited adults. Similarly, variables 
considered as continuous such as Year of Publication and Number of Symptoms have been centred to 
AD2005 and six symptoms, respectively. For example, a2 when Year of publication is included in the model 
represents the SMD between SCIT and placebo as regressed for AD2005 by the model. Therefore, aks have 
not been explicitly reported in the tables to avoid duplication of reporting of results. For every score, the 
data sets were composed of a number of studies. The meta-regression models may require the cancellation 
of the entire record of the study where the covariate value is missing (e.g. it is not reported or it is unclear). 
In this case, the DIC and pD (the estimate of the effective number of parameters in the model) for the null 
model with the same number of studies is included in the meta-analysis.
Implementation
Parameter estimates were obtained via Bayesian modelling and Markov chain Monte Carlo (MCMC) 
modelling. The software for Bayesian modelling WinBUGS 1.4139 was used to implement the models. There 
was no preconceived prior opinion on the values of the intervention and baseline parameters and therefore 
these were given non-informative prior distributions. Heterogeneity parameter was given a priori uniform 
distribution between 0 and 300 (on the between-study SD) and, for sensitivity analysis, a gamma prior 
with parameters both equal to 0.001 (on the between-study variance).266
Multiple chains were run by initialising every chain in different points of the space of parameters; 
convergence and the length of the burn-in period267 were assessed by setting the burn-in period to zero 
and by looking at history plots (available by default in WinBUGS) for those chains simultaneously. The 
length of the chain after the burn-in period was determined so that the MC error was lower than 10–4, 
where the MC error measures the proportion of variability that is consequent to sampling algorithm, i.e. 
the higher the number of iterations the lower the MC error.268 Longer chains were also useful to adjust 
parameter estimates in case of autocorrelation in the MCMC chains.
The choice between random- and fixed-effects models and the significance of regression parameters 
when heterogeneity was explored by means of covariates was assessed by means of the DIC.269 The DIC 
statistic is a compound measure of the model fit (the deviance) and the complexity of the model (pD). The 
lower the DIC, the better the fit; for choosing between two models, a minimum difference of 5 in the DIC 
is recommended.139
Results
Model checking
Convergence was achieved in the first 50 iterations for every model; model results did not appear 
to be sensitive to initial values. Autocorrelation in the MCMC chains was found, especially on the 
between-studies variance parameter (i.e. the maximum lag was > 40 iterations). Therefore, long chains 
were run, with a burn-in period of 10,000 iterations, and a further 100,000 iterations were used to 
build posterior distributions. Model results were not sensitive to the choice of prior distribution for the 
heterogeneity parameter.
The following interpretation of SSs is given as an example.
Symptom scores
For every meta-analysis and meta-regression model, Table 57 presents estimates of parameters and of 
the model fit statistic DIC for symptoms scores. Probabilistic analysis is given in Table 58, where for every 
model, and eventually for all (where possible) or some significant levels of the covariate, the probability of 
each treatment being the best treatment is given.
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The fixed- and random-effects model for symptoms score included 59 studies. The DIC for the random-
effects model (508) is meaningfully lower than the DIC for the fixed-effects model (542), although the 
difference in pD (+34) indicates that it is far more complex. The indirect comparison of SLIT with SCIT is 
in favour of SCIT, whereas the difference between scores is significantly positive {i.e. SCIT corresponds to 
lower SS [d32 0.351 (0.127 to 0.586)]}. The probabilistic analysis also indicates SCIT as the best treatment 
when symptoms scores are considered, with a probability associated with SCIT being the best treatment 
nearly equal to 100%. For every meta-analysis and meta-regression model, probabilistic analyses indicate 
the probability of zero that placebo is the best treatment. The data present a substantial amount of 
unexplained heterogeneity [s2 0.089 (CrI 0.027 to 0.187)]. Meta-regression results are presented below 
separately for each covariate. For simplicity, as the fixed-effects model corresponds to a much worse fit to 
the data than the random-effects model, meta-regression will be fit on the random-effects model, and 
therefore the null model will refer to the random-effects model without covariate effects.
Age of participants (59 records)
Age of participants did not improve model fit significantly, with a difference of –2 points in DIC (506) 
when compared with the null model. In fact, CrIs for regression coefficients included the no-effect value 
of zero [b2 0.455 (CrI –0.434 to 1.358); b3 0.186 (CrI –0.083 to 0.466)] and the between-study variance 
remained unchanged compared with the random-effect null model [s2 0.091 (CrI 0.028 to 0.192)]. The 
probabilistic analysis indicates that there is a high probability a posteriori that SCIT is the best treatment 
for adults (around 96%), reflecting a significantly positive estimates of the indirect comparison of SLIT vs 
SCIT via the estimated SMD score [d32,adult 0.328 (CrI 0.088 to 0.579)]. However, for studies that included 
only children this probability is almost even and the SMD indirectly estimated from the model was not 
significantly different from zero [d32,child 0.059 (CrI –0.837 to 0.966)]. This uncertainty can be explained 
by the fact that there is only one study comparing SCIT with placebo in children and indicates that more 
studies may be needed.
Year of publication (59 records)
Year of publication (time) can be considered a source of differences between studies that depend on time, 
for example a proxy for technological advancements that are not explicitly considered. For symptoms 
scores, year of publication improves the fit of the model to the data compared with the null model (i.e. 
six-point improvement in DIC: 502 compared with 508). In fact, the between-study variance seems to be 
slightly lower than for the null model [s2 0.067 (CrI 0.017 to 0.147)]. The effect of time affects mainly the 
comparison SCIT vs placebo [s2 0.056 (CrI 0.027 to 0.086], whereas there is a 50% posterior probability 
that time has a positive effect (or negative effect) for the comparison of SLIT with placebo [b3 0.001 
(CrI –0.024 to 0.025)], the posterior CrI is nearly symmetrical around the posterior mean. The indirect 
comparison of SLIT vs SCIT favours SCIT until 2005, then from 2006 seems to be more favourable to SLIT.
NIHR Journals Library www.journalslibrary.nihr.ac.uk
AppENDIx 3
164
Ta
b
le
s 
o
f 
re
su
lt
s
TA
B
LE
 5
7 
M
et
a-
re
gr
es
si
on
 p
ar
am
et
er
s 
es
ti
m
at
es
 (
al
ph
as
 a
nd
 b
et
as
),
 r
an
do
m
-e
ff
ec
t 
pa
ra
m
et
er
 e
st
im
at
es
 (
s
2 )
, p
ro
ba
bi
lit
y 
of
 k
th
 t
re
at
m
en
t 
is
 b
es
t 
(p
-b
es
t)
 a
nd
 e
st
im
at
ed
 
st
an
da
rd
is
ed
 s
co
re
 d
iff
er
en
ce
s 
(d
)-
SS
s
Sy
m
p
to
m
 s
co
re
s
M
o
d
el
 (
co
va
ri
at
e 
in
cl
u
d
ed
 in
 t
h
e 
m
o
d
el
)
n
Pa
ra
m
et
er
SC
IT
 v
s 
p
la
ce
b
o
a :
 d
ir
ec
t 
co
m
p
ar
is
o
n
s 
(k
 =
 ‘2
’)
, 
p
o
st
er
io
r 
m
ea
n
 (
95
%
 C
rI
)
SL
IT
 v
s 
p
la
ce
b
o
:a
 d
ir
ec
t 
co
m
p
ar
is
o
n
s 
(k
 =
 ‘3
’)
, p
o
st
er
io
r 
m
ea
n
 (
95
%
 C
rI
)
SL
IT
 v
s 
SC
IT
a :
 in
d
ir
ec
t 
co
m
p
ar
is
o
n
 (
k 
=
 ‘3
2’
),
 
p
o
st
er
io
r 
m
ea
n
  
(9
5%
 C
rI
)
D
IC
 (
p
D
)
Fi
xe
d 
ef
fe
ct
s 
(n
o 
co
va
ria
te
s)
59
d k
–0
.6
04
 (–
0.
72
0 
to
 –
0.
48
9)
–0
.3
17
 (–
0.
37
4 
to
 –
0.
26
1)
0.
28
7 
(0
.1
60
 t
o 
0.
41
6)
54
2 
(6
1)
Ra
nd
om
 e
ff
ec
ts
 (n
o 
co
va
ria
te
s)
 n
u
ll 
m
o
d
el
59
d k
–0
.7
13
 (–
0.
92
1 
to
 –
0.
52
1)
–0
.3
62
 (–
0.
48
4 
to
 –
0.
24
8)
0.
35
1 
(0
.1
27
 t
o 
0.
58
6)
50
8 
(9
5)
s
2
0.
08
9 
(0
.0
27
 t
o 
0.
18
7)
Ra
nd
om
 e
ff
ec
ts
 (a
ge
 o
f 
pa
rt
ic
ip
an
ts
)
59
b k
0.
45
5 
(–
0.
43
4 
to
 1
.3
58
)
0.
18
6 
(–
0.
08
3 
to
 0
.4
66
)
–
50
6 
(9
6)
d k
,c
hi
ld
–0
.2
82
 (–
1.
15
6 
to
 0
.5
86
)
–0
.2
23
 (–
0.
46
1 
to
 0
.0
15
)
0.
05
9 
(–
0.
83
7 
to
 0
.9
66
)
d k
,a
du
lt
–0
.7
36
 (–
0.
95
3 
to
 –
0.
53
7)
–0
.4
09
 (–
0.
55
1 
to
 –
0.
27
6)
0.
32
8 
(0
.0
88
 t
o 
0.
57
9)
s
2
0.
09
1 
(0
.0
28
 t
o 
0.
19
2)
Ra
nd
om
 e
ff
ec
ts
 (y
ea
r 
of
 p
ub
lic
at
io
n)
59
b k
0.
05
6 
(0
.0
27
 t
o 
0.
08
6)
0.
00
1 
(–
0.
02
4 
to
 0
.0
25
)
–
50
2 
(9
2)
d k
,2
00
0
–0
.7
63
 (–
0.
95
6 
to
 –
0.
58
3)
–0
.3
59
 (–
0.
52
9 
to
 –
0.
19
6)
0.
40
4 
(0
.1
59
 t
o 
0.
65
5)
d k
,2
00
5
–0
.4
85
 (–
0.
69
9 
to
 –
0.
27
3)
–0
.3
56
 (–
0.
46
8 
to
 –
0.
25
2)
0.
12
8 
(–
0.
11
3 
to
 0
.3
64
)
d k
,2
01
0
–0
.2
06
 (–
0.
51
9 
to
 0
.1
13
)
–0
.3
53
 (–
0.
51
7 
to
 –
0.
20
)
–0
.1
48
 (–
0.
51
0 
to
 0
.2
0)
s
2
0.
06
7 
(0
.0
17
 t
o 
0.
14
7)
Ra
nd
om
 e
ff
ec
ts
 (n
o.
 o
f 
sy
m
pt
om
sb
)
48
b k
–0
.0
90
 (–
0.
20
9 
to
 0
.0
24
)
0.
02
2 
(–
0.
03
6 
to
 0
.0
78
)
–
44
9 
(7
9)
 
[5
29
 (7
5)
]c
d k
,3
sy
m
–0
.4
10
 (–
0.
91
2 
to
 0
.0
95
)
–0
.4
73
 (–
0.
78
7 
to
 –
0.
15
8)
–0
.0
62
 (–
0.
65
8 
to
 
0.
53
4)
d k
,6
sy
m
–0
.6
79
 (–
0.
93
4 
to
 –
0.
43
9)
–0
.4
07
 (–
0.
58
4 
to
 –
0.
23
5)
0.
27
3 
(–
0.
02
4 
to
 0
.5
78
)
d k
,1
2s
ym
–1
.2
17
 (–
1.
88
4 
to
 –
0.
59
2)
–0
.2
75
 (–
0.
54
7 
to
 –
0.
02
0)
0.
94
2 
(0
.2
68
 t
o 
1.
65
3)
s
2
0.
09
6 
(0
.0
19
 t
o 
0.
21
3)
© Queen’s Printer and Controller of HMSO 2013. This work was produced by Meadows et al. under the terms of a commissioning contract issued by the Secretary of State 
for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals 
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be 
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science 
Park, Southampton SO16 7NS, UK.
DOI: 10.3310/hta17270 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 27
165
Sy
m
p
to
m
 s
co
re
s
M
o
d
el
 (
co
va
ri
at
e 
in
cl
u
d
ed
 in
 t
h
e 
m
o
d
el
)
n
Pa
ra
m
et
er
SC
IT
 v
s 
p
la
ce
b
o
a :
 d
ir
ec
t 
co
m
p
ar
is
o
n
s 
(k
 =
 ‘2
’)
, 
p
o
st
er
io
r 
m
ea
n
 (
95
%
 C
rI
)
SL
IT
 v
s 
p
la
ce
b
o
:a
 d
ir
ec
t 
co
m
p
ar
is
o
n
s 
(k
 =
 ‘3
’)
, p
o
st
er
io
r 
m
ea
n
 (
95
%
 C
rI
)
SL
IT
 v
s 
SC
IT
a :
 in
d
ir
ec
t 
co
m
p
ar
is
o
n
 (
k 
=
 ‘3
2’
),
 
p
o
st
er
io
r 
m
ea
n
  
(9
5%
 C
rI
)
D
IC
 (
p
D
)
Ra
nd
om
 e
ff
ec
ts
 (d
ur
at
io
nb
)
57
b k
1
0.
55
8 
(–
0.
12
6 
to
 1
.2
77
)
–0
.0
11
 (–
0.
31
3 
to
 0
.2
87
)
–
47
7 
(9
5)
 
[4
81
 (9
3)
]c
b k
2
0.
63
9 
(0
.1
41
 t
o 
1.
17
3)
0.
00
4 
(–
0.
30
4 
to
 0
.3
16
)
–
d k
,<
6m
on
th
s
–1
.1
87
 (–
1.
62
1 
to
 –
0.
78
8)
–0
.3
65
 (–
0.
57
7 
to
 –
0.
16
0)
0.
82
2 
(0
.3
79
 t
o 
1.
29
9)
d k
, 6
–1
2m
on
th
s
–0
.6
29
 (–
1.
20
5 
to
 –
0.
06
6)
–0
.3
76
 (–
0.
59
9 
to
 –
0.
16
4)
0.
25
2 
(–
0.
35
7 
to
 0
.8
62
)
d k
,>
12
m
on
th
s
–0
.5
48
 (–
0.
86
3 
to
 –
0.
23
7)
–0
.3
61
 (–
0.
59
2 
to
 –
0.
13
2)
0.
18
7 
(–
0.
19
9 
to
 0
.5
77
)
s
2
0.
11
2 
(0
.0
40
 t
o 
0.
22
1)
Ra
nd
om
 e
ff
ec
ts
 (M
A
C)
b
42
b k
1
–0
.0
95
 (–
0.
59
5 
to
 0
.4
08
)
0.
18
2 
(–
0.
17
6 
to
 0
.5
56
)
–
30
9 
(6
6)
 
[3
10
 (6
0)
]*
b k
2
–0
.4
47
 (–
1.
01
3 
to
 0
.0
72
)
0.
15
1 
(–
0.
21
9 
to
 0
.5
41
)
–
d k
,<
5m
g
–0
.4
60
 (–
0.
84
5 
to
 –
0.
08
9)
–0
.4
76
 (–
0.
81
3 
to
 –
0.
15
5)
–0
.0
16
 (–
0.
51
6 
to
 
0.
48
3)
d k
,5
–6
mg
–0
.5
56
 (–
0.
89
1 
to
 –
0.
22
6)
–0
.2
94
 (–
0.
45
8 
to
 –
0.
13
3)
0.
26
2 
(–
0.
10
8 
to
 0
.6
34
)
d k
,>
20
mg
–0
.9
07
 (–
1.
33
8 
to
 –
0.
53
6)
–0
.3
25
 (–
0.
51
1 
to
 –
0.
13
5)
0.
58
2 
(0
.1
67
 t
o 
1.
06
0)
s
2
0.
05
3 
(0
.0
05
 t
o 
0.
13
)
co
nt
in
ue
d
NIHR Journals Library www.journalslibrary.nihr.ac.uk
AppENDIx 3
166
Sy
m
p
to
m
 s
co
re
s
M
o
d
el
 (
co
va
ri
at
e 
in
cl
u
d
ed
 in
 t
h
e 
m
o
d
el
)
n
Pa
ra
m
et
er
SC
IT
 v
s 
p
la
ce
b
o
a :
 d
ir
ec
t 
co
m
p
ar
is
o
n
s 
(k
 =
 ‘2
’)
, 
p
o
st
er
io
r 
m
ea
n
 (
95
%
 C
rI
)
SL
IT
 v
s 
p
la
ce
b
o
:a
 d
ir
ec
t 
co
m
p
ar
is
o
n
s 
(k
 =
 ‘3
’)
, p
o
st
er
io
r 
m
ea
n
 (
95
%
 C
rI
)
SL
IT
 v
s 
SC
IT
a :
 in
d
ir
ec
t 
co
m
p
ar
is
o
n
 (
k 
=
 ‘3
2’
),
 
p
o
st
er
io
r 
m
ea
n
  
(9
5%
 C
rI
)
D
IC
 (
p
D
)
Ra
nd
om
 e
ff
ec
ts
 (a
lle
rg
en
 t
yp
eb
)
60
d
b k
1
–0
.3
26
 (–
0.
86
8 
to
 0
.2
04
)
0.
05
3 
(–
0.
42
3 
to
 0
.5
38
)
–
52
3 
(1
00
) 
[5
25
 (9
5)
]c
b k
2
0.
19
6 
(–
0.
29
1 
to
 0
.6
99
)
–0
.1
08
 (–
0.
43
8 
to
 0
.2
23
)
–
b k
3
0.
43
7 
(–
0.
46
8 
to
 1
.3
71
)
–1
.0
92
 (–
2.
11
9 
to
 –
0.
06
7)
–
b k
4
0.
27
6 
(–
19
6.
40
 t
o 
19
7.
30
)
–
–
d k
,g
ra
ss
–0
.7
21
 (–
1.
01
3 
to
 –
0.
45
1)
–0
.3
26
 (–
0.
47
3 
to
 –
0.
18
5)
0.
39
6 
(0
.0
90
 t
o 
0.
72
1)
d k
,P
ar
ie
ta
ria
–1
.0
47
 (–
1.
53
2 
to
 –
0.
59
9)
–0
.2
72
 (–
0.
72
8 
to
 0
.1
88
)
0.
77
5 
(0
.1
40
 t
o 
1.
44
6)
d k
,t
re
e
–0
.5
26
 (–
0.
94
1 
to
 –
0.
12
1)
–0
.4
33
 (–
0.
73
5 
to
 –
0.
13
8)
0.
09
2 
(–
0.
40
8 
to
 0
.5
97
)
d k
,A
lte
rn
ar
ia
–0
.2
85
 (–
1.
15
0 
to
 0
.5
94
)
–1
.4
18
 (–
2.
43
1 
to
 –
0.
40
4)
–1
.1
33
 (–
2.
46
0 
to
 
0.
19
9)
d k
,r
ag
w
ee
d
–0
.4
45
 (–
19
7.
20
 t
o 
19
6.
60
)
–0
.4
35
 (–
0.
86
7 
to
 –
0.
00
7)
0.
01
1 
(–
19
7.
0 
to
 
19
6.
70
)
s
2
0.
09
6 
(0
.0
30
 t
o 
0.
20
)
sy
m
, s
ym
pt
om
s.
a 
Th
e 
D
IC
 (p
D
) o
f 
th
e 
nu
ll 
m
od
el
 w
he
n 
th
e 
sa
m
e 
nu
m
be
r 
of
 s
tu
di
es
 is
 in
cl
ud
ed
 in
 t
he
 m
et
a-
an
al
ys
is
 is
 r
ep
or
te
d 
w
ith
in
 s
qu
ar
e 
br
ac
ke
ts
.
b 
A
 n
um
be
r 
of
 s
tu
di
es
 w
er
e 
m
is
si
ng
 f
or
 N
oS
ym
 <
re
f>
 a
nd
 f
or
 D
ur
at
io
n 
<r
ef
>.
c 
D
iff
er
en
ce
s 
d k
 r
el
at
iv
e 
to
 t
he
 c
om
pa
ris
on
 o
f 
A
 v
s 
B 
ne
ed
 t
o 
be
 in
te
rp
re
te
d 
as
 Y
A
 –
 Y
B, 
w
he
re
 Y
A
 a
nd
 Y
B a
re
 t
he
 s
co
re
 f
or
 t
re
at
m
en
t 
A
 a
nd
 B
, r
es
pe
ct
iv
el
y.
d 
Fo
r 
D
ra
ch
en
be
rg
 (2
00
1,
 S
LI
T)
91
 t
he
 d
at
a 
us
ed
 w
er
e 
co
m
bi
ne
d 
sc
or
es
 f
or
 a
lle
rg
en
 t
yp
es
 (A
T)
 T
RE
E 
an
d 
G
RA
SS
. H
ow
ev
er
, w
he
n 
th
e 
ef
fe
ct
 o
f 
di
ff
er
en
t 
A
T 
w
as
 e
xp
lo
re
d 
vi
a 
m
et
a-
re
gr
es
si
on
, s
ep
ar
at
e 
sc
or
es
 f
or
 t
he
 t
w
o 
al
le
rg
en
 t
yp
es
 w
er
e 
us
ed
. T
he
re
fo
re
, t
he
 n
um
be
r 
of
 s
tu
di
es
 in
 t
he
 a
na
ly
si
s 
is
 6
0 
in
st
ea
d 
of
 5
9.
TA
B
LE
 5
7 
M
et
a-
re
gr
es
si
on
 p
ar
am
et
er
s 
es
ti
m
at
es
 (
al
ph
as
 a
nd
 b
et
as
),
 r
an
do
m
-e
ff
ec
t 
pa
ra
m
et
er
 e
st
im
at
es
 (
s
2 )
, p
ro
ba
bi
lit
y 
of
 k
th
 t
re
at
m
en
t 
is
 b
es
t 
(p
-b
es
t)
 a
nd
 e
st
im
at
ed
 
st
an
da
rd
is
ed
 s
co
re
 d
iff
er
en
ce
s 
(d
)-
SS
s 
(c
on
ti
nu
ed
)
© Queen’s Printer and Controller of HMSO 2013. This work was produced by Meadows et al. under the terms of a commissioning contract issued by the Secretary of State 
for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals 
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be 
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science 
Park, Southampton SO16 7NS, UK.
DOI: 10.3310/hta17270 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 27
167
Figure 27 shows a plot of the results (based on SSs) when year of publication is included in the model. 
Dashed vertical lines highlight the period 2007–8 when, in theory, SLIT is more likely to be beneficial 
than SCIT.
Figure 28 shows a plot of the results (based on SSs) when number of symptoms is included in the model.
Figure 29 shows a plot of the results (based on MSs) when year of publication is included in the model.
TABLE 58 Probabilistic analysis for SSs [probability (%) that treatment k is the best under different 
modelling assumptions]
Model (covariate included in the model) Placebo SCIT SLIT
Fixed effect (59) 00.0 > 99 00.0
Random effect (59) 00.0 99.9 00.1
Age group of participants (59)
Childa 00.9 54.9 44.2
Adult 00.0 99.6 00.4
Year of publication (59)
2000 00.0 99.9 00.1
2005 00.0 86.1 13.9
2010 00.0 20.3 79.7
No. of symptoms (48)
3 symptoms 00.0 41.5 58.5
6 symptoms 00.0 96.5 03.5
12 symptoms 00.0 99.7 00.3
Duration
Low 00.0 > 99 00.0
Medium 00.0 80.1 19.9
High 00.0 83.4 16.6
MAC
< 5 mg 00.0 47.4 52.6
5–20 mg 00.0 92.0 08.0
> 20 mg 00.0 99.7 00.3
Allergen type
Grass 00.0 99.4 00.6
Parietaria 00.0 99.1 00.9
Tree 00.0 64.3 35.7
Alternaria 00.1 04.6 95.3
Ragweed 01.2 50.0 48.8
a Few studies on children compared SCIT vs placebo and SLIT vs placebo.
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FIGURE 27 (a) Theoretical and observed SMDs (and credible boundaries) vs year of publication for the direct 
comparisons SCIT vs placebo and SLIT vs placebo, respectively. (b) Given the data included in the meta-regression, 
probability of SCIT and SLIT, respectively, being the best treatment vs year of publication.
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FIGURE 28 (a) Theoretical and observed SMDs (and credible boundaries) vs number of symptoms for the direct 
comparisons SCIT vs placebo and SLIT vs placebo, respectively. (b) Given the data included in the meta-regression, 
probability of SCIT and SLIT, respectively, being the best treatment vs number of symptoms.
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FIGURE 29 (a) Theoretical and observed SMDs (and credible boundaries) vs year of publication for the direct 
comparisons SCIT vs placebo and SLIT vs placebo, respectively. (b) Given the data included in the meta-regression, 
probability of SCIT and SLIT, respectively, being the best treatment vs year of publication.
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TABLE 60 Probabilistic analysis for MSs [probability (%) that treatment k is the best under different 
modelling assumptions]
Placebo SCIT SLIT
Fixed effect (51) 00.0 > 99 00.0
Random effect (51) 00.0 98.4 01.6
Age group of participants (51)
Child 00.0 68.1 31.9
Adult 01.8 43.1 55.1
Year of publication (51)
2000 00.0 96.9 03.1
2005 00.0 90.6 09.4
2010 00.1 64.6 35.3
Duration (48)
Low 00.0 50.9 49.1
Medium 00.0 75.6 24.3
High 00.0 99.1 00.9
MAC (37)
< 5 mg 00.0 15.1 84.9
5–20 mg 00.0 95.3 04.7
> 20 mg 00.0 90.4 09.6
Allergen type (52)
Grass 00.0 99.8 00.2
Parietaria 00.1 42.1 57.9
Tree 00.0 43.0 57.0
Alternaria 00.0 18.0 82.0
Ragweed 00.8 67.8 31.4
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TABLE 62 Probabilistic analysis for SMSs [probability (%) that treatment k is the best under different 
modelling assumptions]
Model (covariate included in the model) Placebo SCIT SLIT
Fixed effect (15) 00.0 50.2 49.8
Random effect (15) 00.0 50.2 49.8
Age group of participants (15)
Child 02.9 47.1 50.0
Adult 00.0 50.2 49.8
Year of publication (15)
2000 00.0 49.8 50.2
2005 00.0 50.4 49.7
2010 00.0 50.3 49.7
Duration (12)
Low 00.1 50.2 49.7
Medium 00.5 49.8 49.8
High 00.0 50.4 49.6
MAC (10)
< 5 mg 00.2 50.0 49.9
5–20 mg 00.7 49.2 50.0
> 20 mg 00.2 49.8 50.0
Allergen type (15)
Grass 00.0 50.3 49.7
Parietaria 00.0 50.4 49.6
Tree 00.7 49.5 49.8
Alternaria 00.1 50.3 49.7
Ragweed 01.0 49.5 49.5
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TABLE 64 Probabilistic analysis for QoL scores [probability (%) that treatment k is the best under different 
modelling assumptions]
Model (covariate included in the model) Placebo SCIT SLIT
Fixed effect (15) 00.0 > 99 00.0
Random effect (15) 00.0 96.4 03.6
Age group of participants (15)
Child 10.5 50.0 39.5
Adult 00.0 95.9 04.1
Year of publication (15)
2000 05.0 45.0 49.9
2005 00.0 64.5 35.5
2010 01.2 81.0 17.8
Duration (15)  
Low 01.3 92.6 06.1
Medium 02.6 76.1 21.3
High 00.2 66.8 33.0
MAC (10)
< 5 mg 10.9 68.3 20.9
5–20 mg 00.6 83.3 16.2
> 20 mg 01.2 91.3 07.5
Allergen type (15)
Grass 00.5 90.2 09.3
Parietaria 01.2 49.1 49.8
Tree 01.5 49.7 48.8
Alternaria 25.0 37.4 37.6
Ragweed 01.5 48.9 49.6
Salsola kali 02.5 47.8 49.7
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TABLE 66 Probabilistic analysis for RQLQ scores [probability (%) that treatment k is the best under different 
modelling assumptions]
Model (covariate included in the model) Placebo SCIT SLIT
Fixed effects (12) 00.0 > 99 00.0
Random effects (12) 00.0 96.2 03.8
Age group of participants (12)
Child 24.7 37.8 37.5
Adult 00.0 96.0 04.0
Year of publication (12)
2000 02.8 26.9 70.3
2005 00.0 46.3 53.7
2010 01.5 86.8 11.8
Duration (12)
Low 01.5 88.9 09.6
Medium 01.9 48.3 49.8
High 00.1 85.8 14.0
MAC (10)
< 5 mg 24.9 37.7 37.4
5–20 mg 00.0 97.0 03.0
> 20 mg 24.8 37.7 37.5
Allergen type (12)
Grass 00.3 94.7 04.9
Parietaria 00.9 49.6 49.5
Tree 01.0 49.7 49.3
Alternaria 24.8 37.9 37.3
Ragweed 01.9 48.4 49.7
Salsola kali 03.0 47.3 49.8
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Appendix 4 Study selection process
The study selection process is shown in Figure 30. For many RCTs, more than one publication was identified 
(e.g. additional abstracts, different outcomes or data at different time points reported in separate 
publications). The numbers above relate to numbers of publications rather than individual RCTs, except 
where highlighted. Reasons for exclusion are listed in Appendix 5; only excluded studies published in 2006 
or after (post Cochrane reviews search dates) have been listed. One of the main reasons for exclusion was 
a lack of double-blinding. There were some discrepancies between studies that were included or excluded 
in the Cochrane reviews and in this report. Reasons for this are also listed in Appendix 5. It may be owing 
to the fact that our inclusion and exclusion criteria were more detailed, whereas the ones in the Cochrane 
reviews were slightly broader.
There were also some publications that may have been relevant, but were not identified in the Cochrane 
reviews (or in their excluded studies list). Many of these appeared to be duplicate publications (e.g. in 
abstract form) of included studies, but there were some that potentially should have been included. It was 
beyond the remit of this report to look at these studies in detail.
Records identified: 6492
Records screened: 3587
Duplicates: 2905
Full-text articles assessed for
eligibility: 460
Unable to locate/unavailable: 25
Excluded: 265 Included articles: 170
Articles on SCIT: 84 Articles on SLIT: 85 Articles on SLIT
versus SCIT: 1
Included in CR: 48 Included in CR: 52
Not in CR: 36
Not in CR: 36 Not in CR: 33
Not in CR: 33
Not identified: 10 Not identified: 15
Excluded: 4 Excluded: 2
More recent: 22 More recent: 16
Of 22 recent articles: Of 16 recent articles:
17 new RCTs 11 new RCTs
In at least one meta- In at least one meta-
analysis: 5 analysis: 5
FIGURE 30 Study selection process.
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Given the vast overlap between studies included in this report and the Cochrane reviews, and the 
consistency of direction of effect for different subgroups, it is unlikely that the discrepancies or missing 
studies noted above would have any significant impact on study results.
All included studies had at least one English-language publication associated with them. Some of the 
excluded studies were in other languages: German papers were translated by one of the authors, Polish 
papers by a Polish colleague, and Spanish or Portuguese papers by two of the authors with the help of a 
dictionary. Some reports in other languages (e.g. Dutch) were clearly reviews or comments. There were no 
potentially relevant papers identified after the Cochrane reviews search dates that could not be sufficiently 
translated to make a decision on inclusion/exclusion.
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Appendix 5 Reasons for exclusion and 
discrepancies between included/excluded studies in 
Cochrane reviews and this report
Studies on pollen allergy included in relevant Cochrane reviews 
but excluded from this review
Study Reason for exclusion
Armentia-Medina A, Blanco Quiros A, Martin-Santos JM, Alvarez Cuesta E, Moneo 
Goiri I, Carreira P, et al. Rush immunotherapy with a standardized Bermuda grass 
pollen extract. Ann Allergy 1989;63:127–35
Only 8 out of 30 patients with a 
history of allergic rhinitis
Caffarelli C, Sensi LG, Marcucci F, Cavagni G. Preseasonal local allergoid 
immunotherapy to grass pollen in children: a double-blind, placebo-controlled, 
randomized trial. Allergy 2000;55:1142–7
Includes some children with asthma 
only, not SAR; results not separable 
for SAR children only
Grammer LC, Shaughnessey MA, Shaughnessy JJ, Patterson R, Grammer LC, 
Shaughnessey MA, et al. Asthma as a variable in a study of immunotherapy for 
allergic rhinitis. J Allergy Clin Immunol 1984;73:557–60
Placebo and untreated treatment 
groups combined in the analysis, so 
not all patients double-blinded
Lizaso Bacaicoa MT, Garcia BE, Gomez B, Zabalegui A, Rodriguez MJ, Tabar AI. 
[Treatment of allergy to mushrooms.] Anales del Sistema Sanitario de Navarra 
2003;26(Suppl. 2):129–37
Not all participants had SAR
Meriney DK, Kothari H, Chinoy P, Grieco MH. The clinical and immunologic efficacy 
of immunotherapy with modified ragweed extract (allergoid) for ragweed hay 
fever. Ann Allergy 1986;56:34–8
Not all patients treatment naive
Pajno GB, Vita D, Parmiani S, Caminiti L, La Grutta S, Barberio G. Impact of 
sublingual immunotherapy on seasonal asthma and skin reactivity in children 
allergic to Parietaria pollen treated with inhaled fluticasone propionate. Clin Exp 
Allergy 2003;33:1641–7
Children with SAA only (with or 
without rhinoconjunctivitis)
Paraskevopoulos G, Jacobson M, Carr V, Calderon M, Till SJ, Francis JN, et al. Grass 
pollen injection immunotherapy: time course of suppression of allergen-induced 
late phase skin response. J Allergy Clin Immunol 2005;115:S266
No relevant symptom or QoL-related 
outcomes
Sabbah A, Hassoun S, Lesellin J, Andre C, Sicard H. A double-blind, placebo-
controlled trial by the sublingual route of immunotherapy with a standardized 
grass-pollen extract. Allergy 1994;49:309–13
Around half of patients not 
treatment naive
Other excluded studies (post 2005)
Study Reason for exclusion
Agostinis F, Foglia C, Bruno ME, Falagiani P. Efficacy, safety and tolerability of 
sublingual monomeric allergoid in tablets given without up-dosing to pediatric 
patients with allergic rhinitis and/or asthma due to grass pollen. Eur Ann Allergy 
Clin Immunol 2009;41:177–80
Not double blind
Agostinis F, Forti S, Di BF. Grass transcutaneous immunotherapy in children with 
seasonal rhinoconjunctivitis. Allergy 2010;65:410–11
Transcutaneous administration, not 
sublingual or subcutaneous
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Study Reason for exclusion
Al Ahmed N, Arifhodzic N, Al Ahmed M. Comparison of clinical efficacy and 
preventive role between subcutaneous and sublingual immunotherapy in children 
with seasonal allergic rhinitis. Allergy 2010;65(XXIX EAACI Congress of the 
European Academy of Allergy and Clinical Immunology, London, UK, 5–9 June 
2010):1550
Not double blind
Ali I, Goksal K, Ozan B, Gulsen D. Long-term allergen-specific immunotherapy 
correlates with long-term allergen-specific immunological tolerance. Adv Ther 
2008;25:29–36
Retrospective evaluation
Alvarez-Cuesta E, Bousquet J, Canonica GW, Durham SR, Mailing HJ, Valovirta E. 
Standards for practical allergen-specific immunotherapy. Allergy 2006;61:1–20
Review
Ariano R, Incorvaia C, La GS, Marcucci F, Pajno G, Sensi L, et al. Safety of 
sublingual immunotherapy started during the pollen season. Curr Med Res Opin 
2009;25:103–7
Not double blind
Asturias JA, Ferrer A, Arilla MC, Andreu C, Madariaga B, Martinez A. Tolerance 
and immunological changes of chemically modified allergen vaccine of Parietaria 
judaica in accelerated schedules. Clin Exp Allergy 2007;147:491–6
Not double blind
Bachert C, Vestenbaek U, Christensen J, Griffiths UK, Poulsen PB. Cost-effectiveness 
of grass allergen tablet (GRAZAX® for the prevention of seasonal grass pollen 
induced rhinoconjunctivitis: a Northern European perspective. Clin Exp Allergy 
2007;37:772–9
CEA
Bartosikova L, Necas J, Bartosik T, Pavlik M, Fránová J. [Contribution of allergen 
immunotherapy using Phostal in the treatment of seasonal allergic rhinitis (two 
years of use)]. Ceska Slov Farm 2008;57:99–102
Not double blind
Bell MC, Jones SM. Efficacy and safety of 5-grass-pollen sublingual immunotherapy 
tablets in pediatric allergic rhinoconjunctivitis. Pediatrics 2009;124:S152
Comment on other study 
(Wahn et al.26)
Berto P, Passalacqua G, Crimi N, Frati F, Ortolani C, Senna G, et al. Economic 
evaluation of sublingual immunotherapy vs symptomatic treatment in adults with 
pollen-induced respiratory allergy: the Sublingual Immunotherapy Pollen Allergy 
Italy (SPAI) study. Ann Allergy Asthma Immunol 2006;97:615–21
EE
Berto P, Frati F, Incorvaia C, Cadario G, Contiguglia R, Di Gioacchino M, et al. 
Comparison of costs of sublingual immunotherapy and drug treatment in grass-
pollen induced allergy: results from the SIMAP database study. Curr Med Res Opin 
2008;24:261–6
Cost comparison
Bochenska-Marciniak M, Tworek D, Kupczyk M, Bogacka E, Kuprys Lipinska I, Kuna 
P. The effectiveness of allergen immunotherapy depending on the regimen on 
rhinoconjunctivitis and asthma symptoms in allergy to grass pollen. Abstract. Am J 
Respir Crit Care Med 2009;179[April (Meeting Abstracts):A2781 [Monday, Section 
B31]
Not placebo controlled
Bordignon V, Burastero SE. Multiple daily administrations of low-dose sublingual 
immunotherapy in allergic rhinoconjunctivitis. Ann Allergy Asthma Immunol 2006; 
97:158–63
Not double blind
Bowser C, Erstein DP, Silverberg JI, Nowakowski M, Joks R. Correlation of plasma 
complement split product levels with allergic respiratory disease activity and 
relation to allergen immunotherapy. Ann Allergy Asthma Immunol 2010;104:42–9
Not RCT
Burastero SE, Mistrello G, Paolucci C, Breda D, Roncarolo D, Zanotta S, 
et al. Clinical and immunological correlates of pre-co-seasonal sublingual 
immunotherapy with birch monomeric allergoid in patients with allergic 
rhinoconjunctivitis. Int J Immunopathol Pharmacol 2009;22:343–52
Not double blind or RCT
Calderon M, Brandt T. Treatment of grass pollen allergy: focus on a standardized 
grass allergen extract: Grazax. Therapeut Clin Risk Manag 2008;4:1255–60
Review
Calderon MA, Birk AO, Andersen JS, Durham SR. Prolonged preseasonal treatment 
phase with Grazax sublingual immunotherapy increases clinical efficacy. Allergy 
2007;62:958–61
Post hoc analysis of three trials
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Study Reason for exclusion
Can D, Tanac R, Demir E, Gulen F, Veral A. Efficacy of pollen immunotherapy in 
seasonal allergic rhinitis. Pediatr Int 2007;49:64–9
Not double blind
Canonica GW, Poulsen PB, Vestenbaek U. Cost-effectiveness of GRAZAX® for 
prevention of grass pollen induced rhinoconjunctivitis in Southern Europe. Respir 
Med 2007;101:1885–94
Cost-effectiveness study
Ciprandi G, Sormani MP, Cirillo I, Tosca M. Upper respiratory tract infections and 
sublingual immunotherapy: preliminary evidence. Ann Allergy Asthma Immunol 
2009;102:262–3
Not an RCT
Corren J, Lemay M, Lin YM, Rozga L, Randolph RK. Clinical and biochemical effects 
of a combination botanical product (ClearGuard™) for allergy: a pilot randomized 
double-blind placebo-controlled trial. Nutrition J 2008;7
Single-dose tablet taken for 3 days 
only
D’Anneo RW, Arena A, Garnmeri E, Bruno ME, Fallagiani P, Riva G, et al. Parietaria 
sublingual allergoid immunotherapy with a co-seasonal treatment schedule. 
Allergol Immunopathol 2008;36:79–84
Not double blind
Didier A, Montagut A, Fadef R, Melac M. Immunological Biomarkers of Grass 
Allergen Tablets in Grass Pollen Rhinoconjunctivitis Patients. J Allergy Clin Immunol 
2008;121(American Academy of Allergy, Asthma and Immunology, 64th Annual 
Meeting, Philadelphia, PA, USA, 14–18 March, 2008):Abstract 478
No relevant outcomes reported
Durham SR. Allergen immunotherapy (desensitisation) for allergic diseases. Clin 
Med 2006;6:348–51
Review
Durham SR. Sublingual immunotherapy: reply. J Allergy Clin Immunol 
2007;119:515–17
Author reply/letter
Durham SR, Birk AO, Andersen JS. Days with severe symptoms: an additional 
efficacy endpoint in immunotherapy trials. Allergy 2011;66:120–3
Secondary analysis of data
Ellis AK, Ratz JD, Chowdry C, Day JH. Controlled allergen challenge clinical trials: 
impact upon seasonal allergic rhinitis symptoms? [P362]. Ann Allergy Asthma 
Immunol 2009;103:A139
Not seasonal exposure (controlled 
allergen challenge)
Eng PA, Borer-Reinhold M, Heijnen IAFM, Gnehm HPE. Twelve-year follow-up after 
discontinuation of preseasonal grass pollen immunotherapy in childhood. Allergy 
2006;61:198–201
Discontinuation study
Friedlander S, Friedlander AS. Clinical effects of ragweed antigen emulsion. A 
double-blind study. J Allergy 1962;33:412–22
Does not appear to be randomised 
(comparative study)
Halken S, Agertoft L, Seidenberg J, Bauer C-P, Payot F, Martin-Munoz MF, et 
al .Five-grass pollen 300-IR SLIT tablets: efficacy and safety in children and 
adolescents. Pediatr Allergy Immunol 2010;21:970–6
Further report of Wahn et al.26 
(included in Cochrane review of 
SLIT); appears to contain no new 
data, although some more detailed 
analysis of AE data
Horak F, Zieglmayer P, Zieglmayer R, Lemell P, Devillier P, Montagut A et al. 
Early onset of action of a 5-grass-pollen 300-IR sublingual immunotherapy 
tablet evaluated in an allergen challenge chamber. J Allergy Clin Immunol 
2009;124:471–7
Symptoms not measured during 
natural exposure (allergen challenge 
chamber)
Horiguchi S, Okamoto Y, Yonekura S, Okawa T, Yamamoto H, Kunii N, et al. A 
randomized controlled trial of sublingual immunotherapy for Japanese cedar 
pollinosis. Int Arch Allergy Immunol 2008;146:76–84
Not double blind
Howland WC, Hamilton RG, Holdich T. Effect of ultra short course subcutaneous 
immunotherapy on specific IgG and IgE levels compared with placebo in patients 
with ragweed pollen-allergic rhinoconjunctivitis. Abstract 17. Ann Allergy Asthma 
Immunol 2009;103:A23
No relevant outcomes reported
Jacobsen L, Niggemann B, Dreborg S, Ferdousi HA, Halken S, Host A, et al. Specific 
immunotherapy has long-term preventive effect of seasonal and perennial asthma: 
10-year follow-up on the PAT study. Allergy 2007;62:943–8
Open follow-up study of RCT
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Study Reason for exclusion
James LK, Shamji MH, Walker SM, Wilson DR, Wachholz PA, Francis JN, et al. 
Long-term tolerance after allergen immunotherapy is accompanied by selective 
persistence of blocking antibodies. J Allergy Clin Immunol 2011;127:509–16
Discontinuation study
Jutel M, Cromwell O. Clinical results from vaccination with recombinant grass 
pollen allergens. Clin Dev Immunol 2006;13:389–94.
Further analysis of Jutel 2005, 
included in Cochrane review
Keiding H, Jorgensen KP. A cost-effectiveness analysis of immunotherapy with SQ 
allergen extract for patients with seasonal allergic rhinoconjunctivitis in selected 
European countries. Curr Med Res Opin 2007;23:1113–20
Cost-effectiveness analysis
Keith P. Significant improvements in quality of life following mpl-adjuvanted ultra 
short course subcutaneous immunotherapy (uSCIT) in patients with seasonal grass 
pollen allergy. Abstract 219. J Allergy Clin Immunol 2009;123:S61
No relevant outcomes reported
Keskin O, Tuncer A, Adalioglu G, Sekerel BE, Sackesen C, Kalayci O. The effects of 
grass pollen allergoid immunotherapy on clinical and immunological parameters in 
children with allergic rhinitis. Pediatr Allergy Immunol 2006;17:396–407
Not double blind
Klunker S, Saggar LR, Seyfert-Margolis V, Asare AL, Casale TB, Durham SR, et al. 
Combination treatment with omalizumab and rush immunotherapy for ragweed-
induced allergic rhinitis: Inhibition of IgE-facilitated allergen binding. J Allergy Clin 
Immunol 2007;120:688–95
No relevant outcomes reported
Kopp MV, Hamelmann E, Zielen S, Kamin W, Bergmann KC, Sieder C, et al. 
Combination of omalizumab and specific immunotherapy is superior to 
immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-
morbid seasonal allergic asthma. Clin Exp Allergy 2009;39:271–9
Comparison of SIT plus omalizumab 
vs SIT only
Larenas-Linnemann D. Briefings from ACAAI 2008 annual meeting. The Annual 
Scientific Meeting of the American College of Allergy, Asthma and Immunology, 
Seattle, WA, USA, 6–11 November, 2008. Therapy 2009;6:279–83
Review
Leonardi S, Spicuzza L, La RM. High-dose sublingual immunotherapy in children at 
8-year follow-up. Clin Exp Allergy 2009;102:259–60
Discontinuation study
Malling HJ, Montagut A, Melac M, Patriarca G, Panzner P, Seberova E, et al. 
Efficacy and safety of 5-grass pollen sublingual immunotherapy tablets in patients 
with different clinical profiles of allergic rhinoconjunctivitis. Clin Exp Allergy 
2009;39:387–93
Subgroup analysis of included RCTs
Martinez-Canavate Burgos A, Vallenzuella-Soria A, Rojo-Hernandez A. 
Immunotherapy with Alternaria alternata: present and future. Allergol 
Immunopathol 2007;35:259–63
Review
Martínez Cócera C, Sastre J, Cimarra M, Quirce S, Fernández Rivas M, Enríquez 
Matas A, et al. Immunotherapy with a Phleum pratense allergen extract induces an 
immune response to a grass-mix allergen extract. J Investig Allergol Clin Immunol 
2010;20:13–19.
Not double blind
Mauro M, Russello M, Incorvaia C, Gazzola GB, Di Cara G, Frati F. Comparison 
of efficacy, safety and immunologic effects of subcutaneous and sublingual 
immunotherapy in birch pollinosis: a randomized study. Eur Ann Allergy Clin 
Immunol 2007;39:119–22
Not double blind
McCormack PL, Wagstaff AJ. Ultra-short-course seasonal allergy vaccine (Pollinex® 
Quattro). Drugs 2006;66:931–8
Review
Milani M, Leonardi A, Pozzan M, Pecora S. Two years specific sublingual 
immunotherapy with alternative extracts. Abstract 493. J Allergy Clin Immunol 
2008;21:S127
Not double blind
Mösges R, Graute V, Christ H, Sieber HJ, Wahn U, Niggemann B. Safety of ultra-
rush titration of sublingual immunotherapy in asthmatic children with tree-pollen 
allergy. Pediatr Allergy Immunol 2010;21:1135–8
Report only on subgroup of children 
with asthma
Naspitz CK, Warner JO. Children are pharmaco-therapeutic orphans. Pediatr 
Allergy Immunol 2010;21:249–50
Editorial
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Study Reason for exclusion
Nasser S, Vestenbaek U, Beriot MA, Poulsen PB. Cost-effectiveness of specific 
immunotherapy with Grazax in allergic rhinitis co-existing with asthma. Allergy 
2008; 63:1624–9
Cost-effectiveness study
Niederberger V, Reisinger J, Valent P, Krauth MT, Pauli G, van HM, et al. Vaccination 
with genetically modified birch pollen allergens: immune and clinical effects on 
oral allergy syndrome. J Allergy Clin Immunol 2007;119:1013–16
Relates to food allergy
Nieminen K, Valovirta E, Savolainen J. Clinical outcome and IL–17, IL–23, IL–27 and 
FOXP3 expression in peripheral blood mononuclear cells of pollen-allergic children 
during sublingual immunotherapy. Pediatr Allergy Immunol 2010;21:E174–84
Secondary analysis of data
Nunes C, Ladeira S. Pre-seasonal Specific Immunotherapy in rhino-conjunctivitis 
versus placebo. J Allergy Clin Immunol 2010;125:AB236
Not double blind
Nunes C, Ladeira S. Pre-seasonal specific short-term immunotherapy versus 
placebo in seasonal rhino-conjunctivitis. Rev Port Imunoalergol 2010;18:39–56
Not double blind
Panzner P, Petras M, Sykora T, Lesna IK, Liska M. Both sublingual and 
supralingual routes of administration are effective in long-term allergen-specific 
immunotherapy. Allergy Asthma Proc 2011;32:142–50
Not double blind
Passali D, Mösges R, Passali GC, Passali FM, Ayoko G, Bellussi L. Safety, tolerability 
and efficacy of sublingual allergoid immunotherapy with three different shortened 
up-dosing administration schedules. Acta Otorhinolaryngol Ital 2010;30:131–7
Not double blind
Patel P, Salapatek AMF. Pollinex® Quattro: a novel and well-tolerated, ultra short-
course allergy vaccine. Expert Rev Vaccine 2006;5:617–29
Review
Penagos M, Compalati E, Tarantini F, Baena-Cagnani R, Huerta J, Passalacqua G, 
et al. Efficacy of sublingual immunotherapy in the treatment of allergic rhinitis in 
pediatric patients 3 to 18 years of age: a meta-analysis of randomized, placebo-
controlled, double-blind trials. Ann Allergy Asthma Immunol 2006;97:141–8
Review
Petersen KD, Gyrd-Hansen D, Linneberg A, Dahl R, Larsen JN, Lowenstein H, et al. 
Willingness to pay for allergy-vaccination among Danish patients with respiratory 
allergy. Int J Technol Assess Health Care 2010;26:20–9.
Economic study
Pfaar O, Klimek L, Fischer I, Sieber J, Amoroso S, Aguilar CM, et al. Safety of 
two cluster schedules for subcutaneous immunotherapy in allergic rhinitis or 
asthma patients sensitized to inhalant allergens. Int Arch Allergy Immunol 
2009;150:102–8
Open-label study (safety)
Piconi S, Trabattoni D, Rainone V, Borgonovo L, Passerini S, Rizzardini G, et al. 
Immunological effects of sublingual immunotherapy: clinical efficacy is associated 
with modulation of programmed cell death ligand 1, IL–10, and IgG4. J Immunol 
2010;185:7723–30
Not double blind. Different treatment 
schedules compared
Pilette C, Nouri-Aria KT, Jacobson MR, Wilcock LK, Detry B, Walker SM, et al. 
Grass pollen immunotherapy induces an allergen-specific IgA2 antibody response 
associated with mucosal TGF-beta expression. J Immunol 2007;178:4658–66
No relevant outcomes reported
Pokladnikova J, Krcmova I, Vlcek J. Economic evaluation of sublingual vs 
subcutaneous allergen immunotherapy. Clin Exp Allergy 2008;100:482–9
EE based on open-label study
Pozzan M, Milani M. Efficacy of sublingual specific immunotherapy in patients 
with respiratory allergy to Alternaria alternata: A randomised, assessor-
blinded, patient-reported outcome, controlled 3-year trial. Curr Med Res Opin 
2010;26:2801–6
Not double blind
Pree I, Reisinger J, Focke M, Vrtala S, Pauli G, van HM, et al. Analysis of epitope-
specific immune responses induced by vaccination with structurally folded 
and unfolded recombinant Bet v 1 allergen derivatives in man. J Immunol 
2007;179:5309–16
No relevant outcomes (in vitro study)
Purohit A, Niederberger V, Kronqvist M, Horak F, Gronneberg R, Suck R, et al. 
Clinical effects of immunotherapy with genetically modified recombinant birch 
pollen Bet v 1 derivatives. Clin Exp Allergy 2008;38:1514–25
Not standard SIT
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Study Reason for exclusion
Railey MD, Adair MA, Burks AW. Allergen immunotherapy for allergic rhinitis. Curr 
Allergy Asthma Rep 2008;8:1–3
Comment
Rak S, Heinrich C, Scheynius A. Comparison of nasal immunohistology in patients 
with seasonal rhinoconjunctivitis treated with topical steroids or specific allergen 
immunotherapy. Allergy 2005;60:643–9
Not placebo controlled with rescue 
medication (SIT + placebo steroids vs 
placebo SIT + steroids)
Reha CM, Ebru A. Specific immunotherapy is effective in the prevention of new 
sensitivities. Allergol Immunopathol 2007;35:44–51
Not double blind
Roberts G, Hurley C, Turcanu V, Lack G. Grass pollen immunotherapy as an 
effective therapy for childhood seasonal allergic asthma. J Allergy Clin Immunol 
2006;117:263–8
SAA, not rhinitis
Roder E, Berger MY, de Groot H, van Wijk RG. Sublingual immunotherapy 
in youngsters: adherence in a randomized clinical trial. Clin Exp Allergy 
2008;38:1659–67
Analysis of adherence data from trial 
reported elsewhere
Rodriguez F, Boquete M, Ibanez MD, Torre-Martinez F, Tabar AI. Once daily 
sublingual immunotherapy without updosing: a new treatment schedule. Int Arch 
Allergy Immunol 2006;140:321–6
Results for patients with SAR not 
separable
Rolinck-Werninghaus C, Keil T, Kopp M, Zielen S, Schauer U, von Berg A, et al. 
Specific IgE serum concentration is associated with symptom severity in children 
with seasonal allergic rhinitis. Allergy 2008;63:1339–44
RCT of omalizumab vs placebo
Romaniuk LI, DuBuske IV, DuBuske LM. Comparative efficacy of subcutaneous 
immunotherapy, sublingual immunotherapy and combined subcutaneous and 
sublingual immunotherapy in patients with seasonal allergic rhinitis and cross-
reactive food allergy. Abstract 82. J Allergy Clin Immunol 2009;123:S25
Results for patients with SAR with 
not separable from those with food 
allergy
Rossi RE, Monasterolo G, Coco G, Silvestro L, Operti D. Evaluation of serum IgG4 
antibodies specific to grass pollen allergen components in the follow up of allergic 
patients undergoing subcutaneous and sublingual immunotherapy. Vaccine 
2007;25:957–64
Not double blind
Sager A, Braeutigam M, Badorrek P, Krug N. Efficacy of a rush immunotherapy 
with a depigmented polymerized extract of grass pollen using an environmental 
challenge chamber (ECC). Abstract 485. J Allergy Clin Immunol 2008;21:S125
No natural exposure-allergen 
chamber
Serra P, Martino M, Muggianu E, Corrias C, Manconi P, Milani M. Efficacy of 
SQ-standardised grass allergy immunotherapy tablet treatment on basophil 
activation test in subjects with grass pollen induced rhinoconjunctivitis. Allergy 
2010;65(XXIX, EAACI, Congress of the European Academy of Allergy and Clinical 
Immunology, London, UK, 5–9 June 2010):684
No relevant outcomes
Simons FER, HayGlass KT. Immunotherapy with a ragweed vaccine [2]. New Eng J 
Med 2007;356:86–7
Correspondence
Sjolin I, Haugaard L, Kopp T, Jansen A, Brüning H, Smedegaard AB, et al. High 
patient compliance on a once daily treatment regimen with the hay fever drug 
Grazax. J Allergy Clin Immunol 2008;121(American Academy of Allergy, Asthma 
and Immunology 64th Annual Meeting, Philadelphia, PA, USA, 14–18 March, 
2008, S128):Abstract 495
Not double blind
Skripak J, Wood RA. A prospective, randomized, double-blind, placebo-controlled 
multi-centre study on the efficacy and safety of sublingual immunotherapy (SLIT) 
in children with seasonal allergic rhinoconjunctivitis to grass pollen. Commentary. 
Pediatrics 2006;118:S22
Comment on another study
Stelmach I, Kaczmarek-Wozniak J, Majak P, Olszowiec-Chlebna M, Jerzynska J. 
Efficacy and safety of high-doses sublingual immunotherapy in ultra-rush scheme 
in children allergic to grass pollen. Clin Exp Allergy 2009;39:401–8
Patients with SAA
Stosovic R, Bogic M, Tomic-Spiric V. Long-term efficacy and safety of sublingual 
immunotherapy in seasonal allergic rhinitis. Allergy 2008;63 (XXVII EAACI, 
Congress of the European Academy of Allergology and Clinical Immunology, 
Barcelona, Spain, 7–11 June, 2008):Abstract 1065
Not double blind
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Study Reason for exclusion
Thien F. Sublingual immunotherapy with a grass allergen tablet improved 
symptoms and quality of life in allergic rhinoconjunctivitis. Evid Base Med 
2006;11:173
Commentary
Wahn U, Bauer C, Agertoft L, Melac M, Le Gall M. Agreement of efficacy 
assessments for five grass pollen sublingual immunotherapy (SLIT) tablets in 
children and adolescents with grass pollen rhinoconjunctivitis and with or without 
mild asthma. Abstract 214. J Allergy Clin Immunol 2009;123:S59
Secondary analysis of data
Williams A, Henzgen M, Rajakulasingam K, Williams A, Henzgen M, 
Rajakulasingam K. Additional benefit of a third year of specific grass pollen 
allergoid immunotherapy in patients with seasonal allergic rhinitis. Eur Ann Allergy 
Clin Immunol 2007;39:123–6
Open-label continuation of trial
Zuberbier T, Sussman G. Epidemiological characteristics and allergen sensitisation 
patterns in subjects with intermittent allergic rhinitis in the international ACCEPT1 
study in association with GA2LEN. Allergy 2008;63 (XXVII EAACI, Congress of the 
European Academy of Allergology and Clinical Immunology, Barcelona, Spain, 
7–11 June 2008):Abstract
Not SIT
Unobtainable studies (reference incorrect or inaccurate and 
therefore unable to locate, or British Library unable to supply 
at the time of ordering)
Arbesman CE. Hyposensitization therapy including repository: a double-blind study J Allergy Clin Immunol 1964;35:12–17
Arbesman CE, Reisman RE, Kunz ML. Clinical and immunologic evaluation of a purified fraction of ragweed pollen (delta). 
A double-blind study. J Allergy Clin Immunol 1965;36:29–38
Ariano R, Panzani RC, Augeri G. Efficacy and safety of oral immunotherapy in respiratory allergy to Parietaria judaica pollen. 
A double-blind study. J Investig Allergol Clin Immunol 1998;8:155–60
Bachert C. New Clinical Documentation on Alk Grass Allergen Tablet. Drugs of Today 2008;44:57–60
Basomba A. [Immunotherapy in pollenosis: a double-blind study.] Rev Espanol Alergol Inmunol Clin 1991;6:22–7
Corthay P, Gumowski PI, Bodmer R, Clot B. Efficacy of sublingual versus subcutaneous immunotherapy to pollen allergens 
after 3 consecutive years of treatment. Annual Meeting of the Swiss Society for Allergology and Immunology, 1996
Durham SR, Hamid QA. The effect of immunotherapy on allergen induced late responses. Arbeiten aus dem Paul Ehrlich 
Institut zu Frankfurt a M 1997;33–9
Frank E, Williams A, Cromwell O, Atkinson P, Rajakulasingam K. Effectiveness of a pre-seasonal allergoid immunotherapy in 
patients with seasonal allergic rhinitis due to grass pollen. J Allergy Clin Immunol 2001;107:S260 POSTER no. 851 (Tuesday 
20 March). American Association of Asthma, Allergy & Immunology, 57th Annual Meeting, 2001
Franklin W, Lowell FC. Comparison of two dosages of ragweed extract in the treatment of pollenosis. J Am Med Assoc 
1967;201:915–17
Hordijk GJ, Antvelink JB, Luwema RA. A placebo controlled study on the efficacy of sublingual immunotherapy with 
standardized grass pollen allergens (Oralgen). XVI Congress of the European Rhinologic Society; VIII Congress of the 
International Rhinologic Society, Ghent, Belgium, 7–13 June 1996:150
Khinchi MS, Poulsen LK, Carat F, Andre C, Malling HJ. Clinical efficacy of sublingual-swallow and subcutaneous 
immunotherapy in patients with allergic rhinoconjunctivitis due to birch pollen. A double-blind, double-dummy placebo-
controlled study. Allergy 2000;54:24
Klimek L, Pfaar O, Sieber J, Amoroso S, Carmen MA, Sges R. A prospective trial to evaluate the safety of two cluster 
regimens in subcutaneous immunotherapy in patients with allergic rhinitis and mild or moderate allergic asthma to grass 
pollen, tree pollen or mites. Allergy 2006;61:Abstract (XXV Congress of the European Academy of Allergology and Clinical 
Immunology)
Leonardi S, Arena A, Bruno ME, Cannaò PM, D’Anneo RW, Falagiani P, et al. Olea sublingual allergoid immunotherapy 
administered with two different treatment regimens. Allergy Asthma Proc 2010;31:e25–9
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Matuska J. Cluster immunotherapy. SR theophylline in prevention of systemic reactions. Eur Respir J 2001;18:430
Monzon S, Venturini M, Colas C, Lezaun A, Casanovas M, Reichelt C, et al. Specific immunotherapy with modified Salsola 
kali extract: preliminary results. Alergol Inmunol Clin 2003;18:20–4
Poddubikova AM, Kostinov MP. [Immunovac-VP4 vaccine used in complex allergen-specific immunotherapy of patients with 
hay fever.] Zh Mikrobiol Epidemiol Immunobiol 2010;44–8
Polosa R, Ligotti F, Mangano G, Mastruzzo C, Sarva M, Spicuzza L, et al. Seasonal variability in BHR and sputum cells 
count in subjects with rhinitis and effect of 3 years’ specific immunotherapy. American Thoracic Society 99th International 
Conference 2003;A031. Poster
Pravettoni V, Pastroello E, Qualizza R, Codecasa L, Vassellatti D. Double blind placebo controlled study of specific 
immunotherapy (ITS) with absorbed aluminum hydroxide allergoid in grass-pollen induced rhinitis. J Allergy Clin Immunol 
1987;79:Abstract (American Academy of Allergy and Immunology 43rd Annual Meeting, Washington DC, 19–25 February 
1987)
Rak S, Stender A, Dahl R. Confirmed clinical safety and efficacy of grass allergen tablets. Eur Respir J 2005;26 (15th 
European Respiratory Society Annual Congress, Copenhagen, Denmark, 17–21 September, 2005):Abstract
Russello M, Maurol M, Incorvaia C, D’Ingianna E, Gazzola GB. Subcutaneous and sublingual immunotherapy in birch 
pollinosis: a comparison of efficacy and safety. Allergy 2004;59(XXIII Congress of the European Academy of Allergology 
and Clinical Immunology, Amsterdam, The Netherlands, 12–16 June 2004):Abstract
Torres Lima M, Wilson DR, Roberts A, Walker SM, Durham SR. Grass pollen sublingual immunotherapy (SLIT) for seasonal 
rhinoconjunctivitis: a randomised controlled trial. J Allergy Clin Immunol 2001;107:837
Torres Lima M, Wilson DR, Pitkin L, Roberts A, Nouri-Aria KT, Jacobson M, et al. Grass pollen immunotherapy (SLIT) for 
seasonal rhinoconjunctivitis: a randomised controlled trial. Clin Exp Allergy 2001;31:42
Valovirta E. PAT: the Preventive Allergy Treatment study design and preliminary results. Wiener Medizinische Wochenschrift 
1999;149:442–3
Walker S. Immunotherapy for pollen allergy. International Primary Care Respiratory Conference, 9–11 June, St Neots, UK 
2000;9:S27. Abstract 065
Yuksel H, Tanac R, Gousseinov A, Demir E. Sublingual immunotherapy and influence on urinary leukotrienes in seasonal 
pediatric allergy. J Investig Allergol Clin Immunol 1999;9:305–13
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Studies not identified in Cochrane reviews
Subcutaneous immunotherapy
Reference Details
Bachert C. [Influence of specific immunotherapy on inflammation of the 
nasal mucosa.] Allergo J 1997;6:157–8
Appears to be report of study reported 
elsewhere but unclear. Thirty-four patients. 
Patient-related outcomes reported
Crimi N, Li GF, Mangano G, Paolino G, Mastruzzo C, Vancheri C, et al. A 
randomized, controlled study of specific immunotherapy in monosensitized 
subjects with seasonal rhinitis: effect on bronchial hyperresponsiveness, 
sputum inflammatory markers and development of asthma symptoms. Ann 
Ital Med Int 2004;19:98–108
Possible duplicate of studies listed as 
excluded in Cochrane review (non-relevant 
outcomes.) In this study, SSs and MSs are 
presented. Thirty patients
Dreborg S, Agrell B, Foucard T, Kjellman NI, Koivikko A, Nilsson S. A double-
blind, multicenter immunotherapy trial in children, using a purified and 
standardized Cladosporium herbarum preparation. Clinical results. Allergy 
1986;41:131–40
Duplicate of Karlsson et al. 1986 listed as 
excluded in Cochrane review, as not SAR. 
Study is in Cladosporium herbarum, a 
mould; authors mention July–September as 
peak mould season, so does appear to have 
seasonal aspect
Durham SR, Varney V, Gaga M, Frew AJ, Jacobson M, Kay AB. 
Immunotherapy and allergic inflammation. Clin Exp Allergy 
1991;21:206–10
Duplicate of study included in Cochrane 
review (Varney 1991)
Frew AJ, Powell RJ, Durham SR. Alutard SQ grass demonstrates clinical 
efficacy in subjects with seasonal allergic rhinoconjunctivitis in a large-scale 
double-blind placebo controlled study of specific allergy vaccination (the 
AVANZ study). Abstract 317. J Allergy Clin Immunol 2004;113:S105
Abstract of study included in Cochrane 
review (Frew et al. 2006161)
Horst M, Hejjaoui A, Horst V, Michel FB, Bousquet J, Horst M et al. Double-
blind, placebo-controlled rush immunotherapy with a standardized 
Alternaria extract. J Allergy Clin Immunol 1990;85:460–72
Appears to be relevant RCT in 24 patients. 
Unclear if published elsewhere
Jean F, Bousquet J, Hejjaoui A, Guerin B, Maasch HJ, Michel FB. Double-
blind placebo controlled rush immunotherapy trial with grass-pollen 
allergen and allergoid. J Allergy Clin Immunol 1985;75:164
Abstract. Likely duplicate of study included 
in Cochrane review
Munro-Ashman D, McEwen H, Feinberg JG. The patient self (P-S) test. 
Demonstration of a rise in blocking antibodies after treatment with Allpyral. 
Int Arch Allergy Appl Immunol 1971;40:448–53
Appears to be relevant RCT in 21 patients
Polosa R, Li Gotti F, Mangano G, Paolino G, Mastruzzo C, Vancheri C, et 
al. Effect of immunotherapy on asthma progression, BHR and sputum 
eosinophils in allergic rhinitis. Allergy 2004;59:1224–8
Duplicate publication of Crimi et al. 2004, 
listed above
Rozniecka M, Kowalski M, Grzegorczyk J, Wojciechowska B, Sliwinska-
Kowalska M, Rozniecki J. [Characteristics of hay fever during pollen 
season with regard to the influence of specific immunotherapy. I. Clinical 
course and biochemical changes in nasal lavage.] Pneumonol Alergol Pol 
1995;63:135–43
Appears to be relevant RCT in 27 patients
NIHR Journals Library www.journalslibrary.nihr.ac.uk
AppENDIx 5
194
Sublingual immunotherapy
Reference Details
Amar SM, Harbeck R, Sills M, O’Brien H, Nelson HS. The response to sublingual 
immunotherapy with grass pollen extract administered as a single extract or as 
part of a multi-allergen extract in patients with seasonal allergic rhinitis caused 
by grass pollen. J Allergy Clin Immunol 2009;123(American Academy of Allergy, 
Asthma and Immunology 65th Annual Meeting. Washington, USA, 13–17 March 
2009):Abstract 277
Further abstract of Amar 2009 
included in Cochrane review
Ariano R, Panzani RC, Mistrello G. Efficacy of sublingual coseasonal 
immunotherapy with a monomeric allergoid in Cupressaceae pollen allergy: 
preliminary data. Eur Ann Allergy Clin Immunol 2005;37:103–8
Not identified in Cochrane review; 
30 patients
Dahl R, Kapp A, Colombo G, de Monchy JGR, Rak S, Emminger W, et al. 
Sublingual grass allergen tablet immunotherapy provides sustained clinical benefit 
with progressive immunologic changes over 2 years. J Allergy Clin Immunol 
2008;121:512–18
Further publication of GT–08 trial; 
not listed as included study, but 
mentioned in text
de Blay F, Barnig C, Kanny G, Purohit A, Leynadier F, De Lara JMT, et al. Sublingual-
swallow immunotherapy with standardized 3-grass pollen extract: a double-blind, 
placebo-controlled study. Ann Allergy Asthma Immunol 2007;99:453–61
Full text of abstract included in 
Cochrane review
Horak F, Siegfried J, Worm M, Melac M, Didier A. Clinical efficacy of sublingual 
immunotherapy (SLIT) with grass pollen tablets in patients with rhinoconjunctivitis 
throughout the pollen season and at peak pollen. Allergy 2008;63(XXVII EAACI 
Congress of the European Academy of Allergology and Clinical Immunology, 
Barcelona, Spain, 7–11 June 2008):Abstract 586
Abstract of Didier et al.24 included in 
Cochrane review
Horiguchi S, Okamoto Y, Yonekura S, Okawa T, Kunii N, Yamamoto H, et al. 
[Lowered effectiveness of immunotherapy for cypress pollinosis by using Japanese 
cedar pollen extract.] Jp J Allergol 2008;57:558–61
Japanese paper identified as likely 
to be included after preliminary 
translation. Full translation not 
obtained
Larsen TH, Poulsen LK, Melac M, Combebias A, Andre C, Malling HJ. Safety and 
tolerability of grass pollen tablets in sublingual immunotherapy: a phase-1 study. 
Allergy 2006;61:1173–6
Not identified in Cochrane review; 
30 patients
Moreno-Ancillo A, Moreno C, Ojeda P, Dominguez C, Barasona MJ, Garcia-
Cubillana A, et al. Efficacy and quality of life with once-daily sublingual 
immunotherapy with grasses plus olive pollen extract without updosing. J Investig 
Allergol Clin Immunol 2007;17:399–405
Not identified in Cochrane review; 
105 patients
Mösges R, Brüning H, Hessler HJ, Götz G, Knaussmann HG. Sublingual 
immunotherapy in pollen-induced seasonal rhinitis and conjunctivitis: a 
randomized controlled trial. Acta Dermatovenerol Alp Panonica Adriat 
2007;16:143–8
Not identified in Cochrane review; 
105 patients
Palma-Carlos AG, Santos AS, Branco-Ferreira M, Pregal AL, Palma-Carlos 
ML. Monoid sublingual immunotherapy. Eur Ann Allergy Clin Immunology 
2006;38:87–9
Likely duplicate publication of Palma-
Carlos 2006 in Cochrane review
Rak S, Yang WH, Pedersen MR, Durham SR. Once-daily sublingual allergen-specific 
immunotherapy improves quality of life in patients with grass pollen-induced 
allergic rhinoconjunctivitis: A double-blind, randomised study. Qual Life Res 
2007;16:191–201
Report of Durham 2006 included in 
Cochrane review
Roder E, Berger MY, Hop WCJ, de GH, Gerth van Wijk R. Efficacy of sublingual 
immunotherapy (SLIT) with grass pollen allergen in children and adolescents. 
J Allergy Clin Immunol 2006;117(American Academy of Allergy, Asthma and 
Immunology 62nd Annual Meeting, Miami Beach, FL, USA, 3–7 March 2006:S89): 
Abstract 346
Duplicate of study in Cochrane 
review
Sieber J, Merk H, Ott H. Seasonal sublingual immunotherapy is efficacious in 
allergic rhinitis from the first treatment season on also under high grass pollen 
exposure: the ECRIT study. Allergy 2008;63(XXVII EAACI Congress of the European 
Academy of Allergology and Clinical Immunology, Barcelona, Spain, 7–11 June 
2008):Abstract 597
Abstract of included study
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Reference Details
Valovirta E, Ljorring C, Jacobsen L. Double-blind, placebo-controlled dose-response 
study of clinical efficacy and safety of sublingual immunotherapy (SLIT) with 
tree pollen extract in children suffering from tree pollen induced hay fever with 
or without SAA. Allergy 2003;58(XXII Congress of the European Academy of 
Allergology and Clinical Immunology)
Likely abstract of included study
Worm M. Efficacy and tolerability of high dose sublingual immunotherapy 
in patients with rhinoconjunctivitis. Eur Ann Allergy Clin Immunology 
2006;38:355–60
Not identified in Cochrane review; 
188 patients.
Studies excluded from Cochrane review but meeting our 
inclusion criteria (not included in this report as not part of 
update)
Subcutaneous immunotherapy
Reference Details
Polosa R, Li Gotti F, Mangano G, Mastruzzo C, Pistorio MP, Crimi N. Monitoring 
of seasonal variability in bronchial hyper-responsiveness and sputum cell counts 
in non-asthmatic subjects with rhinitis and effect of specific immunotherapy. Clin 
Exp Allergy 2003;33:873–81
Excluded from Cochrane review as 
‘other outcomes investigated’. Do give 
symptom/medication scores, but not 
usable in meta-analysis
Varney VA, Hamid QA, Gaga M, Ying S, Jacobson M, Frew AJ, et al. Influence of 
grass-pollen immunotherapy on cellular infiltration and cytokine messenger-RNA 
expression during allergen-induced late-phase cutaneous responses. J Clin Invest 
1993;92:644–51
Excluded from Cochrane review as 
‘other outcomes investigated’. Do give 
symptom/medication scores, but not 
usable in meta-analysis
Weyer A, Donat N, L’Heritier C, Juilliard F, Pauli G, Soufflet B, et al. Grass 
pollen hyposensitization versus placebo therapy. I. Clinical effectiveness and 
methodological aspects of a pre-seasonal course of desensitization with a four-
grass pollen extract. Allergy 1981;36:309–17
Excluded from Cochrane review as 
different immunotherapy preparations 
used. ‘The first five doses were 
administered as aqueous preparations, 
whereas the 12 subsequent higher 
doses were injected in their AlOH3-
adsorbed form in order to avoid 
systemic reactions’
Fontana VJ, Holt LE Jr, Mainland D, Fontana VJ, Holt LEJ, Mainland D. 
Effectiveness of hyposensitization therapy in ragweed hay-fever in children. J Am 
Med Assoc 1966;195:985–92
Excluded from Cochrane review as no 
standardised allergen extract
Sublingual immunotherapy
Reference Details
Okubo K, Gotoh M, Fujieda S, Okano M, Yoshida H, Morikawa H, et al. A 
randomized double-blind comparative study of sublingual immunotherapy for 
cedar pollinosis. Allergol Int 2008;57:265–75
Excluded from Cochrane review as 
‘additional data not available’. States 
that 1–20 drops of extract dropped 
on to pieces of bread, which were 
held sublingually for 2 minutes
Van Niekerk CH, De Wet JI, Van Niekerk CH, De Wet JI. Efficacy of grass-maize 
pollen oral immunotherapy in patients with seasonal hay-fever: a double-blind 
study. Clin Allergy 1987;17:507–13
Excluded from Cochrane review as 
‘not SLIT’; states in paper that 1–15 
drops taken sublingually, kept in the 
mouth for at least 1 minute then 
swallowed
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Appendix 6 Main study characteristics and 
risk of bias
Subcutaneous immunotherapy compared with placebo
Casale 2006159
Study design DBPC RCT
Population symptoms AR (no asthma)
Treatment naive No ‘recent immunotherapy’. 19.5% had previously received SIT
n, age 159 patients (aged between 18 and 50 years); 79 active (two groups, IT with 
or without omalizumab), 80 placebo (two groups, placebo with or without 
omalizumab)
Intervention details Allergen: ragweed
Nine weeks’ pretreatment with active/placebo omalizumab; rush IT with six 
injections over 3–5 hours with short ragweed extract (ALK-Abelló), 0.012 mg Amb 
a 1, up to 1.2 mg Amb a 1. Then increasing doses weekly for 4 weeks to 8 mg, 
followed by 8 weeks of maintenance doses of 12 mg (12 weeks total, including 
ragweed season)
Outcomes SSs, AEs
Risk of bias
Adequate sequence generation Unclear risk
Support for judgement No details
Allocation concealment Unclear risk
Support for judgement No details
Blinding of participants/personnel Low risk
Support for judgement Placebo with increasing concentrations of histamine in order to maintain blinding
Incomplete outcome data Low risk
Support for judgement All patients accounted for. Intention-to-treat (ITT) analysis performed
Free of selective reporting Low risk
Support for judgement All outcomes listed in methodology accounted for in results
Free of other bias? Unclear risk
Support for judgement Overall, 19.5% previously received SIT, slight imbalance between treatment arms
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Ceuppens 2009160
Study design DBPC RCT
Population symptoms Rhinoconjunctivitis (no or mild asthma)
Treatment naive Yes. No previous SIT
n, age 62 adults (aged 18–65 years); 31 active, 31 placebo
Intervention details Allergen: birch
Glutaraldehyde-modified birch pollen extract adsorbed on to AlOH3 (purethal 
birch) – 500 mg extract/ml; 52 mg Bet v1 content/ml. Weekly induction (0.05, 0.1, 
0.2, 0.3, 0.4 and 0.5 ml); three fortnightly doses of 0.5 ml; maintenance dose 
0.5 ml at monthly interval for total of 18–22 months
Outcomes SMSs, AEs
Risk of bias
Adequate sequence generation Unclear risk
Support for judgement No details
Allocation concealment Unclear risk
Support for judgement No details
Blinding of participants/personnel Low risk
Support for judgement ‘Placebo preparations injected subcutaneously’
Incomplete outcome data Low risk
Support for judgement Dropouts (4/62; three in active group, one in placebo group) not included in 
results
Free of selective reporting Low risk
Support for judgement All outcomes listed in methodology accounted for in results
Free of other bias? Low risk
Support for judgement Patients all treatment naive
© Queen’s Printer and Controller of HMSO 2013. This work was produced by Meadows et al. under the terms of a commissioning contract issued by the Secretary of State 
for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals 
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be 
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science 
Park, Southampton SO16 7NS, UK.
DOI: 10.3310/hta17270 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 27
199
Chakraborty 200630
Study design DBPC RCT
Population symptoms Rhinoconjunctivitis or allergic asthma or both
Treatment naive Yes. No previous SIT
n, age 35 patients (aged 20–59 years); 18 active, 17 placebo
Intervention details Allergen: date sugar palm
Standardised allergen extract Phoenix sylvestris (date sugar palm); weekly 
induction phase for 24 weeks from 0.05 mg to 0.5 mg Fr IIa (fraction 11a of 
P. sylvestris); maintenance phase for 18 months at 2-weekly intervals with 
0.5–1 mg Fr IIa. Dose reduced 20–40% in symptomatic patients during 
pollen season
Outcomes SMSs, global measure of overall severity
Risk of bias
Adequate sequence generation Unclear risk
Support for judgement No details
Allocation concealment Unclear risk
Support for judgement No details
Blinding of participants/personnel Low risk
Support for judgement ‘Both the subjects and the administering personnel were blinded as to the 
composition of the injection vials’
Incomplete outcome data Low risk
Support for judgement All patients completed the study
Free of selective reporting Low risk
Support for judgement All outcomes listed in methodology accounted for in results
Free of other bias? Low risk
Support for judgement History of IT an exclusion criterion
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Charpin 2007142
Study design DBPC RCT
Population symptoms Rhinoconjunctivitis (possibly associated with moderate asthma)
Treatment naive Yes. No previous SIT
n, age 40 adults (aged 24–66 years); 22 active, 18 placebo
Intervention details Allergen: cypress
Standardised Juniperus ashei (cypress) extract (Stallergènes); 54 mg Jun a1 
major allergen/ml in 100-index of reactivity (IR) extract. Adsorbed on to AlOH3. 
Induction phase fortnightly injections followed by maintenance phase at 
maximum tolerated dose for 15 months (frequency not reported), covering two 
pollen seasons. Maximum dose of Jun a1 injected was 16.2 mg
Outcomes SMSs, AEs, QoL
Risk of bias
Adequate sequence generation Low risk
Support for judgement Computer-generated randomisation
Allocation concealment Unclear risk
Support for judgement No details
Blinding of participants/personnel Low risk
Support for judgement Matched placebo containing histamine
Incomplete outcome data Unclear risk
Support for judgement Fairly high number of dropouts (8/22 active and 4/18 placebo); similar reasons 
for dropout. Not included in ‘intention-to-treat (ITT) population’
Free of selective reporting Low risk
Support for judgement All outcomes listed in methodology accounted for in results
Free of other bias? Low risk
Support for judgement All patients were treatment naive
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Colas 2006143
Study design DBPC RCT
Population symptoms Allergic rhinoconjunctivitis with or without asthma
Treatment naive Unclear, but no IT during last 4 years
n, age 63 adults (aged 18–50 years, mean 33 years); 41 active, 19 placebo
Intervention details Allergen: Russian thistle
Depigmented and glutaraldehyde polymerised extract of S. kali adsorbed to 
AlOH3. Cluster schedule: first day 0.1, 0.25 and 0.5 ml × 45-mg extract/ml; 
1 week later, 0.1, 0.25 and 0.5 ml × 450 mg/ml; then, starting 1 month later, 
one injection per month totalling 12 maintenance doses 0.5 ml × 450 mg/ml. 
Cumulative dose of Sal k 1 during trial was 597.65 mg
Outcomes SSs, MSs, QoL, AEs, global assessment of health
Risk of bias
Adequate sequence generation Unclear risk
Support for judgement No details
Allocation concealment Unclear risk
Support for judgement No details
Blinding of participants/personnel Low risk
Support for judgement ‘The placebo contained the identical solution as the experimental product, but 
without active ingredient; the presentation and dosage schedules were identical’
Incomplete outcome data Low risk
Support for judgement 3/63 patients (two active, one placebo) dropped out prior to pollen season and 
not due to AEs; not included in analyses
Free of selective reporting Low risk
Support for judgement All outcomes listed in methodology accounted for in results
Free of other bias? Unclear risk
Support for judgement No SIT in previous 4 years, but previous history unknown
NIHR Journals Library www.journalslibrary.nihr.ac.uk
AppENDIx 6
202
Creticos 2006144
Study design DBPC RCT
Population symptoms AR
Treatment naive Unclear. Exclusion criteria stated that no IT within last 5 years, but 20% were 
allowed to have had treatment > 5 years ago
n, age 25 adults (aged 23–60 years); 14 active, 11 placebo
Intervention details Allergen: ragweed
Preseasonal, six injections at weekly intervals, with dose from 0.06 to 12.0 mg AIC 
(Amb a 1-immunostimulatory oligodeoxyribonucleotide conjugate)
Outcomes SSs, MSs, rhinitis-VAS, QoL, AEs (all listed as secondary outcomes)
Risk of bias
Adequate sequence generation Low risk
Support for judgement Random block design provided by Immune Tolerance Network statistical and 
clinical coordinating centre
Allocation concealment Low risk
Support for judgement Blinded coordinator used internet system to receive blinded treatment code
Blinding of participants/personnel Low risk
Support for judgement Full details of blinding given in a web appendix
Incomplete outcome data High risk
Support for judgement 6/14 (active) and 9/11 (placebo) completed year 2; most analyses used only those 
that had completed. Also used subgroups who reached target dose in analysis
Free of selective reporting Unclear risk
Support for judgement All outcomes listed in methodology accounted for in results, although not very 
detailed. Some further information in web appendix
Free of other bias? Unclear risk
Support for judgement No SIT in previous 5 years, but some patients may have had previous SIT
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DuBuske 2011145
Study design DBPC RCT
Population symptoms Moderate to severe AR and/or conjunctivitis
Treatment naive Excluded if previous treatment unless > 3 years ago and with initial success but 
subsequent symptom recurrence
n, age 1028 adults (aged 18–59 years); 514 active, 514 placebo
Intervention details Allergen: Thirteen-grass mix
Grass MATA monophosphoryl lipid (MPL), Pollinex Quattro, Pollinex Complete; 
Allergy Therapeutics UK. Ultra-short course SCIT – four increasing dose injections 
[300, 800, 2000, 2000 standardised units (SU)] 13-grass-pollen allergoid mixture 
in l-tyrosine depot plus 50 mg MPL. Given at approximately weekly intervals pre-
season
Outcomes SMSs, AEs
Risk of bias
Adequate sequence generation Low risk
Support for judgement Interactive voice randomisation system. Performed in blocks at study and site level
Allocation concealment Low risk
Support for judgement Interactive voice randomisation system
Blinding of participants/personnel Low risk
Support for judgement Placebo appeared identical apart from active ingredient
Incomplete outcome data Low risk
Support for judgement Intention-to-treat (ITT) analysis performed for primary efficacy analysis. Missing 
data imputed using matched-pair technique. Similar numbers dropped out in 
both treatment arms
Free of selective reporting Low risk
Support for judgement All outcomes listed in methodology accounted for in results
Free of other bias? Low risk
Support for judgement Excluded if previous treatment unless > 3 years ago and with initial success but 
subsequent symptom recurrence
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Francis 2008146
Study design DBPC RCT
Population symptoms Moderate to severe AR with poor symptom control
Treatment naive No details
n, age 18 adults (mean age between 30 and 37 years); 12 active, 6 placebo
Intervention details Allergen: timothy grass
Modified cluster regimen: weekly visits for 2 months, with two injections per visit 
in increasing dosage from 100 to 100,000 standardised quality units (SQ-Us) of 
timothy grass pollen (whole extract, Alutard SQ, ALK-Abelló). Maintenance dose 
monthly up to 1 year of 1 ml 100,000 SQ-U (20 mg Phl p5) but reduced by 40% 
z1 during pollen season
Outcomes Overall clinical assessment, AEs
Risk of bias
Adequate sequence generation Unclear risk
Support for judgement No details
Allocation concealment Unclear risk
Support for judgement No details
Blinding of participants/personnel Low risk
Support for judgement Placebo with histamine and identical in appearance
Incomplete outcome data Low risk
Support for judgement Appears that all participants included in analysis
Free of selective reporting Low risk
Support for judgement All outcomes listed in methodology accounted for in results
Free of other bias? Unclear risk
Support for judgement SIT history not reported
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Hoiby 2010148
Study design DBPC RCT
Population symptoms Rhinoconjunctivitis with or without allergic asthma
Treatment naive No details
n, age 61 adults, adolescents and children (51/5/5, respectively; aged 7–69 years); active 
31, placebo 30
Intervention details Allergen: birch
Depigoid (Laboratorios LETI SI) standardised depigmented, glutaraldehyde-
polymerised Betula alba adsorbed on to AlHO3. Updosing at 7-day intervals: 
0.2 ml 100 depigmented, glutaraldehyde-polymerised pollen (DPP)/ml, 0.5 ml 
100 DPP/ml, 0.2 ml 1000 DPP/ml, 0.5 ml 1000 DPP/ml; maintenance dose 0.5 ml 
10,000 DPP/ml every 6 weeks for 18 months; maintenance dose corresponded to 
30 mg Bet v 1 before polymerisation
Outcomes SMSs, AEs, QoL
Risk of bias
Adequate sequence generation Low risk
Support for judgement Computer-generated randomisation list
Allocation concealment Unclear risk
Support for judgement ‘Within study centres patients were allocated to the treatment in ascending order’
Blinding of participants/personnel Low risk
Support for judgement ‘No visible difference between placebo and Depigoid® vials.’ No histamine, but 
very few reactions in total so unlikely to have interfered with blinding
Incomplete outcome data Unclear risk
Support for judgement A ‘modified’ intention-to-treat (ITT) population was used excluding patients who 
did not reach maintenance dose, those who did not receive at least one dose 
during 2006 pollen season and those who did not adhere to study protocol. One 
patient unaccounted for. Primary analysis conducted on 45/61 patients. All 61 
patients accounted for in safety results
Free of selective reporting Low risk
Support for judgement All outcomes listed in methodology accounted for in results
Free of other bias? Unclear risk
Support for judgement SIT history not reported
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Kettner 2007149 (abstract only)
Study design DBPC RCT
Population symptoms Rhinoconjunctivitis with or without asthma
Treatment naive No details
n, age 211 patients (age range not stated); 108 active, 103 placebo
Intervention details Allergen: birch
rBet v 1-FV recombinant birch extract, dosage increased to 80 mg then maintained 
1.5 years (frequency of injections not stated)
Outcomes SMSs, AEs
Risk of bias
Adequate sequence generation Unclear risk
Support for judgement No details
Allocation concealment Unclear risk
Support for judgement No details
Blinding of participants/personnel Unclear risk
Support for judgement No details
Incomplete outcome data Unclear risk
Support for judgement Results reported for ‘full analysis set’ only
Free of selective reporting Unclear risk
Support for judgement Full methodology not reported, so unclear how many outcome investigated
Free of other bias? Unclear risk
Support for judgement SIT history not reported
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Klimek 2010150 (abstract only)
Study design DBPC RCT
Population symptoms No details
Symptoms Allergic rhinoconjunctivitis with or without asthma
Treatment naive No details
n, age 148 patients (age range not stated); 112 active, 36 placebo
Intervention details Allergen: grasses and rye
Coseasonal. Updosing with six injections up to 10,000 SQ-U (Alutard SQ grasses 
and rye, ALK-Abelló) with 1–3 injection intervals, then two injections of 10,000 
SQ-U after 14 and 28 days
Outcomes AEs
Risk of bias
Adequate sequence generation Unclear risk
Support for judgement No details
Allocation concealment Unclear risk
Support for judgement No details
Blinding of participants/personnel Unclear risk
Support for judgement No details
Incomplete outcome data Unclear risk
Support for judgement No details
Free of selective reporting Low risk
Support for judgement All outcomes listed in methodology accounted for in results
Free of other bias? Unclear risk
Support for judgement SIT history not reported
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Kuna 2011152
Study design DBPC RCT
Population symptoms Rhinoconjunctivitis with or without asthma
Treatment naive Yes. No previous IT
n, age 50 children and adolescents (aged 5–18); active 30, placebo 20
Intervention details Allergen: Alternaria
AlOH3-adsorbed, standardised A. alternata extract 100% (8 mg/ml Alt a 1 in maintenance 
dose) (Allergopharma) – updosing: 14 injections weekly or fortnightly. Maintenance dose: 1 ml 
35,000 therapeutic units (TUs)/ml or highest tolerated dose every 4–6 weeks for up to 3 years
Outcomes SMSs, AEs, QoL
Risk of bias
Adequate sequence 
generation
Low risk
Support for judgement Computer-generated random number tables
Allocation concealment Low risk
Support for judgement Code concealed by manufacturer
Blinding of participants/
personnel
Low risk
Support for judgement Placebo containing histamine indistinguishable from active treatment. All personnel at the 
study site were blinded
Incomplete outcome 
data 
Unclear risk
Support for judgement Dropouts = 4/30 active and 1/20 placebo. Reason for dropout was difficulties with timings of 
study for all. Not stated whether ‘intention to treat (ITT)’ or other
Free of selective 
reporting
Low risk
Support for judgement All outcomes listed in methodology accounted for in results
Free of other bias? Low risk
Support for judgement No previous SIT
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Ljorring 2009153 (abstract only)
Study design DBPC RCT
Population symptoms Grass-allergic patients. No further details
Treatment naive No details
n, age 162 patients. Age and allocation not reported
Intervention details Allergen: grass
Alutard SQ® grass, 100,000 SQ-U (ALK-Abelló); 1 year. No further details on treatment 
schedule
Outcomes SMSs
Risk of bias
Adequate sequence 
generation
Unclear risk
Support for judgement No details
Allocation concealment Unclear risk
Support for judgement No details
Blinding of participants/
personnel
Unclear risk
Support for judgement No details
Incomplete outcome data Unclear risk
Support for judgement Numbers in analysis not reported
Free of selective reporting Low risk
Support for judgement All outcomes listed in methodology accounted for in results
Free of other bias? Unclear risk
Support for judgement SIT history not reported
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Pauli 2008154
Study design DBPC RCT
Population symptoms Rhinoconjunctivitis with or without asthma
Treatment naive Yes. No previous IT
n, age n = 147 (aged 18–50 years); active 98 (three groups), placebo 36
Intervention details Allergen: birch
One of three AlOH3-adsorbed extracts: birch pollen extract, natural Bet v 1, recombinant 
Bet v 1, standardised for Bet v 1 concentration (Stallergènes). Build-up starting 6 months 
before pollen season by weekly injections from 0.1 ml of 0.5 mg/ml, increasing weekly to 
0.3 ml of 50 mg/ml or maximum tolerated dose. Maintenance dose reached at least 7 weeks 
before pollen season was 15 mg Bet v 1 then given monthly for 2 years
Outcomes SSs, MSs, AEs
Risk of bias
Adequate sequence 
generation
Unclear risk
Support for judgement ‘Minimisation method considering symptom severity and degree of birch sensitisation’
Allocation concealment Unclear risk
Support for judgement No details
Blinding Low risk
Support for judgement Placebo containing histamine to maintain blinding
Incomplete outcome data Low risk
Support for judgement Between 24% and 27% withdrew from each arm of the four groups, none for AEs. 
Intention-to-treat (ITT) analysis performed where possible
Free of selective reporting Low risk
Support for judgement All outcomes listed in methodology accounted for in results
Free of other bias? Low risk
Support for judgement Previous SIT considered major protocol violation (n = 1)
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Pfaar 2010155
Study design DBPC RCT
Population symptoms Rhinoconjunctivitis with or without asthma
Treatment naive No details
n, age 184 adults (aged 18–65 years, mean 38 years); 137 active, 47 placebo
Intervention details Allergen: birch, hazel and alder
Depigoid® (Laboratorios LETI) standardised depigmented, glutaraldehyde-polymerised 
tree pollen extract (33% Corylus avellana, 33% Alnus glutinosa, 34% B. alba) adsorbed 
on to AlOH3. Updosing at 7-day intervals: 0.2 ml 100 DPP/ml, 0.5 ml 100 DPP/ml, 0.2 ml 
1000 DPP/ml, 0.5 ml 1000 DPP/ml; maintenance dose 0.5 ml 10,000 DPP/ml every 6 weeks for 
18 months; maintenance dose corresponded to 11.0 mg Bet v 1 before polymerisation
Outcomes SSs, MSs, SMSs, AEs
Risk of bias
Adequate sequence 
generation
Unclear risk
Support for judgement No details
Allocation concealment Unclear risk
Support for judgement No details
Blinding of participants/
personnel
Low risk
Support for judgement ‘Placebo medication was identical in appearance’
Incomplete outcome data High risk
Support for judgement Primary outcomes analysed on intention-to-treat (ITT) and per protocol basis. Secondary 
outcomes (including SSs and MSs) on per protocol basis only
Free of selective reporting Low risk
Support for judgement All outcomes listed in methodology accounted for in results
Free of other bias? Unclear
Support for judgement Previous SIT history not reported
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Powell 2007156 
Further report of Frew 2006161 included in Cochrane review, see reported as abstract Krishna 2006.151
Study design DBPC RCT
Population symptoms Rhinoconjunctivitis inadequately controlled with medication in previous years
Treatment naive No SIT in previous 5 years
n, age 410 adults (18–60 years, mean 38 years); 203 high dose, 104 medium dose, 103 placebo
Intervention details Allergen: timothy grass
Alutard SQ® P. pratense 10,000 SQ-U (2 mg Phl p 5) or 100,000 SQ-U (20 mg Phl p 5) 
(ALK-Abelló); updosing 15 injections (two/visit) over 8 weeks; maintenance phase every 
6 ± 2 weeks for approximately 12 months
Outcomes QoL
Risk of bias
Adequate sequence 
generation
Low risk
Support for judgement Generated by ALK-Abelló
Allocation concealment Low risk
Support for judgement ALK-Abelló maintained sequence; investigators allocated sequential randomisation number 
from sequence
Blinding of participants/
personnel
Low risk
Support for judgement ‘Placebo and active medication were indistinguishable’
Incomplete outcome data Low risk
Support for judgement 387/410 completed study (169, 87, 91). All randomised subjects included in analysis 
[intention to treat (ITT)]
Free of selective reporting Low risk
Support for judgement All outcomes listed in methodology accounted for in results (note: not all outcomes 
reported in this publication)
Free of other bias? Unclear risk
Support for judgement No SIT in previous 5 years, but unclear if ever treated with SIT
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Sahin 2011157 (abstract only)
Study design DBPC RCT
Population symptoms AR and/or conjunctivitis
Treatment naive No details
n, age 121 adults (aged 18–60 years), 61 active, 59 placebo (1 dropout)
Intervention details Allergen: grass and rye
Highly polymerised allergen extract mixture of grass and rye pollen (Clustoid), two injections/
day for initiation phase (cluster schedule) then once per month for maintenance (length of 
treatment not clear)
Outcomes SSs, MSs, global evaluation by patients, AEs
Risk of bias
Adequate sequence 
generation
Unclear risk
Support for judgement No details
Allocation concealment Unclear risk
Support for judgement No details
Blinding of participants/
personnel 
Unclear risk
Support for judgement No details
Incomplete outcome data Unclear risk
Support for judgement No details
Free of selective reporting Low risk
Support for judgement All outcomes listed in methodology accounted for in results
Free of other bias? Unclear risk
Support for judgement Previous SIT history not reported
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Ventura 2009158
Note: this study has as treatment arms SLIT, SCIT and placebo; there is no direct comparison between SLIT 
and SCIT.
Study design DBPC RCT
Population symptoms Allergic rhinoconjunctivitis
Treatment naive Unclear (not in treatment at time of study)
n, age n = 20 adults (18–55 years); active n = 10, placebo n = 10
Intervention details Allergen: cypress
300 IR/ml J. ashei extract adsorbed on to aluminium hydroxide phosphate (StaloralR, 
Stallergènes Sa). Jun a1 MAC 76 mg/ml of the 100-index of reactivity (IR) allergen extract; daily 
allergen dose in maintenance of 228 µg/ml
Twelve-week induction phase with weekly injections and maintenance phase of 9 months with 
monthly injections
Outcomes SSs
Risk of bias
Adequate sequence 
generation
Low risk
Support for judgement Computer-generated code
Allocation concealment Unclear risk
Support for judgement No details
Blinding participants/
personnel
Low risk
Support for judgement The placebo had the same appearance and taste as SLIT. No further details
Incomplete outcome 
data 
Low risk
Support for judgement Data for all 20 patients reported
Free of selective 
reporting
Low risk
Support for judgement All outcomes listed in methodology accounted for in results
Free of other bias? Unclear risk
Support for judgement SIT history of patients not reported
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Sublingual immunotherapy compared with placebo
Blaiss 2011189
Study design DBPC RCT
Population symptoms Moderate to severe allergic rhinoconjunctivitis; 26% history of asthma, 89% 
multisensitised
Treatment naive Unclear
n, age n = 345, active n = 149, placebo n = 158
Children aged 5–17 years; mean age 12.3 years
Intervention details Allergen: timothy grass
Once-daily sublingual P. pratense grass AIT (allergen immunotherapy tablet) 75,000 SQ-T, 
15 mg Phl p5 (Schering Plough) started 16 weeks before pollen season and continued 
throughout season (23 weeks total)
Outcomes SMSs, SSs, MSs, QoL, AEs
Risk of bias
Adequate sequence 
generation
Low risk
Support for judgement External computer-generated randomisation; stratified by study site and asthma status
Allocation concealment Low risk
Support for judgement External randomisation group using an interactive voice response system
Blinding of participants/
personnel
Low risk
Support for judgement ‘Subjects and investigators were blinded to treatment by using a matching placebo in identical 
packaging to the grass AIT treatment. Blinding was maintained until data were locked’
Incomplete outcome 
data 
Unclear risk
Support for judgement 345 randomised; intention-to-treat (ITT) population n = 307 (all randomised patients with at 
least one data entry). Missing data not imputed. Discontinuations 14.6% intervention group 
and 6.5% placebo group
Free of selective 
reporting
Low risk
Support for judgement All outcomes listed in methodology accounted for in results
Free of other bias? Unclear
Support for judgement SIT history of patients not reported
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Cortellini 2010190
Study design DBPC RCT
Population symptoms Moderate/severe persistent rhinitis with or without intermittent asthma
Treatment naive Yes
n, age n = 27, adolescents and adults (age 14–42); active n = 15, placebo n = 12
Intervention details Allergen: Alternaria
Build-up phase lasted 15 days, starting with one drop from 100-Ru vial, increasing daily 
by one drop, up to five drops. Repeated with 1000-RU (radioallergosorbent test units) vial 
and 10,000-RU vial until maintenance dose reached. Maintenance dose was five drops 
of glycerinated extract, 10,000 RU/ml Alt a 1 (1.5 mg/ml) (Anallergo) every other day for 
10 months (January to October)
Outcomes SSs, MSs, AEs
Risk of bias
Adequate sequence 
generation
Low risk
Support for judgement Computer-generated randomisation list
Allocation concealment Unclear risk
Support for judgement No details
Blinding of participants/
personnel 
Low risk
Support for judgement ‘The placebo was indistinguishable by taste and aspect from the active SLIT.’ ‘Blinding was 
maintained until the last patient had completed the study’
Incomplete outcome 
data 
Low risk
Support for judgement Analysis performed on per-protocol population, not ‘intention to treat (ITT)’ but only one 
dropout of 27 randomised
Free of selective 
reporting
Low risk
Support for judgement All outcomes listed in methodology accounted for in results
Free of other bias? Low risk
Support for judgement No previous SIT
© Queen’s Printer and Controller of HMSO 2013. This work was produced by Meadows et al. under the terms of a commissioning contract issued by the Secretary of State 
for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals 
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be 
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science 
Park, Southampton SO16 7NS, UK.
DOI: 10.3310/hta17270 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 27
217
Didier 201125
Preliminary results also in Didier 2010 abstract.199
Study design DBPC RCT
Population symptoms Rhinoconjunctivitis
Treatment naive No details
n, age n = 633, adults (18–50 years)
2 active (n = 207 in both groups), 1 placebo arm (n = 219)
Intervention details Allergen: five-grass mix
Daily 300-index of reactivity (IR) five-grass pollen tablet (Oralair): either 4 or 2 months’ 
preseasonal treatment, then during the pollen season. Treatment over three consecutive 
pollen seasons
Outcomes SSs (adjusted for rescue medication use), SMSs, individual symptoms scores, symptoms 
and medication-free days, QoL, AEs
Risk of bias
Adequate sequence 
generation
Unclear risk
Support for judgement No details
Allocation concealment Unclear risk
Support for judgement No details
Blinding of participants/
personnel
Low risk
Support for judgement The 2-month group received placebo during the time the 4-month group was receiving their 
active treatment to maintain blinding
Incomplete outcome 
data 
Unclear risk
Support for judgement All a patients analyses performed on patients who had at least one dose of investigational 
product and who had at least one measurement during the pollen season. Frequency of 
discontinuations was similar between the three groups. Dropouts due to AEs were more 
frequent in active treatment arms
Free of selective 
reporting
Low risk
Support for judgement All outcomes listed in methodology accounted for in results
Free of other bias? Unclear risk
Support for judgement SIT history of patients not reported
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Durham 201132 (GT–08 trial), Durham 2010,200 Dahl 2008270  
and Dahl 200693
Note: This study was identified in the Cochrane review; we report on more recent publications with longer 
follow-up data.
Study design DBPC RCT
Population symptoms Significant allergic rhinoconjunctivitis
Treatment naive Unclear (but no grass pollen SIT within last 10 years or any other allergen within last 5 years)
n, age n = 634 (mean age around 34 ± 10 years)
Intervention details Allergen: timothy grass
Grazax® [P. pratense 75,000 SQ-T (standardised quality units tablet)/2800 BAU (bioequivalent 
allergy unit) (ALK-Abelló)]. Treatment started 16 weeks before pollen season and continued 
daily for 3 years (approximately 15 mg) then 2-year follow-up
Outcomes SMSs, AEs
Risk of bias
Adequate sequence 
generation
Unclear risk
Support for judgement Stated only that patients were randomised but no further details
Allocation concealment Unclear risk
Support for judgement No details
Blinding of participants/
personnel
Low risk
Support for judgement Placebo tablet similar in taste, smell and appearance. All personnel associated with the study 
remained blinded
Incomplete outcome 
data 
Unclear risk
Support for judgement Analyses for all randomised patients where data were available. No imputation of missing data. 
Similar completion rates at years 1 and 2, and similar reasons for withdrawals. Further loss to 
follow-up after year 1, as some sites closed and some patients chose not to participate
Free of selective 
reporting
Low risk
Support for judgement All outcomes listed in methodology accounted for in results
Free of other bias? Unclear risk
Support for judgement Patients may have had previous SIT (but not in last 10/5 years for grass or other allergen SIT, 
respectively)
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Fujimura 2011191
Study design DBPC RCT
Population symptoms Moderate or severe symptoms of pollinosis
Treatment naive Yes
n, age n = 103 adults (age 16–73); active n = 58, placebo n = 45
Intervention details Allergen: Japanese cedar
Standardised Japanese cedar pollen extract (Torii Pharmaceuticals). Updosing from 0.2 ml of 
20 Japanese Allergy Unit (JAU)/ml, increasing by 0.2 ml/day for 5 days per week. Maintenance 
dose was 1.0 ml of 2000 JAU/ml given once weekly over 2 years (two pollen seasons)
Outcomes SMSs, AEs, QoL
Risk of bias
Adequate sequence 
generation
Low risk
Support for judgement Random numbers table generated by personnel not directly involved in study
Allocation concealment Low risk
Support for judgement Allocation by personnel not directly involved in study
Blinding of participants/
personnel 
Unclear risk
Support for judgement Stated that study was double blind for two seasons; follow-up season was single blind
Incomplete outcome 
data 
Low-risk SMSs, high-risk-QoL data
Support for judgement Both intention-to-treat (ITT) and on-treatment analysis performed but only on-treatment 
analysis results presented for QoL data
Free of selective 
reporting
Low risk
Support for judgement All outcomes listed in methodology accounted for in results
Free of other bias? Yes
Support for judgement No previous SIT
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Horak 2009202
Further publication of study reported in Didier 200724 (included in Cochrane review). Horak 2009202 
includes further data on QoL not reported in Didier 2007.24
Study design DBPC RCT
Population symptoms Moderate to severe allergic rhinoconjunctivitis
Treatment naive Yes
n, age n = 628 adults (aged 18–45 years); four groups: n = 157 given 100 IR, n = 155 given 300 IR, 
n = 160 given 500 IR, n = 156 given placebo
Intervention details Allergen: five-grass mix
100-index of reactivity (IR), 300-IR or 500-IR standardised lyophilised five-grass pollen tablet 
(300 IR/ml approximately = 25 mg/ml allergen extracts). Daily tablet. Five days’ titration period 
from 100 IR to assigned dose. Maintenance approximately 4 months prior to pollen season 
and throughout pollen the season
Outcomes SSs, QoL, medication-free days, AEs
Risk of bias
Adequate sequence 
generation
Low risk
Support for judgement Computer-generated randomisation list
Allocation concealment Unclear risk
Support for judgement No details
Blinding of participants/
personnel
Low risk
Support for judgement Double blind; blinding maintained during induction phase by giving all patients two tables 
(presumably using placebo to make up difference), with one tablet from day 6
Incomplete outcome data Unclear risk
Support for judgement Only patients with complete data sets included in intention-to-treat (ITT) population 
(569/628, 91%). Discontinuations due to AE only in active treatment groups. Overall, slightly 
more withdrawals from active groups
Free of selective reporting Low risk
Support for judgement All outcomes listed in methodology accounted for; note that clinical outcomes reported in 
Didier 2007 (in Cochrane review). Additional data in this publication only QoL
Free of other bias? Yes
Support for judgement All patients treatment naive
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Nelson 2011192
Study design DBPC RCT
Population symptoms Allergic rhinoconjunctivitis with or without asthma
Treatment naive Unclear (but stated that no SIT in last 5 years)
n, age n = 438 adults (18–65); active n = 213, placebo n = 207
Intervention details Allergen: timothy grass
Once-daily 2800 BAU standardised P. pratense, 75,000 SQ-T, approximately 15 mg Phl p5 
(Schering Plough), starting 16 weeks preseasonal plus coseasonal, throughout the pollen 
season. No build-up dosing
Outcomes SSs, MSs, SMSs, QoL, AEs
Risk of bias
Adequate sequence 
generation
Low risk
Support for judgement Computer-generated randomisation schedule
Allocation concealment Low risk
Support for judgement External randomisation group using an interactive voice-response system
Blinding of participants/
personnel
Low risk
Support for judgement ‘Double-blinding (subjects and investigators) was established by use of a matching placebo 
tablet.’ ‘Blinding was maintained until the database was locked’
Incomplete outcome data Low risk
Support for judgement 391/439 with at least one post-treatment diary entry analysed. Similar numbers and reasons 
for discontinuation in both treatment arms
Free of selective reporting Low risk
Support for judgement All outcomes listed in methodology accounted for in results.
Free of other bias? Unclear risk
Support for judgement Some patients may have had previous SIT (but no SIT in previous 5 years)
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Panizo 2010193
Study design DBPC RCT
Population symptoms Rhinitis with or without asthma
Treatment naive Unclear (but not in last 5 years)
Participant details n = 78 adults (18–65); active = 52, placebo n = 26
Intervention details Allergen: timothy grass
Daily Grazax® 75,000 SQ-T for at least 8 weeks preseasonal, plus coseasonal, throughout the 
season
Outcomes AEs
Risk of bias
Adequate sequence 
generation
Unclear risk
Support for judgement Stated that patients were randomised but no further details
Allocation concealment Unclear risk
Support for judgement No details
Blinding of participants/
personnel
Low risk
Support for judgement ‘Placebo similar in taste, smell and physical appearance’
Incomplete outcome data Low risk (for AE outcome)
Support for judgement All patients included in safety analysis
Free of selective reporting Low risk
Support for judgement All outcomes listed in methodology accounted for in results
Free of other bias? Unclear risk
Support for judgement Some patients may have had previous SIT but no SIT in previous 5 years
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Pfaar 2011194
Study design DBPC RCT
Population symptoms Seasonal allergy symptoms
Treatment naive Unclear (but stated that no SIT in last 3 years)
n, age n = 80 adults (18–65 years); active n = 64 (four groups with different doses, n = 16 in each), 
placebo n = 16 (four in each group)
Intervention details Allergen: timothy grass
Extract of 12 mixed-grass pollens
(Allergy Therapeutics, B2 grass mixture), standardised by major allergen, P. pratense Phl p 
1 ± adjuvant MPL
 z Group 1: 9.45 mg P. pratense
 z Group 2: 9.45 mg P. pratense + 21 mg MPL (monophosphoryl lipid A)
 z Group 3: 9.5 mg P. pratense + 52.5 mg MPL
 z Group 4: 19 mg P. pratense + 52.5 mg MPL
Eight-week treatment period; periods varied for the four groups (preseasonal for three, 
postseasonal for one) 
Outcomes AEs
Risk of bias
Adequate sequence 
generation
Unclear risk
Support for judgement Patients were described as randomised, but no further details
Allocation concealment Unclear risk
Support for judgement No details
Blinding of participants/
personnel
Low risk
Support for judgement ‘Placebo solutions contained buffered glycerine solution and flavouring to match the active 
SLIT’
Incomplete outcome data Low risk
Support for judgement All subjects accounted for
Free of selective reporting Low risk
Support for judgement All outcomes listed in methodology accounted for in results
Free of other bias? Unclear risk
Support for judgement Some patients may have had previous SIT (but no SIT in previous 3 years)
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Reich 2011195
Study design: RCT DBPC RCT
Objective diagnosis Yes
Population symptoms Moderate to severe rhinoconjunctivitis; 41% with history of asthma
Treatment naive Unclear (but no SIT in last 5 years)
n, age n = 276, active n = 219, placebo n = 57
Mean age 35 years
Intervention details Allergen: timothy grass
Once daily sublingual P. pratense grass AIT 75,000 SQ-T, 2800 BAU (Grazax®, ALK) for 
8–10 weeks during pollen season
Outcomes MSs, AEs, global evaluation
Risk of bias
Adequate sequence 
generation
Low risk
Support for judgement Computer generated block randomisation. Randomisation list generated by trial-
independent statistician
Allocation concealment Low risk
Support for judgement Sealed randomisation code envelopes. Patients assigned lowest available randomisation 
numbers
Blinding of participants/
personnel
Low risk
Support for judgement ‘Investigators and patients were blinded throughout the trial.’ Matching placebo with 
taste, smell and appearance similar to the active extract. Drug codes broken only after 
completion of trial
Incomplete outcome data Low risk
Support for judgement All randomised patients included in analyses
Free of selective reporting Low risk
Support for judgement All outcomes listed in methodology accounted for in results
Free of other bias? Unclear risk
Support for judgement History of SIT in previous 5 years an exclusion criterion, but unclear if any patients had ever 
received SIT
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Skoner 2010196
Study design DBPC RCT
Population symptoms Moderate to severe allergic rhinoconjunctivitis
Treatment naive Unclear (but no SIT for ragweed in last 3 years)
n, age n = 115 adults (aged 18–50 years); n = 39 medium dose, n = 36 high dose, n = 40 placebo
Intervention details Allergen: ragweed
Preliminary dosing at first visit: up to four incremental doses of short ragweed pollen extract 
standardised for Amb a 1 content (medium-dose group 0, 0.48, 1.7 and 4.8 mg Amb a 1; 
high-dose group 0, 4.8, 17 and 48 mg extract). Maximum tolerated dose used. Daily dose of 
maintenance dose. Mean maximum tolerated dose was 3.21 (1.64) mg and 30.54 (16.14) mg 
in medium- and high-dose groups. Average cumulative dose 498 (185) mg/ml and 4941 
(1487) mg/ml
Pre-and coseasonal treatment. Average duration 17 weeks (±3)
Outcomes SMSs, AEs
Risk of bias
Adequate sequence 
generation
Low risk
Support for judgement Central block randomisation with stratification based on asthma diagnosis
Allocation concealment Low risk
Support for judgement Sequentially numbered containers, pharmacy control and central randomisation
Blinding of participants/
personnel
Low risk
Support for judgement Placebo masked with colouring
Incomplete outcome data Unclear risk
Support for judgement Patients with missing data excluded from analysis. Data for 90% of patients. Similar 
proportions missing from different groups, but no reasons stated
Free of selective reporting Low risk
Support for judgement All outcomes listed in methodology accounted for
Free of other bias? Unclear risk
Support for judgement Some patients may have had previous SIT (but no SIT in previous 3 years)
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Ventura 2009158
Note: this study has as treatment arms SLIT, SCIT and placebo; there is no direct comparison between SLIT 
and SCIT.
Study design DBPC RCT
Population symptoms Allergic rhinoconjunctivitis
Treatment naive Unclear (not in treatment at time of study)
n, age n = 20 adults (18–55 years); active n = 10, placebo n = 10
Intervention details Allergen: cypress
300 IR/ml J. ashei extract as glycerol saline solution (StaloralR). Daily allergen dose of 
228 µg/ml
30-day induction, 11 months’ maintenance; drops self-administered three times per week
Outcomes SSs
Risk of bias
Adequate sequence 
generation
Low risk
Support for judgement Computer-generated code
Allocation concealment Unclear risk
Support for judgement No details
Blinding of participants/
personnel
Low risk
Support for judgement The placebo had the same appearance and taste as SLIT
Incomplete outcome data Low risk
Support for judgement Data for all 20 patients reported
Free of selective reporting Low risk
Support for judgement All outcomes listed in methodology accounted for in results
Free of other bias? Unclear risk
Support for judgement SIT history of patients not reported
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Voltolini 2010197
Study design DBPC RCT
Population symptoms Moderate/severe persistent rhinitis and slight intermittent to moderate asthma
Treatment naive No details
n, age n = 24 adults (mean ages 44 and 40 years in active and placebo groups, respectively); active 
n = 14, placebo n = 10
Intervention details Allergen: birch
Allergen extract of birch at 10 IR/ml and 300 IR/ml (Stallergènes)
Build-up from 10 index of reactivity (IR) over 11 days to maintenance dose of 300 IR then 
daily for 4 months, repeated over two consecutive years
Outcomes SSs, MSs, asthma days/severity, AEs
Risk of bias
Adequate sequence 
generation
Low risk
Support for judgement Computer-generated randomisation list
Allocation concealment Unclear risk
Support for judgement No details
Blinding of participants/
personnel
Low risk
Support for judgement ‘Placebo vials matched the active treatment in colour and flavour’
Incomplete outcome data Low risk
Support for judgement Analysis of completers only, but only one patient lost to follow-up in each group (reason 
not stated)
Free of selective reporting High risk
Support for judgement MSs measured but not reported. Treatment over two seasons but data reported after 1 year 
only. SSs recorded for three symptoms but reported for two only
Free of other bias? Unclear risk
Support for judgement SIT history of patients not reported
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Subcutaneous immunotherapy compared with sublingual 
immunotherapy
Khinchi 2004210
Study design DBPC RCT
Population symptoms Rhinoconjunctivitis uncontrolled by conventional pharmacotherapy
Treatment naive No SIT within last 5 years
n, age 71 adults (20–58 years); 23 SLIT, 24 SCIT and 15 placebo
Intervention details Allergen: birch
Birch pollen extract standardised in terms of major allergen Bet v 1 administered as glycerine-
saline solution (SLIT, Staloral®) or adsorbed on calcium phosphate (SCIT, Phostal®)
SLIT: 30-day induction phase, maintenance phase 21–23 months. Drops every other day held 
under tongue for 2 minutes. Dose between 0.0164 and 49.2 µg
SCIT: 12-week induction phase (weekly injections) with 0.0164 µg, monthly maintenance 
phase 3.28 µg
Outcomes SSs, MSs, QoL, AEs
Risk of bias
Adequate sequence 
generation
Low risk
Support for judgement Allocation by minimisation
Allocation concealment Unclear risk
Support for judgement No details
Blinding of participants/
personnel
Low risk
Support for judgement ‘All study personnel and participants were blinded to treatment assignment for the 2-year 
duration of treatment in the study.’ Placebo preparations included caramelised sugar for SLIT 
to ensure identical visual appearance and histamine dihydrochloride for injections to ensure 
induction of local reactions for SCIT
Incomplete outcome data Unclear risk
Support for judgement Similar numbers of withdrawals in the three groups. Only patients completing first treatment 
season included in statistical calculations. Results not reported in a way that is consistent 
with most other studies
Free of selective reporting Unclear risk
Support for judgement All outcomes listed in methodology accounted for in results. Second season is not included 
in the evaluation of efficacy (owing to low pollen counts)
Free of other bias? Unclear risk
Support for judgement No SIT in previous 5 years but previous treatment history unknown
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Appendix 7 Results of subgroup analyses
Subcutaneous immunotherapy
Comparison 1 Subcutaneous immunotherapy compared with placebo, all studies
Outcome or 
subgroup 
No. of 
studies
No. of 
participants Statistical method Effect size
1 SSs 17 1184 SMD (IV, random, 
95% CI)
–0.65 (–0.85 to –0.45)
2 MSs 16 1103 –0.55 (–0.75 to –0.34)
3 SMSs 8 617 –0.48 (–0.67 to –0.29)
IV, inverse variance.
Comparison 2 Subcutaneous immunotherapy compared with placebo, adults
Outcome or 
subgroup 
No. of 
studies
No. of 
participants Statistical method Effect size
1 SSs 16 1140 SMD (IV, random, 
95% CI)
–0.68 (–0.89 to –0.47)
2 MSs 15 1059 –0.53 (–0.75 to –0.32)
IV, inverse variance.
Comparison 3 Subcutaneous immunotherapy compared with placebo, < 6 months
Outcome or 
subgroup 
No. of 
studies
No. of 
participants Statistical method Effect size
1 SSs 5 274 SMD (IV, random, 
95% CI)
–1.29 (–2.10 to –0.49)
2 MSs 2 143 –0.34 (–0.68 to –0.01)
3 SMSs 3 221 –0.47 (–0.91 to –0.02)
IV, inverse variance.
Comparison 4 Subcutaneous immunotherapy compared with placebo, 6–12 months
Outcome or 
subgroup 
No. of 
studies
No. of 
participants Statistical method Effect size
1 SSs 2 309 SMD (IV, random, 
95% CI)
–0.54 (–0.78 to –0.29)
2 MSs 3 332 –0.46 (–0.69 to –0.23)
IV, inverse variance.
NIHR Journals Library www.journalslibrary.nihr.ac.uk
AppENDIx 7
230
Comparison 5 Subcutaneous immunotherapy compared with placebo, > 12 months
Outcome or 
subgroup 
No. of 
studies
No. of 
participants Statistical method Effect size
1 SSs 8 442 SMD (IV, random, 
95% CI)
–0.51 (–0.70 to –0.32)
2 MSs 9 469 –0.67 (–1.06 to –0.29)
3 SMSs 3 253 –0.51 (–0.76 to –0.25)
IV, inverse variance.
Comparison 6 Subcutaneous immunotherapy compared with placebo, 
major allergen content < 5 µg
Outcome or 
subgroup 
No. of 
studies
No. of 
participants Statistical method Effect size
1 SSs 3 228 SMD (IV, random, 
95% CI)
–0.43 (–0.69 to –0.16)
2 MSs 2 147 –0.31 (–0.63 to 0.02)
3 SMSs 3 228 –0.39 (–0.70 to –0.07)
IV, inverse variance.
Comparison 7 Subcutaneous immunotherapy compared with placebo, 
major allergen content 5–20 µg
Outcome or 
subgroup 
No. of 
studies
No. of 
participants Statistical method Effect size
1 SSs 5 231 SMD (IV, random, 
95% CI)
–0.54 (–0.80 to –0.27)
2 MSs 6 254 –0.45 (–0.70 to –0.20)
IV, inverse variance.
Comparison 8 Subcutaneous immunotherapy compared with placebo, > 20 µg
Outcome or 
subgroup 
No. of 
studies
No. of 
participants Statistical method Effect size
1 SSs 3 341 SMD (IV, random, 
95% CI)
–1.06 (–2.08 to –0.05)
2 MSs 2 305 –0.55 (–0.96 to –0.13)
IV, inverse variance.
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Comparison 9 Subcutaneous immunotherapy compared with placebo, grass pollen
Outcome or 
subgroup 
No. of 
studies
No. of 
participants Statistical method Effect size
1 SSs 9 552 SMD (IV, random, 
95% CI)
–0.64 (–0.91 to –0.37)
2 MSs 8 483 –0.77 (–1.22 to –0.33)
3 SMSs 5 435 –0.43 (–0.62 to –0.24)
IV, inverse variance.
Comparison 10 Subcutaneous immunotherapy compared with placebo, Parietaria
Outcome or 
subgroup 
No. of 
studies
No. of 
participants Statistical method Effect size
1 SSs 3 353 SMD (IV, random, 
95% CI)
–1.15 (–2.09 to –0.21)
2 MSs 2 318 –0.43 (–0.67 to –0.20)
3 SMSs 2 77 –0.96 (–1.44 to –0.49)
IV, inverse variance.
Comparison 11 Subcutaneous immunotherapy compared with placebo, tree
Outcome or 
subgroup 
No. of 
studies
No. of 
participants Statistical method Effect size
1 SSs 4 235 SMD (IV, random, 
95% CI)
–0.46 (–0.72 to –0.20)
2 MSs 4 235 –0.34 (–0.60 to –0.09)
IV, inverse variance.
Comparison 12 Subcutaneous immunotherapy compared with placebo, QoL
Outcome or 
subgroup 
No. of 
studies
No. of 
participants Statistical method Effect size
All studies 8 955 SMD (IV, random, 
95% CI)
–0.53 (–0.66 to –0.39)
Duration > 12 months 6 662 –0.47 (–0.63 to –0.31)
MAC 5–20 µg 3 381 –0.52 (–0.74 to –0.31)
MAC > 20 µg 3 379 –0.65 (–0.87 to –0.43)
Grass pollen 4 561 –0.44 (–0.61 to –0.26)
Parietaria pollen 2 316 –0.63 (–0.87 to –0.39)
RQLQ 8 955 MD (IV, random, 95% CI) –0.74 (–0.92 to –0.56)
IV, inverse variance.
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Sublingual immunotherapy
Comparison 13 Sublingual immunotherapy compared with placebo, all studies
Outcome or 
subgroup 
No. of 
studies
No. of 
participants Statistical method Effect size
1 SSs 42 4819 SMD (IV, random, 
95% CI)
–0.33 (–0.42 to –0.25)
2 MSs 35 3779 –0.27 (–0.37 to –0.17)
3 SMSs 6 1394 –0.40 (–0.55 to –0.25)
IV, inverse variance.
Comparison 14 Sublingual immunotherapy compared with placebo, adults
Outcome or 
subgroup 
No. of 
studies
No. of 
participants Statistical method Effect size
1 SSs 33 3476 SMD (IV, random, 
95% CI)
–0.38 (–0.49 to –0.27)
2 MSs 27 2604 –0.35 (–0.47 to –0.23)
3 SMSs 5 1087 –0.44 (–0.62 to –0.27)
IV, inverse variance.
Comparison 15 Sublingual immunotherapy compared with placebo, children
Outcome or 
subgroup 
No. of 
studies
No. of 
participants Statistical method Effect size
1 SSs 9 1343 SMD (IV, random, 
95% CI)
–0.24 (–0.35 to –0.13)
2 MSs 8 1175 –0.08 (–0.25 to 0.08)
IV, inverse variance.
Comparison 16 Sublingual immunotherapy compared with placebo, < 6 months
Outcome or 
subgroup 
No. of 
studies
No. of 
participants Statistical method Effect size
1 SSs 15 1882 SMD (IV, random, 
95% CI)
–0.34 (–0.47 to –0.20)
2 MSs 14 1517 –0.33 (–0.47 to –0.19)
3 SMSs 2 376 –0.31 (–0.51 to –0.11)
IV, inverse variance.
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Comparison 17 Sublingual immunotherapy compared with placebo, 6–12 months
Outcome or subgroup 
No. of 
studies
No. of 
participants Statistical method Effect size
1 SSs 15 1539 SMD (IV, random, 
95% CI)
–0.31 (–0.47 to –0.16)
2 MSs 13 1223 –0.31 (–0.53 to –0.08)
3 SMSs 2 417 –0.66 (–1.63 to 0.30)
IV, inverse variance.
Comparison 18 Sublingual immunotherapy compared with placebo, > 12 months
Outcome or subgroup 
No. of 
studies
No. of 
participants Statistical method Effect size
1 SSs 12 1398 SMD (IV, random, 
95% CI)
–0.35 (–0.52 to –0.18)
2 MSs 8 1039 –0.16 (–0.31 to –0.01)
3 SMSs 2 601 –0.48 (–0.64 to –0.31)
IV, inverse variance.
Comparison 19 Sublingual immunotherapy compared with placebo, major 
allergen content < 5 µg
Outcome or 
subgroup 
No. of 
studies
No. of 
participants Statistical method Effect size
1 SSs 6 229 SMD (IV, random, 
95% CI)
–0.53 (–1.03 to –0.03)
2 MSs 5 194 –0.63 (–1.08 to –0.18)
IV, inverse variance.
Comparison 20 Sublingual immunotherapy compared with placebo, major 
allergen content 5–20 µg
Outcome or 
subgroup 
No. of 
studies
No. of 
participants Statistical method Effect size
1 SSs 13 2287 SMD (IV, random, 
95% CI)
–0.29 (–0.37 to –0.20)
2 MSs 12 2285 –0.18 (–0.30 to –0.05)
3 SMSs 3 985 –0.32 (–0.45 to –0.19)
IV, inverse variance.
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Comparison 21 Sublingual immunotherapy compared with placebo, major 
allergen content > 20 µg
Outcome or 
subgroup 
No. of 
studies
No. of 
participants Statistical method Effect size
1 SSs 12 1088 SMD (IV, random, 
95% CI)
–0.33 (–0.48 to –0.18)
2 MSs 10 708 –0.26 (–0.47 to –0.06)
IV, inverse variance.
Comparison 22 Sublingual immunotherapy compared with placebo, grass pollen
Outcome or 
subgroup 
No. of 
studies
No. of 
participants Statistical method Effect size
1 SSs 26 4045 SMD (IV, random, 
95% CI)
–0.31 (–0.39 to –0.22)
2 MSs 19 3005 –0.20 (–0.31 to –0.08)
3 SMSs 4 1299 –0.36 (–0.48 to –0.24)
IV, inverse variance.
Comparison 23 Sublingual immunotherapy compared with placebo, ragweed
Outcome or 
subgroup 
No. of 
studies
No. of 
participants Statistical method Effect size
1 SSs 3 244 SMD (IV, random, 
95% CI)
–0.44 (–0.48 to –0.18)
2 MSs 3 244 –0.34 (–0.60 to –0.09)
IV, inverse variance.
Comparison 24 Sublingual immunotherapy compared with placebo, Parietaria
Outcome or 
subgroup 
No. of 
studies
No. of 
participants Statistical method Effect size
1 SSs 4 124 SMD (IV, random, 
95% CI)
–0.27 (–0.62 to 0.09)
2 MSs 4 124 –0.49 (–0.85 to –0.13)
IV, inverse variance.
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Comparison 25 Sublingual immunotherapy compared with placebo, tree
Outcome or 
subgroup 
No. of 
studies
No. of 
participants Statistical method Effect size
1 SSs 9 380 SMD (IV, random, 
95% CI)
–0.42 (–0.77 to –0.06)
2 MSs 9 380 –0.38 (–0.62 to –0.13)
IV, inverse variance.
Comparison 26 Sublingual immunotherapy compared with placebo, QoL
Outcome or 
subgroup 
No. of 
studies
No. of 
participants Statistical method Effect size
1 All studies 7 1878 SMD (IV, random, 
95% CI)
–0.37 (–0.52 to –0.22)
2 Adults 6 1658 –0.39 (–0.56 to –0.21)
3 < 6 months 4 908 –0.45 (–0.74 to –0.17)
4 > 12 months 2 601 –0.37 (–0.54 to –0.21)
5 MAC 5–20 µg 2 507 –0.32 (–0.49 to –0.14)
6 MAC > 20 µg 2 323 –0.70 (–0.93 to –0.48)
7 RQLQ 4 924 MD (IV, random, 95% CI) –0.34 (–0.49 to –0.18)
IV, inverse variance.
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Bousquet 1990170
Brewczynski 1999171
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Drachenberg 200191
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Ortolani 1984174
Ortolani 1994167
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Walker 2001173
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Total (95% CI)
Heterogeneity: τ2 = 0.09; χ2 = 36.19, df = 15 (p = 0.002); I2 = 59%
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3.3
166.5
0.75
0.44
3.31
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2.01
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0
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82.24
10.43
1
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114.93
0.44
0.32
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0.57
0.12
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64.38
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14
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74
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8
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19
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2.66
135.39
0.41
0.54
2.93
3.44
1.63
0.98
7.1
856
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5.1%
5.1%
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9.6%
9.0%
5.8%
10.5%
6.9%
1.5%
3.8%
7.5%
5.4%
4.9%
8.0%
100.0%
-4 -2 0 2 4
Study or subgroup
Test for overall effect: z = 6.32 (p < 0.00001)
Mean SD Total Mean SD Total Weight IV, random, 95% CI
SCIT Placebo Standard mean difference Standard mean difference
IV, random, 95% CI
Favours SCIT Favours placebo
-0.27 (-0.65 to 0.12)
-0.88 (-1.60 to -0.16)
-1.34 (-2.05 to -0.63)
-0.98 (-1.97 to 0.02)
-0.67 (-1.44 to 0.09)
-0.41 (-0.73 to -0.09)
-0.46 (-0.83 to -0.10)
-0.81 (-1.44 to -0.17)
-0.49 (-0.75 to -0.24)
-0.55 (-1.08 to -0.02)
-3.06 (-4.69 to -1.43)
-2.40 (-3.29 to -1.51)
-0.48 (-0.96 to -0.00)
-0.46 (-1.13 to 0.22)
-0.50 (-1.24 to 0.23)
-0.45 (-0.89 to -0.01)
-0.68 (-0.89 to -0.47)
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Heterogeneity: τ2 = 0.09; χ2 = 33.54, df = 14 (p = 0.002); I2 = 58%
9.03
9.9
38.6
17.2
3.98
68.58
6
0.54
0.35
2.93
2.73
0.7
0
2146
-1308
16.03
7
37.6
10.4
4.15
96.15
6.07
0.71
0.47
2.95
4.48
1.4
4.6
2513
983
49
17
20
10
14
77
18
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29
11
33
19
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13.63
14.5
66.4
36.8
5.23
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48.66
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4.29
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2.2
1.9
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19.67
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51.7
35.46
4.41
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17.95
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1.73
3.53
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3.1
4.8
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1899
56
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8
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9.3%
5.7%
6.0%
3.6%
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11.2%
7.5%
4.4%
8.1%
5.3%
4.9%
100.0%
-4 -2 0 2 4
Study or subgroup
Test for overall effect: z = 4.82 (p < 0.00001)
Mean SD Total Mean SD Total Weight IV, random, 95% CI
SCIT Placebo Standard mean difference Standard mean difference
IV, random, 95% CI
Favours SCIT Favours placebo
-0.25 (-0.64 to 0.13)
-0.58 (-1.26 to 0.11)
-0.61 (-1.26 to 0.05)
-0.76 (-1.73 to 0.22)
-0.28 (-1.03 to 0.46)
-0.29 (-0.61 to 0.03)
-3.56 (-4.82 to -2.29)
-0.23 (-0.59 to 0.13)
-0.45 (-1.06 to 0.16)
-0.43 (-0.69 to -0.18)
-0.22 (-0.74 to 0.30)
-0.59 (-1.43 to 0.25)
-0.40 (-0.88 to 0.08)
-1.17 (-1.89 to -0.44)
-0.94 (-1.71 to -0.16)
-0.53 (-0.75 to -0.32)
FIGURE 31 Subcutaneous immunotherapy vs placebo, adults, SSs.
FIGURE 32 Subcutaneous immunotherapy vs placebo, adults, MSs.
Subcutaneous immunotherapy
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Study or subgroup Mean SD Total Mean SD Total Weight IV, random, 95% CI
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FIGURE 33 Subcutaneous immunotherapy vs placebo, < 6 months, SSs.
FIGURE 34 Subcutaneous immunotherapy vs placebo, < 6 months, MSs.
FIGURE 35 Subcutaneous immunotherapy vs placebo, < 6 months, SMSs.
FIGURE 36 Subcutaneous immunotherapy vs placebo, 6–12 months, SSs.
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3.3
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0
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32.6
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2632
10
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227
122.4
5.06
218
0.8
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12.9%
10.1%
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-0.98 (-1.97 to 0.02)
-0.67 (-1.44 to 0.09)
-0.41 (-0.73 to -0.09)
-0.81 (-1.44 to -0.17)
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-0.29 (-0.88 to 0.31)
-0.48 (-0.96 to -0.00)
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-0.51 (-0.70 to -0.32)
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Heterogeneity: τ2 = 0.23; χ2 = 28.04, df = 8 (p = 0.0005); I2 = 71%
Test for overall effect: z = 3.43 (p = 0.0006)
17.2
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68.58
6
0.35
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2.3
0
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100.0%
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Study or subgroup Mean SD Total Mean SD Total Weight IV, random, 95% CI
SCIT Placebo Standard mean difference Standard mean difference
IV, random, 95% CI
Favours SCIT Favours placebo
-0.76 (-1.73 to 0.22)
-0.28 (-1.03 to 0.46)
-0.29 (-0.61 to 0.03)
-3.56 (-4.82 to -2.29)
-0.45 (-1.06 to 0.16)
-0.22 (-0.74 to 0.30)
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-0.40 (-0.88 to 0.08)
FIGURE 37 Subcutaneous immunotherapy vs placebo, 6–12 months, MSs.
FIGURE 38 Subcutaneous immunotherapy vs placebo, > 12 months, SSs.
FIGURE 39 Subcutaneous immunotherapy vs placebo, > 12 months, MSs.
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20.7%
36.2%
100.0%
-4 -2 0 2 4
Favours SCIT Favours placebo
Study or subgroup Mean SD Total Mean SD Total Weight IV, random, 95% CI
SCIT Placebo Standard mean difference Standard mean difference
IV, random, 95% CI
-0.21 (-0.60 to 0.17)
-0.84 (-1.47 to -0.21)
-0.33 (-0.77 to 0.10)
-0.39 (-0.70 to -0.07)
FIGURE 40 Subcutaneous immunotherapy vs placebo, > 12 months, SMSs.
FIGURE 41 Subcutaneous immunotherapy vs placebo, < 5 µg, SSs.
FIGURE 42 Subcutaneous immunotherapy vs placebo, < 5 µg, MS.
FIGURE 43 Subcutaneous immunotherapy vs placebo, < 5 µg, SMSs.
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Bodtger 2002169
Charpin 2007142
Jutel 2005166
Kuna 2011152
Pauli 2008154
Total (95% CI)
Heterogeneity: τ2 = 0.00; χ2 = 1.71, df = 4 (p = 0.79); I2 = 0%
Test for overall effect: z = 4.00 (p < 0.0001)
2.2
3.3
3.93
85
0
1
2.42
3.28
140
6.8
16
14
29
25
33
117
3.3
5.06
5.82
140
3.41
1.4
2.66
3.44
240
7.1
17
14
28
19
36
114
13.5%
11.9%
24.8%
19.4%
30.3%
100.0%
-4 -2 0 2 4
Favours SCIT Favours placebo
Study or subgroup Mean SD Total Mean SD Total Weight IV, random, 95% CI
SCIT Placebo Standard mean difference Standard mean difference
IV, random, 95% CI
-0.88 (-1.60 to -0.16)
-0.67 (-1.44 to 0.09)
-0.55 (-1.08 to -0.02)
-0.29 (-0.88 to 0.31)
-0.48 (-0.96 to -0.00)
-0.54 (-0.80 to -0.27)
Bodtger 2002169
Charpin 2007142
Jutel 2005166
Kuna 2011152
Mirone 2004176
Pauli 2008154
Total (95% C I)
Heterogeneity: τ2 = 0.00; χ2 = 2.49, df = 5 (p = 0.78); I2 = 0%
Test for overall effect: z = 3.54 (p = 0.0004)
9.9
3.98
2.73
2.3
0.7
0
7
4.15
4.48
5
1.4
4.6
17
14
29
25
11
33
129
14.5
5.23
3.78
21.4
2.2
1.9
8.5
4.41
4.92
35
3.1
4.8
17
14
28
19
12
36
126
13.2%
11.3%
23.0%
16.2%
8.9%
27.4%
100.0%
-4 -2 0 2 4
Favours SCIT Favours placebo
Study or subgroup Mean SD Total Mean SD Total Weight IV, random, 95% CI
SCIT Placebo Standard mean difference Standard mean difference
IV, random, 95% CI
-0.58 (-1.26 to 0.11)
-0.28 (-1.03 to 0.46)
-0.22 (-0.74 to 0.30)
-0.81 (-1.43 to -0.19)
-0.59 (-1.43 to 0.25)
-0.40 (-0.88 to 0.08)
-0.45 (-0.70 to -0.20)
Frew 2006161
Ortolani 1994167
Walker 2001173
Total (95% CI)
Heterogeneity: τ2 = 0.69; χ2 = 16.37, df = 2 (p = 0.0003); I2 = 88%
Test for overall effect: z = 2.06 (p = 0.04)
3.31
0.61
-1212
2.42
0.12
2632
187
18
17
222
4.59
2.3
-115
2.93
0.98
1159
89
17
13
119
37.9%
29.9%
32.3%
100.0%
-4 -2 0 2 4
Favours SCIT Favours placebo
Study or subgroup Mean SD Total Mean SD Total Weight IV, random, 95% CI
SCIT Placebo Standard mean difference Standard mean difference
IV, random, 95% CI
-0.49 (-0.75 to -0.24)
-2.40 (-3.29 to -1.51)
-0.50 (-1.24 to 0.23)
-1.06 (-2.08 to -0.05)
FIGURE 44 Subcutaneous immunotherapy vs placebo, 5–20 µg, SSs.
FIGURE 45 Subcutaneous immunotherapy vs placebo, 5–20 µg, MSs.
FIGURE 46 Subcutaneous immunotherapy vs placebo, > 20 µg, SSs.
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Frew 2006161
Walker 2001173
Total (95% CI)
Heterogeneity: τ2 = 0.04; χ2 = 1.47, df = 1 (p = 0.23); I2 = 32%
Test for overall effect: z = 2.58 (p = 0.010)
2.93
-1308
2.95
983
187
16
203
4.29
101
3.53
1899
89
13
102
77.4%
22.6%
100.0%
-4 -2 0 2 4
Favours SCIT Favours placebo
Study or subgroup Mean SD Total Mean SD Total Weight IV, random, 95% CI
SCIT Placebo Standard mean difference Standard mean difference
IV, random, 95% CI
-0.43 (-0.69 to -0.18)
-0.94 (-1.71 to -0.16)
-0.55 (-0.96 to -0.13)
Bousquet 1990170
Brewczynski 1999171
Corrigan 2005164
Drachenberg 200191
Jutel 2005166
Ortolani 1984174
Varney 1991172
Walker 2001173
Zenner 1997168
Total (95% CI)
63.6
59.5
166.5
0.75
3.93
2.01
1531
-1212
82.24
32.5
32.6
114.93
0.44
3.28
0.57
1875
2632
64.38
20
10
77
74
29
8
19
17
41
295
108.6
122.4
218
0.95
5.82
5.86
2230
-115
115.98
33.2
85.13
135.39
0.41
3.44
1.63
856
1159
83.67
18
8
77
50
28
7
16
13
40
257
9.2%
5.7%
18.7%
17.4%
12.8%
2.5%
9.8%
8.8%
15.1%
100.0%
Study or subgroup Mean SD Total Mean SD Total Weight IV, random, 95% CI
SCIT Placebo Standard mean difference Standard mean difference
IV, random, 95% CI
Heterogeneity: τ2 = 0.07; χ2 = 15.84, df = 8 (p = 0.04); I 2 = 49%
Test for overall effect: z = 4.64 (p < 0.00001)
-4 -2 0 2 4
Favours SCIT Favours placebo
-1.34 (-2.05 to -0.63)
-0.98 (-1.97 to 0.02)
-0.41 (-0.73 to -0.09)
-0.46 (-0.83 to -0.10)
-0.55 (-1.08 to -0.02)
-3.06 (-4.69 to -1.43)
-0.46 (-1.13 to 0.22)
-0.50 (-1.24 to 0.23)
-0.45 (-0.89 to -0.01)
-0.64 (-0.91 to -0.37)
Bousquet 1990170
Brewczynski 1999171
Corrigan 2005164
Dolz 1996175
Drachenberg 200191
Jutel 2005166
Varney 1991172
Walker 2001173
Total (95% CI)
Heterogeneity: τ2 = 0.29; χ2 = 32.04, df = 7 (p < 0.0001); I2 = 78%
Test for overall effect: z = 3.41 (p = 0.0006)
38.6
17.2
68.58
6
0.54
2.73
2146
-1308
37.6
10.4
96.15
6.07
0.71
4.48
2513
983
20
10
77
18
74
29
19
16
263
66.4
36.8
101.21
48.66
0.71
3.78
14,491
101
51.7
35.46
126.01
17.95
0.77
4.92
15,066
1899
18
8
77
10
50
28
16
13
220
12.9%
9.6%
16.3%
7.3%
15.9%
14.3%
12.1%
11.5%
100.0%
-4 -2 0 2 4
Favours SCIT Favours placebo
Study or subgroup Mean SD Total Mean SD Total Weight IV, random, 95% CI
SCIT Placebo Standard mean difference Standard mean difference
IV, random, 95% CI
-0.61 (-1.26 to 0.05)
-0.76 (-1.73 to 0.22)
-0.29 (-0.61 to 0.03)
-3.56 (-4.82 to -2.29)
-0.23 (-0.59 to 0.13)
-0.22 (-0.74 to 0.30)
-1.17 (-1.89 to -0.44)
-0.94 (-1.71 to -0.16)
-0.77 (-1.22 to -0.33)
FIGURE 47 Subcutaneous immunotherapy vs placebo, > 20 µg, MSs.
FIGURE 48 Subcutaneous immunotherapy vs placebo, grass pollen, SSs.
FIGURE 49 Subcutaneous immunotherapy vs placebo, grass pollen, MSs.
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Corrigan 2005164
Drachenberg 200191
Jutel 2005166
Pastorello 1992177
Zenner 1997168
Total (95% CI)
Heterogeneity: τ2 = 0.00; χ2 = 2.68, df = 4 (p = 0.61); I2 = 0%
Test for overall effect: z = 4.42 (p < 0.00001)
235.08
0.65
6.66
1.7
153.8
172.02
0.48
6.02
0.57
63.47
77
74
29
10
41
231
319.21
0.83
9.59
3.15
174.45
201.67
0.47
7.23
1.54
58.95
77
50
28
9
40
204
35.9%
28.0%
13.3%
3.7%
19.1%
100.0%
-4 -2 0 2 4
Favours SCIT Favours placebo
Study or subgroup Mean SD Total Mean SD Total Weight IV, random, 95% CI
SCIT Placebo Standard mean difference Standard mean difference
IV, random, 95% CI
-0.45 (-0.77 to -0.13)
-0.38 (-0.74 to -0.01)
-0.44 (-0.96 to 0.09)
-1.22 (-2.22 to -0.22)
-0.33 (-0.77 to 0.10)
-0.43 (-0.62 to -0.24)
Ferrer 2005165
Frew 2006161
Ortolani 1994167
Total (95% CI)
Heterogeneity: τ2 = 0.59; χ2 = 16.49, df = 2 (p = 0.0003); I2 = 88%
Test for overall effect: z = 2.39 (p = 0.02)
0.44
3.31
0.61
0.32
2.42
0.12
22
187
18
227
0.8
4.59
2.3
0.54
2.93
0.98
20
89
17
126
33.2%
37.9%
28.9%
100.0%
-4 -2 0 2 4
Favours SCIT Favours placebo
Study or subgroup Mean SD Total Mean SD Total Weight IV, random, 95% CI
SCIT Placebo Standard mean difference Standard mean difference
IV, random, 95% CI
-0.81 (-1.44 to -0.17)
-0.49 (-0.75 to -0.24)
-2.40 (-3.29 to -1.51)
-1.15 (-2.09 to -0.21)
Ferrer 2005165
Frew 2006161
Total (95% CI)
Heterogeneity: τ2 = 0.00; χ2 = 0.00, df = 1 (p = 0.95); I2 = 0%
Test for overall effect: z = 3.61 (p = 0.0003)
0.35
2.93
0.47
2.95
22
187
209
0.92
4.29
1.73
3.53
20
89
109
14.7%
85.3%
100.0%
-4 -2 0 2 4
Favours SCIT Favours placebo
Study or subgroup Mean SD Total Mean SD Total Weight IV, random, 95% CI
SCIT Placebo Standard mean difference Standard mean difference
IV, random, 95% CI
-0.45 (-1.06 to 0.16)
-0.43 (-0.69 to -0.18)
-0.43 (-0.67 to -0.20)
Ferrer 2005165
Ortolani 1994167
Total (95% CI)
Heterogeneity: τ2 = 0.00; χ2 = 0.33, df = 1 (p = 0.56); I2 = 0%
Test for overall effect: z = 3.97 (p < 0.0001)
0.62
12.88
0.37
3.61
22
18
40
1.27
17.81
1.03
4.91
20
17
37
56.3%
43.7%
100.0%
-4 -2 0 2 4
Favours SCIT Favours placebo
Study or subgroup Mean SD Total Mean SD Total Weight IV, random, 95% CI
SCIT Placebo Standard mean difference Standard mean difference
IV, random, 95% CI
-0.84 (-1.47 to -0.21)
-1.12 (-1.84 to -0.40)
-0.96 (-1.44 to -0.49)
FIGURE 50 Subcutaneous immunotherapy vs placebo, grass pollen, SMSs.
FIGURE 51 Subcutaneous immunotherapy vs placebo, Parietaria, SSs.
FIGURE 52 Subcutaneous immunotherapy vs placebo, Parietaria, MSs.
FIGURE 53 Subcutaneous immunotherapy vs placebo, Parietaria, SMSs.
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Balda 1998163
Bodtger 2002169
Charpin 2007142
Pauli 2008154
Total (95% CI)
Heterogeneity: τ2 = 0.00; χ2 = 2.56, df = 3 (p = 0.47); I2 = 0%
Test for overall effect: z = 3.45 (p = 0.0006)
6.56
2.2
3.3
0
10.43
1
2.42
6.8
49
16
14
33
112
9.07
3.3
5.06
3.41
8.19
1.4
2.66
7.1
56
17
14
36
123
45.8%
13.1%
11.6%
29.5%
100.0%
-4 -2 0 2 4
Favours SCIT Favours placebo
Study or subgroup Mean SD Total Mean SD Total Weight IV, random, 95% CI
SCIT Placebo Standard mean difference Standard mean difference
IV, random, 95% CI
-0.27 (-0.65 to 0.12)
-0.88 (-1.60 to -0.16)
-0.67 (-1.44 to 0.09)
-0.48 (-0.96 to -0.00)
-0.46 (-0.72 to -0.20)
Balda 1998163
Bodtger 2002169
Charpin 2007142
Pauli 2008154
Total (95% CI)
Heterogeneity: τ2 = 0.00; χ2 = 0.73, df = 3 (p = 0.87); I2 = 0%
Test for overall effect: z =  2.62 (p =  0.009)
9.03
9.9
3.98
0
16.03
7
4.15
4.6
49
17
14
33
113
13.63
14.5
5.23
1.9
19.67
8.5
4.41
4.8
56
17
14
36
123
44.8%
14.0%
12.0%
29.2%
100.0%
-4 -2 0 2 4
Favours SCIT Favours placebo
Study or subgroup Mean SD Total Mean SD Total Weight IV, random, 95% CI
SCIT Placebo Standard mean difference Standard mean difference
IV, random, 95% CI
-0.25 (-0.64 to 0.13)
-0.58 (-1.26 to 0.11)
-0.28 (-1.03 to 0.46)
-0.40 (-0.88 to 0.08)
-0.34 (-0.60 to -0.09)
Colas 2006143
Corrigan 2005164
Ferrer 2005165
Jutel 2005166
Powell 2007156
Walker 2001173
Total (95% CI)
Heterogeneity: τ2 = 0.00; χ2 = 3.06, df = 5 (p = 0.69); I2 = 0%
Test for overall effect: z = 5.81 (p < 0.00001)
1.9
1.63
1.39
1.43
1.4
1.6
1
1.09
1.03
1.31
2
1.2
41
77
21
29
203
22
393
2.7
1.95
2.06
2.27
2.3
2.4
1.1
1.27
1.18
1.51
1.6
1.5
19
77
20
28
103
22
269
8.1%
25.3%
6.5%
9.0%
44.2%
7.0%
100.0%
-0.77 (-1.33 to -0.20)
-0.27 (-0.59 to 0.05)
-0.59 (-1.22 to 0.03)
-0.59 (-1.12 to -0.06)
-0.48 (-0.72 to -0.24)
-0.58 (-1.18 to 0.03)
-0.47 (-0.63 to -0.31)
-4 -2 0 2 4
Favours SCIT Favours placebo
Study or subgroup Mean SD Total Mean SD Total Weight IV, random, 95% CI
SCIT Placebo Standard mean difference Standard mean difference
IV, random, 95% CI
FIGURE 54 Subcutaneous immunotherapy vs placebo, tree pollen, SSs.
FIGURE 55 Subcutaneous immunotherapy vs placebo, tree pollen, MSs.
FIGURE 56 Subcutaneous immunotherapy vs placebo, QoL, > 12 months.
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Colas 2006143
Frew 2006161
Walker 2001173
Total (95% CI)
Heterogeneity: τ2 = 0.00; χ2 = 0.22, df = 2 (p = 0.89); I2 = 0%
Test for overall effect: z = 5.84 (p < 0.00001)
1.9
1.4
1.6
1
1.42
1.2
41
183
22
246
2.7
2.29
2.4
1.1
1.34
1.5
19
92
22
133
15.0%
72.1%
12.9%
100.0%
-4 -2 0 2 4
Favours SCIT Favours placebo
Study or subgroup Mean SD Total Mean SD Total Weight IV, random, 95% CI
SCIT Placebo Standard mean difference Standard mean difference
IV, random, 95% CI
-0.77 (-1.33 to -0.20)
-0.64 (-0.89 to -0.38)
-0.58 (-1.18 to 0.03)
-0.65 (-0.87 to -0.43)
Corrigan 2005164
Jutel 2005166
Powell 2007156
Walker 2001173
Total (95% CI)
Heterogeneity: τ2 = 0.00; χ2 = 1.71, df = 3 (p = 0.64); I2 = 0%
Test for overall effect: z = 4.95 (p < 0.00001)
1.63
1.43
1.4
1.6
1.09
1.31
2
1.2
77
29
203
22
331
1.95
2.27
2.3
2.4
1.27
1.51
1.6
1.5
77
28
103
22
230
29.6%
10.6%
51.7%
8.2%
100.0%
-4 -2 0 2 4
Favours SCIT Favours placebo
Study or subgroup Mean SD Total Mean SD Total Weight IV, random, 95% CI
SCIT Placebo Standard mean difference Standard mean difference
IV, random, 95% CI
-0.27 (-0.59 to 0.05)
-0.59 (-1.12 to -0.06)
-0.48 (-0.72 to -0.24)
-0.58 (-1.18 to 0.03)
-0.44 (-0.61 to -0.26)
Ferrer 2005165
Frew 2006161
Total (95% CI)
Heterogeneity: τ2 = 0.00; χ2 = 0.02, df = 1 (p = 0.90); I2 = 0%
Test for overall effect: z = 5.21 (p < 0.00001)
1.39
1.4
1.03
1.42
21
183
204
2.06
2.29
1.18
1.34
20
92
112
14.3%
85.7%
100.0%
-4 -2 0 2 4
Favours SCIT Favours placebo
Study or subgroup Mean SD Total Mean SD Total Weight IV, random, 95% CI
SCIT Placebo Standard mean difference Standard mean difference
IV, random, 95% CI
-0.59 (-1.22 to 0.03)
-0.64 (-0.89 to -0.38)
-0.63 (-0.87 to -0.39)
FIGURE 58 Subcutaneous immunotherapy vs placebo, QoL, major allergen content, > 20 µg.
FIGURE 59 Subcutaneous immunotherapy vs placebo, QoL, grass.
FIGURE 60 Subcutaneous immunotherapy vs placebo, QoL, Parietaria.
Creticos 2006146
Jutel 2005166
Powell 2007156
Total (95% CI)
Heterogeneity: τ2 = 0.00; χ2 = 1.46, df = 2 (p = 0.48); I2 = 0%
Test for overall effect: z = 4.80 (p < 0.00001)
0.5
1.43
1.4
0.6
1.31
2
9
29
203
241
1.6
2.27
2.3
1.2
1.51
1.6
9
28
103
140
4.5%
16.2%
79.3%
100.0%
-4 -2 0 2 4
Favours SCIT Favours placebo
Study or subgroup Mean SD Total Mean SD Total Weight IV, random, 95% CI
SCIT Placebo Standard mean difference Standard mean difference
IV, random, 95% CI
-1.10 (-2.11 to -0.09)
-0.59 (-1.12 to -0.06)
-0.48 (-0.72 to -0.24)
-0.52 (-0.74 to -0.31)
FIGURE 57 Subcutaneous immunotherapy vs placebo, QoL, major allergen content, 5–20 µg.
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Heterogeneity: τ2 = 0.04; χ2 = 62.78, df = 32 (p = 0.0009); I2 = 49%
Test for overall effect: z = 6.94 (p<0.00001)
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1.6
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19
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9
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14
61
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37
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18
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184
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176
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-4 -2 0 2 4
Favours SLIT Favours placebo
Study or subgroup Mean SD Total Mean SD Total Weight IV, random, 95% CI
SLIT Placebo Standard mean difference Standard mean difference
IV, random, 95% CI
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Sublingual immunotherapy
FIGURE 61 Sublingual immunotherapy vs placebo, adults, SSs.
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FIGURE 62 Sublingual immunotherapy vs placebo, adults, MSs.
FIGURE 63 Sublingual immunotherapy vs placebo, adults, SMSs.
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FIGURE 65 Sublingual immunotherapy vs placebo, children, MSs.
NIHR Journals Library www.journalslibrary.nihr.ac.uk
AppENDIx 7
248
Blaiss 2011189
Bowen 200497
Casanovas 199498
Dahl 200693
Di Rienzo 2006102
Dubakiene 2003103
Durham 2006104
Feliziani 1995105
Hordijk 1998106
Peter 2009112
Pradalier 1999114
Skoner 2010196
Vervloet 2006117
Voltolini 2001197
Wahn 200926
Total (95% CI)
Heterogeneity: τ2 = 0.02; χ2 = 23.96, df = 14 (p = 0.05); I2 = 42%
Test for overall effect: z = 4.94 (p < 0.00001)
3.71
3.95
5.46
2.1
0.4
0.48
2.48
109.7
3.21
0.732
2.33
0.19
2.68
130
3.25
4.88
2.45
3.56
1.7
0.3
0.3
2.1
92.46
3.05
0.483
1.6
1.16
1.64
154
2.86
149
37
9
61
18
47
131
18
35
176
63
33
19
15
131
942
4.91
5.03
10.98
3.3
0.8
0.64
2.96
215.8
5.13
0.78
2.65
1
2.44
83
4.51
5.03
2.54
7.1
2.2
0.5
0.43
2.09
114.2
3.6
0.544
2
2.3
2.06
79
2.931
158
39
6
32
14
53
129
16
36
189
63
36
19
15
135
940
12.2%
5.9%
1.3%
6.2%
2.7%
7.0%
11.5%
2.9%
5.5%
13.0%
8.2%
5.5%
3.6%
2.9%
11.5%
100.0%
-4 -2 0 2 4
Favours SLIT Favours placebo
Study or subgroup Mean SD Total Mean SD Total Weight IV, random, 95% CI
SLIT Placebo Standard mean difference Standard mean difference
IV, random, 95% CI
-0.24 (-0.47 to -0.02)
-0.43 (-0.88 to 0.03)
-1.00 (-2.11 to 0.12)
-0.63 (-1.07 to -0.19)
-0.98 (-1.72 to -0.23)
-0.42 (-0.82 to -0.03)
-0.23 (-0.47 to 0.02)
-1.00 (-1.72 to -0.28)
-0.57 (-1.04 to -0.09)
-0.09 (-0.30 to 0.11)
-0.18 (-0.53 to 0.17)
-0.43 (-0.91 to 0.04)
0.13 (-0.51 to 0.76)
0.37 (-0.35 to 1.10)
-0.43 (-0.68 to -0.19)
-0.34 (-0.47 to -0.20)
Blaiss 2011189
Bowen 200497
Casanovas 199498
Dahl 200693
Di Rienzo 2006102
Dubakiene 2003103
Durham 2006104
Feliziani 1995105
Hordijk 1998106
Pradalier 1999114
Skoner 2010196
Vervloet 2006117
Voltolini 2001195
Wahn 200926
Total (95% CI)
Heterogeneity: τ2 = 0.02; χ2 = 19.96, df = 13 (p = 0.10); I2 = 35%
Test for overall effect: z = 4.67 (p < 0.00001)
0.91
1.05
1.69
2.4
3.2
0.13
1.4
24.06
0.16
1.77
0.0003
3.39
22
0.6
3.66
1.6
2.46
3.9
0.7
0.17
2.13
25.72
0.37
2.3
1.64
3.94
30
0.611
149
37
9
61
18
47
131
18
35
63
33
19
15
131
766
1.33
1.26
2.13
4.2
4.9
0.17
2.03
75.9
0.31
2.13
0.63
4.71
39
0.79
2.51
1.24
2.22
4.1
1.5
0.19
2.39
50.3
0.45
2.7
1.06
5
34
0.647
158
39
6
32
14
53
129
16
36
63
36
19
15
135
751
14.5%
6.7%
1.7%
7.1%
2.7%
8.1%
13.5%
3.0%
6.4%
9.4%
6.2%
3.9%
3.1%
13.6%
100.0%
-4 -2 0 2 4
Favours SLIT Favours placebo
Study or subgroup Mean SD Total Mean SD Total Weight IV, random, 95% CI
SLIT Placebo Standard mean difference Standard mean difference
IV, random, 95% CI
-0.13 (-0.36 to 0.09)
-0.15 (-0.60 to 0.30)
-0.17 (-1.21 to 0.86)
-0.45 (-0.88 to -0.02)
-1.48 (-2.28 to -0.68)
-0.22 (-0.61 to 0.17)
-0.28 (-0.52 to -0.03)
-1.29 (-2.04 to -0.54)
-0.36 (-0.83 to 0.11)
-0.14 (-0.49 to 0.21)
-0.46 (-0.93 to 0.02)
-0.29 (-0.93 to 0.35)
-0.52 (-1.25 to 0.21)
-0.30 (-0.54 to -0.06)
-0.33 (-0.47 to -0.19)
FIGURE 66 Sublingual immunotherapy vs placebo, < 6 months, SSs.
FIGURE 67 Sublingual immunotherapy vs placebo, < 6 months, MSs.
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FIGURE 68 Sublingual immunotherapy vs placebo, < 6 months, SMSs.
FIGURE 69 Sublingual immunotherapy vs placebo, 6–12 months, SSs.
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FIGURE 70 Sublingual immunotherapy vs placebo, 6–12 months, MSs.
FIGURE 71 Sublingual immunotherapy vs placebo, 6–12 months, SMSs.
FIGURE 72 Sublingual immunotherapy vs placebo, > 12 months, SSs.
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FIGURE 73 Sublingual immunotherapy vs placebo, > 12 months, MSs.
FIGURE 74 Sublingual immunotherapy vs placebo, > 12 months, SMSs.
FIGURE 75 Sublingual immunotherapy vs placebo, major allergen content, < 5 µg, SSs.
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FIGURE 76 Sublingual immunotherapy vs placebo, major allergen content, < 5 µg, MSs.
FIGURE 77 Sublingual immunotherapy vs placebo, major allergen content, 5–20 µg, SSs.
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FIGURE 78 Sublingual immunotherapy vs placebo, major allergen content, 5–20 µg, MSs.
FIGURE 79 Sublingual immunotherapy vs placebo, major allergen content, 5–20 µg, SMSs.
FIGURE 80 Sublingual immunotherapy vs placebo, major allergen content, > 20 µg, SSs.
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FIGURE 81 Sublingual immunotherapy vs placebo, major allergen content, > 20 µg, MSs.
FIGURE 82 Sublingual immunotherapy vs placebo, grass pollen, SSs.
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FIGURE 83 Sublingual immunotherapy vs placebo, grass pollen, MSs.
FIGURE 84 Sublingual immunotherapy vs placebo, grass pollen, SMSs.
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5.03
1
2.14
2.54
2.3
51
39
36
126
40.6%
31.2%
28.3%
100.0%
-4 -2 0 2 4
Favours SLIT Favours placebo
Study or subgroup Mean SD Total Mean SD Total Weight IV, random, 95% CI
SLIT Placebo Standard mean difference Standard mean difference
IV, random, 95% CI
-0.45 (-0.84 to -0.05)
-0.43 (-0.88 to 0.03)
-0.43 (-0.91 to 0.04)
-0.44 (-0.69 to -0.18)
Andre 200395
Bowen 200497
Skoner 2010196
Total (95% CI)
Heterogeneity: τ2 = 0.00; χ2 = 1.10, df = 2 (p = 0.58); I2 = 0%
Test for overall effect: z = 2.66 (p = 0.008)
2.41
1.05
0.0003
3.09
1.6
1.64
48
37
33
118
4
1.26
0.63
4.24
1.24
1.06
51
39
36
126
40.4%
31.6%
28.0%
100.0%
-4 -2 0 2 4
Favours SLIT Favours placebo
Study or subgroup Mean SD Total Mean SD Total Weight IV, random, 95% CI
SLIT Placebo Standard mean difference Standard mean difference
IV, random, 95% CI
-0.42 (-0.82 to -0.02)
-0.15 (-0.60 to 0.30)
-0.46 (-0.93 to 0.02)
-0.34 (-0.60 to -0.09)
D'Ambrosio 199999
La Rosa 199986
Passalacqua 1999111
Troise 1995116
Total (95% CI)
Heterogeneity: τ2= 0.00; χ2 = 1.38, df = 3 (p = 0.71); I2 = 0%
Test for overall effect: z = 1.48 (p = 0.14)
509
1.21
189
87
514.2
1.66
113
76
14
16
15
15
60
897.06
1.61
191
102
678.2
1.56
108
58
16
17
15
16
64
23.2%
26.9%
24.6%
25.3%
100.0%
-4 -2 0 2 4
Favours SLIT Favours placebo
Study or subgroup Mean SD Total Mean SD Total Weight IV, random, 95% CI
SLIT Placebo Standard mean difference Standard mean difference
IV, random, 95% CI
-0.62 (-1.36 to 0.12)
-0.24 (-0.93 to 0.44)
-0.02 (-0.73 to 0.70)
-0.22 (-0.92 to 0.49)
-0.27 (-0.62 to 0.09)
FIGURE 85 Sublingual immunotherapy vs placebo, ragweed, SSs.
FIGURE 86 Sublingual immunotherapy vs placebo, ragweed, MSs.
FIGURE 87 Sublingual immunotherapy vs placebo, Parietaria, SSs.
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D'Ambrosio 199999
La Rosa 199986
Passalacqua 1999111
Troise 1995116
Total (95% CI)
Heterogeneity: τ2 = 0.00; χ2 = 2.75, df = 3 (p = 0.43); I2 = 0%
Test for overall effect: z = 2.68 (p = 0.007)
48.1
2.28
42
17
46.6
3.89
49.5
21
14
16
15
15
60
124.37
2.36
83
33
121
3.95
65
33
16
17
15
16
64
23.2%
27.9%
23.8%
25.1%
100.0%
-4 -2 0 2 4
Favours SLIT Favours placebo
Study or subgroup Mean SD Total Mean SD Total Weight IV, random, 95% CI
SLIT Placebo Standard mean difference Standard mean difference
IV, random, 95% CI
-0.79 (-1.54 to -0.04)
-0.02 (-0.70 to 0.66)
-0.69 (-1.43 to 0.05)
-0.56 (-1.28 to 0.16)
-0.49 (-0.85 to -0.13)
Ariano 200196
Casanovas 199498
Di Rienzo 2006102
Drachenberg 200191
Dubakiene 2003103
Valovirta 200690
Vervloet 2006117
Voltolini 2001197
Vourdas 199889
Total (95% CI)
Heterogeneity: τ2 = 0.17; χ2 = 20.17, df = 8 (p = 0.010); I2 = 60%
Test for overall effect: z = 2.29 (p = 0.02)
1.8
5.46
0.4
34
0.48
1.5
2.68
130
1.07
1.75
3.56
0.3
27.8
0.3
1.4
1.64
154
1.63
10
9
18
18
47
27
19
15
34
197
5.38
10.98
0.8
35
0.64
2.2
2.44
83
1.38
1.57
7.1
0.5
21.9
0.43
1.4
2.06
79
2.01
10
6
14
5
53
29
19
15
32
183
6.7%
6.8%
10.7%
7.9%
16.1%
13.9%
12.3%
11.0%
14.7%
100.0%
-4 -2 0 2 4
Favours SLIT Favours placebo
Study or subgroup Mean SD Total Mean SD Total Weight IV, random, 95% CI
SLIT Placebo Standard mean difference Standard mean difference
IV, random, 95% CI
-2.06 (-3.19 to -0.93)
-1.00 (-2.11 to 0.12)
-0.98 (-1.72 to -0.23)
-0.04 (-1.03 to 0.95)
-0.42 (-0.82 to -0.03)
-0.49 (-1.03 to 0.04)
0.13 (-0.51 to 0.76)
0.37 (-0.35 to 1.10)
-0.17 (-0.65 to 0.32)
-0.42 (-0.77 to -0.06)
Ariano 200196
Casanovas 199498
Di Rienzo 2006102
Drachenberg 200191
Dubakiene 2003103
Valovirta 200690
Vervloet 2006117
Voltolini 2001197
Vourdas 199889
Total (95% CI)
Heterogeneity: τ2 = 0.03; χ2 = 10.24, df = 8 (p = 0.25); I2 = 22%
Test for overall effect: z = 3.02 (p = 0.002)
2.5
1.69
3.2
15.6
0.13
2.9
3.39
22
1.39
2.1
2.46
0.7
17.4
0.17
3.4
3.94
30
3.41
10
9
18
18
47
27
19
15
34
197
5.3
2.13
4.9
23.2
0.17
3.9
4.71
39
1.77
4.9
2.22
1.5
20.7
0.19
4.6
5
34
3.85
10
6
14
5
53
29
19
15
32
183
6.3%
5.0%
7.9%
5.4%
22.2%
15.3%
11.4%
9.3%
17.2%
100.0%
-4 -2 0 2 4
Favours SLIT Favours placebo
Study or subgroup Mean SD Total Mean SD Total Weight IV, random, 95% CI
SLIT Placebo Standard mean difference Standard mean difference
IV, random, 95% CI
-0.71 (-1.62 to 0.20)
-0.17 (-1.21 to 0.86)
-1.48 (-2.28 to -0.68)
-0.41 (-1.40 to 0.59)
-0.22 (-0.61 to 0.17)
-0.24 (-0.77 to 0.28)
-0.29 (-0.93 to 0.35)
-0.52 (-1.25 to 0.21)
-0.10 (-0.59 to 0.38)
-0.38 (-0.62 to -0.13)
FIGURE 88 Sublingual immunotherapy vs placebo, Parietaria, MSs.
FIGURE 89 Sublingual immunotherapy vs placebo, tree, SSs.
FIGURE 90 Sublingual immunotherapy vs placebo, tree, MSs.
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Di Rienzo 2006102
Didier 201125
Durham 2010200
Horak 2009202
Nelson 2011192
Peter 2009112
Total (95% CI)
Heterogeneity: τ2 = 0.03; χ2 = 14.48, df = 5 (p = 0.01); I2 = 65%
Test for overall effect: z = 4.33 (p < 0.0001)
0.5
-0.43
0.78
-0.3
1.3
-1.127
1.52
1.02
0.71
0.44
1.31
1.531
18
149
160
143
172
176
818
1.83
0
1.01
0
1.57
-0.81
1.14
1.02
0.71
0.44
1.4
1.601
14
165
127
148
197
189
840
4.6%
18.9%
18.4%
18.3%
19.9%
19.9%
100.0%
-4 -2 0 2 4
Favours SLIT Favours placebo
Study or subgroup Mean SD Total Mean SD Total Weight IV, random, 95% CI
SLIT Placebo Standard mean difference Standard mean difference
IV, random, 95% CI
-0.95 (-1.69 to -0.21)
-0.42 (-0.64 to -0.20)
-0.32 (-0.56 to -0.09)
-0.68 (-0.92 to -0.44)
-0.20 (-0.40 to 0.01)
-0.20 (-0.41 to 0.00)
-0.39 (-0.56 to -0.21)
Blaiss 2011189
Di Rienzo 2006102
Horak 2009202
Peter 2009112
Total (95% CI)
Heterogeneity: τ2 = 0.06; χ2 = 11.54, df = 3 (p = 0.009); I2 = 74%
Test for overall effect: z = 3.09 (p = 0.002)
1.45
0.5
-0.3
-1.127
1.04
1.52
0.44
1.531
109
18
143
176
446
1.77
1.83
0
-0.81
1.05
1.14
0.44
1.601
111
14
148
189
462
28.3%
10.7%
29.8%
31.3%
100.0%
-4 -2 0 2 4
Favours SLIT Favours placebo
Study or subgroup Mean SD Total Mean SD Total Weight IV, random, 95% CI
SLIT Placebo Standard mean difference Standard mean difference
IV, random, 95% CI
-0.31 (-0.57 to -0.04)
-0.95 (-1.69 to -0.21)
-0.68 (-0.92 to -0.44)
-0.20 (-0.41 to 0.00)
-0.45 (-0.74 to -0.17)
Didier 201125
Durham 2010200
Total (95% CI)
Heterogeneity: τ2 = 0.00; χ2 = 0.35, df = 1 (p = 0.56); I2 = 0%
Test for overall effect: z = 4.53 (p < 0.00001)
-0.43
0.78
1.02
0.71
149
160
309
0
1.01
1.02
0.71
165
127
292
52.3%
47.7%
100.0%
-4 -2 0 2 4
Favours SLIT Favours placebo
Study or subgroup Mean SD Total Mean SD Total Weight IV, random, 95% CI
SLIT Placebo Standard mean difference Standard mean difference
IV, random, 95% CI
-0.42 (-0.64 to -0.20)
-0.32 (-0.56 to -0.09)
-0.37 (-0.54 to -0.21)
FIGURE 91 Sublingual immunotherapy vs placebo, QoL, adults.
FIGURE 92 Sublingual immunotherapy vs placebo, QoL, < 6 months.
FIGURE 93 Sublingual immunotherapy vs placebo, QoL, > 12 months.
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Blaiss 2011189
Durham 2010200
Total (95% CI)
Heterogeneity: τ2 = 0.00; χ2 = 0.01, df = 1 (p = 0.92); I2 = 0%
Test for overall effect: z = 3.51 (p = 0.0004)
1.45
0.78
1.04
0.71
109
160
269
1.77
1.01
1.05
0.71
111
127
238
43.7%
56.3%
100.0%
-4 -2 0 2 4
Favours SLIT Favours placebo
Study or subgroup Mean SD Total Mean SD Total Weight IV, random, 95% CI
SLIT Placebo Standard mean difference Standard mean difference
IV, random, 95% CI
-0.31 (-0.57 to -0.04)
-0.32 (-0.56 to -0.09)
-0.32 (-0.49 to -0.14)
Di Rienzo 2006102
Horak 2009202
Total (95% CI)
Heterogeneity: τ2 = 0.00; χ2 = 0.45, df = 1 (p = 0.50); I2 = 0%
Test for overall effect: z = 6.13 (p < 0.00001)
0.5
-0.3
1.52
0.44
18
143
161
1.83
0
1.14
0.44
14
148
162
9.2%
90.8%
100.0%
-4 -2 0 2 4
Favours SLIT Favours placebo
Study or subgroup Mean SD Total Mean SD Total Weight IV, random, 95% CI
SLIT Placebo Standard mean difference Standard mean difference
IV, random, 95% CI
-0.95 (-1.69 to -0.21)
-0.68 (-0.92 to -0.44)
-0.70 (-0.93 to -0.48)
FIGURE 94 Sublingual immunotherapy vs placebo, QoL, major allergen content, 5–20 µg.
FIGURE 95 Sublingual immunotherapy vs placebo, QoL, major allergen content, > 20 µg.
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Appendix 8 Symptom scores across studies
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Appendix 9 Characteristics of ongoing trials
Source: ClinicalTrials.gov and UK Clinical Research Network Portfolio Database and metaRegister (controlled-trials.com) searched August 2011.
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Appendix 10 Reasons for exclusion: cost-
effectiveness studies and reviews
Reference Reason for exclusion
Allison C, Fraser J. Grazax: an oral vaccine for the treatment of grass pollen allergy (hay 
fever). Issues Emerg Health Tech 2007;107:1–4
Not EE, does not report 
relevant information
Alvarez-Cuesta E, Gonzelez-Mancebo E. Immunotherapy in bronchial asthma. Curr Opin 
Pulm Med 2000;6:50–4
Not EE, does not report 
relevant information
Bachert CJ, Jorissen M, Bertrand B, Khattaev N, Bousquet J. Allergic Rhinitis and its 
Impact on Asthma update (ARIA 2008). The Belgian perspective’, B-ENT 2008;4:253–7
No relevant information 
reported
Baiardini I, Braido F, Tarantini F, Porcu A, Bonini S, Bousquet PJ, et al., GA2LEN. ARIA-
suggested drugs for allergic rhinitis: what impact on quality of life? A GA2LEN review. 
Allergy 2008;63:660–9
No relevant information 
reported
Barnes PJ. Is immunotherapy for asthma worthwhile? N Engl J Med 1996;334:531–2 Editorial, No relevant 
information reported
Belliveau PP. Omalizumab: A monoclonal anti-IgE antibody. Medsc Gen Med 2005;7:27 No relevant information 
reported
Bergmann KC, Wolf H, Schnitker J, et al. Quality of life and compliance of patients 
treated with specific immunotherapy using grass and rye allergens (LQC study). Allergo J 
2000;9:480–8
No relevant information 
reported
Bernstein JA. Cost-benefit analysis for allergen immunotherapy. Immunol Allergy Clin 
2000;20:593–608
No relevant information 
reported
Bernstein JA. Pharmacoeconomic considerations for allergen immunotherapy. Clin Allergy 
Immunol 2004;8:151–64
Not EE, does not report 
relevant information
Berto P, Frati F, Incorvaia C, Cadario G, Contiguglia R, Di Gioacchino M, et al. Comparison 
of costs of sublingual immunotherapy and drug treatment in grass-pollen induced 
allergy: results from the SIMAP database study. Curr Med Res Opin 2008;24:261–6
Not EE, does not report 
relevant information
Büchner KS. An economic evaluation of a specific immunotherapeutic drug. Summary 
of results from an Infratest Suisse study, conducted for the Federal Republic of Germany 
(West). Allergo J 1995;4:156–63
No relevant information 
reported
Canonica GW, Passalacqua G. Sublingual immunotherapy in the treatment of adult 
allergic rhinitis patients. Allergy 2006;61:20–3
Not a review of EEs
Canonica GW, Passalacqua P. Disease-modifying effect and economic implications of 
sublingual immunotherapy. J Allergy Clin Immunol 2011;127:44–5
Commentary, does not report 
relevant information
Carr,WW, Nelson MR, Hadley JA. Managing rhinitis: Strategies for improved patient 
outcomes. Allergy Asthma Proc 2008;29:349–57
No relevant information 
reported
Compalati E, Penagos E. Specific immunotherapy for respiratory allergy: state of the art 
according to current meta-analyses. Ann Allergy Asthma Immunol 2009;102:22–8.
No relevant information 
reported
Cox L. Sublingual immunotherapy and allergic rhinitis. Current Allergy Asthma Rep 
2008;8:102–10
Not a review of EEs.
del Cuvillo A, Montoro J, Bartra J, Valero A, Ferrer M, Jauregui I, et al. Validation of 
ARIA duration and severity classifications in Spanish allergic rhinitis patients: The ADRIAL 
cohort study. Rhinology 2010;48:201–5
No relevant information 
reported
Douglass JA, Thien FC, O’Hehir RE. Immunotherapy in asthma. Thorax 1997;52:S22–9 No relevant information 
reported
Fell WR, Mabry RL, Mabry C. Quality of life analysis of patients undergoing 
immunotherapy for allergic rhinitis. Ear Nose Throat J 1997;76:528–32
No relevant information 
reported
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Reference Reason for exclusion
Goksel O, Sin B, Aydy’n O, Mungan D, Demirel Y, Pinar M, et al. Grass pollen 
preseasonal immunotherapy: the effect on direct medical cost and quality of life. Allergy 
2009;64:458 (poster 1200)
Conference poster, no relevant 
information reported
Goldman M. Sublingual immunotherapy: The quest for innovative adjuvants. Clin Exp 
Allergy 2008;38:1705–6
Editorial, no relevant 
information reported
Goldschmidt O. Treatment of allergic rhinoconjunctivitis seen from health economical 
point of view. Allergologie 1998;21:S68–72
No relevant information 
reported
Greiner AN. Allergic rhinitis: impact of the disease and considerations for management. 
Med Clin North Am 2006;90:17–38
No relevant information 
reported
Hadley JA. Overview of otolaryngic allergy management: An eclectic and cost- effective 
approach. Otolaryngol Clin North Am 1998;31:69–82
Not immunotherapy
Hankin CS, Cox L, Lang D, Levin A, Gross G, Eavy G, et al. Allergy immunotherapy among 
Medicaid-enrolled children with allergic rhinitis: patterns of care, resource use, and costs. 
J Allergy Clin Immunol 2008;121:227–32
Not EE, does not report 
relevant information
Hankin CS, Cox L, Leatherman B, Lang D, Gross G, Fass P, et al. Allergy immunotherapy 
confers significant health care cost savings within 3 months of initiation: a matched 
retrospective cohort study of Medicaid-enrolled children newly diagnosed with allergic 
rhinitis. Value Health 2009;12:A122
Conference proceeding, 
does not report any relevant 
information
Hankin CS, Cox L, Lang D, Bronstone A, Fass P, Leatherman B, et al. Allergen 
immunotherapy and health care cost benefits for children with allergic rhinitis: a 
large-scale, retrospective, matched cohort study. Ann Allergy Asthma Immunol 
2010;104:79–85
Not EE, does not report 
relevant information
Hankin CS, Cox L, Lang D, Bronston A, Fass P, Leatherman B, et al. 2011, Does allergen-
specific immunotherapy reduce the risk, reverse, and/or mitigate asthma in children 
with allergic rhinitis? The pediatric improved access to allergen-specific immunotherapy 
- asthma incidence rates among Medicaid enrollees (pediatric-IMAGINE-AIRE) study, 
funded by the Joint Council of Allergy, Asthma and Immunology. J Allergy Clin Immunol 
2011;127:AB73
Conference proceeding, 
does not report any relevant 
information
Incorvaia C, Agostinis F, Amoroso S, Ariano R, Barbato A, Bassi M, et al. 
Pharmacoeconomics of subcutaneous allergen immunotherapy. Eur Ann Allergy Clin 
Immunol 2007;39:17–20
Not EE, does not report 
relevant information
Kay AB, Lessof MH. Allergy: Conventional and alternative concepts. A report of the Royal 
College of Physicians Committee on Clinical Immunology and Allergy. Clin Exp Allergy 
1992;22:1–44.
No relevant information 
reported
Kozma CM, Sadik MK, Watrous ML. Economic outcomes for the treatment of allergic 
rhinitis. Pharmacoeconomics 1996;10:4–13
No relevant information 
reported
Lockey RF, Hankin CS. Health economics of allergen-specific immunotherapy in the 
United States. J Allergy Clin Immunol 2011;127:39–43
Editorial, no relevant 
information reported
McCrory DC, Williams JW, Dolor RJ, Gray RN, Kolimaga JT, Reed S, et al. Management of 
allergic rhinitis in the working-age population. Evidence Report: Technology Assessment 
(Summary) 2003;67:1–4
No relevant information 
reported
McEwen LM. Immunotherapy and hayfever. BMJ 1991;302:530–1 Correspondence, no relevant 
information reported
Mosbech H, Osterballe O. Does the effect of immunotherapy last after termination of 
treatment? Follow-up study in patients with grass pollen rhinitis. Allergy 1988;43:523–9
No relevant information 
reported
Nalebuff, D. J. PRIST, RAST, and beyond. Diagnosis and therapy. Otolaryngol Clin North 
Am 1985;18:725–44
Not immunotherapy
Nash DB, Sullivan SD, Mackowiak J. Optimizing quality of care and cost effectiveness in 
treating allergic rhinitis in a managed care setting. Am J Manag Care 2000;6:S3–15
No relevant information 
reported
Passalacqua G, Guerra L, Fumagalli F, Compalati E, Canonica GW. An update 
on sublingual immunotherapy. Allergy and Clinical Immunology International 
2005;17:181–5
No relevant information 
reported
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Reference Reason for exclusion
Passalacqua G, Guerra L, Pasquali M, Canonica GW. Non-injection routes for allergen 
immunotherapy: Focus on sublingual immunotherapy. Inflamm Allergy Drug Targets 
2006;5:43–51
No relevant information 
reported
Poulsen PB, Pedersen KM, Christensen J, Vestenbaek U. Economic evaluation of a tablet-
based vaccination against hay fever in Denmark. Ugeskrift Laeger 2008;170:138–42
Data reported in Bachert 2007 
(included in review)
Reed SD, Lee TA, McCrory DC. The economic burden of allergic rhinitis: a critical 
evaluation of the literature. Pharmacoeconomics 2004;22:345–61
No relevant information 
reported
Sanico AM. Latest developments in the management of allergic rhinitis. Clin Rev Allergy 
Immunol 2004;27:181–9
No relevant information 
reported
Schafer T, Riehle A, Wichmann HE, Ring J. Alternative medicine in allergies: prevalence, 
patterns of use, and costs. Allergy 2002;57:694–700
Not immunotherapy
Tamayama K, Hoshi SL, Kondo M, Okubo I. Cost-effectiveness analysis of pre-seasonal 
medication for cedar pollinosis in Japan. Yakugaku Zasshi 2010;130:1725–36
Not immunotherapy
Thomas, M. Allergic rhinitis: evidence for impact on asthma. BMC Pulm Med 2006;6:S4 Not a review of EEs
Tripathi A, Patterson R. Impact of allergic rhinitis treatment on quality of life. 
Pharmacoeconomics 2001;19:891–9
No relevant information 
reported
Wang ZH, Hankin CS, Cox L, Bronstone A. Allergen immunotherapy significantly reduces 
healthcare costs among US adults with allergic rhinitis: a retrospective matched cohort 
study Jointly Funded by the AAAAI and ACAAI. J Allergy Clin Immunol 2011;127:AB150
Conference proceeding, 
does not report any relevant 
information
Weiner JM. Allergen injection immunotherapy. Med J Aust 2006;185:234 No relevant information 
reported
Weiss KB, Haus M, Ikura Y. The costs of allergy and asthma and the potential benefit of 
prevention strategies. Allergy 2000;55:1083–4
No relevant information 
reported
Whitehead S, Taylor MJ, Christensen J. An economic evaluation of Grazax for the 
treatment of grass pollen induced rhinoconjunctivitis in children. Value Health 
2009;12:A125 (PRS 26)
Conference proceeding, 
does not report any relevant 
information
Yilmaz M, Bingol G, Altintas D, Kendirli SG. Effect of SIT on quality of life. Allergy 
2000;55:302
No relevant information 
reported
Yuta A, Miyamoto Y, Hattori R, Ogihara H, Takeuchi K, Majima Y. The influence of medical 
economy from the aspect of medical direct costs by a difference of the number of the 
pollen scattering on an allergen-specific immunotherapy for Japanese cedar pollinosis. 
Jpn J Allergol 2007;56:1366–71
Not EE, does not report 
relevant information
Full text not obtainable (British Library unable to supply at the 
time of ordering)
Blaiss MS. Cost-effectiveness of H1-antihistamines. Clin Allergy Immunol 2002;17:319–36
Grevers G. Rising prevalence, high costs. Hay fever remains a challenge. MMW Fortsch Med 2008;150:28
Pedersen KM. Economic evaluation of new medicines: when safety and efficacy are not enough. Drugs Today 
2008;44:69–71
Pruzinec P. Economical evaluation of the allergen vaccination profit comparing to the symptomatic therapy of allergic 
diseases. Klin Imunol Alergol 2003;13:25–7
Scadding GK. Hay fever and asthma: are we failing our patients? Drugs Today 2008;44:19–24
Solari JE, Loo J, Felices A, Casas J. Immunotherapy for patients with persistent allergic rhinitis unsatisfied with free chronic 
pharmacotherapy. Allergol Immunopathol 2006;34:102–6
Warner-Klein MK. Sublingual immunotherapy of allergic diseases. Expert Opin Drug Deliv 2006;3:599–612
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Identified after report completed
Hagen A, Gorenoi V, Schönermark MP. Spezifische Immuntherapie (SIT) zur Behandlung der allergischen Rhinitis. Köln, 
Germany: Deutsche Agentur für HTA des Deutschen Instituts für Medizinische Dokumentation und Information; 2010
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studies
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Economic evaluations
Title: Pharmacoeconomics of allergen immunotherapy compared with symptomatic drug treatment in 
patients with allergic rhinitis and asthma
Ariano 2006222 Journal
Allergy and Asthma 
Proceedings
Type of economic analysis
Cost–consequence analysis
Study population
Patients with seasonal Parietaria pollen-
induced AR and asthma
Perspective
Societal, national health-
care system and patient 
Research question
Evaluation of the economic advantage of subcutaneous allergen immunotherapy plus standard antiallergic drugs compared 
with standard antiallergic drugs alone
Intervention (comparator)
Subcutaneous allergen 
immunotherapy + standard antiallergic drugs 
(standard antiallergic drugs only)
Country
Italy
Time horizon
6 years
Effectiveness data
SSs
Sample size
30
Discount rate
Not reported
Cost year (currency)
Not reported (US$)
Structure of model: N/A Assumptions of model: N/A
Resource and cost data
Directs costs – GP or specialist visits, drugs, specialist examinations
Results
 z Immunotherapy + drug treatment was associated with better SSs compared with drug treatment only over 6 years
 z Immunotherapy + drug treatment was associated with better patient satisfaction scores compared with drug treatment 
only over 6 years
 z Net savings associated with immunotherapy plus drug treatment were €623 (US$830) per year at year 6 (net savings 
start 3 years after treatment)
Sensitivity analysis: None
Assumption tested: N/A Result: N/A
Author’s conclusion
Subcutaneous immunotherapy is associated with significant economic advantages over antiallergic drug treatment in the 
long term
General comments
 z Small patient numbers (n = 30) and loss to follow-up up to year 6 not stated
 z SSs were evaluated at baseline and annually for 6 years. No utility-based outcome measure was used
 z As is the case with CCA, no single measure of economic benefit was derived making it difficult to conclusively comment 
on whether the interventions were value for money
 z No discounting is applied to costs and therefore cost estimates may not be appropriate
 z As the price year is not reported, future reflation exercises based on results from this study will be hindered
 z The authors also classified side effects as 0 = absent, 1 = local reactions such as itching and oedema around the site of 
the injection, 2 = slight systemic reaction, such as rhinitis or conjunctivitis, and 3 = moderate/severe systemic reactions, 
such as asthma, urticaria, angioedema and/or anaphylactic shock. However, there are no details on differences between 
groups and it is unclear if costs for side effects were included in the EE
 z Data used were from a prospective randomised long-term study
N/A, not applicable.
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Title: Cost-effectiveness of grass allergen tablet (GRAZAX) for the prevention of seasonal grass pollen 
induced rhinoconjunctivitis – a Northern European perspective
Bachert 2007228 Journal
Clinical and Experimental Allergy
Type of economic analysis
Cost–utility analysis
Study population
Patients with grass pollen-induced 
rhinoconjunctivitis
Perspective
Societal
Research question
Assessment of cost-effectiveness of Grazax (grass allergen tablet) compared with symptomatic treatment in seven northern 
European countries
Intervention (comparator)
Sublingual Grazax (symptomatic 
treatment)
Country
UK, Germany, Netherlands, Sweden, 
Denmark, Norway and Finland
Time horizon
Nine years (3 years with Grazax 
treatment and 6 years post Grazax 
discontinuation)
Effectiveness data
QALYs – based on EQ-5D
Sample size
493
Discount rate
3–5% (depending on 
country)
Cost year (currency)
2005 (euros)
Structure of model: N/A Assumptions of model: N/A
Resource and cost data
Directs costs: visits to physician, acute ward visits, use of symptomatic rescue medication for AR and asthma and 
hospitalisation
Indirect costs: productivity losses (hours missed from work owing to AR)
Results
 z Grazax associated with more QALY gains compared with symptomatic treatment (0.0287 additional QALYs per season 
and 0.222 QALYs gained over 9 years discounted at 4%)
 z At an annual cost of < €2200 for the societal perspective, and based on a threshold of €29,000 (£20,000) per QALY, 
Grazax is cost-effective compared with standard (symptomatic) treatment in northern Europe
Sensitivity analysis
Univariate deterministic 
Assumption tested
 z Including direct costs only
 z Using the upper threshold of €43,800 (£30,000) for 
cost-effectiveness (societal perspective)
Result
 z Annual cost of Grazax should be below €2200 to be cost-
effective at €29,000 threshold
 z Annual cost of Grazax should be below €3400 to be cost-
effective
Author’s conclusion
For a tablet below €6, Grazax is a cost-effective intervention for the prevention of grass pollen-induced rhinoconjunctivitis
General comments
 z Data used in the cost–utility analysis were collected prospectively alongside a randomised parallel group, DBPC trial 
conducted during the 2005 pollen season
 z Although not many sensitivity analyses has been explicitly reported, it is important to note that wide ranges of values 
were used in the CUA, which increases the rigour of the results, for example discount rates (1.5–5%), annual costs for 
Grazax (€1200–4400), EQ-5D (country-specific versions of EQ-5D)
 z No information has been given about private patient costs (other than indirect costs attributed to hours missed from 
work)
 z Country-specific resource use and unit cost data were used
 z Neither actual EQ-5D inputs (based on country specific valuations) nor QALY estimates for each arm are presented in 
the paper, which makes it impossible to apply effectiveness measures from this study in other studies
 z The burden of AR was assumed to be uniform across all northern European countries
 z This analysis was undertaken alongside a multinational clinical trial
 z The study was funded by a manufacturer of SIT products
N/A, not applicable.
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Title : Influence of time horizon and treatment patterns on cost-effectiveness measures: the case of allergen-
specific immunotherapy with Grazax
Beriot-Mathiot 2007232 Journal
Journal of Medical Economics
Type of economic analysis
Cost–utility analysis
Study population
Patients with grass pollen-induced 
rhinoconjunctivitis
Perspective
Societal
Research question
Estimation of cost-effectiveness of two treatment patterns for Grazax (seasonal and WHO-recommended pattern) 
relative to standard care, as well as the effect that time horizon has on this estimation. The seasonal scenario involves 
administering Grazax 16 weeks prior to, and during, the pollen season, whereas the WHO-recommended scenario involves 
daily intake of Grazax for 3 years
Intervention (comparator)
Seasonal or WHO-recommended sublingual 
Grazax (symptomatic treatment)
Country
UK, Netherlands, Denmark and 
Sweden
Time horizon
15 years (3 years with GRAZAX 
treatment and 12 years post 
GRAZAX discontinuation)
Effectiveness data
QALYs – based on EQ-5D
Sample size
493
Discount rate
3%
Cost year (currency)
2004/5 (euros)
Structure of model: N/A Assumptions of model: N/A
Resource and cost data
Directs costs: visits to physician, acute ward visits, use of symptomatic rescue medication for AR and asthma and 
hospitalisation
Indirect costs: productivity losses (hours missed from work owing to AR)
Results
 z In the seasonal scenario, Grazax is more cost-effective than standard care with an ICER of €21,829. This ICER is 
independent of the time horizon considered
 z In the WHO-recommended SIT scenario, Grazax is more cost-effective than standard care (at a threshold of €29,200) 
if the sustained effect of treatment is 2 years. The ICER decreases from €47,844 at the 1-year time horizon to €7894 at 
the 9-year time horizon
 z The WHO-recommended SIT scenario is the most cost-effective when the time horizon is 6.3 years or more
Sensitivity analysis
Univariate deterministic
Assumption tested
 z Changing the time point when seasonal treatment 
commences from 16 weeks to 8 weeks before the pollen 
season
Result
 z Grazax was still more cost-effective than standard 
care with an even lower ICER of €13,797
Author’s conclusion
Grazax is cost-effective both for the WHO-recommended SIT and the seasonal treatment
General comments
 z Data used in the cost–utility analysis were collected prospectively alongside a randomised parallel group, DBPC trial 
conducted during the 2005 pollen season
 z The only sensitivity analysis carried out was changing the time point at which seasonal treatment commences
 z No information has been given about private patient costs (other than indirect costs attributed to hours missed from 
work)
 z Country-specific resource use and unit cost data were used
 z Some actual EQ-5D inputs were provided, but not disaggregated for the SIT or standard treatment group. In the 
same vein, QALY estimates for each arm were also not presented in the paper which makes it impossible to apply 
effectiveness measures from this study in other studies
 z This analysis was undertaken alongside a multinational clinical trial
 z It is not clear what the treatment used in the no-SLIT control group is, but it seems to be standard treatment
N/A, not applicable; WHO, World Health Organization.
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Title: Cost-effectiveness of sublingual immunotherapy in children with allergic rhinitis and asthma
Berto 2005223 Journal
European Annals of 
Allergy and Clinical 
Immunology
Type of economic analysis
Cost–consequence analysis 
Study population
Children with either seasonal or 
perennial AR and asthma
Perspective
Societal
Research question
Assessment of the cost of treating children with AR using sublingual immunotherapy (SLIT)
Intervention (comparator)
SLIT (no SLIT control – for second analysis)
Country
Italy
Time horizon
Four years (1 year pre-SLIT 
and 3 years on SLIT)
Effectiveness data
No. of asthma and rhinitis exacerbations, visits, 
absence from nursery or school
Sample size
135
Discount rate
Not reported
Cost year (currency)
Not reported (euros)
Structure of model: N/A Assumptions of model: N/A
Resource and cost data
Directs costs: concomitant pharmacological treatment for allergic disease, specialist visits, SLIT
Indirect costs: productivity losses (nursery/school days lost – proxy for working days lost by parents)
Results
 z Compared with the pre-SLIT period and with no-SLIT control groups, SLIT was associated with substantial reductions in 
the no. of exacerbations, no. of school/nursery days lost and number of medical visits
 z Mean direct and indirect costs per year during the SLIT period (again compared with pre-SLIT and no-SLIT groups) were 
also lower
Sensitivity analysis
None
Assumption tested: N/A Result: N/A
Author’s conclusion
High-dose SLIT may be effective in reducing the cost of AR and asthma
General comments
 z Data were based on a sample from only one allergy centre in northern Milan but sample characteristics are not given 
making it difficult to know how generalisable the results are
 z The interventions are not very well or clearly described
 z As is the case with CCA, no single measure of economic benefit was derived, making it difficult to conclusively 
comment on whether the interventions were value for money
 z No discounting is applied to costs and therefore cost estimates may not be appropriate
 z It is not clear what the treatment is used in the no-SLIT control group, but it seems to be standard treatment
N/A, not applicable.
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Title: Economic evaluation of sublingual immunotherapy vs symptomatic treatment in adults with pollen-
induced respiratory allergy: the Sublingual Immunotherapy Pollen Allergy Italy (SPAI) study
Berto 2006226 Journal
Annals of Allergy, Asthma 
and Immunology
Type of economic analysis
Cost-effectiveness analysis
Study population
Young adults with seasonal pollen-
induced AR with or without asthma
Perspective
National health-care 
system (NHS) and societal 
Research question
Assessment of cost and consequences of SLIT added to pharmacotherapy in comparison to pharmacotherapy alone
Intervention (comparator)
SLIT + pharmacotherapy (pharmacotherapy only)
Country
Italy
Time horizon
6 years
Effectiveness data
No. of patients improved; number of asthma cases 
avoided
Sample size
2230
Discount rate
3%
Cost year (currency)
2002 (euros and US $)
Structure of model
Decision-tree model 
Assumptions of model
Same rate of hospitalisation attributed to both the SLIT and no-SLIT 
groups
Resource and cost data
NHS perspective: direct medical costs (visits, diagnostic procedures, drugs, SLIT and hospitalisations)
Societal perspective: direct (as above), indirect (working days lost) and patient out-of-pocket costs
Results
From both the NHS and societal perspectives and for both outcomes (cost per additional improved patient and cost per 
additional asthma case avoided), SLIT dominates no-SLIT (i.e. it is cheaper and more effective)
Sensitivity analysis
Univariate deterministic
Assumption tested
 z Changing perspective from NHS to societal
 z Varying distribution of disease and severity level
 z Varying the cost of hospitalisations (from 
€1491.11 to €864.00)
Result
 z SLIT still dominates no-SLIT
 z SLIT still dominates no-SLIT
 z SLIT still dominates no-SLIT
Author’s conclusion
SLIT is less expensive and more effective that pharmacotherapy alone from both perspectives and for both effectiveness 
outcomes
General comments
 z It is not clear whether the two arms are comparable in terms of baseline characteristics
 z The lack of details on the study sample characteristics makes it difficult to ascertain how generalisable the results of the 
study are to a wider population
 z Effectiveness estimates were based on a retrospective cohort study in which clinicians enrolled in the study reported the 
outcomes for 100 of their patients. It is not clear whether this introduced any selection bias and, if it did, what effect it 
had on the results
 z The data used to populate the model was not clearly presented making it problematic to replicate the decision tree 
model-based analysis
 z The study was funded by a manufacturer of SIT products
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Title: Cost-effectiveness of specific subcutaneous immunotherapy in patients with allergic rhinitis and allergic 
asthma
Brüggenjürgen 2008229 Journal
Annals of Allergy, Asthma 
and Immunology
Type of economic analysis
Cost–utility analysis
Study population
Patients with either seasonal or 
perennial AR and allergic asthma
Perspective
Societal and third-party 
payer
Research question
Assessment of cost-effectiveness of SCIT in addition to ST compared with ST alone
Intervention (comparator)
SCIT + ST (ST alone)
Country
Germany
Time horizon
15 years
Effectiveness data
Utilities
Sample size
2000
Discount rate
3%
Cost year (currency)
Not reported (euros)
Structure of model
Markov model
Assumptions of model
Markov cycle length = 1 year
Six disease/health states: mild AR; moderate to severe AR; 
moderate to severe AR and mild allergic asthma; moderate to 
severe AR and severe allergic asthma; no symptoms; and dead
Resource and cost data
Annual costs from Schramm et al.271 
Direct costs associated with disability, early retirement 
and loss of work
Other data
Transition probabilities from published literature sources
Results
 z From a societal point of view at 15 years, SCIT + ST dominates ST only (ICER of €–19,787 per QALY) (break-even point is 
reached after 10 years)
 z From a third-party payer’s perspective, SCIT + ST is associated with an ICER of €8308 per QALY
Sensitivity analysis: Univariate deterministic 
Assumption tested
 z Shortening SCIT treatment length from 3 to 2 years
 z Varying price of SCIT
 z Varying the discount rate between 0% and 10%
 z Using third-party payers’ perspective
 z Extending SCIT to all patients
Result
 z SCIT + ST still dominates but is associated with even greater 
cost savings
 z Reducing cost of SCIT resulted in even greater savings – 
SCIT + ST still dominates
 z SCIT + ST still dominates ST alone
 z SCIT + ST was associated with an ICER of €8308 per QALY
 z SCIT + ST was associated with an ICER of €3713 per QALY
Author’s conclusion
Subcutaneous immunotherapy + ST was associated with cost savings and improved medical outcomes
General comments
 z No probabilistic sensitivity analysis carried out
 z It is not clear what instrument was used to derive the ‘utilities’ – reference cited is a report on acupuncture
 z Assumptions that could not be validated by any literature sources were based on the consensus of a board of experts in 
paediatrics, dermatology, allergy, pneumonia and otolaryngology
 z The interventions were not presented clearly in the article
 z The resource use and cost data details were not reported in sufficient details to allow for replication
 z Further, future reflation exercises will be hindered as the price year was not reported
 z Because of the foregoing (i.e. lack of detail), it is hard to assess the rigour of the results obtained
 z Study was funded by a manufacturer of SIT products
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Title: Cost-effectiveness of GRAZAX for the prevention of grass pollen induced rhinoconjunctivitis in 
Southern Europe
Canonica 2007230 Journal
Respiratory Medicine
Type of economic 
analysis
Cost–utility analyses
Study population
Patients with seasonal grass pollen-induced 
rhinoconjunctivitis
Perspective
Societal
Research question
Assessment of cost-effectiveness of Grazax (grass allergen tablet) compared with symptomatic treatment in four southern 
European countries
Intervention 
(comparator)
Sublingual Grazax 
(symptomatic treatment)
Countries
Spain, France, Italy and Austria
Time horizon
Nine years (3 years with GRAZAX 
treatment and 6 years post GRAZAX 
discontinuation)
Effectiveness data
QALYs – based on EQ-5D
Sample size
634
Discount rate
3–6% (depending 
on country)
Cost year (currency)
2004/5 (Euros)
Structure of model: N/A Assumptions of model: N/A
Resource and cost data
Directs costs: visits to physician and acute wards, symptomatic medication, 
asthma medication, eventual hospitalisation
Indirect costs: productivity losses (hours missed from work due to AR)
Other data
Risk of developing asthma
Results
 z Grazax associated with more QALY gains compared with symptomatic treatment (0.0167 additional QALYs per season 
and 0.134 discounted QALYs gained over 9 years)
 z At an annual cost of between €1500 and €1900, and based on a threshold of €29,000 (£20,000) per QALY, Grazax is 
cost-effective compared with standard (symptomatic) treatment
Sensitivity analysis
Univariate deterministic
Assumption tested
 z Impact of allergic asthma (including future costs related to asthma)
 z Excluding patients from Spain from the analysis (due to low pollen 
counts in Spain in 2005 which had impact on QoL)
 z Using the upper threshold of €43,800 (£30,000) for cost-
effectiveness (societal perspective)
Result
 z ICERs associated with Grazax become even 
more favourable
 z Mean QALY in Grazax group increased from 
0.9492 to 0.9686
 z Annual cost of Grazax should be < €2550 to 
be cost-effective
Author’s conclusion
Grazax is cost-effective compared with standard (symptomatic) treatment in southern Europe
General comments
 z Data used in the cost–utility analysis were collected prospectively alongside a randomised parallel group, DBPC trial 
conducted during the 2005 pollen season
 z Even although not many sensitivity analyses has been explicitly reported, it is important to note that ranges of values 
were used in the CUA, for example discount rates (3–6%), annual costs for Grazax (€900–2900), EQ-5D (country-
specific versions of EQ-5D)
 z No information has been given about private patient costs (other than indirect costs attributed to hours missed from 
work)
 z Neither actual EQ-5D inputs (based on country-specific valuations) nor QALY estimates for each arm are presented in 
the paper, which makes it impossible to apply effectiveness measures from this study in other studies
 z This analysis was undertaken alongside a multinational clinical trial
N/A, not applicable.
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Title: Health economic model of allergen–specific immunotherapy in seasonal allergic rhinitis from a health 
care payer’s perspective
Claes 2009224 Journal
Allergo Journal
Type of economic analysis
Cost analysis
Study population
Paediatric and adult patients with SAR
Perspective
Health insurers
Research question
Comparative assessment of costs of five forms of immunotherapy:
 z Long-term subcutaneous immunotherapy (LT SCIT)
 z sublingual immunotherapy (SLIT)
 z short-term subcutaneous immunotherapy with maintenance injections (ST SCIT + injections)
 z short-term subcutaneous immunotherapy without maintenance injections (ST SCIT)
 z short-term subcutaneous immunotherapy with an adjuvant-supported allergoid (allergoid + MPL) (ST SCIT MPL)
Intervention (comparator)
LT SCIT (SLIT; ST SCIT; ST SCIT + 
injections; ST SCIT MPL)
Country
Germany
Time horizon
Three years
Other scenarios look at 
15-year time period
Effectiveness data
For base case assume 100% 
effectiveness for all different 
treatment strategies
Sample size
Not stated. Hypothetical 
paediatric and adult cohorts
Discount rate
5%
Cost year (currency)
Not reported (euros)
Structure of model
Markov model
Assumptions of model
Markov cycle length = 1 week
Base case: 100% effectiveness for all treatments being 
compared, no discontinuations and 100% compliance
Resource and cost data
Costs of diagnosis, clinician time, services, 
supplies (e.g. injections), SAR medication, 
hospital visits, costs of treating asthma
Other data
Transition probabilities (children) given for development over time of 
SAR (from non-SAR population), lower airway symptoms or asthma. 
Data mainly from PAT study272
Results
 z Three-year average direct costs for the five forms of immunotherapy were: €2584 (LT SCIT), €4269 (SLIT), €1533 (ST 
SCIT), €2523 (ST SCIT + injections) and €2080 (ST SCIT MPL)
 z Direct costs of the ST SCIT MPL arm, compared with those of other forms SCIT and SLIT, are higher at the beginning of 
therapy
 z Other scenarios show that, compared with other forms of immunotherapy, ST SCIT and ST SCIT MPL have favourable 
sustainability and adherence-related outcomes
Sensitivity analysis
Univariate deterministic
Assumption tested
 z Variation in discontinuation rates, discount rates, time 
horizon (5, 12 and 15 years), some costs and effectiveness 
(source for effectiveness data not clear)
Result
 z Sensitivity analyses have an influence on costs, but 
overall no effect on the relative cost differences 
between different treatment strategies
Author’s conclusion
Short-term SCIT and allergoid + MPL seem to be associated with fewer costs compared with other forms of 
immunotherapy. After 3 years giving no SIT is still the cheapest option, whereas after 15 years it becomes the most 
expensive option
General comments
 z The authors assume 100% effectiveness, 0% discontinuation rates and 100% compliance for all therapies (base case), 
which seems infeasible
 z Some of these assumptions are varied in sensitivity analyses but at least for effectiveness do not seem to be based on 
any clinical data
 z Only total direct costs considered, no utilities estimated (not a CBA)
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Title: A cost-effectiveness analysis of immunotherapy with SQ allergen extract for patients with seasonal 
allergic rhinoconjunctivitis in selected European countries
Keiding and Jørgensen 2007233 Journal
Current Medical Research 
and Opinion
Type of economic analysis
Cost-effectiveness analysis and cost–utility 
analyses
Study population
Patients with seasonal (grass-induced) 
allergic rhinoconjunctivitis
Perspective
Not stated
Research question
Assessment of cost-effectiveness of Alutard SQ (ASQ) compared with emergency/standard treatment in six European 
countries
Intervention (comparator)
Subcutaneous ASQ (emergency/standard 
treatment)
Countries
Austria, Denmark, Finland, Germany, 
Netherlands and Sweden
Time horizon
Nine years (updosing and 
maintenance in year 1, 
follow-up in years 2 and 3, 
and emergency treatment 
for rest of time)
Effectiveness data
Symptom free and well-days (based on RQLQ), 
MSs, VAS, QALYs – based on mapping from 
RQLQ to EQ-5D
Sample 
size
Not 
reported
Discount rate
3% 
Cost year (currency)
2005 (euros)
Structure of model: N/A Assumptions of model: N/A
Resource and cost data
Directs costs: updosing visits, maintenance visits, cost of ASQ, cost of specific immunotherapy, rescue medication, other 
direct costs
Indirect costs: productivity gain (through reduced number of working days lost)
Results
 z ICERs associated with ASQ are between €9716 and €25,863 per QALY without accounting for indirect costs. When 
indirect costs are included, ASQ dominates emergency treatment in all countries except two, in which it is associated 
with low ICERs (€6458 per QALY for The Netherlands and €5024 per QALY for Sweden)
 z ASQ was more favourable when outcomes were expressed as cost per symptom-free day and cost per well-day
Sensitivity analysis
None reported
Assumption tested: N/A Result: N/A
Author’s conclusion
ASQ is cost-effective compared with emergency treatment regardless of whether indirect costs are included or not
General comments
 z Indirect costs relating to loss of working days were not considered, as data were not available in all of the six countries; 
instead those relating to productivity gain through reduced number of working days lost were used
 z Difficult to assess the robustness of the results as sensitivity analyses were not conducted or reported
 z The sample size should have also been given to give an idea of the how robust the analyses were
 z The ‘other direct costs’ could have been enumerated to enable testing of the costing procedure. In addition, the cost 
perspective should have also been specified
 z Data for the study came from the UK Immunotherapy Study Group (UKIS) trial
 z A 10-cm VAS was used to measure allergic symptoms with ‘0’ representing ‘no symptoms’ and ‘10’ representing 
‘severe symptoms’
N/A, not applicable.
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Title: Cost-effectiveness of specific immunotherapy with Grazax in allergic rhinitis co-existing with asthma
Nasser 2008231 Journal
Allergy
Type of economic analysis
Cost–utility analysis
Study population
Patients with grass pollen-induced 
rhinoconjunctivitis including those with co-existing 
asthma
Perspective
Societal
Research question
Assessment of cost-effectiveness of Grazax (tablet-base allergen-SIT) plus ST compared with ST only
Intervention (comparator)
Sublingual Grazax + ST (ST only)
Countries
United Kingdom, Germany, Netherlands, Denmark, 
Sweden, Spain, Austria and Italy
Time horizon
Nine years (3 years of GRAZAX 
treatment and 6 years of 
sustained effect)
Effectiveness data
QALYs – based on EQ-5D
Sample size
151
Discount rate
3.5%
Cost year (currency)
2005 (UK £)
Structure of model: N/A Assumptions of model: N/A
Resource and cost data
Directs costs: emergency physician visits, acute ward visits, acute ward visits, hospitalisations
Indirect costs: hours missed from work, reduced productivity
Results
 z Grazax was associated with more QALY gains than symptomatic treatment (0.0250 additional QALYs per season and 
0.197 QALYs gained over 9 years discounted at 3.5%)
 z Grazax was associated with a cost per QALY gained of £4319
Sensitivity analysis
Univariate deterministic
Assumptions tested
 z Excluding influence of reduced productivity at work
 z Varying time horizon to 7 years but including 
influence of reduced productivity at work
 z Varying time horizon to 7 years but excluding 
influence of reduced productivity at work)
 z Varying annual costs of Grazax from £1000 to 
£3000
Results
 z Grazax was associated with an ICER of £8816 per QALY gained
 z Grazax was associated with an ICER of £7272 per QALY gained
 z Grazax was associated with an ICER of £11,769 per QALY 
gained
 z Grazax remains cost-effective up to an annual cost of £1850 
(£5.07 per tablet). Base-case price was £2.25 per tablet
Author’s conclusion
SIT with Grazax is cost-effective compared with standard (symptomatic) treatment
General comments
 z Data used in the cost–utility analysis were collected prospectively alongside a randomised parallel group, DBPC trial 
conducted during the 2005 pollen season
 z No information has been given about private patient costs (other than indirect costs attributed to hours missed 
from work)
 z Actual EQ-5D inputs (based on country-specific valuations) are not presented in the paper
 z No EQ-5D values or QALY estimates for each arm are presented in the paper, which makes it impossible to apply 
effectiveness measures from this study in other studies
 z This analysis was undertaken alongside a multinational clinical trial
N/A, not applicable.
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Title: Pharmacoeconomic assessment of specific immunotherapy vs current symptomatic treatment for 
allergic rhinitis and asthma in France
Author
Omnes 2007227
Journal
European Annals of Allergy 
and Clinical Immunology
Type of economic analysis
Cost-effectiveness analysis
Study population
Adults and children suffering 
from either seasonal or perennial 
AR (with or without asthma)
Perspective
Health insurers
Research question
Assessment of comparative cost-effectiveness of three strategies: (i) symptomatic treatment (CST) alone; (ii) injectable 
specific immunotherapy (SCIT) plus CST (SCIT + CST); and (iii) sublingual immunotherapy (SLIT) plus CST (SLIT + CST)
Intervention (comparator)
SCIT + CST (SLIT + CST; CST only)
Country
France
Time horizon
Six years (adult population) and 
7 years (juvenile population)
Effectiveness data
Proportions of individuals with rhinitis or allergic asthma 
in the four models (juvenile, adult, dust mite allergy 
and pollen allergy), distribution of severity levels, and 
treatment efficacy (the numbers of improved patients 
and asthma cases)
Sample size
1000
Discount 
rate
3%
Cost year 
(currency)
2003 (euros)
Structure of model
Decision-tree model
Resource and cost data
Direct costs: costs associated with drugs, visits and diagnostic tests. Expert opinion (Delphi panel) and recommendations 
from both French and international guidelines used to determine resource quantities
Indirect costs: no. of work-days lost
Results
Adults (6 years)
When compared with CST only:
 z The incremental costs per asthma case avoided with SCIT + CST were €393 and €1327 for dust mite and pollen allergy, 
respectively
 z The incremental costs per asthma case avoided with SLIT + CST were €3158 and €1708 for dust mite and pollen allergy, 
respectively
Children (over 7 years)
When compared with CST only:
 z The incremental costs per asthma case avoided with SCIT + CST were €583 and €597 for dust mite and pollen allergy, 
respectively
 z The incremental costs per asthma case avoided with SLIT + CST were €3938 and €824 for dust mite and pollen allergy, 
respectively
Sensitivity analysis: Univariate deterministic
Assumptions tested
 z Use of the official GP’s tariff for SCIT from the 
nomenclature générale des actes professionnels 
(NGAP) nomenclature instead of the GP’s tariff in 
adult model
 z Alternative distributions of severity levels were derived 
from two published studies in adult model
 z Ranges of values defined by the Delphi panel were 
also used for other clinical data in child model
Results
 z SCIT became the dominant strategy compared with CST in 
dust mite and pollen allergy
 z Results were unchanged
 z Results were unchanged
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Author’s conclusion
Injectable specific immunotherapy (SCIT) is a more cost-effective treatment in children with pollen allergy and in adults 
with dust mite allergy in comparison with both CST and sublingual SIT. Sublingual SIT was more cost-effective than CST in 
pollen-induced rhinitis, especially in children
General comments
 z Most (all) of the epidemiological data for the adult (child) model were based on expert opinion, i.e. a Delphi panel of 
11 members (10 allergologists and one epidemiologist); although this was justified (due to heterogeneity in published 
estimates), this was one weakness of the study
 z Another limitation of the analysis was the lack of more rigorous assessment of uncertainty, for example using 
probabilistic sensitivity analysis
 z Other aspects of the study were adequately addressed
 z Although no head-to-head comparisons were made between SCIT + CST and SLIT + CST, SCIT + CST was associated with 
better outcome, i.e. lower ICERs, when both were compared with CST only
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Title: Health-economic analyses of subcutaneous specific immunotherapy for grass pollen and mite allergy
Petersen 2005234 Journal
Allergol et Immunopathol
Type of economic analysis
CBA and CEA
Study population
Patients with grass pollen or mite allergy 
(seasonal or perennial allergy)
Perspective
Societal
Research question
Assessment of the health and monetary consequences of treating allergy with SIT compared with standard (symptomatic) 
treatment
Intervention (comparator)
SCIT (standard/symptomatic treatment)
Country
Denmark
Time horizon
Eight years (3 years treatment with 
SIT and 5 years’ extrapolation)
Effectiveness data
Monetary benefits and measure of 
psychological well-being
Sample 
size
204
Discount rate
5%
Cost year (currency)
2002 (Danish krone, DKK)
Structure of model: N/A – retrospective 
observational study
Assumptions of model: N/A
Resource and cost data
Direct costs: medicine use; visits to medical doctors; visits to emergency rooms; visits to doctors on emergency duty; 
hospital stays pre-, per- and post-SIT
Patient costs: transportation; time costs
Indirect costs: work-related sick days; leisure activity sick days
Results
Subcutaneous immunotherapy is associated with an ICER of DKK 2.784 per patient/year of improved well-being. From a 
CBA perspective, SCIT was shown to be net beneficial
Sensitivity analysis: Univariate deterministic
Assumption tested
Varying the time horizon considered after the 
start of SIT from 4 to 9 years
Result
Cost per patient year of improved well-being lies in the range DKK 
16,408 to DKK 2784
Author’s conclusion
SIT is associated with increases in societal welfare
General comments
 z The methodology for determining outcomes in the CBA is also not very clear (it seems only indirect costs associated 
with sick days were included in estimation)
 z The results of the CEA (based on cost per year improvement in psychological well-being) are difficult to generalise
 z It is also not clear what technique was used to value the monetary benefits used in the CBA
N/A, not applicable.
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Title: Economic evaluation of sublingual vs subcutaneous allergen immunotherapy
Pokladnikova 2007225 Journal
Annals of Allergy, Asthma 
and Immunology
Type of economic analysis
CCA
Study population
Patients with seasonal allergic 
rhinoconjunctivitis
Perspective
Third-party payer, patient 
and societal
Research question
Evaluation of the cost and cost-effectiveness of SLIT compared with SCIT and standard ST
Intervention (comparator)
SLIT (SCIT; ST)
Country
Czech Republic
Time horizon
15 years
Effectiveness data
RQLQ score; VAS score; symptomatic 
medication reduction; health-care utilisation
Sample size
64 (19 = SLIT, 23 = SCIT 
and 22 = ST)
Discount rate
0%
Cost year (currency)
2002 (euros)
Structure of model: N/A – within-trial-
based analysis
Assumptions of model: N/A
Resource and cost data
 z Direct medical costs: costs of treatment and health-care services. Health-care services include specialist visits 
(consultations, laboratory tests, diagnostic tests, nurse services)
 z Costs associated with adverse effects of treatment (medication, emergency department visits and hospitalisations)
 z Patient costs: medication co-payment, over-the-counter drugs, travel costs, loss of income due to allergy symptoms, 
treatment and productivity costs (using human capital approach)
Results
 z Clinical benefits for SLIT were comparable to those for SCIT but SCIT patients showed a slightly better improvement 
especially in VAS and symptomatic MSs
 z Compared with SCIT, SLIT was associated with lower costs (from all perspectives)
Sensitivity analysis
Univariate deterministic 
Assumption tested
 z Varying costs of interventions by ± 50% for the third-
party payer perspective
Result
 z SLIT associated with lower costs compared with SCIT
Author’s conclusion
Compared with SCIT, SLIT is a less expensive alternative from all perspectives except for patients who do not experience loss 
of income and travel costs associated with treatment (from the patients’ perspective)
General comments
 z SA conducted for only third-party payer perspective, making it difficult to ascertain the rigour of all the results
 z The sample also seems to be fairly small, implying that one needs to interpret the results obtained with caution
 z As is the case with CCA, no single measure of economic benefit was derived, making it difficult to conclusively 
comment on whether the interventions were value for money
 z Data used in this study was derived from an open-label randomised clinical trial
N/A, not applicable.
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Title: Economic evaluation of specific immunotherapy (SIT) vs symptomatic treatment of allergic rhinitis in 
Germany
Schädlich and Brecht 2000235 Journal
Pharmacoeconomics
Type of economic analysis
CEA, CCA
Study population
Patients with either pollen or mite 
allergy (seasonal or perennial 
allergy)
Perspective
Societal, national health-care 
system and SHI provider
Research question
Evaluation of the economic consequences of SIT lasting 3 years in comparison to those of continuous symptomatic 
treatment
Intervention (comparator)
Specific subcutaneous immunotherapy (continuous 
symptomatic treatment)
Country
Germany
Time horizon
10 years
Effectiveness data
No. of additional patients free from asthma 
symptoms; break-even points of costs/expenses per 
patient and difference in costs/expenses per patient 
after 10 years
Sample size
Cohort of 
2000 patients
Discount rate
5% 
Cost year (currency)
1997 (Deutschmarks, DM)
Structure of model
Decision-tree model 
Assumptions of model
Base-case results based on average values of clinical effectiveness 
parameters and average case-related treatment costs and statutory 
health insurer (SHI) expenses
Resource and cost data
Directs costs: drugs (injections), medical services, diagnoses, adverse effects, SHI costs, 
rehabilitation
Indirect cost: loss of productivity caused by absence from work, premature retirement and 
premature death
Results
 z Break-even point reached between 6 and 8 years after commencement of therapy
 z Net savings associated with therapy were between DM650 and DM1190 per patient after 10 years
 z SIT associated with ICERs of between DM3640 and DM7410 per additional patient free from asthmatic symptoms
Sensitivity analysis
Univariate deterministic
Assumption tested
 z Use of best-/worst-case scenarios for SIT
 z Impact of exogenous parameters on target variables
Results
 z Best-case scenario – SIT was superior; worst-case scenario 
– symptomatic treatment superior
 z Direct medical cost for symptomatic treatment has 
greatest impact on the target variable followed by 
average increase of asthma prevalence with symptomatic 
treatment
Author’s conclusion
SIT results in net savings after 10 years from societal, health-care and SHI perspectives
General comments
 z Target variables used in CCA not very clearly described, i.e. break-even points of costs/expenses per patient and 
difference in costs/expenses
 z Difficult to ascertain the internal validity of the estimate of benefit as there is limited reporting of the literature review 
from where these estimates are sourced
 z The results provided have, however, been subjected to some rigorous sensitivity analysis
SHI, statutory health insurance.
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Reviews
Title: Economic studies of immunotherapy: a review
Berto 2008247 Journal
Current Opinion in Allergy 
and Clinical Immunology
Type of economic analysis
Review of cost analyses (cost and cost–
cost analyses) and EEs
Study population
Patients with seasonal and PAR and asthma
Perspective
Societal, national health-
care system and patient
Research question
Assessment of evidence on the economic advantages offered by immunotherapy
Intervention (comparator)
Immunotherapy (standard 
pharmaceutical treatment – for cost–
cost analyses and EEs)
Countries
USA, UK, Spain, Italy, Germany, France, northern 
EU, southern EU, Austria, Denmark, Finland, 
Netherlands and Sweden
Time horizon
10 years
Effectiveness data
QALYs and other (unreported) physical/
natural outcomes
Sample 
size
14 
papers
Discount rate: N/A Cost year (currency)
Not reported (euros)
Structure of model: N/A Assumptions of model: N/A
Resource and cost data
Directs costs: outpatient and inpatient visits, specialist visits, immunotherapy, symptomatic medication, asthma medication, 
eventual hospitalisation
Indirect costs: productivity losses (working days lost by patients and nursery/school days lost – proxy for working days lost 
by parents)
Results
 z Cost analyses: costs per patient/year varied from €96 to €348.50
 z Cost–cost analyses: average costs/patient for immunotherapy ranged from €288 to €1182, whereas those for pre-
immunotherapy/controls ranged from €116 to €2672
 z EEs: immunotherapy is more cost-effective than standard treatment
Sensitivity analysis: None
Assumption tested: N/A Result: N/A
Author’s conclusion
Immunotherapy can be cheaper and also more cost-effective than standard therapy alone
General comments
 z The results of the review are not reported in enough detail, for example the outcomes used in the cost-effectiveness 
analyses were not presented
 z The results of head-to-head comparisons between SCIT and SLIT are not reported in sufficient detail
N/A, not applicable.
NIHR Journals Library www.journalslibrary.nihr.ac.uk
AppENDIx 11
294
Title: The Health Economics of Allergen Immunotherapy
Hankin 2011237 Journal
Immunology and Allergy Clinics 
of North America
Type of economic analysis
Review of cost analyses (cost and cost-to-
cost analyses) and EEs
Study population
Patients with seasonal or PAR and/or 
asthma
Perspective
Health-care system, societal and 
patient
Research question
Evaluation of the economic benefit of allergen-specific immunotherapy (SIT) compared
Intervention (comparator)
SIT [standard drug treatment (SDT) in 
certain instances]
Countries
USA, Germany, France, Italy, Denmark 
and northern Europe
Time horizon
From 1995 to 2011
Effectiveness data
QALYs, net benefits and other physical/
natural outcomes
Sample 
size
15 studies
Discount rate
N/A
Cost year (currency)
2010 (US$)
Structure of model: N/A – systematic 
review
Assumptions of model: N/A
Resource and cost data
 z Direct costs: encounters (visits), tests, allergic reactions, procedures, drugs, hospital services, SIT
 z Indirect costs: productivity losses (days lost from work, disability and premature death)
Results
SIT provides cost benefits ranging from $96 to $5465. Average annual costs for SIT per patient ranged from US$247 
to US$10,200; average annual costs for STD per patient ranged from US$1,335 to US$24,243; mean cost of allergy 
medications per patient year varied from US$23 to $37 and costs per QALY gained ranged from US$14,536 to US$38,695
Sensitivity analysis: N/A
Assumption tested: N/A Result: N/A
Author’s conclusion
SIT has cost benefits over SDT and therefore introduction of new SDTs must be carefully assessed in terms of clinical 
effectiveness and cost-effectiveness
General comments
 z The details of the studies included in the review are presented with adequate details making a distinction between cost 
analyses and EEs
N/A, not applicable.
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Appendix 12 Quality assessment of economic 
evaluations
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Philips criteria: model-based economic evaluations
Berto 
2006226
Brüggenjürgen 
2008229
Omnes 
2007227
Schädlich 
and Brecht 
2000235
Claes 
2009224
Structure
1. Is there a clear statement of the 
decision problem?
Y Y Y Y Y
2. Is the objective of the model specified 
and consistent with the stated decision 
problem?
Y Y Y Y Y
3. Is the primary decision-maker 
specified?
Y Y Y Y Y
4. Is the perspective of the model stated 
clearly?
Y Y Y Y Y
5. Are the model inputs consistent with 
the stated perspective?
Y Y Y Y Y
6. Is the structure of the model 
consistent with a coherent theory of 
the health condition under evaluation?
N N Y Y Y
7. Are the sources of the data used to 
develop the structure of the model 
specified?
Y Y Y N Y
8. Are the structural assumptions 
reasonable given the overall objective, 
perspective and scope of the model?
UC Y UC UC UC
9. Is there a clear definition of the 
options under evaluation?
Y N Y N Y
10. Have all feasible and practical options 
been evaluated?
N N Y N Y
11. Is there justification for the exclusion 
of feasible options?
Y N N/A N N/A
12. Is the chosen model type appropriate 
given the decision problem and 
specified casual relationships within 
the model?
Y Y Y Y Y
13. Is the time horizon of the model 
sufficient to reflect all important 
differences between the options?
Y Y Y Y N
14. Do the disease states (state transition 
model) or the pathways (decision 
tree model) reflect the underlying 
biological process of the disease 
in question and the impact of 
interventions?
Y Y Y Y Y
15. Is the cycle length defined and justified 
in terms of the natural history of 
disease?
N/A Y N/A N/A Y
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Berto 
2006226
Brüggenjürgen 
2008229
Omnes 
2007227
Schädlich 
and Brecht 
2000235
Claes 
2009224
Data
16. Are the data identification methods 
transparent and appropriate given the 
objectives of the model?
Y N N N N
17. Where choices have been made 
between data sources, are these 
justified appropriately?
UC N N N N
18. Where expert opinion has been 
used are the methods described and 
justified?
N/A N/A Y UC N/A
19. Is the choice of baseline data 
described and justified?
N N/A N N N/A
20. Are transition probabilities calculated 
appropriately?
UC UC Y Y UC
21. Has a half-cycle correction been 
applied to both costs and outcomes?
N N UC N N
22. If not, has the omission been justified? N N UC N UC
23. Have the methods and assumptions 
used to extrapolate short-term results 
to final outcomes been documented 
and justified?
N N N N N
24. Are the costs incorporated into the 
model justified?
Y N Y Y Y
25. Has the source for all costs been 
described? 
N N N N N
26. Have discount rates been described 
and justified given the target decision-
maker?
Y Y Y Y Y
27. Are the utilities incorporated into the 
model appropriate?
N/A UC N/A N/A N/A
28. Is the source of utility weights 
referenced?
N/A N N/A N/A N/A
29. If data have been incorporated 
as distributions, has the choice of 
distributions for each parameter been 
described and justified?
N/A N/A N/A N/A N/A
30. If data are incorporated as point 
estimates, are the ranges used for 
sensitivity analysis stated clearly and 
justified?
N N N Y N
31. Has heterogeneity been dealt with 
by running the model separately for 
different subgroups?
N N Y N N
32. Have the results been compared with 
those of previous models and any 
differences in results explained?
Y N N Y Y
N, no; N/A, not applicable; UC, unclear; Y, yes.
Philips criteria: model-based economic evaluations
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Appendix 13 Transition probabilities
Adult Markov model transition probabilities
Subcutaneous immunotherapy arm
Start immunotherapy
 z Given that an adult with hay fever first started on SCIT treatment, what is the probability that they:
 | continue with SCIT without adding any symptomatic treatment?
 | then add on treatments to control all of their symptoms?
 | then add on treatments to control some of their symptoms (symptoms partly controlled)?
 z Given that an adult with hay fever is on SCIT only (without any symptomatic treatment), what is the 
probability that they:
 | will survive within 1 year?
 | will quit SCIT within 1 year?
 z Given that an adult with hay fever is on SCIT and treatments to control all of their symptoms, what is 
the probability that they:
 | will survive within 1 year?
 | will quit SCIT within 1 year?
 z Given that an adult with hay fever is on SCIT and treatments to control only some of their symptoms, 
what is the probability that they:
 | will survive within 1 year?
 | will quit SCIT within 1 year?
On immunotherapy, no symptomatic treatment
 z Given that an adult with hay fever has carried on from the previous year on SCIT only (without any 
symptomatic treatment), what is the probability that they:
 | continue with this treatment from the second year onwards?
 | will add on treatments to control all of their symptoms from the second year onwards?
 | will add on treatments to control only some of their symptoms from the second year onwards?
 z Given that an adult with hay fever has carried on from the previous year on SCIT only (without any 
symptomatic treatment):
 | and then continued with this treatment from the second year onwards, what is the probability 
that they will quit SCIT treatment?
 | and then added treatments to control all of their symptoms from the second year onwards, what 
is the probability that they will quit SCIT treatment?
 | and then added treatments to control only some of their symptoms from the second year 
onwards, what is the probability that they will quit SCIT treatment?
On immunotherapy, symptoms controlled
 z Given that an adult with hay fever has carried on from the previous year on SCIT and treatments to 
control all of their symptoms, what is the probability that they:
 | continue only with SCIT from the second year onwards?
 | continue with this treatment from the second year onwards?
 | will continue with SCIT but switch to treatments that control only some of their symptoms at 
some point within the second year?
 z Given that an adult with hay fever has carried on from the previous year on SCIT and treatments to 
control all of their symptoms:
 | but then continued with only SCIT treatment at some point within the second year, what is the 
probability that they will quit SCIT treatment?
NIHR Journals Library www.journalslibrary.nihr.ac.uk
AppENDIx 13
302
 | and then continued with this treatment from the second year onwards, what is the probability 
that they will quit SCIT treatment?
 | and then switched to treatments that control all of their symptoms at some point within the 
second year, what is the probability that they will quit SCIT treatment?
On immunotherapy, symptoms part controlled
 z Given that an adult with hay fever has carried on from the previous year on SCIT and treatments to 
control only some of their symptoms, what is the probability that they:
 | will continue only with SCIT from the second year onwards?
 | will continue with SCIT but switch to treatments that control all of their symptoms at some point 
within the second year?
 | will continue with this treatment from the second year onwards?
 z Given that an adult with hay fever has carried on from the previous year on SCIT and treatments to 
control only some of their symptoms:
 | but then continued with only SCIT treatment at some point within the second year, what is the 
probability that they will quit SCIT treatment?
 | and then continued with SCIT and switched to treatments that control all of their symptoms at 
some point within the second year, what is the probability that they will quit SCIT treatment?
 z Given that an adult with hay fever has carried on from the previous year on SCIT and treatments to 
control all of their symptoms and then continued with this treatment from the second year onwards, 
what is the probability that they will quit SCIT treatment?
Completed immunotherapy, no symptomatic treatment
 z Given that an adult with hay fever completed treatment with SCIT in the first year and is not on any 
other treatment, what is the probability that they:
 | continue this way from the second year onwards?
 | will add treatments to control all of their symptoms at some point within the second year?
 | will add treatments to control some of their symptoms at some point within the second year?
Completed immunotherapy, symptoms controlled
 z Given that an adult with hay fever completed treatment with SCIT in the first year and is on treatment 
to control all of their symptoms, what is the probability that they:
 | will not have any symptomatic treatment from the second year onwards?
 | will continue with this treatment from the second year onwards?
 | will switch to treatments that control only some of their symptoms at some point within the 
second year?
Completed immunotherapy, symptoms part controlled
 z Given that an adult with hay fever completed treatment with SCIT in the first year and is on treatment 
to control only some of their symptoms, what is the probability that they:
 | will not have any symptomatic treatment from the second year onwards?
 | will switch to treatments to control all of their symptoms at some point within the second year?
 | will continue with the same treatment from the second year onwards?
Early quit immunotherapy, no symptomatic treatment
 z Given that an adult with hay fever quit treatment with SCIT early in the first year and is not on any 
other treatment, what is the probability that they:
 | continue this way from the second year onwards?
 | will add treatments to control all of their symptoms at some point in the second year?
 | will add treatments to control some of their symptoms at some point in the second year?
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Early quit immunotherapy, symptoms controlled
 z Given that an adult with hay fever quit treatment with SCIT early in the first year and is on treatment 
to control all of their symptoms, what is the probability that they:
 | will not have any symptomatic treatment from the second year onwards?
 | will continue with this treatment from the second year onwards?
 | will switch to treatments that control only some of their symptoms at some point within the 
second year?
Early quit immunotherapy, symptoms part controlled
 z Given that an adult with hay fever quit treatment with SCIT early in the first year and is on treatment 
to control only some of their symptoms, what is the probability that they:
 | will not have any symptomatic treatment from the second year onwards?
 | will switch to treatments that control all of their symptoms at some point within the second year?
 | will continue with the same treatment from the second year onwards?
Sublingual immunotherapy arm
Same as for SCIT arm: replace ‘SCIT’ with ‘SLIT’.
Symptomatic treatment-only arm
 z Given that an adult with hay fever first started on symptomatic treatment only, what is the probability 
that they:
 | will continue without any symptomatic treatment?
 | will continue with treatments to control all of their symptoms?
 | will continue with treatments to control some of their symptoms?
No symptomatic treatment
 z Given that an adult with hay fever has carried on from the previous year on no symptomatic 
treatment, what is the probability that they:
 | will continue without any symptomatic treatment from the second year onwards?
 | will add treatments to control all of their symptoms at some point within the second year?
 | will add treatments to control only some of their symptoms at some point within the second year?
Symptoms controlled
 z Given that an adult with hay fever has carried on from the previous year on treatments that control all 
of their symptoms, what is the probability that they:
 | will continue without any symptomatic treatment from the second year onwards?
 | will continue with this treatment from the second year onwards?
 | switch to treatments that control only some of their symptoms at some point within the 
second year?
Symptoms part controlled
 z Given that an adult with hay fever has carried on from the previous year on treatments that control 
only some of their symptoms, what is the probability that they:
 | will continue without any symptomatic treatment from the second year onwards?
 | switch to treatments that control all of their symptoms at some point within the second year?
 | will continue with this treatment from the second year onwards?
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Child Markov model transition probabilities
Subcutaneous immunotherapy arm
Start immunotherapy
 z Given that a child with hay fever first started on SCIT treatment, what is the probability that in the first 
hay fever season:
 | the patient does not require symptomatic treatment?
 | they then add on treatments to control all of their symptoms?
 | they then add on treatments to control some of their symptoms (symptoms partly controlled)?
 z Given that a child with hay fever is on SCIT only (without any symptomatic treatment), what is the 
probability that they will also have asthma after 1 year?
 z Given that a child with hay fever is on SCIT and treatments to control all of their symptoms, what is 
the probability that they will also have asthma after 1 year?
 z Given that a child with hay fever is on SCIT and treatments to control only some of their symptoms, 
what is the probability that they will also have asthma after 1 year?
 z Given that a child with hay fever is on SCIT only (without any symptomatic treatment), what is the 
probability that they will quit SCIT after 1 year if they do not have asthma?
 z Given that a child with hay fever is on SCIT and treatments to control all of their symptoms, what is 
the probability that they will quit SCIT after 1 year if they do not have asthma?
 z Given that a child with hay fever is on SCIT and treatments to control only some of their symptoms, 
what is the probability that they will quit SCIT within 1 year if they do not have asthma?
 z Given that a child with hay fever is on SCIT only (without any symptomatic treatment), what is the 
probability that they will quit SCIT after 1 year if they have asthma?
 z Given that a child with hay fever is on SCIT and treatments to control all of their symptoms, what is 
the probability that they will quit SCIT after 1 year if they have asthma?
 z Given that a child with hay fever is on SCIT and treatments to control only some of their symptoms, 
what is the probability that they will quit SCIT within 1 year if they have asthma?
On immunotherapy, no symptomatic treatment without asthma
 z Given that a non-asthmatic child with hay fever has carried on from the previous year on SCIT only 
(without any symptomatic treatment); what is the probability that in the current year:
 | the child does not require symptomatic treatment?
 | they then add on treatments to control all of their symptoms?
 | they then add on treatments to control some of their symptoms (symptoms partly controlled)?
 z Given that a non-asthmatic child with hay fever has carried on from the previous year on SCIT only 
(without any symptomatic treatment):
 | and then continued with this treatment during the second year, what is the probability that they 
develop asthma by the end of the third year?
 | and then added treatments to control all of their symptoms during the second year, what is the 
probability that they develop asthma by the end of the third year?
 | and then added treatments to control only some of their symptoms during the second year, what 
is the probability that they develop asthma by the end of the third year?
 | and then continued with this treatment during the second year, what is the probability that they 
will quit SCIT treatment before the start of the third year if they did not develop asthma?
 | and then added treatments to control all of their symptoms during the second year, what is the 
probability that they will quit SCIT treatment before the start of the third year if they did not 
develop asthma?
 | and then added treatments to control only some of their symptoms during the second year, what 
is the probability that they will quit SCIT treatment before the start of the third year if they did not 
develop asthma?
 | and then continued with this treatment during the second year, what is the probability that they 
will quit SCIT treatment before the start of the third year if they developed asthma?
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 | and then added treatments to control all of their symptoms during the second year, what 
is the probability that they will quit SCIT treatment before the start of the third year if they 
developed asthma?
 | and then added treatments to control only some of their symptoms during the second year, 
what is the probability that they will quit SCIT treatment before the start of the third year if they 
developed asthma?
On immunotherapy, no symptomatic treatment with asthma
 z Given that an asthmatic child with hay fever has carried on from the previous year on SCIT only 
(without any symptomatic treatment), what is the probability that in the current year:
 | the child does not require symptomatic treatment?
 | they then add on treatments to control all of their symptoms?
 | they then add on treatments to control some of their symptoms (symptoms partly controlled)?
 z Given that an asthmatic child with hay fever has carried on from the previous year on SCIT only 
(without any symptomatic treatment):
 | and then continued with this treatment during the second year, what is the probability that they 
will quit SCIT treatment before the start of the third year?
 | and then added treatments to control all of their symptoms during the second year, what is the 
probability that they will quit SCIT treatment before the start of the third year?
 | and then added treatments to control only some of their symptoms during the second year, what 
is the probability that they will quit SCIT treatment before the start of the third year?
On immunotherapy, symptoms controlled without asthma
 z Given that a non-asthmatic child with hay fever has carried on from the previous year on SCIT and 
treatments to control all of their symptoms, what is the probability that in the current year:
 | the child does not require symptomatic treatment?
 | they continue with treatments to control all of their symptoms?
 | they switch to treatments to control some of their symptoms (symptoms partly controlled)?
 z Given that a non-asthmatic child with hay fever has carried on from the previous year SCIT and 
treatments to control all of their symptoms:
 | but then continued with only SCIT treatment during the second year, what is the probability that 
they develop asthma by the end of the third year?
 | and then continued with this treatment during the second year, what is the probability that they 
develop asthma by the end of the third year?
 | and then switched to treatments that control only some of their symptoms during the second 
year, what is the probability that they develop asthma by the end of the third year?
 | but then continued with only SCIT treatment during the second year, what is the probability that 
they will quit SCIT treatment before the start of the third year if they did not develop asthma?
 | and then continued with this treatment during the second year, what is the probability that they 
will quit SCIT treatment before the start of the third year if they did not develop asthma?
 | and then switched to treatments that control only some of their symptoms during the second 
year, what is the probability that they will quit SCIT treatment before the start of the third year if 
they did not develop asthma?
 | but then continued with only SCIT treatment during the second year, what is the probability that 
they will quit SCIT treatment before the start of the third year if they developed asthma?
 | and then continued with this treatment during the second year, what is the probability that they 
will quit SCIT treatment before the start of the third year if they developed asthma?
 | and then switched to treatments that control only some of their symptoms during the second 
year, what is the probability that they will quit SCIT treatment before the start of the third year if 
they developed asthma?
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On immunotherapy, symptoms controlled with asthma
 z Given that an asthmatic child with hay fever has carried on from the previous year on SCIT and 
treatments to control all of their symptoms, what is the probability that in the current year:
 | the child does not require symptomatic treatment?
 | they continue with treatments to control all of their symptoms?
 | they switch to treatments to control some of their symptoms (symptoms partly controlled)?
 z Given that an asthmatic child with hay fever has carried on from the previous year SCIT and treatments 
to control all of their symptoms:
 | but then continued with only SCIT treatment during the second year, what is the probability that 
they will quit SCIT treatment before the start of the third year?
 | and then continued with this treatment during the second year, what is the probability that they 
will quit SCIT treatment before the start of the third year?
 | and then switched to treatments that control only some of their symptoms during the second 
year, what is the probability that they will quit SCIT treatment before the start of the third year?
On immunotherapy, symptoms part controlled without asthma
 z Given that a non-asthmatic child with hay fever has carried on from the previous year on SCIT and 
treatments to control only some of their symptoms, what is the probability that in the current year:
 | the child does not require symptomatic treatment?
 | they switch to treatments to control all of their symptoms?
 | they continue with treatments to control only some of their symptoms (symptoms 
partly controlled)?
 z Given that a non-asthmatic child with hay fever has carried on from the previous year on SCIT and 
treatments to control only some of their symptoms:
 | but then continued with only SCIT treatment during the second year, what is the probability that 
they develop asthma by the end of the third year?
 | but then switched to treatments to control all of their symptoms during the second year, what is 
the probability that they develop asthma by the end of the third year?
 | and then continued with this treatment during the second year, what is the probability that they 
develop asthma by the end of the third year?
 | but then continued with only SCIT treatment during the second year, what is the probability that 
they will quit SCIT treatment before the start of the third year if they did not develop asthma?
 | but then switched to treatments to control all of their symptoms during the second year, what is 
the probability that they will quit SCIT treatment before the start of the third year if they did not 
develop asthma?
 | and then continued with this treatment during the second year, what is the probability that they 
will quit SCIT treatment before the start of the third year if they did not develop asthma?
 | but then continued with only SCIT treatment during the second year, what is the probability that 
they will quit SCIT treatment before the start of the third year if they developed asthma?
 | but then switched to treatments to control all of their symptoms during the second year, what 
is the probability that they will quit SCIT treatment before the start of the third year if they 
developed asthma?
 | and then continued with this treatment during the second year, what is the probability that they 
will quit SCIT treatment before the start of the third year if they developed asthma?
On immunotherapy symptoms part controlled with asthma
 z Given that an asthmatic child with hay fever has carried on from the previous year on SCIT and 
treatments to control only some of their symptoms, what is the probability that in the current year:
 | the child does not require symptomatic treatment?
 | they switch to treatments to control all of their symptoms?
 | they continue with treatments to control only some of their symptoms (symptoms 
partly controlled)?
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 z Given that an asthmatic child with hay fever has carried on from the previous year on SCIT and 
treatments to control only some of their symptoms but then continued with only SCIT treatment 
during the second year, what is the probability that they will quit SCIT treatment before the start of 
the third year?
 z Given that an asthmatic child with hay fever has carried on from the previous year on SCIT and 
treatments to control only some of their symptoms but then switched to treatments to control all 
of their symptoms during the second year, what is the probability that they will quit SCIT treatment 
before the start of the third year?
 z Given that an asthmatic child with hay fever has carried on from the previous year on SCIT and 
treatments to control only some of their symptoms and then continued with this treatment during 
the second year, what is the probability that they will quit SCIT treatment before the start of the 
third year?
Completed immunotherapy no symptomatic treatment without asthma
 z Given that a non-asthmatic child with hay fever completed 3 years’ treatment with SCIT and did not 
require symptomatic treatment in the previous year, what is the probability that in the current year:
 | the child does not require symptomatic treatment?
 | they then add treatments to control all of their symptoms?
 | they then add treatments to control some of their symptoms (symptoms partly controlled)?
 z Given that a non-asthmatic child with hay fever completed 3 years’ treatment with SCIT only (without 
any symptomatic treatment):
 | and then continued with no symptomatic treatment during the second year, what is the 
probability that they develop asthma by the end of the third year?
 | and then added treatments to control all of their symptoms during the second year, what is the 
probability that they develop asthma by the end of the third year?
 | and then added treatments to control only some of their symptoms during the second year, what 
is the probability that they develop asthma by the end of the third year?
Completed immunotherapy, no symptomatic treatment with asthma
 z Given that an asthmatic child with hay fever has completed 3 years’ treatment with SCIT and did not 
require symptomatic treatment in the previous year, what is the probability that in the current year:
 | the child does not require symptomatic treatment?
 | they then add treatments to control all of their symptoms?
 | they then add treatments to control some of their symptoms (symptoms partly controlled)?
Completed immunotherapy, symptoms controlled without asthma
 z Given that a non-asthmatic child with hay fever completed 3 years’ treatment with SCIT and was on 
treatment to control all of their symptoms in the previous year, what is the probability that in the 
current year:
 | the child does not require symptomatic treatment?
 | they continue with treatments to control all of their symptoms?
 | they switch to treatments to control only some of their symptoms?
 z Given that a non-asthmatic child with hay fever completed 3 years’ treatment with SCIT and was on 
treatment to control all of their symptoms in the previous year:
 | but continued without any SCIT or treatments to control their symptoms during the second year, 
what is the probability that they develop asthma by the end of the third year?
 | and then continued with treatments to control all of their symptoms during the second year, what 
is the probability that they develop asthma by the end of the third year?
 | and then switched to treatments to control only some of their symptoms during the second year, 
what is the probability that they develop asthma by the end of the third year?
NIHR Journals Library www.journalslibrary.nihr.ac.uk
AppENDIx 13
308
Completed immunotherapy symptoms controlled with asthma
 z Given that an asthmatic child with hay fever completed 3 years’ treatment with SCIT and was on 
treatment to control all of their symptoms in the previous year, what is the probability that in the 
current year:
 | the child does not require symptomatic treatment?
 | they continue with treatments to control all of their symptoms?
 | they switch to treatments to control only some of their symptoms?
Completed immunotherapy symptoms part controlled without asthma
 z Given that a non-asthmatic child with hay fever completed 3 years’ treatment with SCIT and was on 
treatment to control only some of their symptoms in the previous year, what is the probability that in 
the current year;
 | the child does not require symptomatic treatment?
 | they switch to treatments to control all of their symptoms?
 | they continue with treatments to control only some of their symptoms?
 z Given that a non-asthmatic child with hay fever completed 3 years’ treatment with SCIT and was on 
treatment to control only some of their symptoms in the previous year
 | but continued without any SCIT or treatments to control their symptoms during the second year, 
what is the probability that they develop asthma by the end of the third year?
 | and then switched to treatments to control all of their symptoms during the second year, what is 
the probability that they develop asthma by the end of the third year?
 | and then continued with treatments to control only some of their symptoms during the second 
year, what is the probability that they develop asthma by the end of the third year?
Completed immunotherapy symptoms part controlled with asthma
 z Given that an asthmatic child with hay fever completed 3 years’ treatment with SCIT and was on 
treatment to control only some of their symptoms in the previous year, what is the probability that in 
the current year:
 | the child does not require symptomatic treatment?
 | they switch to treatments to control all of their symptoms?
 | they continue with treatments to control only some of their symptoms?
Early quit immunotherapy, no symptomatic treatment without asthma
 z Given that a non-asthmatic child with hay fever quit treatment with SCIT before the start of the third 
year and is not on any other treatment, what is the probability that in the current year:
 | the child does not require symptomatic treatment?
 | they then add treatments to control all of their symptoms?
 | they then add treatments to control some of their symptoms (symptoms partly controlled)?
 z Given that a non-asthmatic child with hay fever quit treatment with SCIT before the start of the third 
year and was not on any other treatment
 | and continued without any treatment during the second year, what is the probability that they 
develop asthma by the end of the third year?
 | but then added treatments to control all of their symptoms during the second year, what is the 
probability that they develop asthma by the end of the third year?
 | but then added treatments to control only some of their symptoms during the second year, what 
is the probability that they develop asthma by the end of the third year?
Early quit immunotherapy, no symptomatic treatment with asthma
 z Given that an asthmatic child with hay fever quit treatment with SCIT before the start of the third year 
and is not on any other treatment, what is the probability that in the current year:
 | the child does not require symptomatic treatment?
 | they then add treatments to control all of their symptoms?
 | they then add treatments to control some of their symptoms (symptoms partly controlled)?
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Early quit immunotherapy, symptoms controlled without asthma
 z Given that a non-asthmatic child with hay fever quit treatment with SCIT before the start of the 
third year and is on treatment to control all of their symptoms, what is the probability that in the 
current year:
 | the child does not require symptomatic treatment?
 | they continue with treatments to control all of their symptoms?
 | they switch to treatments to control only some of their symptoms?
 z Given that a non-asthmatic child with hay fever quit treatment with SCIT before the start of the third 
year and was on treatment to control all of their symptoms
 | and then continued without any treatments to control their symptoms during the second year, 
what is the probability that they develop asthma by the end of the third year?
 | and then continued with treatments to control all of their symptoms during the second year, what 
is the probability that they develop asthma by the end of the third year?
 | and then switched to treatments to control only some of their symptoms during the second year, 
what is the probability that they develop asthma by the end of the third year?
Early quit immunotherapy, symptoms controlled with asthma
 z Given that an asthmatic child with hay fever quit treatment with SCIT before the start of the third year 
and is on treatment to control all of their symptoms, what is the probability that in the current year:
 | the child does not require symptomatic treatment?
 | they continue with treatments to control all of their symptoms?
 | they switch to treatments to control only some of their symptoms?
Early quit immunotherapy, symptoms part controlled without asthma
 z Given that a non-asthmatic child with hay fever quit treatment with SCIT before the start of the third 
year and is on treatment to control only some of their symptoms, what is the probability that in the 
current year:
 | the child does not require symptomatic treatment?
 | they switch to treatments to control all of their symptoms?
 | they continue with treatments to control only some of their symptoms (symptoms 
partly controlled)?
 z Given that a non-asthmatic child with hay fever quit treatment with SCIT before the start of the third 
year and is on treatment to control only some of their symptoms
 | and then continued without any treatments to control their symptoms during the second year, 
what is the probability that they develop asthma by the end of the third year?
 | and then switched to treatments to control all of their symptoms during the second year, what is 
the probability that they develop asthma by the end of the third year?
 | and then continued with treatments to control only some of their symptoms during the second 
year, what is the probability that they develop asthma by the end of the third year?
Early quit immunotherapy, symptoms part controlled with asthma
 z Given that an asthmatic child with hay fever quit treatment with SCIT before the start of the third 
year and is on treatment to control only some of their symptoms, what is the probability that in the 
current year:
 | the child does not require symptomatic treatment?
 | they switch to treatments to control all of their symptoms?
 | they continue with treatments to control only some of their symptoms (symptoms 
partly controlled)?
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Sublingual immunotherapy arm
Same as for SCIT arm: replace ‘SCIT’ with ‘SLIT’.
Symptomatic treatment-only arm
No symptomatic treatment without asthma
 z Given that a non-asthmatic child with hay fever has carried on from the previous year on no 
symptomatic treatment, what is the probability that in the current year:
 | the child does not require symptomatic treatment?
 | they then add treatments to control all of their symptoms?
 | they then add treatments to control some of their symptoms (symptoms partly controlled)?
 z Given that a non-asthmatic child with hay fever has carried on from the previous year on no 
symptomatic treatment:
 | and then continued without symptomatic treatment during the subsequent year, what is the 
probability that they develop asthma by the end of the third year?
 | and then switched to treatments to control all of their symptoms during the subsequent year, 
what is the probability that they develop asthma by the end of the third year?
 | and then switched to treatments to control only some of their symptoms during the subsequent 
year, what is the probability that they develop asthma by the end of the third year?
No symptomatic treatment with asthma
 z Given that an asthmatic child with hay fever has carried on from the previous year on no symptomatic 
treatment, what is the probability that in the current year:
 | the child does not require symptomatic treatment?
 | they then add treatments to control all of their symptoms?
 | they then add treatments to control some of their symptoms (symptoms partly controlled)?
Symptoms controlled without asthma
 z Given that a non-asthmatic child with hay fever has carried on from the previous year on treatments 
that control all of their symptoms, what is the probability that in the current year:
 | the child does not require symptomatic treatment?
 | they continue with treatments to control all of their symptoms?
 | they switch to treatments to control only some of their symptoms (symptoms partly controlled)?
 z Given that a non-asthmatic child with hay fever has carried on from the previous year on treatments 
that control all of their symptoms
 | and then continued without symptomatic treatment during the subsequent year, what is the 
probability that they develop asthma by the end of the third year?
 | and then continued with this treatment during the subsequent year, what is the probability that 
they develop asthma by the end of the third year?
 | and then switched to treatments to control only some of their symptoms during the subsequent 
year, what is the probability that they develop asthma by the end of the third year?
Symptoms controlled with asthma
 z Given that an asthmatic child with hay fever has carried on from the previous year on treatments that 
control all of their symptoms, what is the probability that in the current year:
 | the child does not require symptomatic treatment?
 | they continue with treatments to control all of their symptoms?
 | they switch to treatments to control only some of their symptoms (symptoms partly controlled)?
Symptoms part controlled without asthma
 z Given that a non-asthmatic child with hay fever has carried on from the previous year on treatments 
that control only some of their symptoms, what is the probability that in the current year:
 | the child does not require symptomatic treatment?
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 | they switch to treatments to control all of their symptoms?
 | they continue with treatments to control only some of their symptoms (symptoms 
partly controlled)?
 z Given that a non-asthmatic child with hay fever has carried on from the previous year on treatments 
that control only some of their symptoms
 | and then continued without symptomatic treatment during the subsequent year, what is the 
probability that they develop asthma by the end of the third year?
 | and then switched to treatments to control all of their symptoms during the subsequent year, 
what is the probability that they develop asthma by the end of the third year?
 | and then continued with this treatment during the subsequent year, what is the probability that 
they develop asthma by the end of the third year?
Symptoms part controlled with asthma
 z Given that an asthmatic child with hay fever has carried on from the previous year on treatments that 
control only some of their symptoms, what is the probability that in the current year:
 | the child does not require symptomatic treatment?
 | they switch to treatments to control all of their symptoms?
 | they continue with treatments to control only some of their symptoms (symptoms 
partly controlled)?
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Appendix 14 Cost-effectiveness analysis based on 
six-weekly injections
The resource use and unit costs for SCIT and ST are the same as in the main analysis. The only difference is in the number of injections/clinic visits. The total number of clinic visits over a 3-year period was 
assumed to be 36, i.e. 19 in year 1 (including updosing), eight in year 2 and nine in year 3.
Shown below are the costs and ICERs when the 6-week maintenance schedule is used. The effectiveness 
estimates based on change in RQLQ were assumed to remain the same.
TABLE 67 Costs: SCIT (6-weekly maintenance schedule)
Year 1 Year 2a Year 3a
Staff during clinic visits
Consultant £702.81 £285.91 £310.78
Band 8 nurse £208.74 £84.92 £92.30
Supplies/consumablesb
£3.80 £1.55 £1.68
SCIT medication
Allergy medicine
Alutard £1051.82 £725.18 £788.24
Symptomatic medicine
Desloratadine £24.15 £23.33 £22.54
Budesonide £41.86 £40.45 £39.08
Productivity loss
Hours missed from work £49.74 £48.05 £46.43
Hours at work with reduced productivity £95.14 £91.92 £88.82
Total annual costs £2178.06 £1301.32 £1389.86
Total cumulative costs £2178.06 £3479.38 £4869.24
a Costs discounted at 3.5%.
b Supplies are made of swabs, syringes, hypodermic needles and gloves.
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TABLE 68  Subcutaneous immunotherapy costs for years 4–10 (6-weekly maintenance schedule)
Year 4 Year 5 Year 6 Year 7 Year 8 Year 9 Year 10
Staff during clinic visits
Consultant – – – – – – –
Band 8 nurse – – – – – – –
SCIT medication
Alutard – – – – – – –
Symptomatic medicine
Desloratadine £21.78 £21.05 £20.33 £19.65 £18.98 £18.34 £17.72
Budesonide £37.76 £36.48 £35.25 £34.06 32.90 31.79 £30.72
Productivity loss
Hours missed from work £44.86 £43.34 £41.88 £40.46 £39.09 £37.77 £36.49
Hours at work with 
reduced productivity
£85.81 £82.91 £80.11 £77.40 £74.78 £72.25 £69.81
Total annual costs £190.21 £183.78 £177.56 £171.56 £165.76 £160.15 £154.74
Total cumulative 
costsa,b
£5059.45 £5243.23 £5420.79 £5592.35 £5758.11 £5918.27 £6073.00
a Costs discounted at 3.5%.
b Includes cumulative cost of SCIT incurred in years 1–3.
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TABLE 69 Economic evaluation results: SCIT vs ST (based on direct comparisons, 6-weekly maintenance schedule)
Cost difference (£) at 
3 years 4085
4 years 4032
5 years 3980
6 years 3930
7 years 3882
8 years 3835
9 years 3790
10 years 3746
RQLQ difference 0.740 (95% CI 0.560 to 0.920)
ICER (£): costs/unit improvement in RQLQ 5521 (95% CI 4441 to 7295)
Total QALY gain in 3 years 0.0957 (95% CI 0.0724 to 0.1189)
ICER (£): costs per QALY 42,705 (95% CI 34,349 to 56,431)
Total QALY gain in 4 years 0.1254 (95% CI 0.0949 to 0.1559)
ICER (£): costs per QALY 32,145 (95% CI 25,856 to 42,478)
Total QALY gain in 5 years 0.1542 (95% CI 0.1167 to 0.1917)
ICER (£): costs per QALY 25,815 (95% CI 20,764 to 34,113)
Total QALY gain in 6 years 0.1820 (95% CI 0.1377 to 0.2262)
ICER (£): costs per QALY 21,599 (95% CI 17,373 to 28,541)
Total QALY gain in 7 years 0.2088 (95% CI 0.1580 to 0.2596)
ICER (£): costs per QALY 18,591 (95% CI 14,953 to 24,566)
Total QALY gain in 8 years 0.2347 (95% CI 0.1776 to 0.2918)
ICER (£): costs per QALY 16,338 (95% CI 13,141 to 21,589)
Total QALY gain in 9 years 0.2598 (95% CI 0.1966 to 0.3230)
ICER (£): costs per QALY 14,588 (95% CI 11,734 to 19,278)
Total QALY gain in 10 years 0.2840 (95% CI 0.2149 to 0.3531)
ICER (£): costs per QALY 13,191 (95% CI 10,610 to 17,431)
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FIGURE 96 Cost-effectiveness of SCIT vs ST (direct comparison, 6-weekly maintenance schedule).
© Queen’s Printer and Controller of HMSO 2013. This work was produced by Meadows et al. under the terms of a commissioning contract issued by the Secretary of State 
for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals 
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be 
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science 
Park, Southampton SO16 7NS, UK.
DOI: 10.3310/hta17270 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 27
317
TABLE 70 Economic evaluation results: SCIT vs ST (based on indirect comparisons, 6-weekly maintenance schedule)
Cost difference (£) at 
3 years 4085
4 years 4032
5 years 3980
6 years 3930
7 years 3882
8 years 3835
9 years 3790
10 years 3746
RQLQ difference 0.764 (95% CI 0.425 to 1.116)
ICER (£): costs/unit improvement in RQLQ 5347 (95% CI 3661 to 9613)
Total QALY gain in 3 years 0.0988 (95% CI 0.0549 to 0.1443)
ICER (£): costs per QALY 41,363 (95% CI 28,317 to 74,356)
Total QALY gain in 4 years 0.1295 (95% CI 0.0720 to 0.1892)
ICER (£): costs per QALY 31,136 (95% CI 21,315 to 55,971)
Total QALY gain in 5 years 0.1592 (95% CI 0.0885 to 0.2325)
ICER (£): costs per QALY 25,004 (95% CI 17,117 to 44,948)
Total QALY gain in 6 years 0.1879 (95% CI 0.1045 to 0.2744)
ICER (£): costs per QALY 20,920 (95% CI 14,322 to 37,607)
Total QALY gain in 7 years 0.2156 (95% CI 0.1199 to 0.3149)
ICER (£): costs per QALY 18,007 (95% CI 12,327 to 32,370)
Total QALY gain in 8 years 0.2423 (95% CI 0.1348 to 0.3540)
ICER (£): costs per QALY 15,825 (95% CI 10,833 to 28,447)
Total QALY gain in 9 years 0.2682 (95% CI 0.1492 to 0.3918)
ICER (£): costs per QALY 14,130 (95% CI 9673 to 25,401)
Total QALY gain in 10 years 0.2932 (95% CI 0.1631 to 0.4283)
ICER (£): costs per QALY 12,777 (95% CI 8747 to 22,968)
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FIGURE 97 Cost-effectiveness of SCIT vs ST (indirect comparison, 6-weekly maintenance schedule).
FIGURE 98 Cost-effectiveness of SCIT vs SLIT (6-weekly maintenance schedule).
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TABLE 71 Economic evaluation results: SCIT vs SLIT (based on indirect comparisons 6-weekly maintenance schedule)
Cost difference (£) at
3 years 1417
4 years 1498
5 years 1575
6 years 1650
7 years 1723
8 years 1793
9 years 1860
10 years 1926
RQLQ difference 0.517 (95% CI –0.0710 to 1.045)
ICER (£): costs/unit improvement in RQLQ 2741 (1356 to SLIT dominates)
Total QALY gain in 3 years 0.0668 (95% CI –0.0092 to 0.1351)
ICER (£): costs per QALY 21,203 (95% CI 10,490 to SLIT dominates)
Total QALY gain in 4 years 0.0876 (–0.0120 to 0.1771)
ICER (£): costs per QALY 17,090 (95% CI 8455 to SLIT dominates)
Total QALY gain in 5 years 0.1077 (–0.0148 to 0.2177)
ICER (£): costs per QALY 14,624 (95% CI 7235 to SLIT dominates)
Total QALY gain in 6 years 0.1271 (–0.0175 to 0.2569)
ICER (£): costs per QALY 12,982 (95% CI 6423 to SLIT dominates)
Total QALY gain in 7 years 0.1459 (–0.0200 to 0.2948)
ICER (£): costs per QALY 11,810 (95% CI 5843 to SLIT dominates)
Total QALY gain in 8 years 0.1640 (–0.0225 to 0.3315)
ICER (£): costs per QALY 10,932 (95% CI 5409 to SLIT dominates)
Total QALY gain in 9 years 0.1815 (–0.0249 to 0.3668)
ICER (£): costs per QALY 10,251 (95% CI 5072 to SLIT dominates)
Total QALY gain in 10 years 0.1984 (–0.0272 to 0.4010)
ICER (£): costs per QALY 9707 (95% CI 4802 to SLIT dominates)
‘ST dominates’ means that ST is more effective and also cheaper.
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Appendix 15 Funnel plots
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FIGURE 99 Funnel plot: SCIT vs placebo, SSs. SE, standard error.
FIGURE 100 Funnel plot: SLIT vs placebo, SSs. SE, standard error.
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